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Like many first world nations, Australia has demonstrated an increasingly 
pharmaceuticalized response to Attention Deficit Hyperactivity Disorder (ADHD).  Per capita 
rates of prescriptions of ADHD medications grew 277 percent between 1995 and 2010. 
However, there have been large and inconsistent intertemporal variations between state 
jurisdictions (shifting over time in relative terms).  Most notably, in Western Australia (WA) 
in 2002 the child Pharmaceutical Benefits Scheme (PBS) per capita prescribing rate was 142 
percent above the national average.  However, after 2003, while in other states prescribing 
rates grew, they fell by 50 percent in WA, and by 2011 they were 11 percent below the 
national average. 
There has been significant academic, public and media interest not only about the growing 
and inconsistent prescribing rates, but also about concerns that conflicts of interests and 
‘regulatory capture’ may have affected significant policy development and regulatory 
processes in relation to ADHD. Regulatory capture occurs if an entity that is supposed to 
advance the public interest instead acts to benefit commercial or industry interests in ways 
that are contrary to the public interest.  
The thesis draws heavily on the work of British sociologist John Abraham, who contends 
that regulatory capture is the most significant explanation of the process of 
pharmaceuticalization for many health conditions, including ADHD. Here key ADHD policy 
development processes are analysed to evaluate the extent of regulatory capture in 
Australian national and state jurisdictions. These include the development of national 
treatment guidelines and state-specific reviews of WA and New South Wales (NSW) 
prescribing practices.   
For the purposes of this thesis, the term ‘regulatory capture’ is taken to have a broad scope, 
encompassing capture of any or all of the actors, both government and non-government, 
which have the declared intention of protecting and enhancing the public good. Examples of 
non-government actors include professional organisations, researchers, and patient 
advocacy groups. 
 
The history of ADHD policy and regulation nationally from 1992 to 2012, in WA from 1993 to 
2011 and in NSW from 2007 to 2011 is that regulatory capture occurred in the majority of 
policy development and regulatory processes. These ‘captured’ processes have been 
associated with subsequent ADHD child pharmaceuticalization. Conversely the only ADHD-
critic dominated process identified occurred in WA in 2002 and was associated with 
subsequent ADHD child de-pharmaceuticalization. The findings of this thesis are consistent 
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From 2001 until 2013 I was a member of the Western Australian Parliament.  A significant 
amount of my energies during this time were expended trying to influence both State and 
Commonwealth Government responses - and ultimately clinical practice - in relation to 
diagnosis and treatment of Attention Deficit Hyperactivity Disorder (ADHD).  In my inaugural 
speech I identified that my activism stemmed from my time as a teacher at a Perth all boys’ 
high school (1995-2001) where I experienced: 
students on AD[H]D medication sitting compliantly in class. They were not 
hyperactive or impulsive, but they were far from switched on. Their medication had 
not made them more attentive but it had made them more compliant and easier to 
manage.1  
At the time of my inaugural speech (2001), I accepted the validity of the ‘disorder’ for 
children ‘carefully diagnosed’ but expressed concern that ‘misdiagnosis and the resultant 
over-prescription of amphetamines is a threat to the health and happiness of many Western 
Australian children’.2  As I became more immersed in the debate my position hardened so 
that by 2006 I stated that: 
I did argue that ADHD is over-diagnosed and over-prescribed. I now say ADHD is a fraud – 
this is how my position has changed, not because kids do not have real things going on in 
their lives, but simply because the bar for diagnosing the condition is far too low.3  
Much of my criticism of ADHD prescribing stems from the fact that the diagnostic criteria for 
ADHD include normal childhood behaviours like fidgeting, disliking homework and playing too 
loudly.  However, I acknowledge some children do exhibit extreme behaviours that warrant 
investigation and support.  I believe in such cases it is essential to identify the underlying cause 
of these problematic behaviours.  Potential causes of ADHD-type behaviours include sleep 
deprivation, bullying or abuse, dietary problems, neurotoxin exposure, immaturity, 
                                               
1
  Martin Whitely MLA (2001), ‘Inaugural speech’, Hansard, Parliament of Western Australia, Thursday 3 
May, pp. 152b–179a. 
2
  Martin Whitely MLA (2001), ‘Inaugural speech’. 




dysfunctional teaching or parenting, sight or hearing problems or any of a multitude of 
environmental, social, educational or medical circumstances.   
I contend that the often promoted concept that ADHD is caused by a biochemical brain 
imbalance is at best an unproven hypothesis.  Furthermore, when this unproven hypothesis is 
assumed to be the cause of attention and hyperactivity problems of an individual child, and 
used as the rationale for drugging the child with amphetamines, this constitutes a dangerous 
fraud. In a book I wrote in 2010 titled Speed Up and Sit Still- the controversies of ADHD diagnosis 
and treatment I concluded:   
The whole [ADHD] fraud hangs on the unsupported assumption of a biochemical brain 
imbalance and the generalised [almost universal] temporary behaviour-altering qualities 
of low-dose amphetamines. Stimulant medication acts in precisely the way it is intended 
to. It stimulates. This does not mean that it is treating a problem or fixing a chemical 
imbalance. Stimulants are simply acting as temporary behaviour modifiers, with 
compelling evidence of long-term educational disadvantage and cardiovascular 
damage.4   
I am therefore obviously not a neutral observer in regards to the science of ADHD.  I have been 
active in many of the policy processes described within this thesis with the aim of lowering 
ADHD child prescribing rates.  However, this thesis does not seek to examine the legitimacy of 
the condition or the issue of whether rising or falling ADHD child prescribing rates are ‘good 
outcomes’.  Instead it identifies the effect of regulatory capture on prescribing rates. 
My strong views and history of public advocacy have presented a challenge in objectively 
and dispassionately analysing processes that I have significantly influenced.  I have 
attempted to present the viewpoints and actions of those that I identify as ‘ADHD 
proponents’ accurately and respectfully in this thesis, even though at times in other forums 
the debate has been passionate and personalised.   
In summary, the merit of opposing views on the contentious issues of ADHD diagnosis and 
treatment is not the subject of this thesis. The focus is evaluating the relative impact of 
                                               
4
  Martin Whitely (2010), Speed Up & Sit Still: The Controversies of ADHD Diagnosis and Treatment, Perth, 
UWA Publishing, p. 145 
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ADHD proponents and critics on policy and regulatory processes and identifying any 




Chapter 1.  Introduction: Regulatory Capture and Australian ADHD Child 
Prescribing 
 
1.1  The significance of and need for the Study 
Attention Deficit Hyperactivity Disorder (ADHD) is the most commonly diagnosed and 
medicated childhood psychiatric disorder in the world.5 6  There are large variations in 
international, state and localised ADHD medication prescribing rates.7  Both the diagnosis 
and treatment of ADHD are controversial and the subject of considerable debate within the 
psychiatric, paediatric and general medical professions, the media, and the public. 
The controversy centres primarily around three key issues: 
1. The validity of the diagnosis 
2. The safety and efficacy of the medications used to treat the disorder  
3. The relationship between ADHD and drug abuse. 
Extensive research effort has been expended in regard to these issues.  There is also 
widespread interest in ADHD prescribing rates, particularly for children, resulting from 
concerns about the safety and efficacy of ADHD medications.   
The process and effect of public policy development, particularly in relation to government 
approved diagnosis and treatment guidelines of ADHD, and the regulatory frameworks in 
regard to the prescription of psychotropic drugs used to treat ADHD in Australia, have been 
little studied.  Similarly, the extent to which commercial and private professional interests 
have influenced Australian ADHD policy and regulation has not been extensively studied.  
This thesis examines the relationship between Australian State and Commonwealth 
Government policies and their implementation in relation to ADHD and national, inter-state 
                                               
5  Inyang Takon (2011), ‘Clinical use of a modified release methylphenidate in the treatment of childhood 
attention deficit hyperactivity disorder’, Annals of General Psychiatry,10:25. Available at 
http://www.annals-general-psychiatry.com/content/10/1/25; US National Library of Medicine, ‘Attention 
Deficit Hyperactivity Disorder’, Medline Plus, 11 April 2011.  Available at 
http://www.nlm.nih.gov/medlineplus/ency/article/001551.htm (accessed 13 December 2011). 
6
  Sung V, Hiscock H, Sciberras E, Efron D. (2008), ‘Sleep problems in children with attention-
deficit/hyperactivity disorder: Prevalence and the effect on the child and family’, Archives of Pediatrics 
and Adolescent Medicine, 162(4):  pp. 336-342.    
7  Philip Hazell (1995), ‘Stimulant treatment for attention deficit hyperactivity disorder’, Australian 
Prescriber: an independent review, 18:60-3; Available: 
http://www.australianprescriber.com/magazine/18/3/60/3/ (accessed 13 December 2011); I McKenzie, C 
Wurr (2004), ‘Diagnosing and treating attentional difficulties: a nationwide survey’, Archives of Disease in 
Childhood,  Vol 89;10 :pp. 913-916. 
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and inter-temporal ADHD medication prescribing rates for children.  It focuses on the 
commercial, professional and political influences upon changes in policies and regulatory 
practice and identifies associated changes in ADHD prescribing rates.  
ADHD diagnosis and treatment makes a significant call upon the public purse.  Through the 
Pharmaceutical Benefits Scheme (PBS) - which subsidises the cost of many prescription 
medications - the Commonwealth Government subsidises ADHD drugs: dexamphetamine 
(brand names Adderall, Dexedrine, Dexostrat), methylphenidate (Ritalin, Ritalin LA and 
Concerta) and atomoxetine (Strattera).  In 2011 Australia-wide 80,647 people - of whom 
62,834 (approximately 78 percent) were children8 - were dispensed a total of 539,875 
prescriptions of PBS subsidised ADHD medications at a cost to taxpayers of $23,842,437.9  A 
small proportion of these prescriptions were for conditions other than ADHD,10 but these 
figures do not include non-PBS subsidised prescriptions.  Although it is not possible to 
identify the quantum, the Commonwealth Government also subsidises, via Medicare co-
payments, the fees of psychiatrists, paediatricians and general practitioners involved in the 
diagnosis and treatment of ADHD.  
In addition to Commonwealth expenditures, state governments spend an indeterminate 
amount giving free medications via public health services and providing child and adolescent 
health and mental health services that diagnose and treat ADHD.  They also expend 
resources monitoring the prescribing and dispensing of ADHD psychostimulants because of 
concerns about their diversion for illicit use. 
Although there has been a consistent pattern of increasing national ADHD child prescribing 
rates across Australia, there are large and inconsistent intertemporal variations between 
States (shifting over time in relative terms).  For example Western Australian per capita PBS 
prescribing rates throughout the 1990s and early 2000s were multiples of those in other 
                                               
8  These statistics were provided to Martin Whitely, upon request, from the Australian Government, 
Department of Health and Ageing (2012), Letter to Martin Whitely dated 21 April 2012, PBS Information 
Management Section, Pharmaceutical Benefits Division, Canberra.  
9  Australian Government, Department of Health and Ageing, Medicare Australia.  PBS information is 
available from the Medicare Australia website via self-generated reports.  Available at 
http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-stats.htm-copy3  
10  In 2011 4.6% of those dispensed psycho-stimulants in Western Australia were for the treatment of conditions 
other than ADHD (Brain Damage 0.2%, Depression 2.1%, Narcolepsy 2.3%) Department of Health (2012), 
Western Australian Stimulant Regulatory Scheme 2011 Annual Report, Pharmaceutical Services Branch, 
Health  Protection Group, Department of Health, Perth: p. 20. 
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states.  In 2002 WA’s child per capita PBS prescribing rate of dexamphetamine (at the time 
the only PBS subsidised ADHD drug) was approximately 2.8 times the national average 
(excluding WA).  Of the 31,738 Australian children who received a PBS dexamphetamine 
prescription, 7,500 (24 percent) lived in WA, despite WA having approximately 10 percent of 
the total population.  The 2002 figures were even more startling for Western Australian 
adults where the rate was 7.1 times the national average (excluding WA) and 44 percent of 
Australian adults who received a PBS dexamphetamine prescription lived in WA.11 
However after 2003, while in other Australian states child prescribing per capita rates grew, 
they fell in Western Australia by 50 percent and by 2011 were 11 percent below the 
national average (see Figure 5 at 4.4.1).  There is considerable media and public interest in 
these geographical and inter-temporal variations in child prescribing rates and speculation 
as to the reasons for these variations. 
Rapid growth in the prescribing of mental health medications in Australia is not limited to 
ADHD medications. From 2000 to 2011 there was a 58.2 percent increase in the dispensing 
of psychotropic drugs in Australia, driven by large increases in per capita prescribing rates of 
antidepressants (up 95.3 percent), atypical antipsychotics (up 217.7 percent) and ADHD 
medications (up 72.9 percent).12 Understanding the drivers of increasing rates of prescribing 
ADHD medications may offer insights into similar increases for other psychotropic 
medications. 
Controversy in regard to the diagnosis and treatment of ADHD is not a uniquely Australian 
experience.  Worldwide, but particularly in many developed nations, there is a highly 
polarised debate about these issues, with competing commercial, medical-professional, 
community and ideological interests seeking to influence policy and regulatory processes in 
relation to ADHD.  
Therefore the integrity and effectiveness of policy development and regulatory processes, 
including the development of government-endorsed policy in relation to the diagnosis and 
                                               
11  Department of Health and Ageing, Letter to Martin Whitely dated 21 April 2012 
12  Stephenson CP, Karanges E, McGregor IS, (2013) ‘Trends in the utilisation of psychotropic medications in 
Australia from 2000 to 2011’,  Australian and New Zealand Journal of Psychiatry, 47(1), pp.74-87 
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treatment of ADHD, and their effects on child prescribing rates, is of significant interest to 
many stakeholders. 
Additionally many of the Australian regulatory and policy development processes relating to 
ADHD are similar to processes conducted by the same government and non-government 
agencies for other physical health and mental health disorders.  Therefore the rigour of 
these processes is a significant public policy issue.   
1.2 The Research Questions 
The motivation for this thesis is to understand why there has been a significant increase in 
Australian ADHD child prescribing rates over the last twenty years with large and 
inconsistent intertemporal variations between state per capita rates.  
Most notably, WA ADHD child prescribing per capita rates have been outliers.  As outlined in 
section 1.1, in 2002 Western Australia’s per capita rates PBS child prescribing rates were 
approximately 180 percent higher than the national average and by 2011 were 11 percent 
below the national average.  Two central questions in this thesis are: why has WA been an 
outlier and why has it dramatically changed its relative position? 
In addition to concerns about inconsistent geographical and intertemporal prescribing rates 
there has been significant media coverage of concerns that conflicts of interests and 
‘regulatory capture’ have affected significant policy development and regulatory processes 
in relation to ADHD.  This thesis will identify relevant conflicts of interest in these processes 
and address the question: What is the relationship between regulatory capture in regulatory 
and policy development processes and ADHD per capita child prescribing rates?      
1.3 Working Hypothesis 
The central hypothesis of this research is as follows: The occurrence or absence of 
regulatory capture of the development and implementation of ADHD policy has contributed 
significantly to variations in Australian national and state ADHD medication child prescribing 




Implicit in this hypothesis are the assertions that: 
1. There are alternative viewpoints as to the validity of the disorder and the safety and 
efficacy of pharmaceutical treatments; and 
2. Supporters of, and beneficiaries from, these divergent viewpoints coalesce and 
compete to influence policy development and the regulation of the diagnosis and 
treatment of ADHD. 
The thesis draws heavily on the work of British sociologist John Abraham.  Abraham 
contends regulatory capture is the most significant explanation of the process of 
pharmaceuticalization – the increasing per capita rates of prescribing pharmaceutical 
interventions for health and mental health conditions including ADHD.13  Abraham bases his 
theory on British and U.S. experience. 14 15  This thesis addresses the question of whether 
Abraham’s explanation of pharmaceuticalization is applicable to ADHD in Australia.   
1.4 Methodology 
The basic task of this thesis is to test the proposition that regulatory capture explains rising 
child ADHD per capita prescribing rates within Australia from 1992 to 2012.   
Regulatory capture occurs if an entity that is supposed to advance the public interest 
instead acts to benefit commercial or industry interests in ways that are contrary to the 
public interest.  For the purposes of this thesis the term ‘regulatory capture’ is taken to have 
a broad scope encompassing capture of any or all of the actors, both government and non-
government, which have the declared intention of protecting and enhancing the public 
good.  In regard to ADHD examples of these non-government actors include professional 
organisations such as the Royal Australian College of Physicians, researchers and patient 
advocacy groups.     
                                               
13  John Abraham (2010), ‘The Sociological Concomitants of the Pharmaceutical Industry and Medications’ 
in  Chloe E. Bird, Peter Conrad, et al (eds.), Handbook of Medical Sociology,  6th edn, Nashville: pp.304-
305 
14  John Abraham (2010), ‘Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health 
Dimensions’, Sociology, Vol. 44:4, pp.603-622. 
15  John Abraham (2003), ‘Learning from Drug Disasters and Reforming Medicines Regulation’, Critical 
public health, 13;3, pp.269-279. 
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Within this thesis a number of ADHD policy development processes are analysed to evaluate 
the incidence of regulatory capture in Australian national and state jurisdictions.  These 
include the development of national ADHD treatment guidelines and state specific reviews 
of Western Australian and New South Wales ADHD prescribing practices. 
There is no single objective method of identifying regulatory capture.  A common method 
used throughout the thesis is to identify any potential conflicts of interest of participants in 
policy development and regulatory processes.  For the purpose of this thesis ‘conflicts of 
interest’ are broadly defined to include ‘commercial conflict of interest’ and/or ‘professional 
conflict of interest’ and/or ‘ideological bias’ in regard to ADHD. 
‘Commercial conflicts of interest’ are evidenced by financial ties to entities with a 
commercial interest in ADHD diagnosis and treatment.  A common example is a member of 
a regulatory process receiving payment from ADHD drug manufacturers.  An example of a 
‘professional conflict of interest’ would be a frequent prescriber of ADHD medications 
reviewing the appropriateness of current and past ADHD prescribing practices.  ‘Ideological 
bias’ is defined as when a person or organisation involved in a policy development or 
regulatory process has expressed a strong inflexible view about the appropriateness of 
ADHD diagnosis or treatment.  
Regulatory capture occurs when, as a result of bias, outcomes favour the interests of 
industry over the public.  Important evidence of whether regulatory capture exists includes 
identifying who is involved in the process. In the case of ADHD a process dominated by 
ADHD proponents is likely to be ‘captured’.  However, the outcomes of the process must 
advantage commercial interests at the expense of the public benefit.    
Although it is less obvious a process can still be ‘captured’ if the participants in the process 
are not biased.  For example, an independent objective committee could still come up with 
captured outcomes if they relied on data or research that was not scientifically rigorous and 
produced policy outcomes that benefited industry but disadvantaged patients.  Evidence of 
policy outcomes that are based on poor quality biased data or research is also evidence of 
regulatory capture.  Therefore in addition to identifying bias amongst participants the 
10 
 
‘rigour’ of evidence used to support policy and regulatory processes is identified throughout 
the thesis.  
It is impossible to quantify or grade the extent to which a policy or regulatory process has 
been ‘captured’.  There is far from perfect information.  In some cases the identity of 
participants is not publicly disclosed or there is no disclosure of potential conflicts of 
interests.  In other processes there is no disclosure of the evidence and the deliberative 
processes undertaken to develop a policy or make regulatory decisions.  Considerable effort 
has been made to discover relevant information. However, for the reasons described above, 
beyond identifying processes as captured, balanced, neutral or critic dominated, there is no 
attempt to grade or rank the relative degree of capture of the processes analysed in the 
thesis.     
There are three commonly expressed views as to the appropriateness of ADHD diagnosis or 
treatment practices and all are critical of current diagnosing and prescribing rates but for 
different reasons.  One view is that ADHD is an under-diagnosed, under-medicated, inherited, 
biochemical imbalance in the brain that is best treated with safe, ‘effective’ medication.16  
Throughout the thesis those promoting this view are described as ADHD proponents. 
At the other end of the spectrum are those who believe ADHD is not a valid psychiatric diagnosis 
and that the medications used to treat people diagnosed with ADHD cause significantly more 
harms than benefits. 17   A third view is that ADHD is a real but rare psychiatric disorder that is 
frequently misdiagnosed and the medications used to treat it are grossly over-prescribed.18  
Throughout the thesis I categorise people holding either of these two views as ADHD critics. 
ADHD proponents generally regard rising child prescribing rates as a ‘good outcome’, 
arguing more children’s needs are being identified and appropriately treated. In contrast 
some ADHD critics believe it is a legitimate but over-diagnosed disorder and argue that 
ADHD medication is often prescribed carelessly and without clear indication of the 
                                               
16
  David Hay, ‘Why is ADHD so under-diagnosed and treated?’, ABC News: The Drum, 4 September 2008.  
Available at http://www.abc.net.au/news/2008-08-29/why-is-adhd-so-under-diagnosed-and-treated/491866 
(accessed 8 January 2013) 
17  Baugham Jr. Fred A., and Craig Hovey (2006), The ADHD Fraud: How Psychiatry Makes ‘Patients’ of 
Normal Children, Trafford Publishing, Victoria BC 
18  Allen Frances (March 2012), ‘Attention Deficit Disorder is Over-Diagnosed and Over-Treated’, 
Huffington Post, 5 March 2012.  Available at  http://www.huffingtonpost.com/allen-frances/attention-
deficit-disorder_b_1206381.html (accessed 9 January 2013)    
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condition.  They regard falling ADHD child prescribing rates as a ‘good outcome’, arguing 
fewer children are likely to be damaged by inappropriate, harmful ‘labelling’ and 
‘drugging’.19  Other ADHD critics argue ADHD is not a legitimate diagnosis and no child 
should be prescribed ADHD medications.20  Although I have a long and public history as an 
ADHD critic this thesis will not address the issue of whether rising or falling prescribing are 
‘good outcomes’.  Rather it will try to identify the effect of regulatory capture on prescribing 
rates. 
The theory of ‘regulatory capture’ is described in detail at 2.5 below. In regards to ADHD, 
commercial regulatory capture would occur if the interests of pharmaceutical companies, 
who manufacture ADHD drugs, or other commercial interests that benefit from diagnosing 
and treating ADHD, dominate public interest.  ADHD critics are seeking to either reduce or 
eliminate its diagnosis and treatment with pharmaceuticals.  ADHD policy development and 
regulatory processes can become dominated by either ADHD proponents or critics.  
However domination by ADHD critics does not constitute the widely accepted definition of 
‘regulatory capture’ as it would likely result in diminishing or destroying commercial 
interests in ADHD.   
Therefore any process (including policy development processes) dominated by ADHD critics 
is throughout this thesis referred to as ‘critic dominated’.  Alternatively where there is no 
influence by either proponents or critics, regulatory processes are classified as ‘neutral’ and 
where there is significant input from both proponents and critics they are classified as 
‘balanced’.  In summary throughout the thesis regulatory and policy processes will be 
classified as being either ‘proponent captured’, ‘critic dominated’, ‘neutral’ or ‘balanced’.     
There are three primary public interest purposes for the regulation of ADHD.  First the 
Commonwealth and State governments and professional bodies like the Royal Australian 
College of Physicians have an interest in, or responsibility for, ensuring patient welfare 
through the development of appropriate diagnosis and treatment guidelines.  Second, the 
Commonwealth Governments subsidises, and State Governments directly deliver, diagnostic 
services and treatments.  Third, State Governments also regulate the prescribing and 
                                               
19  Frances, ‘Attention Deficit Disorder is Over-Diagnosed and Over-Treated’ . 
20
  Baughman and  Hovey, The ADHD Fraud. 
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dispensing of ADHD medications in order to prevent their illicit use as the most commonly 
prescribed pharmaceuticals for the treatment of ADHD are either an amphetamine 
(dexamphetamine) or classed as a near amphetamine (methylphenidate).21 
Assessing the success of an ADHD regulatory regime and conversely any adverse public 
interest outcomes of regulatory capture would ideally involve evaluating both patient 
outcomes and diversion rates of prescribed ADHD medications.  A fall in medication 
diversion and abuse rates is widely regarded as a desirable outcome by most proponents 
and critics.  WA data about inter-temporal patterns of the diversion and abuse of ADHD 
medications allows some assessment of the effectiveness of regulation designed to restrict 
diversion and illicit use.  Where available this information will be identified.  
It is, however, beyond the scope of this thesis to evaluate patient outcomes.  Without the 
ability to identify and evaluate patient outcomes the best measure of the outcome of 
regulatory capture is to collate information about regulatory processes and child ADHD per 
capita prescribing rates.   
There is no single data source that provides accurate statistics of state ADHD child 
prescribing rates for the entire study period 1992 to 2012.  Accurate statistical data of ADHD 
PBS funded by state specific child patient numbers is available from the Australia 
Department of Health and Ageing for the period 2002 to 2011.  
However, it was not until July 2007 that all ADHD medications were subsidised via the PBS.  
The first drug subsidised via the PBS was dexamphetamine in 1992. Ritalin, although 
commonly prescribed, was not subsidised until 1 August 2005.  Ritalin LA (long acting), 
Concerta and Strattera were added in 2007.  As these medications became subsidised the 
Commonwealth Government data source became more comprehensive and useful for this 
analysis.  
There has been significant unsubsidised prescribing of ADHD medications, particularly prior 
to 2007.  The Commonwealth Department of Health and Ageing (DoHA) has produced a 
                                               
21  DSM IV recognises the abuse and addiction to amphetamines (both methamphetamine and dexamphetamine) 
and methylphenidate in a common class of ‘Amphetamine or Amphetamine-Like – Related Disorders’. 
American Psychiatric Association (2000), Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision, American Psychiatric Association, Washington DC, p. 223. 
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series of reports titled ‘Australian Statistics on Medicines’ that identify the annual national 
total of both PBS subsidised and unsubsidised ADHD prescriptions from 1995 to 2010.  
These reports do not identify individual state rates or patient numbers or ages.  This data is 
therefore only useful for identifying national trends in prescribing.  
It was not until 2002 that age specific, state specific patient numbers were collected.  This 
data however was not reported until, upon my request, DoHA provided me with age 
specific, drug specific, state based data in April 2012.  Between 1992 and 2002 
Commonwealth Government state specific prescribing data was limited to total PBS 
prescription numbers and there is no reliable estimate of patient numbers or their ages.  
Nonetheless several sources provide data that allows estimation of state prescribing rates, 
particularly for Western Australia and to a lesser extent New South Wales.  The availability 
of these state based statistics along with the availability of significant historical data on 
policy and regulatory processes in these states are the reasons these states were chosen for 
a detailed analysis.   
The methodology used to establish these state based estimates is discussed in detail in 
chapters 4 and 6.  These estimates, together with the data from the Department of Health 
and Ageing, form the basis for evaluating the relationship between regulatory processes and 
child prescribing rates.   
WA was chosen for detailed analysis between 1994 and 2012 because it has the most 
comprehensive and detailed historical data about both ADHD prescribing rates and 
regulation and policy development practices of all Australian jurisdictions. In addition it has 
historically been an outlier with per capita prescribing rates showing a considerably 
different pattern in Western Australia compared to other Australian jurisdictions. 
Data for NSW is not as comprehensive.  However in recent years, namely from 2007 to 
2012, NSW per capita child prescribing rates have grown significantly and are now the 
highest in Australia.  This followed a significant regulatory and policy process in 2007.    
14 
 
In summary, the methodology involves identifying regulatory capture in relevant policy 
development and regulatory processes and identifying corresponding movements in ADHD 
child prescribing per capita rates. 
1.5 Structure of the Thesis 
Thus far Chapter 1: Introduction has provided a justification for the research question and 
established the main exploratory arguments.  Chapter 1 has also described the methodology 
and introduced some key concepts used in the rest of the thesis. 
Chapter 2: Background Information and the Theoretical Framework provides background 
information about the controversial aspects of ADHD, namely the validity of the diagnosis, 
the safety and efficacy of its treatments and its relationship to illicit drug use. 
The chapter then outlines the competing explanations for the pharmaceuticalization of 
ADHD, i.e. increased ADHD child prescribing rates.  The first viewpoint is the biomedicalized 
viewpoint whereby ADHD proponents contend that ADHD pharmaceuticalization is a 
consequence of scientific breakthroughs and better recognition of a neurobiological 
condition.  The competing medicalization view of ADHD critics is that diagnosing ADHD is an 
inappropriate application of the medical model and results in the harmful use of 
psychotropic drugs. 
Finally the chapter outlines the theoretical basis of the concept of regulatory capture.  In 
effect this chapter identifies the competing viewpoints seeking to influence the 
development and regulation of ADHD policy and practice both internationally, and within 
Australia, and provides a theoretical framework against which to analyse the conflict.  
Chapter 3: Imported Regulatory Capture explores the effect of imported, primarily 
American, ‘regulatory capture’ on Australian ADHD diagnosis and treatment practice. 
Chapter 4: Statistics on Australian National and Western Australian and New South Wales 
ADHD prescribing rates presents relevant statistical data about national, WA and NSW child 
and adult prescribing per capita rates from 1992 to 2011.  This data is referred to 
extensively in subsequent chapters.   
15 
 
Chapter 5: Australian National ADHD policy and Regulatory Capture explores the 
relationship between regulatory capture and changes in national ADHD child prescribing 
rates identified in chapter 4. 
Chapter 6: Western Australian and New South Wales ADHD policy and Regulatory Capture 
explores the relationship between the degree and direction of regulatory capture and 
changes in WA and NSW ADHD child and adult prescribing rates as identified in chapter 4. 
Chapter 7: Discussion, Conclusions and Recommendations finishes the thesis by testing the 





Chapter 2.  Literature Review - Competing perspectives on ADHD 
Pharmaceuticalization, Biomedicalism versus Medicalization and Regulatory 
Capture 
Chapter 1 described the methodology and introduced some key concepts used in the rest of 
the thesis.  This chapter identifies the competing viewpoints of people and organisations 
seeking to influence the development and regulation of ADHD and outlines the theoretical 
basis of the concept of ‘regulatory capture’. 
2.1 The Controversies about ADHD 
The three major controversies contested by ADHD proponents and ADHD critics are: 
1. The validity of the diagnosis. 
2. The safety and efficacy of the pharmaceuticals used to treat it. 
3. The relationship between ADHD and drug addiction and abuse.  
These are discussed in turn below. 
2.1.1 The validity of the diagnosis 
ADHD is a psychiatric disorder characterised by dysfunctional levels of inattention and/or 
impulsive/hyperactive behaviour.  It is defined in the fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV), the American Psychiatric Association’s 
catalogue of mental illness.22   DSM-IV was first published in 1994 and revised in 2000 however, 
there were no changes to the diagnostic criteria for ADHD in the revision. Earlier editions of the 
Diagnostic and Statistical Manual of Mental Disorders had included ADHD’s predecessors, 
Attention Deficit Disorder (DSM-III 1980) and Hyperactive Disorder of Children (DSM-II 1968). 
Although it is the most commonly diagnosed and medicated childhood psychiatric disorder in 
the world, there is a range of professional opinions as to the validity of ADHD as a psychiatric 
disorder.  Proponents believe ADHD is a common genetically determined neurobiological 
disorder - that is, a ‘biochemical brain imbalance’- which is under-diagnosed and under-
medicated.  Leading international ADHD proponent US psychologist Dr Russell Barkley23 
describes the disorder as ‘a developmental failure in brain circuitry that underlies inhibition and 
                                               
22  American Psychiatric Association , Diagnostic and Statistical Manual of Mental Disorders, 4th edn. 
23  Dr Russell Barkley is a Research Professor in the Department of Psychiatry at the State University of New 
York Upstate Medical University and author of numerous works on ADHD. 
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self-control.  This loss of self-control in turn impairs other important brain functions crucial for 
maintaining attention.’24  At the other end of the spectrum some ADHD critics argue ADHD is a 
fraudulent construct.25  A third, middle view, is that ADHD is a rare but real condition that is 
frequently misdiagnosed and over-prescribed.  
Much of the controversy stems from the fact that the diagnosis of ADHD is based on 
observations of behaviour, as ‘there are no laboratory tests, neurobiological assessments, or 
attentional assessments that have been established as diagnostic in the clinical assessment of 
Attention Deficit/Hyperactivity Disorder’.26  These behaviours include making careless mistakes, 
not seeming to listen, not following through on instructions, disliking homework, losing things, 
being forgetful in daily activities, fidgeting, climbing excessively, having difficulty playing quietly, 
talking excessively and interrupting.27  Box 1 contains the full DSM-IV ADHD diagnostic criteria. 
 
Box 1 - Extract from DSM-IV: ADHD Diagnostic Criteria 
 
A. Diagnostic Criteria for Attention Deficit/Hyperactivity Disorder: 
Either (1) or (2): 
 
1. six (or more) of the following symptoms of inattention have persisted for at least 6 months 




a. often fails to give close attention to details or makes careless mistakes in schoolwork, work, or 
other activities 
b. often has difficulty sustaining attention in tasks or play activities 
c. often does not seem to listen when spoken to directly 
d. often does not follow through on instructions and fails to finish schoolwork, chores, or duties 
in the workplace  
(not due to oppositional behavior or failure to understand instructions) 
e. often has difficulty organizing tasks and activities 
f. often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort 
(such as schoolwork or homework) 
g. often loses things necessary for tasks or activities (e.g., toys, school assignments, pencils, 
books, or tools) 
                                               
24  Dr Russel Barkley quoted in Alistair Smith (2004), The Brains Behind It: New Knowledge about the Brain 




25  Baughman and Hovey, The ADHD Fraud. 
26  American Psychiatric Association,  Diagnostic and Statistical Manual of Mental Disorders, 4th edn, pp.88-89. 




h. is often easily distracted by extraneous stimuli 
i. is often forgetful in daily activities 
 
2. six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at least 6 




a. often fidgets with hands or feet or squirms in seat 
b. often leaves seat in classroom or in other situations in which remaining seated is expected 
c. often runs about or climbs excessively in situations in which it is inappropriate (in adolescents 
or adults, may be limited to subjective feelings of restlessness) 
d. often has difficulty playing or engaging in leisure activities quietly 
e. is often “on the go” or often acts as if “driven by a motor” 




g. often blurts out answers before questions have been completed 
h. often has difficulty awaiting turn 
i. often interrupts or intrudes on others (e.g., butts into conversations or games) 
 
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present 
before age 7 years. 
 
C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or 
work] and at home). 
 
D. There must be clear evidence of clinically significant impairment in social, academic, or 
occupational functioning. 
 
E. The symptoms do not occur exclusively during the course of a Pervasive Developmental 
Disorder, Schizophrenia, or other Psychotic Disorder and are not better accounted for by another 
mental disorder (e.g., Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a Personality 
Disorder). 
 
   
ADHD critics contend these are all normal behaviours, particularly for children and especially 
boys.  ADHD proponents counter this assertion by arguing that all psychiatric disorders - many 
of which are also treated with medication - are diagnosed using behavioural criteria.  However, 
ADHD critics contend that at least conditions like schizophrenia involve extreme behaviours 
such as delusions or catatonia.  In response, proponents acknowledge that while many people 
without ADHD are occasionally impulsive and/or hyperactive, what distinguishes ADHD 
sufferers from the rest of the population is their level of behavioural impairment or dysfunction.  
Specifically, ‘there must be clear evidence of clinically significant impairment in social, academic 
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or occupational functioning’ and ‘some impairment from the symptoms…[must be] present in 
two or more settings (e.g. at school or work and at home)’.28  All eighteen behavioural criteria 
include the word often.  How ‘often’ a child ‘fidgets or squirms in their seat’, or ‘interrupts’ or 
‘avoids homework’ or ‘fails to remain seated when remaining seated is expected’ or ‘is 
distracted by external stimuli’ etc. so that they exhibit ‘some impairment’, is not defined in 
DSM-IV.  The DSM-IV diagnostic criteria do not specify age-appropriate levels of attention or 
impulsivity control.  The same eighteen behavioural diagnostic criteria are applied whether the 
child is two or seventeen. 
The diagnosing clinician does not have to observe any of the symptoms or any impairment.  He 
or she may base their diagnosis on third-party accounts of a child’s behaviour.  The child’s 
parents and teachers usually provide these and are typically asked to fill in a questionnaire 
detailing if their child always, often, sometimes or never displays behaviour like avoiding 
homework and chores, losing toys, not listening, fidgeting, butting in, talking excessively or 
being easily distracted or forgetful. The most commonly used questionnaire is the Connors 
rating scale which basically formats the 18 diagnostic ADHD criteria in a tickbox questionnaire 
format. 
‘There are three Connors rating scales. One is designed for parents, another is for 
teachers, and a third Connors test asks adolescents to rate their own behavior. 
Completing an ADHD Connors test takes from 5 to 30 minutes, depending on whether 
you’re given the short or long version of the test. Long versions of the Connors ratings 
scales have about 60 to 90 questions, while short versions have less than 30 questions’29   
DSM-IV states: ‘Signs of the disorder may be minimal or absent when the person is receiving 
frequent rewards for appropriate behaviour, is under close supervision, is in a novel setting, is 
engaged in especially interesting activities, or is in a one-to-one situation (e.g., the clinician’s 
office.)’30  Therefore, according to the American Psychiatric Association’s DSM-IV and other 
proponents, children with ADHD may behave appropriately and not display ADHD symptoms 
when they are rewarded, when people pay attention to them (close supervision) and when they 
                                               
28  American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn, pp.92-93. 
29  ‘ADHD Connors Test’, The ADD/ADHD Support Site.  Available at http://www.attentiondeficit-add-
adhd.com/adhd-connors-test.htm (accessed 7 May 2013).  
30  American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn, pp.86-87. 
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are having new experiences.  Conversely, children with ADHD may be inattentive, easily 
distracted and display ADHD symptoms when their good behaviour goes unrewarded, no one 
pays any attention to them, or they are bored.  
Critics contend that the diagnostic process is unreliable, subjective and unscientific.  They 
argue that this results in normal childhood behaviours being pathologised as the symptoms 
of disease and that on occasions labelling a child with ADHD hampers the identification of 
real disease and/or abuse or other problems.  ADHD critic, prominent social and political 
historian Francis Fukuyama, considers part of the reason for the explosion in ADHD 
diagnosis rates is that modern time-poor societies are impatient with difference: 
ADHD isn’t a disease at all but rather just the tail of the bell curve 
describing the distribution of perfectly normal behaviour.  Young human 
beings, and particularly young boys, were not designed by evolution to sit 
around at a desk for hours at a time paying attention to a teacher, but 
rather to run and play and do other physically active things.  The fact that 
we increasingly demand they sit still in classrooms, or that parents and 
teachers have less time to spend with them on interesting tasks, is what 
creates the impression that there is a growing disease.31  
The diagnostic criteria for ADHD are defined in terms most applicable to children and require 
‘some hyperactive-impulsive or inattentive symptoms that caused impairment were present 
before age 7 years’.32   In recent years considerable energy has been put into promoting the 
recognition of ‘Adult ADHD’. (Refer to 6.4.2)  However, as children, unlike adults, do not have 
the capacity for informed consent, and there are additional concerns about the effects of ADHD 
drugs on the developing brains and bodies of children, the issue of child ADHD is more 
controversial than adult ADHD. 
Although ADHD diagnostic criteria are set by the APA, it is not only psychiatrists who use them.  
Paediatricians and even in some cases general practitioners diagnose and prescribe for the 
disorder and are frequently involved in research and developing policies in regard to its 
                                               
31  Francis Fukuyama, Professor of International Political Economy at John Hopkins University, cited in  
Baughman and Hovey, The ADHD Fraud, p.17. 
32  American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn, pp.92-93. 
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diagnosis and treatment. 
2.1.2 The safety and efficacy of the pharmaceuticals used to treat ADHD 
Although the behavioural basis of the diagnosis is controversial, the use of pharmaceutical 
interventions to treat the disorder is the primary source of controversy. 
While many ADHD proponents acknowledge the aetiology of ADHD is uncertain they act on the 
assumption that ADHD is a neurobiological disorder caused by a biochemical brain imbalance.  
The assumption of a biochemical imbalance invites a biochemical, i.e. pharmaceutical, 
treatment.  The most commonly used drugs to treat ADHD are the amphetamine-based 
psychostimulants dexamphetamine (current brand names Adderall, Dexedrine, Dexostrat) and 
methylphenidate (Ritalin, Concerta, Attenta).33  Another ADHD drug, Strattera, the brand name 
for atomoxetine hydrochloride, is not amphetamine-based and was prescribed to 
approximately 8.7 percent (7,054) of the 80,647 Australians who received PBS subsidised ADHD 
medications in 2011.34 
2.1.2.1 ADHD Stimulants 
Proponents of ADHD medications argue that 'stimulants like dexamphetamine and 
methylphenidate (such as Ritalin) work by acting on the neurotransmitters that release the 
chemical dopamine.  Greater amounts of dopamine help to curb the hyperactive and impulsive 
behaviours typical of the child with ADHD.'35  They contend that the temporary sharpening 
(narrowing) of focus resulting from the use of stimulants makes children more available for 
learning, enabling them to achieve better academic results in the long run.36 
                                               
33  Other less commonly used brand names for methylphenidate include Methylin,  Daytrana,  Rubifen,  Equasym 
and Metadate. 
34  Note: Some patients (3,320 in 2011) receive Pharmaceutical Benefits Scheme sponsored prescriptions for a 
combination of ADHD drugs. While 7,054 Australians received PBS subsidised Strattera it is very likely 
that a significant number also received other PBS ADHD drugs as Strattera is only supposed to be 
prescribed as a second line treatment when stimulants prove ineffective or have unacceptable side effects. 
Department of Health and Ageing, Letter to Martin Whitely dated 21 April 2012. 
35  ‘Attention deficit hyperactivity disorder - drug therapy’, Better Health Channel, nd.  Available at 
http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/attention_deficit_hyperactivity_disorder_-
_drug_therapy?open (accessed 28 December, 2011) 
36  Government of Western Australia (2010), Raine ADHD Study: Long-term outcomes associated with stimulant 
medication in the treatment of ADHD in children, Department of Health, Perth, p.30. 
The short term studies referred to in the Raine Study are Howard B. Abikoff, et al. (2007), ‘Methylphenidate 
effects on Functional Outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment 
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Critics counter this contention by arguing that when taken orally in low doses psycho-
stimulants will temporarily sharpen focus in most people regardless of their ADHD status.37  
The stimulant effects are very short, lasting a matter of hours with ‘no evidence that the 
medications promote or cause psychological, social, or emotional growth’ in the long 
term.38  Critics also contend that ‘there is a paucity of evidence on the long-term effects of 
psycho-stimulant medication on children’39 and that the little long term evidence there is 
indicates no lasting benefits, and significant risks from sustained use (see 6.7).  Established 
potential adverse effects of psychostimulants include common and relatively mild short 
term side effects like insomnia and headaches and rare, life threatening side effects such as 
psychosis, strokes and suicide.  These potential side effects are outlined in a comprehensive 
extract from the U.S FDA-approved prescribing information made available to clinicians for 
Dexedrine (a brand of dexamphetamine) provided at Appendix 1.40  It is very similar to the 
US prescribing information for Ritalin (a brand of methylphenidate).41 
2.1.2.2 Atomoxetine (Brand name Strattera) 
Strattera is manufacturer Eli Lilly’s brand name for atomoxetine hydrochloride, a noradrenaline 
reuptake inhibitor.  Unlike dexamphetamine and methylphenidate, Strattera is not 
amphetamine based and is considered to be non-addictive and unsuitable for illicit use.  It was 
first trialled in 1982 as an antidepressant branded Tomoxetine but was found to be ineffective.42  
                                                                                                                                                  
Study (PATS)’, Journal of Child and Adolescent Psychopharmacology, 17(5), pp. 581–92; C. L. Carlson & M. 
R. Bunner (1993), ‘Effects of Methylphenidate on the Academic Performance of Children with Attention-
Deficit Hyperactivity Disorder and Learning Disabilities’, School Psychology Review, 22(2), pp. 184–98; Irene 
M. Loe & Heidi M. Feldman (2007), ‘Academic and educational outcomes of children with ADHD’, Journal 
of Pediatric Psychology, 32(6), pp. 643–54. 
37  Lori Jeanne Peloquin and Rafael Klorman (1986), ‘Effects of Methylphenidate on Normal Children's 
Mood, Event-Related Potentials, and Performance in Memory, Scanning and Vigilance, Journal of 
Abnormal Psychology, Vol. 95, No. 1, pp.88-98.  
38  Lydia Furman (2005), ‘What is Attention-Deficit Hyperactivity Disorder (ADHD)?’ Journal of Child 
Neurology, Vol. 20 No. 12, p.998. 
39  Western Australia Legislative Assembly (2004), Attention Deficit Hyperactivity Disorder in Western Australia, 
Education and Health Standing Committee, Report No. 8, p. 42. 
40
  Extract from U.S. Prescribing Information for Dexedrine produced by Glaxo Smith Kline.  Available at 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017078s040lbl.pdf (accessed 21 March 2013)  
41  Extract from U.S. Prescribing Information for Ritalin (methylphenidate hydrochloride) produced by 
Novartis Pharmaceuticals.  Available at 
http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf 
(accessed 31 March 2013) 
42  G. Chouinard, L. Annable, and J. Bradwejn (1984), ‘An early phase II clinical trial of tomoxetine (LY139603) 
in the treatment of newly admitted depressed patients’, Psychopharmacology, 83, p.126. 
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Strattera came onto the Australian market in early 2004. Strattera is only supposed to be 
prescribed as a second line treatment when stimulants prove ineffective or have 
unacceptable side effects.  Despite claims of it being a milder ADHD drug than 
psychostimulants, concerns soon emerged about its safety.  On 17 December 2004 the US 
FDA issued a talk paper, ‘New Warning for Strattera’, which stated: 
The drug’s labeling is being updated with a bolded warning about the 
potential for severe liver injury in patients taking Strattera.  The label warns 
that severe liver injury can progress to liver failure in a small percentage of 
patients.  It cautions clinicians to discontinue the drug in patients who 
develop jaundice or laboratory evidence of liver injury.  It also notes that the 
actual number of cases of severe liver injury from the drug is not known 
because of under-reporting.43 
Less than a year later, on 29 September 2005, the FDA issued a public health advisory 
announcing they had put the highest possible black box warning on Strattera for suicidal 
ideation: 
Strattera increases the risk of suicidal thinking in children and adolescents 
with ADHD.  Patients who are started on therapy should be observed closely 
for clinical worsening, suicidal thinking or behaviours, or unusual changes in 
behaviour.  Families and caregivers should be advised to closely observe the 
patient and to communicate changes or concerning behaviours with the 
prescriber.44 
In March 2006 the Australian Therapeutic Goods Administration (TGA) followed the FDA’s 
lead and issued an equivalent ‘suicidality’ warning.  In November 2011 the TGA added a 
                                               
43  Food and Drug Administration (March 2005), Warning on Liver Injury from Strattera: FDA Patient Safety 
News: Show #37. Available at http://www.accessdata.fda.gov/psn/printer.cfm?id=302 (accessed 18 July 
2007). 
44
  Food and Drug Administration (29 September 2005), Public Health Advisory: Suicidal Thinking in 
Children and Adolescents Being Treated with Strattera (Atomoxetine). Available 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSaf
etyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051733.htm (accessed 13 
September 2009); ‘In review of 2,200 patients, 1, 357 of whom were taking Strattera, researchers found 
that 0.4 per cent of the children taking the drug reported suicidal thinking, compared to no cases in children 
taking a placebo.  There was also one suicide attempt in the Strattera group. ’ Amanda Gardner (2005), 
‘FDA Issues Alert on ADHD Drug Strattera’, Healthday Reporter, 29 September 2005.  
24 
 
warning about ‘clinically significant increases in heart rate and blood pressure’.  The safety 
advisory warns ‘Atomoxetine [Strattera]  is contraindicated in patients with symptomatic 
cardiovascular diseases, moderate to severe hypertension or severe cardiovascular 
disorders, whose condition would be expected to deteriorate if they experienced increases 
in blood pressure or in heart rate that could be clinically important.’45  It followed new data 
obtained from clinical trials sponsored by Eli Lilly.   
An extract of the Prescribing Information for Strattera is contained in Appendix 2. 
2.1.3 ADHD and Drug Abuse 
Proponents contend that the ‘under-recognition’ of ADHD is a cause of illicit drug abuse.  They 
argue that early identification of ADHD and subsequent medication prevents undiagnosed 
individuals using illicit drugs to self-medicate.46  ADHD critics counter that the amphetamine and 
amphetamine-like drugs most commonly used to treat ADHD are often diverted for illicit use or 
abused. 
The effects of ADHD stimulants are similar to illicit amphetamines.  In the US prescription 
methamphetamine (brand name Desoxyn) is used as an ADHD treatment.  
Methamphetamine and cocaine, when taken orally in low doses, have temporary ‘focus 
narrowing’ effects similar to dexamphetamine and Ritalin.  With a therapeutic dose of 
stimulants in their system most people become more narrowly focussed. 47 
Dr Peter Breggin contends; 
The big difference (between ADHD stimulants and cocaine) appears to be 
the time it takes for the drug to reach the brain.  Inhaled or injected cocaine 
hits the brain in seconds, while pills of Ritalin (and other ADHD stimulants) 
normally consumed take about an hour to reach the brain.  Like cocaine, 
                                               
45  Department of Health and Ageing (2011), Therapeutic Goods Administration, ‘Atomoxetine (Strattera)  - 
risk of increased blood pressure and/or heart rate’, 2 November 2011.  Available at 
http://www.tga.gov.au/safety/alerts-medicine-atomoxetine-111102.htm)  (accessed 5 June 2012). 
46  For instance, see Dave Coghill (2005), ‘Attention-deficit hyperactivity disorder: should we believe the mass 
media or peer-reviewed literature?’, The Psychiatrist, 29, pp.288–91;  Dr Ken Whiting (2003), Fact Sheet: 
Attention Deficit/Hyperactivity Disorder 2003 Update, Learning and Attentional Disorders Society of WA, 
Perth. 
47  Peter R. Breggin M.D. (1998), Talking back to Ritalin: What doctors aren’t telling you about stimulants 
for children, Common Courage Press, Monroe, p.73. 
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chronic use of Ritalin produces psychomotor stimulant toxicity, including 
aggression, agitation, disruption of food intake, weight loss, stereotypic 
movements and death.48 
The American Psychiatric Association recognises that amphetamines, methylphenidate and 
cocaine are ‘neuro-pharmacologically alike’.49  DSM-IV recognises the abuse and addiction 
of these drugs in a common class of ‘Amphetamine or Amphetamine-Like – Related 
Disorders’.  It states: ‘Prescribed stimulants have sometimes been diverted into the illegal 
market…Most of the effects of amphetamines and amphetamine-like drugs are similar to 
those of cocaine.’50 Furthermore, the diagnostic criteria for ‘Amphetamine Intoxication’ 
include ‘recent use of amphetamine or a related substance (e.g. methylphenidate)’ and 
many of their potential side effects, including impaired social or occupational functioning, 
tachycardia, elevated blood pressure, nausea or vomiting, weight loss dyskinesia and 
dystonia, are common to both illicit amphetamines and prescribed psychostimulants.51  All 
ADHD stimulants are addictive and carry similar warnings for abuse as the following warning 
in Box 2 for Dexedrine (a brand of dexamphetamine).52 
Box 2 - Extract from Prescribing Information for Dexedrine (a brand of dexamphetamine) 
AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE.  ADMINISTRATION OF AMPHET-
AMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST 
BE AVOIDED.  PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS 
OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, 
AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY.  MISUSE OF 
AMPHETAMINES MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIO-VASCULAR ADVERSE 
EVENTS. 
 
The potential for illicit diversion is recognised in laws enacted by all Australian states and 
territories which make it illegal to possess, sell or use them without a prescription.  In WA for 
                                               
48  Breggin, Talking back to Ritalin, p.73. 
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example anyone found in possession of, or using, dexamphetamine or methylphenidate without 
a prescription may be fined up to $2000 and/or receive a prison term of up to two years.  
Anyone convicted of selling or intent to sell dexamphetamine or methylphenidate illegally may 
receive a fine of up to $100,000 and/or a prison term of up to twenty-five years.53  
Nonetheless, ADHD proponents contend that in the absence of controlled doses of prescription 
stimulants, adolescents and adults with ADHD will seek and take illicit drugs in uncontrolled 
doses.  There is also considerable support amongst ADHD proponents for the use of prescription 
stimulants as a substitution therapy for those addicted to illicitly obtained amphetamines.54       
2.2 Pharmaceuticalization 
Abraham coined the term ‘pharmaceuticalization’ to describe the process by which ‘social, 
behavioral, or bodily conditions are treated, or deemed to be in need of 
treatment/intervention, with pharmaceuticals by doctors, patients, or both.’55  
Pharmaceuticalization is a statistical reality for ADHD in Australia as prescribing rates have 
grown enormously during the period analysed in this thesis. 
Abraham contends that pharmaceuticalization is frequently an inappropriate result of 
‘making the social medical’.  However he believes that ‘not all pharmaceuticalization 
involves making the social medical.’  He cites the treatment of bacterial infections, 
previously without effective drug remedies, with new antibiotics as an example of 
pharmaceuticalization that benefits consumers.56  In similar cases of genuine technological 
advancement he acknowledges that ‘pharmaceuticalization’ is in the public interest.  
ADHD prescribing in Australia is just one example, of many, of pharmaceuticalization.  The 
disputed questions around ADHD pharmaceuticalization are not if it is occurring, but rather 
why it is happening and is it appropriate?  
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2.2.1 Competing Explanations for ADHD Pharmaceuticalization 
Abraham has identified two competing explanations for the process of 
pharmaceuticalization: ‘biomedicalism’ which endorses pharmaceuticalization, and 
‘medicalization’ which criticises it.  He contends that the validity of the two explanations 
depends upon the condition or disorder being ‘treated’.  ADHD proponents typically 
subscribe to a biomedicalized explanation that encourages increased treatment with 
‘medications’.  In contrast ADHD critics typically subscribe to a medicalization explanation of 
ADHD that either opposes any use of ADHD medication or seeks to reduce the number of 
children prescribed ADHD drugs. 
2.2.1.1 The Biomedicalized Viewpoint of ADHD Proponents 
Abraham defines those who ‘assert or give the impression that the expansion of 
pharmaceutical markets and prescribing over the last few decades is best understood as the 
innovative responses of biomedical science to growing and new health needs’ as subscribing 
to the ‘biomedicalization thesis’. 57  Many, including WA Professor of Psychology David Hay, 
argue that ADHD pharmaceuticalization has not gone far enough.  Hay contends ADHD is an 
under-diagnosed, under-medicated, inherited, biochemical imbalance in the brain that is 
best treated with safe, effective medication.58   
Proponents of ADHD contend it is a legitimate medical neurobiological condition treatable 
with safe effective medications.  Abraham refers to this approach to ADHD as an example of 
the ‘biomedicalism thesis’ and identifies it as being in direct opposition to the 
‘medicalization thesis’ of ADHD that he expressly supports.59  
Some ADHD proponents acknowledge the proposal that it is caused by a biochemical brain 
imbalance as a hypothesis or theory.  For example in DSM-5 the American Psychiatric 
Association classifies ADHD as a neurodevelopment disorder, whilst as was the case with 
DSM-IV, acknowledging the aetiology is uncertain.60 61  Many other ADHD proponents are 
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less restrained and treat this theory as fact by declaring ADHD a ‘genetic, neurobiological 
disorder’ or a ‘biochemical brain imbalance.’62  
The major developments in successive editions of the DSM definition of ADHD and in the 
professional understanding of ADHD have been the result of medico-political processes such 
as committee consensus or votes rather than scientific discovery.  For example, in 2002, a 
self-described ‘independent consortium’ of eighty-four ‘leading scientists’ signed the 
‘International Consensus Statement on ADHD’ contained in box 3 below. 63  The first 
signatory was prominent ADHD proponent, American psychologist Dr Russell Barkley. 
 
Box 3 - International Consensus Statement on ADHD 
Clinical Child and Family Psychology Review, Vol. 5, No. 2, June 2002 ( C ° 2002) 
January 2002 
 
We, the undersigned consortium of international scientists, are deeply concerned about the periodic 
inaccurate portrayal of attention deficit hyperactivity disorder (ADHD) in media reports. This is a 
disorder with which we are all very familiar and toward which many of us have dedicated scientific 
studies if not entire careers. We fear that inaccurate stories rendering ADHD as myth, fraud, or 
benign condition may cause thousands of sufferers not to seek treatment for their disorder. It also 
leaves the public with a general sense that this disorder is not valid or real or consists of a rather 
trivial affliction. 
We have created this consensus statement on ADHD as a reference on the status of the scientific 
findings concerning this disorder, its validity, and its adverse impact on the lives of those diagnosed 
with the disorder as of this writing (January 2002).  Occasional coverage of the disorder casts the 
story in the form of a sporting event with evenly matched competitors. The views of a handful of 
non-expert doctors that ADHD does not exist are contrasted against mainstream scientific views that 
it does, as if both views had equal merit. Such attempts at balance give the public the impression 
that there is substantial scientific disagreement over whether ADHD is a real medical condition.  
In fact, there is no such disagreement—at least no more so than there is over whether smoking 
causes cancer, for example, or whether a virus causes HIV/AIDS. The U.S. Surgeon General, the 
American Medical Association, the American Psychiatric Association, the American Academy of Child 
and Adolescent Psychiatry, the American Psychological Association, and the American Academy of 
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Pediatrics, among others, all recognize ADHD as a valid disorder. Although some of these 
organizations have issued guidelines for evaluation and management of the disorder for their 
membership, this is the first consensus statement issued by an independent consortium of leading 
scientists concerning the status of the disorder.  
Among scientists who have devoted years, if not entire careers, to the study of this disorder there is 
no controversy regarding its existence. 
ADHD and Science 
We cannot overemphasize the point that, as a matter of science, the notion that ADHD does not 
exist is simply wrong. All of the major medical associations and government health agencies 
recognize ADHD as a genuine disorder because the scientific evidence indicating it is so 
overwhelming. 
Various approaches have been used to establish whether a condition rises to the level of a valid 
medical or psychiatric disorder. A very useful one stipulates that there must be scientifically 
established evidence that those suffering the condition have a serious deficiency in or failure of a 
physical or psychological mechanism that is universal to humans. That is, all humans normally would 
be expected, regardless of culture, to have developed that mental ability. 
And there must be equally incontrovertible scientific evidence that this serious deficiency leads to 
harm to the individual. Harm is established through evidence of increased mortality, morbidity, or 
impairment in the major life activities required of one’s developmental stage in life. Major life 
activities are those domains of functioning such as education, social relationships, family functioning, 
independence and self-sufficiency, and occupational functioning that all humans of that 
developmental level are expected to perform. 
As attested to by the numerous scientists signing this document, there is no question among the 
world’s leading clinical researchers that ADHD involves a serious deficiency in a set of psychological 
abilities and that these deficiencies pose serious harm to most individuals possessing the disorder. 
Current evidence indicates that deficits in behavioral inhibition and sustained attention are central 
to this disorder—facts demonstrated through hundreds of scientific studies. And there is no doubt 
that ADHD leads to impairments in major life activities, including social relations, education, family 
functioning, occupational functioning, self-sufficiency, and adherence to social rules, norms, and 
laws. Evidence also indicates that those with ADHD are more prone to physical injury and accidental 
poisonings. This is why no professional medical, psychological, or scientific organization doubts the 
existence of ADHD as a legitimate disorder. 
The central psychological deficits in those with ADHD have now been linked through numerous 
studies using various scientific methods to several specific brain regions (the frontal lobe, its 
connections to the basal ganglia, and their relationship to the central aspects of the cerebellum). 
Most neurological studies find that as a group those with ADHD have less brain electrical activity and 
show less reactivity to stimulation in one or more of these regions.  And neuro-imaging studies of 
groups of those with ADHD also demonstrate relatively smaller areas of brain matter and less 
metabolic activity of this brain matter than is the case in control groups used in these studies. 
These same psychological deficits in inhibition and attention have been found in numerous studies 
of identical and fraternal twins conducted across various countries (US, Great Britain, Norway, 
Australia etc.) to be primarily inherited. The genetic contribution to these traits is routinely found to 
be among the highest for any psychiatric disorder (70–95% of trait variation in the population), 
nearly approaching the genetic contribution to human height. One gene has recently been reliably 
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demonstrated to be associated with this disorder and the search for more is underway by more than 
12 different scientific teams worldwide at this time.  
Numerous studies of twins demonstrate that family environment makes no significant separate 
contribution to these traits. This is not to say that the home environment, parental management 
abilities, stressful life events, or deviant peer relationships are unimportant or have no influence on 
individuals having this disorder, as they certainly do. Genetic tendencies are expressed in interaction 
with the environment.  
Also, those having ADHD often have other associated disorders and problems, some of which are 
clearly related to their social environments. But it is to say that the underlying psychological deficits 
that comprise ADHD itself are not solely or primarily the result of these environmental factors. 
This is why leading international scientists, such as the signers below, recognize the mounting 
evidence of neurological and genetic contributions to this disorder. This evidence, coupled with 
countless studies on the harm posed by the disorder and hundreds of studies on the effectiveness of 
medication, buttresses the need in many, though by no means all, cases for management of the 
disorder with multiple therapies. These include medication combined with educational, family, and 
other social accommodations. 
This is in striking contrast to the wholly unscientific views of some social critics in periodic media 
accounts that ADHD constitutes a fraud, that medicating those afflicted is questionable if not 
reprehensible, and that any behavior problems associated with ADHD are merely the result of 
problems in the home, excessive viewing of TV or playing of video games, diet, lack of love and 
attention, or teacher/school intolerance. 
ADHD is not a benign disorder. For those it afflicts, ADHD can cause devastating problems. Follow-up 
studies of clinical samples suggest that sufferers are far more likely than normal people to drop out 
of school (32–40%), to rarely complete college (5–10%), to have few or no friends (50–70%), to 
underperform at work (70–80%), to engage in antisocial activities (40–50%), and to use tobacco or 
illicit drugs more than normal. Moreover, children growing up with ADHD are more likely to 
experience teen pregnancy (40%) and sexually transmitted diseases (16%), to speed excessively and 
have multiple car accidents, to experience depression (20–30%) and personality disorders (18–25%) 
as adults, and in hundreds of other ways mismanage and endanger their lives. 
Yet despite these serious consequences, studies indicate that less than half of those with the 
disorder are receiving treatment. The media can help substantially to improve these circumstances. 
It can do so by portraying ADHD and the science about it as accurately and responsibly as possible 
while not purveying the propaganda of some social critics and fringe doctors whose political agenda 
would have you and the public believe there is no real disorder here. 
To publish stories that ADHD is a fictitious disorder or merely a conflict between today’s Huckleberry 
Finns and their caregivers is tantamount to declaring the earth flat, the laws of gravity debatable, 
and the periodic table in chemistry a fraud. ADHD should be depicted in the media as realistically 
and accurately as it is depicted in science—as a valid disorder having varied and substantial adverse 
impact on those who may suffer from it through no fault of their own or their parents and teachers. 
 
As evidenced in the consensus statements ADHD proponents consider it is a valid psychiatric 
disorder because ‘those suffering the condition have a serious deficiency [that] leads to harm to 
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the individual’. This includes harm ‘in the major life activities…such as education, social 
relationships, family functioning, independence and self-sufficiency, and occupational 
functioning’.  Critics respond that ADHD is a collection of loosely defined mildly dysfunctional 
behavioural symptoms, which is mistakenly regarded as the biological cause. They contend 
diagnosing ADHD involves identifying dysfunction in what is already identified as a dysfunctional 
population. Psychologist and Professor Emeritus at California State University, David Keirsey, 
criticises the circularity of the argument stating, ‘It’s preposterous to say that the symptoms of 
attention deficit cause the deficit of attention.’64 
The claim in the consensus statement that the signatories were an ‘independent consortium’ is 
contested by ADHD critics on a number of grounds.  First, there is the obvious personal 
motivation in validating the authenticity of a controversial disorder for those ‘who have devoted 
years, if not entire careers’ to its study.  In addition, many of the consortium of ‘leading 
scientists’ earn their incomes either through diagnosing and prescribing for ADHD or conducting 
drug-company funded research into the ‘disorder’. 
In the International Consensus Statement the legitimacy of ADHD is stated as an indisputable 
truth.  Critics are dismissed as 'flat earthers' with the level of certainty around ADHD deemed to 
be equivalent to that supporting, 'the laws of gravity' and the 'periodic table'.   The ADHD critic 
view that ‘behavior problems associated with ADHD’ result from a variety of causes including 
‘diet’ is dismissed as ‘wholly unscientific’.  However, there is significant evidence that diet can 
contribute to inattentive and hyperactive behaviour in children.65 66 
British psychiatrist and ADHD critic Sami Timimi believes the Consensus Statement was a 
response to the authors being ‘shaken by criticism’ of ADHD diagnosing and prescribing.67  
Timimi is highly critical of the Consensus Statement and sees it as an attempt to shut down 
debate: 
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Not only is it completely counter to the spirit and practice of science to cease 
questioning the validity of ADHD as proposed by the consensus statement, there is an 
ethical and moral responsibility to do so.  It is regrettable that they wish to close down 
debate prematurely and in a way not becoming of academics.  The evidence shows 
that the debate is far from over.68  
According to Timimi, the authors of the Consensus Statement ‘are well-known advocates of 
drug treatment for children with ADHD’ who in the statement did ‘not declare their financial 
interests and/or their links with pharmaceutical companies.’69  Despite Timimi’s concerns 
and the obvious false circularity of quoting consensus as evidence the International 
Consensus Statement is sometimes cited as evidence of the validity of ADHD diagnosis and 
treatment.  One example is in the 2007 Clinical Excellence Commission Prescribing Review of 
ADHD in Children and Adolescents in New South Wales commissioned by the New South 
Wales Government (outlined at 6.2). 
Consensus amongst ADHD medication advocates has also driven significant Australian ADHD 
policy processes.  The Australian Draft Guidelines on ADHD document was completed in 
2009 by a committee, the majority of whom had commercial connections to ADHD drug 
manufacturers. Two thirds of the 203 draft recommendations of the guidelines committee 
were made without any supporting scientific evidence.  They were based entirely on 
reference group consensus and justified as ‘best practice based on clinical experience and 
expert opinion’.  In particular, key recommendations in the draft guidelines promoting the 
widespread use of a range of psychotropic drugs were based upon the consensus opinion of 
the guidelines committee. (Refer to 5.3.2 for full details) 
Other claims in the consensus statement about differences in brain structure and activity and 
genetic differences in ADHD patients are contested by critics and are discussed in greater detail 
below.   
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2.2.1.2 The ‘Medicalization’ perspective of ADHD critics 
The term ‘medical model’ was described by Scottish psychiatrist R. D. Laing in 1971 as a ‘set 
of procedures in which all doctors are trained’.70  Laing described the process of the medical 
model as a sequential process whereby doctors:  
1. are told of a problem and complaint;  
2. determine the patient’s history; 
3. conduct  a physical examination and if required ancillary tests;  
4. then diagnose and  treat; 
5. and describe the patient’s prognosis with and without treatment. 
According to Laing the medical model aims ‘to find medical treatments for diagnosed 
symptoms and syndromes and treats the human body as a very complex mechanism.’71  
Laing was critical of the application of the medical model to psychiatry, arguing that 
‘because the diagnosis of a mental illness was based on conduct or patient behavior and not 
on physical pathology, such a "diagnosis" essentially contravened standard medical 
procedure and hence the medical model.’72  Although he is associated with the anti-
psychiatry movement, Laing practiced as a psychiatrist and accepted the existence of mental 
illness.  Laing contended that mental illness is most often transitory and often not a 
damaging experience and its pattern of onset and recovery is very different from the 
pathway of physical illness.   
The term ‘medicalization’ is often used by critics of aspects of psychiatric practice (including 
ADHD critics) as a shorthand description for the incomplete and therefore inappropriate 
application of the ‘medical model’.  Incomplete because, as Laing described, in the absence 
of the third step - objective scientific evidence from a physical examination, blood test, 
brain scan for example -  flimsy evidence is inappropriately regarded as sufficient proof of a 
medical/biological condition. 
Abraham described those (himself included) who are critical of medicalization as a means of 
achieving social control and compliance as adherents to the ‘medicalization thesis’.  The 
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medicalization thesis asserts ‘that the growth in medical conditions partly reflects medical 
dominance in society and the significance of the “sick role” in redefining social deviance or 
dysfunctionality’.73  ADHD critics typically regard the increasing reliance on medications to 
treat ADHD - the pharmaceuticalization of ADHD - as an inappropriate medicalization of 
childhood behaviours. 
Abraham contends that until recently medicalization theorists ‘focused primarily on 
interactions between the medical professions, patients, and health-care organizations’.  He 
argues medicalization theorists had largely ‘overlooked the influence of the pharmaceutical 
industry, the drug regulatory state, or patients as organized interests.’74  In his view the 
pharmaceutical industry and allied interests have been central drivers in the growth of a 
number of psychiatric disorders, including ADHD and depression, and other disorders like 
erectile dysfunction.  Furthermore he believes that, along with patient support groups, key 
opinion leaders, usually academics or high profile medical experts, are key to the process of 
pharmaceuticalization: 
Subtle aspects of drug promotion include the integration of senior members 
of the medical profession and medical science into pharmaceutical 
marketing strategies by first paying them through grants or consultancies to 
be involved in the development of company products and then funding 
them to act as “opinion leaders” who speak favorably about the drug at 
various symposia attended by doctors.75 
Although Abraham acknowledges that in some cases pharmaceuticalization  may be the 
result of scientific advancement and improvement in patient care, he argues that most 
often the massive rapid worldwide increases in pharmaceutical markets is primarily a 
product of economic and sociological factors:  
The biomedicalism thesis, popular among many scientists and media 
discourses, that growing pharmaceuticalization simply reflects discoveries in 
biomedical science that correspond to health needs, is not plausible.  Some 
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pharmaceuticalization may fall into this category, but there is no good 
reason to support the thesis that most of it can be explained in this way.  
Indeed, there is evidence to suggest that, while pharmaceuticalization has 
increased the number of medications needed by patients and public health 
is actually decreasing, along with pharmaceutical innovation.  Growing 
pharmaceuticalization seems to be best explained by sociological factors 
such as the political economy of the pharmaceutical industry and associated 
medicalisation (especially promotion and advertising activities involving 
physicians and clinicians), deregulatory ideology toward drug development 
and innovation, and access-oriented collaborative consumerism, which 
outweighs the countervailing effects of adversarial consumerism. 76 
As evidence of the primacy of medicalization rather than biomedicalism as an explanation for 
pharmaceuticalization, Abraham argues that pharmaceutical advertising and promotion 
expenditures are ‘growing at a much faster rate than are pharmaceutical research and 
development (R&D) in most Western industrialized countries…if the major drivers of 
pharmaceuticalization were scientific discoveries that meet new medical needs, rather than 
socioeconomic forces, then one would expect clearer evidence of growth in R&D relative to 
marketing activities.’77 
This appears to be a relatively weak, derivative argument as it measures the cost of inputs into 
research as compared to marketing.  Other industries also have similar pattern of relative 
expenditure on research and marketing. For example the mobile phone industry expends huge 
sums on marketing yet it has experienced rapid improvements in technology, function and price 
which in part at least accounts for the massive increase in sales volumes. 
Stronger evidence of inappropriate pharmaceuticalization would come from evidence of 
commercial and professional conflicts of interests, or from evidence of poor quality research 
resulting in pharmaceuticalized policy outcomes.  This thesis concentrates on identifying the 
prevalence of such occurrences, rather than comparing relative expenditure on marketing and 
research.  
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In 2010 Abraham wrote that ‘over the last forty years, the diagnostic criteria for ADHD have 
been consistently widened, making it virtually impossible to disentangle increased 
identification of ADHD sufferers from increased medicalization, and leading to concern that 
the threshold between normal behavior and ADHD has been set too low.’ 78  He cited two 
studies.  One ‘estimated that the official diagnostic criteria for ADHD apply to almost 20 
percent of school-age children in the United States.’79  The second, ‘a large-scale 
epidemiological study found that nearly 50 percent of U.S. children satisfied the symptom-
criteria for official ADHD diagnosis’.80  Abraham concluded that ‘fundamentally, the 
diagnostic criteria are problematic because of their overlap with normal experience or other 
psychiatric diagnoses’.81   
Abraham also contends that marketing a disorder, in this case ADHD, to create a need for 
the pharmaceutical is a common international experience: ‘Disease-awareness campaigns, 
involving an alliance between pharmaceutical manufacturers and the medical 
establishment, are vital to the process of pharmaceuticalization.’  He cites examples of 
‘industry-sponsored disease-awareness campaigns aimed at doctors’ prior to ADHD that 
‘have exaggerated the benefits and neglected serious adverse effects of tranquilizers in the 
1970s and 1980s, and of antidepressants since the early 1990s.’82  Abraham specifically 
identifies ADHD diagnosis and prescribing as a product of a ‘pharmaceuticalization-
medicalization complex’ and rejects the hypothesis that it is legitimately explained via the 
biomedicalization model.  He dismisses the claim that ADHD is ‘an organic brain dysfunction 
- either due to reduced metabolism and inhibition in regions of the brain associated with 
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attention and motor activity’ as an unjustified application of the biomedical model.  
Abraham cites a number of technical limitations in the evidence supporting this claim.83 
American neurologist and author of The ADHD Fraud, Fred Baughman is scathing in his criticisms 
of the Diagnostic and Statistical Manual approach to diagnosing all psychiatric disorders, 
including ADHD.  He condemns the psychiatric diagnostic process as contrary to the process of 
defining and diagnosing legitimate disease: 
Normally, as a condition is studied and more is learned about it, the diagnostic signs 
(signs = objective abnormalities) are narrowed down to a specific set of objective 
criteria that can be reliably applied. With ADHD the opposite happened.84  
Other ADHD critics, including Queensland psychologist Dr Bob Jacobs, are less concerned about 
the inability to objectively identify abnormalities or difference but are more concerned with the 
medicalization of difference: 
Even if researchers found a consistent difference between children who act a certain 
way (‘ADHD’) and children who don’t, and even if they could somehow prove that the 
difference caused the behaviours, there is no reason to believe there is any ‘disorder’.  
There may be physiological differences between people who are right-handed and 
left-handed, or people who prefer the colour red over the colour blue.  But it doesn’t 
make either group ‘sick’.  We know that people have individual physical differences, 
but it is dangerous ground to say that those differences are a ‘disorder’, just because 
they are in the minority, or because they cause problems with fitting into society’s 
rigid structures (like school).85  
Despite Jacobs’ contention that difference does not constitute disease, much of the 
scientific argument about ADHD has been on the grounds contested by Baughman- that is, 
debating the existence of neurological and/or genetic difference between ADHD children 
and ‘normal’ children.  ADHD proponents have sought to prove the validity of ADHD by 
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establishing the existence of such differences.  Critics contend the many claims of new 
research purporting to prove this difference however, have been shown to be false. 
The ‘Holy Grail’ for many proponents of ADHD is establishing its ‘genetic basis’, the logic 
being that this would validate it as a psychiatric disorder.  In September 2010 British 
researchers claimed to have proven the genetic basis of ADHD.86  A psychiatrist who was a 
co-author of the study, Cardiff University Professor Anita Thapar, proclaimed ‘now we can 
say with confidence that ADHD is a genetic disease.’87 
The study that Professor Thapar claimed established that ADHD is a ‘genetic disease’ 
involved the comparison of the genetic codes of 366 children ‘with ADHD’ with that of 1047 
‘non-ADHD’ control children.  Researchers found 13.9 percent (51) of children with ADHD 
had short lengths of their genetic code that were either duplicated or missing.  This 
compared with 7.4 percent (78) of the ‘control children’.88  The average recorded IQ of the 
366 children ‘with ADHD’ was 86, fourteen points below the general population average of 
100.  Whilst the IQ of the 1047 ‘non ADHD children’ was not specified, presumably they 
were as intelligent as the general population (average IQ of 100).  Furthermore when 33 
intellectually impaired ‘ADHD children’ (IQ lower than 70) were excluded from the ADHD 
cohort only 11 percent of the remaining 333 had the hypothesised ADHD genetic 
abnormality.89  Even with the intellectually impaired children removed the average IQ (89) 
of the 333 remaining in the ADHD group was significantly lower than the human average of 
100.90  This evidence is more suggestive of a relationship between the identified genetic 
                                               
86  Examples include Kate Kelland (2010), ‘Study finds first evidence that ADHD is genetic’, Reuters, 30 
September 2010.  Available at http://www.reuters.com/article/2010/09/30/us-adhd-genes-
idUSTRE68S5UD20100930 (accessed 22 November 2012);  Elizabeth Landau (2010), ‘ADHD is a 
genetic condition, study says’, CNN Health, 29 September 2010.  Available at 
http://thechart.blogs.cnn.com/2010/09/29/adhd-is-a-genetic-condition-study-says/ (accessed 14 November 
2012); ‘Study finds genetic link to ADHD’, ABC Online News, 30 September 2010.  Available at 
http://www.abc.net.au/news/2010-09-30/study-finds-genetic-link-to-adhd/2280292 (accessed 22 November 
2012) 
87  ‘Study finds genetic link to ADHD’, ABC Online News, 30 September 2010.  Available at 
http://www.abc.net.au/news/2010-09-30/study-finds-genetic-link-to-adhd/2280292 
88
  Williams, Dr N.M. & Thapar, Prof. A., et al (2010), ‘Rare chromosomal deletions and duplications in 
attention-deficit hyperactivity disorder: a genome-wide analysis’, The Lancet, Vol. 376:9750, pp.1401-
1408.  Available at http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961109-
9/abstract (accessed 24 October 2012). 
89  Williams, et al, ‘Rare chromosomal deletions’. 
90  Note: Whilst there is considerable anecdotal evidence of bright but under-stimulated and bored children 
being diagnosed with ADHD it could be for the geographical population of this study (at least) that having 
a low IQ increases a child’s chances of being diagnosed with ADHD. 
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abnormality and intellectual disadvantage than it is of ADHD.  Nonetheless the claims of 
proof of ADHD’s genetic basis were reported internationally in mainstream media with little 
critical analysis.91 
ADHD is a collection of behaviours, with children diagnosed being on average less attentive 
and/or more impulsive/hyperactive than their peers.  Finding a genetic basis for ADHD 
would therefore mean finding a genetic basis for inattentive and/or impulsive/hyperactive 
behaviour.  It is entirely reasonable to think behaviour is a combination of nature and 
nurture.  However, as Jacobs concluded, conceding that ADHD may be in part a ‘genetic 
difference’ is vastly different from accepting it is a ’genetic disease’.   
US psychiatrist and ADHD critic Peter Breggin argues that many of the studies that claim to 
show differences in ‘ADHD brains’ are similarly flawed.  He claims these studies compared 
brains that had never been medicated with brains that had been exposed to psycho-
stimulants.  Psycho-stimulants, Breggin contends, ‘routinely cause gross malfunctions in the 
brain of the child’ and ‘can cause shrinkage (atrophy) or other permanent physical 
abnormalities’.92 
In 2000 American psychopharmacology researcher Dr Gahan Pandina identified that most of 
the supposed breakthroughs relate to brain-imaging using Positron Emission Tomography 
(PET) scanners or Magnetic Resonance Imaging (MRI) technology.  Pandina contends that 
none of the claims have been sustained and all mainstream medical authorities recognize 
that the technologies have no role in the diagnosis of ADHD.  He argued that even the more 
optimistic of assessments recognize brain-imaging technologies as having no diagnostic 
value, merely unfulfilled potential.93  A year later in 2001 American researchers confirmed 
neuro-imaging can do little more than assess the shape and size of the brain:  
Although gross differences in size or symmetry of brain structures can be quantified, 
individual cells and cell layers cannot yet be visualized.  This means that, although 
                                               
91  Examples include Kelland, ‘Study finds first evidence that ADHD is genetic’;  Landau , ‘ADHD is a 
genetic condition’. 
92  Breggin, Talking Back to Ritalin, p.358. 
93  Gahan J. Pandina (2000), ‘Review of Neuroimaging Studies of Child Adolescent Psychiatric Disorders from 
the past 10 years (Statistical Data Included)’, Journal of the American Academy of Child & Adolescent 
Psychiatry, Vol. 39 No. 7, pp.815–28. 
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the volume and shape of brain structures may be determined, the underlying cause 
of any differences cannot.’94 
This remains the case despite numerous media reports about imminent breakthroughs in the 
science of diagnosing ADHD.  One recent example was in October 2012 when a radio program 
ran a piece promoting claims that neuroimaging and genetic tests for ADHD are ‘just around the 
corner’.  The enthusiastic researcher was quoted as saying ‘neuroimaging and genetics are 
extremely exciting research tools’, although he conceded in relation to a scientific test for ADHD 
‘We're just not quite there yet’ and it was likely to take another 15 to 20 years.95    
In summary some critics like Baughman oppose ADHD diagnosis because they believe it is as 
Laing identified - a misapplication of the medical model.  They believe the third step 
identified by Laing, conducting a physical examination and if required ancillary tests to 
identify objective abnormality, is missing.  Other ADHD critics like Jacobs are critical of the 
lack of acceptance of difference irrespective of whether it has been objectively verified via 
the rigorous application of the medical model described by Laing.  
The diagnostic criteria of ADHD – in particular making careless mistakes, not ‘seeming to’ 
listen, failing to finish school work, being disorganised, disliking schoolwork or homework, 
blurting out answers and leaving a seat when remaining seated is expected – are all 
evidence of a child’s failure to comply in a school environment.  Numerous ADHD critics 
contend that ADHD medications are used as a means of achieving control and compliance 
and minimising social deviance in classrooms.  Although teachers do not diagnose children 
with ADHD, they, along with parents, provide the critical behavioural evidence for the 
doctors who make the diagnosis.  In 2003 US research demonstrated that ‘in the majority of 
cases teachers are the first to suggest a diagnosis of ADHD’.96  Even if teachers are not the 
first to suggest a diagnosis they still play a central role in the process.  
Dr Linda Graham, an Australian academic researcher in the education field, contends that a 
                                               
94  Sarah Durston, E. Hilleke, et al (2001), ‘Anatomical MRI of the Developing Human Brain: What Have We 
Learned?’, Journal of the American Academy of Child & Adolescent Psychiatry, Vol. 40 Issue 9, pp.1012–
20. 
95  'Brain scans and genetic tests for ADHD diagnoses’, AM, 3 October 2012.  Available at 
http://www.abc.net.au/am/content/2012/s3602551.htm (accessed 8 October 2012).   
96  Linda Graham (2006), ‘The Politics of ADHD’, in Proceedings of the Australian Association for Research in 
Education (AARE) Annual Conference, Adelaide, p.14. 
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diagnosis of ADHD removes responsibility from the school and shifts ‘the focus away from what 
might be wrong with schooling to centre only on what is ‘wrong’ with the child.’97  She argues the 
environment is not modified to fit the child; instead the child is modified (medicated) to fit the 
environment.  
These are not new concerns.  In 1970, in response to the relatively uncommon but emerging 
practice of ‘medicating’ to alleviate hyperactivity, American author and educator John Holt, 
when testifying about the US education system before a United States House of 
Representatives’ committee said:  
We consider it [hyperactivity] a disease because it makes it difficult to run our 
schools as we do, like maximum security prisons, for the comfort and the 
convenience of the teachers and administrators who work in them.  The energy of 
children is ‘bad’ because it is a nuisance to the exhausted and overburdened adults 
who do not want to or know how to and are not able to keep up with it.  Given the 
fact that some children are more energetic and active than others, might it not be 
easier, more healthy, and more humane to deal with this fact by giving them more 
time and scope to make use of and work off their energy?…Everyone is taken care 
of, except, of course, the child himself, who wears a label which to him reads 
clearly enough ‘freak,’ and who is denied from those closest to him, however 
much sympathy he may get, what he and all children most need – respect, faith, 
hope, and trust.98  
In January 2007, The Sunday Mail reported that ADHD diagnosed students whose parents were 
refusing to allow them to be medicated were being excluded from Queensland schools, even 
though it was illegal to do so.  The article reported the case of Denise, a Northside Brisbane 
mother and her son John, who had been branded a ‘bad’ child all through pre-school.  ‘This 
came to a head when he had only been in Grade 1 for approximately four months when the 
                                               
97  Linda J. Graham (2008), ‘Drugs, labels and (p)ill-fitting boxes: ADHD and children who are hard to teach’, in 
Discourse: Studies in the Cultural Politics of Education, Vol. 29, No. 1, p.94. 
98  Ronald Lipman (1970), ‘Federal involvement in the use of behaviour modification drugs on grammar school 
children of the right to privacy inquiry. Hearing before a Subcommittee of the Committee on Government 
Operations House of Representatives, Ninety-First Congress, Second Session, 29 September 1970, p. 33. 
Available at http://www.fredsworld02.com/pdf/federal%20involvement.pdf (accessed 9 April 2008).  
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principal came to me and told me I either put my son on medication or he would be expelled.’99 
Linda Graham made similar claims: ‘Parents of children who can be described as “hyperactive” 
or “distractible” are under pressure to medicate their children so they can fit into an 
overwrought, under-funded public education system.’100  In Australia this practice is not limited 
to Queensland.  In 2006, a public primary school located in a disadvantaged area of Sydney 
made headlines by threatening to formally exclude an eight-year-old girl unless her mother 
medicated her for suspected ADHD.101  I have heard of similar exclusions and threats of 
exclusion in Western Australia.102 
The practice of excluding un-medicated ADHD diagnosed children from schools became so 
common in the US that some states took action to protect children and their parents from state-
enforced medicating.  In 1999, Colorado legislated to prevent school personnel from 
recommending psychotropic drugs to students, with other states following.  However, the 
legislation does not stop teachers and other school employees recommending to parents that 
their child should be assessed by a doctor.103  ADHD critics contend that the threat of school 
exclusions unless medicated is evidence of inappropriate medicalization and 
pharmaceuticalization.  
2.3 Injury versus Access Orientated Consumerism 
Abraham identifies two potentially conflicting forms of consumer-driven pressure on 
government: one aims to enable, the other to restrict, access to pharmaceuticals.  What he 
terms ‘injury orientated consumerism’ is pressure generated by reports of iatrogenic harm 
from the nominally therapeutic use of pharmaceuticals.  This pressure can result in decisions 
to either restrict or remove the access to, or subsidy of, a particular pharmaceutical product 
or class of products.  ‘Access orientated consumerism’ refers to the pressure brought on 
government to license and subsidise pharmaceutical products to fill or better serve 
perceived unmet medical need.   
                                               
99  Daryl Passmore (2007), ‘Here, now be a good little child’, The Sunday Mail, 14 January 2007.   
100  Daryl Passmore (2007), ‘Out of Control’, Courier Mail, 14 January 2007. Available at 
http://www.couriermail.com.au/news/sunday-mail/out-of-control/story-e6frep2o-1111112825767 (accessed 24 
June 2009). 
101  Graham, ‘Drugs, labels and (p)ill-fitting boxes’, p.95. 
102  Martin Whitely (2010), Speed Up & Sit Still: The Controversies of ADHD Diagnosis and Treatment, Perth, 
UWA Publishing, p.82. 
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  Whitely, Speed Up & Sit Still p. 82 
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Abraham considers that, from a utilitarian public benefit perspective, injury orientated 
consumerism has generally been ineffective in protecting consumers from iatrogenic harm.  
Conversely, he believes access orientated consumerism has over-achieved in that 
ineffective, unnecessarily costly, or worse still, harmful medications have been licensed for 
market or subsidised.104 
An Australian example of competition between ADHD proponent driven access orientated 
consumerism and ADHD critic driven injury orientated consumerism in regards to the 
subsidisation of Strattera via the PBS is discussed at 4.6. 
2.4 Summary of ADHD proponent’s and ADHD critic’s positions 
ADHD Proponents  
Proponents typically contend that ADHD is a neurobiological condition with at least in part a 
genetic/biological cause that can be treated with safe effective medications and that it is 
underdiagnosed and under-treated.  They also contend that individuals with undiagnosed 
and untreated ADHD frequently self-medicate with alcohol and illicit drugs. 
They proffer a biomedicalized explanation of ADHD pharmaceuticalization.  Specifically they 
argue that improvements in diagnostic criteria, and greater access to appropriate 
pharmaceutical treatments, accounts for the increase in ADHD per capita child prescribing 
rates.  They have led access orientated consumer lobbying to facilitate greater access to 
subsidised pharmaceutical treatments. 
ADHD Critics 
ADHD critics include two subgroups: those who believe it is a real but rare, over-diagnosed 
and over-medicated condition; and those who believe that ADHD is not a valid psychiatric 
disorder and the drugs used to treat it are unsafe and ineffective in the long term.105  Both 
subgroups contend that the psycho-stimulants most commonly used to treat ADHD are 
addictive and frequently abused or diverted for illicit use.  
                                               
104  Abraham, ‘The Sociological Concomitants’, p.295. 
105
  The situation is further complicated by a subset of ADHD critics who believe that ADHD is real but 
caused by some other single factor. They tend to promote the use of a single alternative treatment as being 
the appropriate universal response to ADHD. In terms of the ‘contest’ to influence Australian policy, 
regulation and practice there is little evidence that they have been significant.  
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Critics also contend inappropriate medicalization accounts for increased ADHD 
pharmaceuticalization.  They point to the lack of objective ‘scientific’ tests and the 
broadening of diagnostic criteria as evidence of unjustified pharmaceuticalization.  They 
have led injury orientated consumer lobbying efforts to restrict access to ADHD 
pharmaceuticals. 
Table 1 below summarises the most commonly argued perspectives of ADHD Proponents 
and ADHD Critics. 
Issue ADHD Proponents contend: ADHD Critics contend: 
What is 
ADHD? 
ADHD is a psychiatric disorder/disease 
characterised by extreme levels of 
dysfunctional inattentive and/or 
hyperactive/impulsive behaviour that 
effects a significant minority 
(estimates vary between 3 and 11% 
and even higher) of children and in 
many cases (60%) continues into 
adulthood. Leaving ADHD untreated 
destines an ADHD child to a future of 
academic, economic and social failure.  
There are two different views amongst 
ADHD critics: 
 ADHD is a real but rare condition 
affecting a tiny minority of 
children that is over-diagnosed 
and over-medicated, or 
 ADHD is not a valid psychiatric 
disorder. It a label inappropriately 
applied to children whose 
behaviour is distressing and/or 
inconvenient to adults. 
How is it 
diagnosed? 
ADHD is diagnosed using behavioural 
diagnostic criteria developed by the 
American Psychiatric Association and 
outlined in DSM-IV. Specialist 
clinicians, usually paediatricians or 
child psychiatrists, expert in the 
diagnosis of the disorder assess the 
behaviour of the child against age 
appropriate norms and exclude other 
potential causes of aberrant 
behaviour. 
The diagnosis of ADHD is unscientific. It 
involves the subjective application of 
vague behavioural diagnostic criteria. 
Furthermore the behaviours are part of 
the normal range of childhood 
behaviours. Where children do have 
significant behavioural issues the label 
‘ADHD child’ dumbs down an individual 
child’s often complex circumstances and 






Proponents acknowledge that the 
aetiology of ADHD is uncertain. 
However they describe it as a 
neurobiological condition. They 
contend that there is strong evidence 
that it occurs as a result of a 
genetically determined chemical 
imbalance in the brain. 
They contend that children with ADHD 
often have comorbid conditions that 
require separate but concurrent 
treatment.  
Critics contend there are multiple 
potential causes of behaviours 
characterised as ADHD including: 
 Intolerance of boisterous or day-
dreamy children, particularly 
boys. 
 Trauma from bullying or physical, 
emotional or even sexual abuse. 
 Bright children being bored or dull 
children failing to keep up. 
 Inadequate teaching or parenting. 
 Exposure to neurotoxins, sleep 





The use of psycho-stimulants (and 
where stimulants are ineffective 
atomoxetine), balance an ADHD 
child’s brain chemistry. This makes the 
child better able to focus and learn. It 
helps the child modify their 
dysfunctional impulsive and 
hyperactive behaviour prevents self-
medication with illicit drugs and 
improves relationships with others. All 
medications carry risks. However 
psycho-stimulants are comparatively 
safe having been used to treat 
hyperactive behaviour since the 
1930s.  
The oral administration of psycho-
stimulants increase focus in most people 
irrespective of their ADHD status. The 
increased focus resulting from the 
administration of psycho-stimulants to 
ADHD children is mistakenly regarded as 
the drugs addressing the child’s 
biochemical imbalance. Furthermore 
although ADHD medications often modify 
behaviour in the short term they have no 
sustained benefits involve considerable 
short term risk and psycho-stimulants are 
addictive and frequently cause long term 
educational, psychiatric and 





Increased awareness of the long 
under-recognised condition has 
resulted in increased ADHD 
pharmaceutical prescribing rates. 
The pharmaceutical driven marketing of 
the contrived ‘disorder’ to time-poor 
parents desperate for quick fixes that 





However the disorder remains under-
recognised with ADHD prescribing 
rates considerably lower than ADHD 
prevalence rates. 
childhood behaviours has created the 
demand for ADHD drugs. This marketing 
has been supplemented by 
pharmaceutical company controlled 
biased research and a lack of rigorous 
scientific oversight. 
 
2.5 The Theory of Regulatory Capture  
In 2005 European economic researcher Marianne Ojo identified two competing theories of 
regulation.  The first, Ojo describes as the ‘Public interest theory of Regulation’ which holds 
that ‘regulation is seen as catering for the interests of the public.’  The second, the ‘Private 
interest theory of Regulation’, holds that ‘parties affected by regulation…try to influence 
such regulations in such a way that it gives them favorable outcomes.’  This theory holds 
that ‘regulatory capture’ by ‘private interests of those being regulated overwhelm those 
interests of the public’.106 
One of the prominent early theorists in regard to the concept of regulatory capture was 
George J Stigler, a Chicago economist and close colleague of the leader of the Chicago 
School of Economics and father of monetarism, Milton Friedman.  In 1971 Stigler wrote:  
The state - the machinery and power of the state - is a potential resource or threat 
to every industry in the society. With its power to prohibit or compel, to take or 
give money, the state can, and does electively help or hurt a vast number of 
industries.107  
Stigler argued ‘as a rule, regulation is acquired by the industry and is designed and 
operated primarily for its benefit.’108  The basis of Stigler’s theory is that industry has a 
                                               
106   Ojo Marianne (2005), ‘The External Auditor’s Role in Bank Regulation and Supervision : Helping the 
Regulator Avoid Regulatory Capture’, Munich Personal RePEc Archive (MPRA) Paper No. 1293.  
Available at http://mpra.ub.uni-muenchen.de/1293/ (accessed 15 January 2012).   
107  George J. Stigler (1971), 'The Theory of Economic Regulation', Bell Journal of Economics and 
Management Science , p.3. 
108
  Stigler, 'The Theory of Economic Regulation', p.3. 
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greater stake in, and capacity to, control regulation than individual disaggregated 
consumers and that ‘profit maximisation’ is the key driver. 
Specifically Stigler contends regulatory capture occurs because entities, most often 
commercial enterprises, with a significant interest in the outcome of a policy or regulatory 
decision, focus attention and resources on influencing the outcome.  In contrast the public, 
who are less immediately and foreseeably affected by the outcome, are far less inclined to 
seek to influence the outcome.  This imbalance in lobbying resources results in a skewing of 
policy and regulatory outcomes from the ‘captured’ agency that favour the organized, 
vested interests of the entity whose activities is at face value being regulated.109 
In 1974 US economist and jurist Richard A Posner expanded on Stigler’s work.  Posner 
argued that ‘regulation is not about the public interest at all, but is a process, by which 
interest groups seek to promote their (private) interest.’110  Posner identified three 
different classes of proponents of regulatory capture.  The first class, the ‘Marxists and the 
Muckrakers’, were summarily dismissed.  Posner wrote that the theory ‘put forward by 
Marxists and by Ralph Nader-type muckrakers, can be summarized in the following 
syllogism.  Big business – the capitalists- control the institutions of our society.  Among 
those institutions is regulation.  The capitalists must therefore control regulation.’111  
Posner dismisses this perspective, citing examples of beneficial regulation and examples of 
regulation favouring the interests of small business. 
The second class of proponents of a theory of regulatory capture identified by Posner were 
political scientists, whose theory he also considered unsatisfactory because, like the ‘Marxist 
and Muckrackers’, he believes it is unable to explain the complexity and variety of 
regulatory outcomes.  
Posner’s third category of ‘regulatory capture’ theorists include himself and others like 
Stigler from the Chicago Neo-classical economic tradition. Posner believes the outcomes of 
regulatory capture and the ‘political process’ involved are best explained by the ‘general 
                                               
109  George J. Stigler (1961), ‘The Economics of Information,’ Journal of Political Economy, 69(3), pp.213-
225. 
110  R. Posner (1974), ‘Theories of Economic Regulation’, Bell Journal of Economics and Management 
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assumption that human behaviour can be best understood as the response of rational self-
interested beings to their environment.’112 
Other proponents of the theory of regulatory capture, including Bernstein,113 Huntington,114 
Laffont and Tirole,115 and Levine and Forrence116 agree that the notion that government 
agencies and regulators typically act to enhance the public good is naïve.  They argue 
therefore that regulatory agencies should, where possible, be protected from outside 
influence.  In circumstances where this is not achievable it may be preferable not to have a 
designated regulatory agency, as the existence of the agency may create the mistaken belief 
that proper oversight and regulation is occurring. 
Grabosky and Braithwaite argue that regulatory capture is more likely where the following 
preconditions exist: 
1. only one industry is being regulated 
2. the regulator is part of a larger organisation  
3. there is conflict between the regulator and the regulated, 
4. regular contact occurs between the regulator and the regulated, and/or where 
significant personnel interchange occurs between the regulator and the 
regulated.117 
They also consider that, historically, regulatory agencies in Australia demonstrate fairly 
low levels of punitive enforcement.118  Furthermore they argue that Australian regulatory 
agencies tend not to use their extensive powers to their fullest extent.  The extent to 
                                               
112  Posner, ‘Theories of Economic Regulation’, p.356;  Stigler,‘The theory of economic regulation’, pp.3-21; 
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which these conditions apply to the regulation of ADHD within Australia is identified in 
later chapters.119 
Australian economist Greg McMahon defines regulatory capture in two steps. ‘Capture’ is 
described as ‘behaviours, active and passive, by responsible authorities, which… protect 
the… illegal, unethical, immoral or anti-public interest practices that those authorities are 
charged with “policing”’.120  Regulators are defined as the ‘widest class of professionals 
and authorities within corporations, organisations or jurisdictions holding formal 
administrative cum legislative cum ethical responsibilities for maintaining accountability 
within those units of society, community and government.’121   
McMahon contends regulatory capture occurs when a government or non-government 
agency created to act in the public interest instead advances the commercial or special 
interests that dominate the industry or sector it is charged with regulating, at the expense 
of the public interest.  Specific examples of regulators identified by McMahon ‘include 
auditors and accountants, lawyers and police, clergy and ethicists, medical practitioners and 
nurses, government and private industry ‘watchdog’ authorities, the professional-at-arms, 
and researchers and scientists’. 122  
Regulatory capture occurs when policy and regulatory outcomes from the ‘captured’ agency 
favour the organized, vested interests of the entity whose activities are at face value being 
regulated.  For the purposes of this thesis McMahon’s broad scope definition of regulatory 
capture is used, which encompasses capture of all of the agencies both government and 
non-government which have the declared intention of protecting and enhancing the public 
good. 
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Dominance of a process by ADHD proponents is not the only evidence of regulatory capture. 
A process can be captured even if participants are attempting to act in the public interest. 
Outcomes that favour industry’s interests over the public’s interest are the ultimate 
evidence of regulatory capture.  For example, regulatory committees that have no particular 
bias in their membership can still be captured if they rely primarily on corrupted and biased 
evidence.  
Hanson and Yosifon agree with McMahon that the phenomenon of ‘capture’ goes beyond 
government agencies and regulators in that vested interests have an incentive to control 
any entity, including non-government agencies, that has influence on their self-interest.  
Hanson and Yosifon refer to the successful capturing of these broader processes as ‘deep 
capture’.123  The potential for regulatory capture, even Hanson and Yosifon’s deep capture, 
in medical settings is considerable.  Doctors, nurses and other health professionals, 
researchers, patient advocacy groups, elected representatives, professional associations, 
medical standard setters and government regulators responsible for licensing and 
subsidising pharmaceuticals, all have the potential to be diverted from pure public interest 
considerations by external influence.  
There is growing recognition that the scientific process does not simply steadily advance 
’the certainty of our knowledge and control of the natural world’.124  Rather it is a process 
whereby key decisions about methodology and the interpretation of information produced 
through research are influenced by political, cultural and economic drivers.125  This presents 
challenges for those interpreting research and evaluating the risks and benefits of potential 
treatments and increases the potential for regulatory capture.    
McMahon identifies a broad scope of potential beneficiaries from regulatory capture.  The 
beneficiaries, ‘the captors…include organisations or coalitions or classes/networks of 
individuals who would be the focus of the accountability regime but for their success in 
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capturing that regime’.  Examples can include major industries, corrupt officials, important 
customers, large corporations, political associations, professional elites, community 
leaders, and in-house wrongdoers.’126  In the case of ADHD, individual clinicians, 
researchers, pharmaceutical companies, academics and paid opinion leaders, patient 
support groups and professional associations have an interest in both policy development 
and implementation.  
McMahon identifies three ‘levels’ of regulatory capture. 
At a first level of capture, the regulator allows the regulated to breach the 
law, ethic, good practice rule, moral principle or public interest duty that the 
regulator is responsible for upholding.  At a second level, the regulator 
assists the regulated to avoid the regulatory consequences after the fact.  At 
a deepest level of development, the ‘capture’ is so complete that the 
regulator may assist the regulated to defeat the regulatory regime before 
the fact.127 
In contrast to McMahon and Yosifon’s three levels of regulatory capture Australian 
academics Michael Briody and Tim Prenzler identify two degrees of regulatory capture.128  
The first, ‘systemic capture’, involves the ‘procuration of an entire regulatory system by 
the regulated industry’.  The second, less direct form of regulatory capture identified is 
‘undue influence’, which involves ‘personnel exchange, identification with values through 
frequent contact and direct corruption’.129  These distinctions between McMahon’s three 
levels, Briody and Prenzler’s two degrees, and Hanson’s moderate and deep capture are 
somewhat arbitrary and not indicative of any inconsistencies between their basic 
contentions.   
For the purpose of this thesis patterns of regulatory capture is defined using the criteria 
outlined at 1.4.  Regulatory (as in regulatory capture) is taken to include all agents, both 
government and non-government, that are supposed to be, or purport to be, acting in the 
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public interest.  For instance it includes non-government organisations such as patient 
support groups and professional associations such as the Royal Australian College of 
Physicians.   Although these organisations are not ‘regulators’ they do have professed 
aims of acting to promote patient welfare.  Furthermore government agencies have for 
significant processes delegated their responsibility for policy development and regulation 
to non-government agencies as was the case for the 2009 NHMRC ADHD Draft Guidelines.  
(Refer to 5.3.2)  
2.6 Abraham on Regulatory Capture and Pharmaceuticalization 
John Abraham argues the sociological foundations of the medicalization thesis are 
frequently valid.  He believes that these factors, in combination with the commercial 
interests and political influence of the pharmaceutical industry, which he terms 
‘socioinstitutional processes involving the marketing strategies of the pharmaceutical 
industry’, have caused increased diagnosis and treatment rates for a range of diseases and 
disorders.  Abraham describes this interaction of the ‘pharmaceuticalization-medicalisation 
complex’ as being ‘one aspect of the medical-industrial complex.’130 
As discussed at 2.4, Abraham contends ‘the biomedicalism thesis… is a weak explanatory 
factor because a significant amount of growth in pharmaceuticalization is inconsistent with 
scientific evidence.’131  In 2010 he wrote that there are ‘five main biosociological 
explanatory factors’ that contribute to pharmaceuticalization: biomedicalism, 
medicalization, pharmaceutical industry promotion and marketing, consumerism, and 
regulatory-state ideology or policy.  
Abraham contends that of these factors, regulatory capture is the most significant driver of 
pharmaceuticalization:  
industry promotion, medicalization, and consumerism can all encourage the 
growth of pharmaceuticalization, such growth is substantially, though not 
entirely, dependent on a regulatory state that is willing to grant marketing 
approval to drugs that offer no therapeutic advance, to lower regulatory 
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53 
 
standards of efficacy in order to accelerate more NMEs [new molecular 
entities] on to the market, and indeed to relax restrictions or prohibitions on 
DTCA [direct to consumer advertising] of prescription medications.132  
According to Abraham:  
regulatory capture is especially important because the risk-benefit assessment of 
drugs has a high degree of technical uncertainty, which is inherent in toxicology, 
clinical trials, and epidemiology.  Therefore, it is crucial to know how far regulators 
are willing to give the manufacturer the benefit of scientific doubt about safety and 
efficacy of their product.  Indeed, regulators too often consistently award industry 
the benefit of scientific doubt when reviewing products.133 
Abraham bases his theory of ‘neo-liberal corporate bias’ on 150 years of pharmaceutical 
regulation history in the United Kingdom supplemented by an analysis of U.S trends.134  By 
neo-liberal Abraham means that the ‘state should be minimal and subject to the tests of the 
market’.135  This laissez-faire, self-regulatory philosophy, combined with a pro commercial 
interest bias, heavily favours the interests of the pharmaceutical industry often at the 
expense of consumer interests.  While Abraham draws predominantly on British experience, 
the United Kingdom’s regulatory environment is similar to Australia’s in that government is 
central to the provision of health services and direct to consumer advertising of prescription 
medications is outlawed.  
In 2007 Abraham was criticised by Alison Edgley, who wrote: ‘contrary to Abraham’s theory, 
medicines regulation is a more complex process than simply being neo-liberal and always 
“industry-friendly”.’136  Edgley argued that ‘in the current UK political environment where 
health care is still largely organized through state provision, the state, rather than being 
subject to a form of ‘regulatory capture’, is also able to employ regulatory processes in ways 
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that promote its own interests – interests that one could suggest are neither clearly in the 
interests of industry, nor the public.’ 
In response Abraham countered: 
The theory of corporate bias does not imply that the state has no interests of its 
own. On the contrary, unlike pluralist theory, it recognizes that the state has its own 
interests…As to the nature of the British state’s own interests when taking 
regulatory action against industry, I found overwhelmingly that, throughout history, 
the primary motive seems to have been budgetary savings, rather than patients’ 
interests per se’.137   
He added that:  
‘any major social theory is also necessarily complex, rather than absolutist…No 
sensible social theory would ever claim that there has never been and never will be a 
regulatory development introduced independently of industry interests… [but 
nonetheless] the most significant driver of regulatory change is industry interest, 
but… the role of other interests, especially those of the state [are] the second most 
important influence.’138 
The relevant question for this thesis is whether Abraham’s neo liberal corporate bias theory on 
pharmaceuticalization and regulatory capture applies in an Australian context.  Specifically have 
corporate interests and, to a lesser degree government interests - in the form of reduced costs 
and political acceptability - dominated the public interest in regard to the regulation of ADHD?  
2.7 What policies have been proposed regarding regulatory capture and the pharmaceutical 
industry? 
Abraham has recommended reforming the way medical and psychiatric research is conducted, 
in order to contend with undue influence by the pharmaceutical industry.  He has proposed 
having regulatory agencies conduct key safety research (animal carcinogenetic tests for 
example) on new drugs.   He proposed the pharmaceutical companies would pay regulators for 
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conducting the research.  Abraham suggests this would be best done on an international co-
operative cross jurisdictional basis, with sharing of results and responsibility between nations.  
He also believes this would be enhanced by the coordinated publication of a research journal.139 
Abraham had the opportunity to influence UK national policy in 2004-5 when he was a ‘special 
advisor’ to a House of Commons Committee.140  In response to concerns about the impact of 
inappropriate pharmaceutical industry influence on medical and psychiatric practice, the 
Committee conducted an inquiry titled The Influence of the Pharmaceutical Industry Fourth 
Report of Session 2004–05.141    
The Committee concluded that: 
 ‘Our over-riding concerns are about the volume, extent and intensity of the 
industry’s influence, not only on clinical medicine and research but also on patients, 
regulators, the media, civil servants and politicians… 
 The regulatory system, the medical profession and Government have all failed to 
ensure that industry’s activities are more clearly allied to the interests of patients 
and the National Health Service. 
 The influence of the pharmaceutical industry is such that it dominates clinical 
practice, to an extent that deprives it of independent and constructively critical 
feedback; this is a discipline it needs and which can help it to improve. 
 The traditional secrecy in the drug regulatory process has insulated regulators from 
the feedback that would otherwise check, test and stimulate their policies and 
performance.  
 The closeness that has developed between regulators and companies has deprived 
the industry of rigorous quality control and audit. 
 Other bodies are in a position to provide feedback and quality control. They include 
academic, research, clinical and professional institutions, as well as the media and 
patient groups. However, representatives of these interests have had only limited 
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success in containing excessive industry influence. This can be partly attributed to 
lack of transparency, limited resources, significant dependency on industry funding, 
and some conflicts of interest.’142 
The report detailed ‘problems with SSRIs antidepressants, notably Seroxat, and the COX-2 
inhibitors, Vioxx and Celebrex’. It found unethical behaviour by drug manufacturers in failing 
to disclose adverse information when applying to licence new drugs. However, it also found 
that ‘prescribers must take their share of the blame for the problems that have resulted’ as 
some ‘medicines have been indiscriminately prescribed on a grand scale’. It attributed this 
reckless prescribing to ‘intensive promotional activity’ and ‘data secrecy and uncritical 
acceptance of drug company views’.143  
The Committee concluded that the consequences of the above-mentioned failings were the 
‘unsafe use of drugs’ and ‘increasing medicalization of society’. They also found that the 
‘drift towards medicalization is a global phenomenon‘, and despite the problems identified 
above the ‘UK may have a better record than many others [countries]’.  
The Committee made a number of specific recommendations to tackle what it termed a ‘pill 
for every ill’ culture ‘compounded by an excessive reliance on results from premarketing 
clinical trials, together with a failing system of pharmacovigilance’. The recommendations 
included: 
 A ‘clinical trials register be maintained by an independent body and the results of all 
clinical trials data, containing full trials information, be put on the register at launch 
as a condition of the marketing licence’. 
 Limitations on, and health regulator’s approval of, promotional materials sent to and 
promotional visits to potential prescribers. 
 ‘When companies are found to be in breach of advertising regulations or to have 
published misleading findings, the allowance for promotion and research, 
respectively, provided under the [National Health] Scheme should be reduced’.  
 Full public disclosure of information used by pharmaceutical companies to apply to 
license and otherwise regulate drugs.  
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 Systemic random audits of raw data used in research supporting licensing etc. 
 Greater follow up of adverse reactions within research trials that prevented ongoing 
participation. 
 Establishing 5 year post market surveillance of the safety and efficacy of newly 
licenced medicines. 
 Improved post marketing reporting of adverse events by healthcare professionals. 
 Restrictions on what professions can prescribe new medications for two years post 
licensing (for example only psychiatrists to prescribe new psychotropic medications)  
 A ‘public inquiry whenever a drug is withdrawn on health grounds’ in order to 
prevent similar occurrences. 
 Improved training of medical students on ‘how to judge clinical trial results 
effectively, recognise adverse drug reactions and deal with drug company 
representatives’.  
 ‘Mandatory post-graduate training for all prescribers to keep up-to-date with 
prescribing changes’.  
 ‘Stricter regulation of individual prescriber’s practices’. 
 Establishment of a publicly available ‘register of interests’ of ‘all substantial gifts, 
hospitality and honoraria’ received by prescribers and researchers. 
 Public disclosure of industry sponsorship of ‘disease awareness campaigns’ and 
‘patient [support] groups. 
Given the cultural and institutional similarities between Australia and the United Kingdom, 
the House of Commons Committee conclusions and recommendations may have relevance 
in Australia.  Chapters 5 and 6 detail the extent of regulatory capture in Australia in relation 
to ADHD and the applicability of the Committee’s recommendations to Australian policy is 
discussed at Chapter 7 (see 7.10).  
2.8 Summary 
The competition between ADHD critics and proponents is part of a broader contest to 
determine the direction of psychiatric practice.  Breggin, who supports non-pharmaceutical 
[environmental] psychiatric practice, argues: ‘psychiatry is more like a two-party political 
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system with the biological [biomedicalized] and environmental parties constantly vying for 
power. Biological psychiatry is now the party in power.’144   
Opponents of biological psychiatry like Breggin and Abraham contend that greater access to 
resources and stronger economic incentives account for its dominance.  Supporters see it as 
a result of technological and societal progress.   
Both ADHD proponents and critics acknowledge the reality of ADHD pharmaceuticalization.  
Proponents consider this outcome is in the public interest. They contend it is a result of 
better diagnostic practices, a wider range of pharmaceutical treatments and greater 
awareness of a previously under-recognised condition.   
ADHD critics reject this biomedicalization theory.  They contend that ADHD 
pharmaceuticalization is contrary to the public interest and is a result of the aggressive, 
inaccurate promotion of both the consequences of ‘untreated ADHD’ and the benefits and 
safety of the pharmaceuticals used to treat it.  They also contend that the dominance of 
regulatory and policy process by ADHD proponents and the pharmaceutical industry has 
supported the marketing of ADHD and its treatments. Critics further argue that ADHD 
proponents and ADHD drug manufacturers have greater access to resources and stronger 
economic incentives and this has resulted in regulatory capture of ADHD policy and 
regulatory processes.   
ADHD proponents counter that critics are a vocal and populist fringe that ignore the 
overwhelming scientific evidence supporting the validity of the disorder and the safety and 
efficacy of ‘medications’ used to treat it.  They argue that ‘major medical associations and 
government health agencies recognize ADHD as a genuine disorder because the scientific 
evidence indicating it is so overwhelming.’145    
The debate is further complicated by some ADHD critics like Frances believing ADHD is a 
valid but massively over-diagnosed and over-hyped psychiatric disorder and others like 
Baughman believing it is an entirely fraudulent construct.  
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Subsequent chapters detail how the competition between proponents and critics has played 
out internationally and locally in regards to the regulation of ADHD in Australia.  
60 
 
Chapter 3.  ADHD and Imported Regulatory Capture 
 
This chapter explores the influence of processes in the United States of America on Australian 
ADHD policy and practice.  The Diagnostic and Statistical Manual of Mental Disorders which 
defines ADHD was developed by the American Psychiatric Association.  In addition much of the 
research used as evidence in the development of Australian ADHD diagnosis and treatment 
guidelines and policies originates in the USA.  The chapter identifies and analyses issues in 
regard to regulatory capture of US processes and the imported effects on Australia.   
3.1 Defining ADHD 
Internationally there are two alternative frameworks for diagnosing mental illness: the 
Diagnostic and Statistical Manual of Mental Disorders (DSM), produced by the American 
Psychiatric Association (APA); and chapter five of the International Clarification of Diseases 10 
(ICD-10), produced by the World Health Organization (WHO).   
Unlike the DSM which deals only with mental illness, ICD covers the complete range of medical 
conditions and physical illness.  In regard to mental illness, both systems outline diagnostic 
criteria and provide a numerical code that can be used to identify a disorder when clinicians 
claim payment from health insurers and government authorities.  When the APA developed 
DSM-IV (in 1994), it endeavoured to standardise the codes to the ICD although minor 
differences remain.  It is standard practice in the USA to use the diagnostic criteria of the DSM 
and claim payment using the ICD code.146   
The ICD-10 numerical coding system is often used in the Australian health system by clinicians 
and hospitals to obtain Medicare co-payment entitlements, however DSM-IV is the most 
commonly used diagnostic system.147  This is despite the fact that Australia is a member of the 
WHO and not the APA. 
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Although ICD-10 is the official classification system for mental illness in Australia, most 
psychiatrists use the DSM.148 In contrast ICD-10 is the predominant diagnostic system in 
Europe.149  The eighteen behavioural diagnostic criteria for ‘Hyperkinetic Disorder’ outlined 
in ICD-10 are virtually identical to those for ADHD in DSM-IV.  There are, however, two 
subtle but important distinctions.  First, for a diagnosis of hyperkinetic disorder under ICD-
10, an individual is required to display at least six of nine of the inattentive and three of five 
of the hyperactive and one of four of the impulsive behaviours.  For a DSM-IV diagnosis of 
ADHD, six of nine of the inattentive behaviours or six of nine of the hyperactive/impulsive 
behaviours are sufficient.  Second, unlike the DSM definition of ADHD, ICD-10 states 
hyperkinetic disorder should not be diagnosed if another condition that may explain the 
behaviour is diagnosed.150  
Although many of the criticisms of subjectivity of assessment of behaviours are common to both 
the DSM-IV and ICD-10, historical data indicates that fewer children are diagnosed using ICD-10.  
It has been found by two separate parliamentary inquiries - one in Western Australia and the 
other in South Australia - that as a likely consequence, the rates of psycho-stimulant use per 
head in the USA, Canada and Australia (using DSM-IV) between 1994 and 2000 were multiples 
of the UK rate (predominantly using ICD-10).151  The Western Australian Parliamentary Inquiry in 
2004 found that ‘The use of different diagnostic tools may explain the variation in ADHD 
prevalence rates between Australia (DSM-IV) and the United Kingdom (ICD-10).’152   A South 
Australian Parliamentary Inquiry two years earlier made a similar finding: ‘The DSM-IV allows for 
multiple diagnosis with co-morbid conditions such as conduct disorder, while ICD-10 does 
not…As a result, prevalence studies from other countries using the ICD-10 (e.g. UK) indicate 
much lower ADHD rates than those from Australia and the USA.’153 
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This is true not only for ADHD.  DSM-IV generally contains broader, diagnostic criteria than ICD-
10.  A 2005 study compared diagnosis rates for a range of childhood psychiatric disorders using 
the diagnostic criteria in DSM-IV and the equivalent disorder in ICD-10.  For the majority of 
disorders, including ADHD, rates of diagnosis were higher using DSM-IV, possibly because of the 
looser criteria.154  
Rather than being developed as competing diagnostic systems, the ICD and DSM have had 
different development pathways that have converged over time. The first edition of the DSM 
was published by the APA in 1952.  As the name indicates it is restricted exclusively to outlining 
the diagnostic criteria of mental illness.  The ICD included a section on mental disorders for the 
first time in its sixth edition (ICD-6) in 1949.155    
The ICD’s origins can be traced to the 18th Century. It was developed as an attempt to 
systematically identify all potential ‘causes of death’ and so it is related to general medicine 
rather than mental disorders.  The current version of ICD still performs this broad function. 
The development of the DSM has reflected the shift within psychiatry from a psychoanalytic 
dominated approach, emphasising personal historical circumstances and later 
consequences, to a system of defining behavioural symptoms of an increasing number of 
discreet although often comorbid (co-existing) disorders. The development of ICD has 
lagged the DSM in following this trend.  According to the American Psychological 
Association, the peak body for US psychologists:  
Before 1980, psychiatric diagnostic systems reflected the dominant psychoanalytic 
ideas of the time, emphasizing the role of experience, downplaying biology.  
"The American Psychiatric Association can really be credited with a revolution in 
psychiatric nosology with the publication of DSM-III by introducing a descriptive 
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nosological system based on co-occurring clusters of symptoms", said WHO 
psychologist Geoffrey Reed, PhD.   
There was very little international participation in the DSM-III, but at the time it may 
have been impossible to make such a big shift at the international level, he 
explained. As a result, DSM-III and ICD-8 (the version in effect at the time) were quite 
different from one another but as the descriptive phenomenological approach to 
diagnose mental disorders became dominant, the DSM and ICD have become very 
similar, partly because of collaborative agreements between the two organizations 
[The American Psychiatric Association and The World Health Organisation].156 
Despite the gradual convergence, as previously discussed significant but subtle differences 
exist in the diagnostic criteria for ADHD and other disorders that are associated with lower 
rates of prescribing in jurisdictions using ICD-10 rather than DSM-IV. 
In the USA ICD and the DSM are often used in a complementary manner.  DSM is used as the 
dominant diagnostic criteria and ICD codes are used for administrative purposes in order to 
receive payment.157  The situation is similar in Australia.  The dominant role of the DSM-IV 
diagnostic criteria in Australia in recent decades means that the deliberations of the APA 
have had a significant influence on Australian psychiatric practice.   
The reasons that DSM-IV has been more frequently used than ICD-10 in Australia are 
unclear.  It appears unlikely that the rationale is based on any objective assessment of 
patient welfare in jurisdictions using the DSM-IV criteria compared to those using ICD-10’s 
definition of Hyperkinetic Disorder.  In relation to ADHD the USA has the highest child 
prescribing rate in the world with at least 2.7 million children currently taking ADHD 
'medications'158  ADHD critic American psychologist Dr Leonard Sax contends that as many 
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of the supposed benefits of medication for ADHD children relate to education, ‘you would 
expect American children to be racing ahead in their school work’, but as it is, ‘France, 
Germany, and Japan continue to maintain their traditional lead over the United States in 
tests of math and reading ability.’159  Although Sax’s analysis ignores the complexity of the 
factors determining relative national education outcomes, it does raise obvious questions 
about the appropriateness of following the lead of the US in identifying and responding to 
perceived educational disadvantage without comparing outcomes associated with alternate 
approaches.  Regardless of the record of the USA in terms of children’s wellbeing, Australian 
guidelines developed in 1997 and 2009 have recommended the use of the DSM-IV in 
preference to ICD-10 without providing a comprehensive rationale (refer to 5.3).   
3.2 The American Psychiatric Association and Regulatory Capture 
The APA is the dominant professional organisation of psychiatrists in the USA, and the 
largest psychiatric organisation in the world, with approximately 36,000 members.160  It is 
self-regulated and is led by its President and a Board of Trustees with an Executive 
Committee. Along with the DSM – over which it has total editorial control - it publishes for 
sale journals and other material. 
In the lead up to DSM-IV’s publication in 1994 a subcommittee of the American Psychiatric 
Association was tasked with developing and amending the diagnostic criteria for ‘Disorders 
Usually First Diagnosed in Infancy, Childhood and Adolescence’.  The subcommittee decided by 
consensus to loosen the diagnostic criteria for ADHD. In 2006 US research revealed that the 
majority (61.9 percent) of members of that 1994 sub-committee had ties to the pharmaceutical 
industry.161 
Commercial ties to the pharmaceutical industry within the APA subcommittees that developed 
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DSM-IV were not limited to members of the sub-committee responsible for ADHD.  
Of the 170 DSM panel members 95 (56%) had one or more financial associations with 
companies in the pharmaceutical industry. One hundred percent of the members of the 
panels on ‘Mood Disorders’ and ‘Schizophrenia and Other Psychotic Disorders’ had 
financial ties to drug companies. The leading categories of financial interest held by 
panel members were research funding (42%), consultancies (22%) and speakers bureau 
(16%).162  
The researchers concluded that ‘there are strong financial ties between the industry and those 
who are responsible for developing and modifying the diagnostic criteria for mental illness. The 
connections are especially strong in those diagnostic areas where drugs are the first line of 
treatment for mental disorders.’163  
Even within the APA questions have long been asked about the appropriateness of their 
relationship with the pharmaceutical industry.  In 1985 Fred Gottlieb, APA Speaker of the House, 
told the APA:  
I do not suggest that either they [the drug companies] or we [the American 
Psychiatric Association] are evil folks. But I continue to believe that accepting 
such money is, in the long run, inimical to our independent functioning. We have 
evolved a somewhat casual and quite cordial relationship with the drug houses, 
taking their money readily…We seem to discount available data that drug 
advertising promotes irrational prescribing practices. We seem to think that we 
as psychiatrists are immune from the kinds of unconscious emotional bias in 
favour of those who are overtly friendly toward us…We persist in ignoring an 
inherent conflict of interest.164 
More recently in 2008 the US Senate Finance Committee, driven by Iowa Republican Senator 
Charles Grassley, began an investigation into the APA because of its financial ties to the 
pharmaceutical industry.165  Grassley’s probing led to revelations that the pharmaceutical 
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industry contributed approximately 30 per cent of the APA’s $US62.5 million in funding in 2006. 
Approximately half that money was from drug advertisements in APA journals and exhibits at 
the APA annual meeting.  The other half was for sponsorship of ‘fellowships, conferences and 
industry symposiums at the annual meeting.’166  
There has been relatively recent recognition of the problem from the top level of the APA by 
retiring President, Dr Steven S. Sharfstein.  In 2008 Sharfstein wrote a commentary piece on the 
relationship between psychiatry and the pharmaceutical industry entitled ‘Big Pharma and 
American Psychiatry: the Good, the Bad, and the Ugly’: 
There is widespread concern of the over-medicalization of mental disorders and 
the overuse of medications. Financial incentives and managed care have 
contributed to the notion of a ‘quick fix’ by taking a pill and reducing the emphasis 
on psychotherapy and psychosocial treatments. There is much evidence that there 
is less psychotherapy provided by psychiatrists than 10 years ago. This is true 
despite the strong evidence base that many psychotherapies are effective used 
alone or in combination with medications…In a time of economic constraint, a ‘pill 
and an appointment’ has dominated treatment.  
…There are examples of the ‘ugly’ practices that undermine the credibility of our 
profession. Drug company representatives will be the first to say that it is the 
doctors who request the fancy dinners,  cruises, tickets to athletic events, and so 
on. But can we really be surprised that several states have passed laws to force 
disclosure of these gifts?  
So-called ‘preceptorships’ are another example of the ‘ugly’; that is, drug 
companies who pay physicians to allow company reps to sit in on patient sessions 
allegedly to learn more about care for patients and then advise the doctor on 
appropriate prescribing. Drug company representatives bearing gifts are frequent 
visitors to psychiatrists’ offices and consulting rooms. We should have the wisdom 
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and distance to call these gifts what they are—kickbacks and bribes.167 
Despite Sharfstein’s criticisms his replacement as President of the APA, Alan Schatzberg had 
a serious conflict of interest. As a result of probing by Senator Grassley it was revealed that 
Schatzberg was the principal investigator in a US Federal Government sponsored study 
conducted into a drug, mifepristone, as a possible treatment for depression. Mifepristone 
was being developed by a company Schatzberg had set up and in which he owned US$4.8 
million worth of shares.168 169  Schatzberg countered that he had complied with his 
employer’s (Stanford University) disclosure policies and US federal guidelines that pertained 
to his research.  He also argued that constraining researchers from trying to bring 
medications to market would result in ‘less opportunities to help patients with severe 
illnesses’.170 However, what is not in dispute is that the APA elected as President, a 
researcher who took US taxpayer funds to research a drug he has a substantial personal 
financial interest in, at a time when the retiring APA President criticised American psychiatry 
for failing to manage pharmaceutical industry conflict of interests. 
The co-dependent relationship between the APA and pharmaceutical companies is attributed to 
declining incomes for both the APA and individual American psychiatrists in the 1970s.  Critics 
contend that, partly in response to increasing competition from non-medical mental health 
practitioners, psychiatry has increasingly become dominated by the ‘pill for every ill’ 
biomedicalized model.171 172  Psychologists, counsellors and social workers are all able to offer 
professional talking therapies as alternatives to psychiatry.  The licence to medically intervene 
either pharmacologically or through surgery is psychiatry’s major marketing edge.  Breggin 
contends: 
‘In the early 1980s, the APA made a decision that changed its history and that of our 
society.  It decided to create an economic and political partnership with the drug 
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companies.  The partnership would enable psychiatry to use drug company funds to 
promote the medical model, psychopharmacology, and the authority and influence of 
psychiatry…Psychiatry’s decision to save itself by going into partnership with the drug 
companies was an openly discussed survival plan.’173 
Elements of the co-operative relationship include that in 1982 the pharmaceutical industry 
funded the establishment of a Washington based APA Political Action Committee to lobby 
Congress.  The pharmaceutical industry also partly paid for the APA's media training workshops.  
Prominent psychiatrists were paid by pharmaceutical companies to deliver rehearsed speeches 
and became 'thought leaders' frequently quoted in the media.174  One US psychiatrist, Stefan 
Kruszewski, who delivered paid speeches for Pfizer, Glaxo-Smith Kline and Johnson and 
Johnson, claimed he was pressured to lie in presentations.175 
Some of these thought leaders have agreed to be listed as authors of ghostwritten articles 
written by pharmaceutical company employees that promote their products in return for gifts 
‘and trips to luxurious settings’.  In addition, supposedly ‘independent’ researchers served as 
‘consultants to companies whose products they are studying, join advisory boards and speakers’ 
bureaus, enter into patent and royalty arrangements’.176 
As well as the abovementioned changes there was a significant move away from research at 
American academic medical centres to American commercial research facilities during the 
1990s.  Part of the explanation is likely to be that the commercial research sector completes 
drug trials faster and at lower cost than academic medical centers.177 Given that universities 
are at least not notionally profit motivated, there is arguably a greater potential for 
commercial researchers to tailor their results to suit the needs of their potential ongoing 
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client particularly if the client represents a significant proportion of their potential revenue 
base.     
The close commercial relationship between the APA and the pharmaceutical industry that 
emerged in the 1970s and 1980s coincided with the shift from a psychoanalytical focus in 
DSM-II published in 1968 to a biological focus in DSM-III published in 1980.178  The biological 
focus of DSM-III, and the later DSM-IV, aligned with the interests of pharmaceutical 
manufacturers producing products that treat perceived biochemical imbalances.  
In a very short period of time, mental illnesses were transformed from broad, 
etiologically defined entities that were continuous with normality to symptom-
based, categorical diseases. The third edition of the American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-III) was 
responsible for this change…Its symptom-based diagnoses reflect a growing 
standardization of psychiatric diagnoses. This standardization was the product of 
many factors, including: (1) professional politics within the mental health 
community, (2) increased government involvement in mental health research and 
policymaking, (3) mounting pressure on psychiatrists from health insurers to 
demonstrate the effectiveness of their practices, and (4) the necessity of 
pharmaceutical companies to market their products to treat specific diseases.179   
Many of the concerns discussed in this section of the chapter relate to commercial relations 
dealings between the APA and the pharmaceutical industry.  However, the Chairperson of DSM-
IV development taskforce, Dr Allen Frances, believes that financial conflicts of interest are not 
necessarily as important as what he terms ‘intellectual conflicts of interest’. He contends 
‘experts always overvalue their pet area and want to expand its purview, until the point that 
everyday problems come to be mislabelled as mental disorders.’180  There is little systemic 
evidence to support or refute Frances’ contention, but if true it supplements rather than refutes 
concerns about the scientific validity of the diagnostic criteria in the DSM.   
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3.3 History of ADHD: the broadening of the diagnostic criteria 
As discussed above and identified by Abraham (refer to 2.5), since the 1970s there has 
been a progressive broadening in the diagnostic criteria for ADHD and the conditions that 
predated ADHD.  The history of the forerunners of ADHD begins in 1902 when Dr Fredric 
Still documented cases involving impulsiveness, labeling it a ‘defect of moral control’.  It 
was later renamed ‘minimal brain damage’.  In 1922 the symptoms were further defined 
and given the name ‘post encephalitic behaviour disorder’.181 
The use of stimulants to modify behaviour began in 1937 when American doctor Charles 
Bradley was the first to recommend stimulants to treat hyperactive children. 
…[Bradley] observed the ‘calming’ effect of stimulants on children when he gave 
Benzedrine (trademark for amphetamine) to a group of 30 children in order to 
treat headaches that resulted from spinal taps they were given.  The Benzedrine 
did not do anything for the headaches, but it did make the children less active and 
more compliant, in a fashion he called ‘spectacular.182  
Bradley had identified the effects of amphetamines on ‘normal’ children but proposed 
amphetamines as a treatment for hyperactive children.  In 1950 he undertook a study of 275 
hyperactive children given amphetamines.  He reported ‘between 60 per cent and 70 per cent 
to be much improved while on the drugs’.183  
In 1956 the stimulant Ritalin was first used as a treatment for hyperactive children.  During the 
1960s the use of stimulant medication to treat hyperactive children became more common.  
However it was not until the 1990s that, facilitated by the loosening of the DSM-IV diagnostic 
criteria, prescribing rates exploded in North America (and Australia).184 
Except for Still’s ‘defects of moral control’, early emphasis was on aetiology-based descriptions 
of the disorder’s predecessors.  This is despite the fact that the cause or causes had never been 
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established.  The term ‘minimal brain dysfunction’ used in the early 1960s was altered in the 
late 1970s to ‘hyperactive disorder of childhood’.  During the 1970s, further symptoms such as a 
lack of focus and daydreaming were added to the diagnostic list.  Impulsiveness was also 
expanded at this time to include verbal, cognitive and motor impulsiveness.  In 1980 the APA 
voted to change the name of the disorder to ‘attention deficit disorder’ (ADD) and its definition 
was again expanded.  The new definition was based on the assumption that attention 
difficulties are sometimes independent of impulse problems and hyperactivity – the disorder 
was redefined as primarily a problem of inattention, rather than of hyperactivity.  In keeping 
with this approach, two subtypes of ADD were presented in DSM-III (APA 1980): ADD/H, with 
hyperactivity, and ADD/WO, without hyperactivity or passive ADD.  The recognition of passive 
ADD has been the subject of debate ever since.  
With DSM-III-R (APA 1987), the revised version of DSM-III, the name of the condition was 
changed to the one used today, Attention Deficit Hyperactivity Disorder (ADHD), and the 
symptoms were again merged into a single disorder without any subtypes.  Specifically, DSM-III-
R required a child to display six of nine inattentive behaviours and six of nine 
impulsive/hyperactive behaviours.185  This diagnostic requirement did away with the possibility 
that an individual could have the disorder without being hyperactive.  A child had to display 
both inattentive and hyperactive/impulsive behaviours.  This change went against the long term 
trend of loosening the diagnostic criteria. 
Subsequent to the release of DSM-IIIR a number of studies were published justifying the 
existence of passive or inattentive ADD without the hyperactivity element.  In response to this 
backlash, the definition was changed yet again in the fourth edition of the manual published in 
1994 (DSM-IV).  The 1987 decision was effectively reversed as the criteria were broadened so 
that a ‘patient’ needed to display six of nine inattentive or six of nine hyperactive/impulsive 
behaviours.  
The APA did not change the name ADHD, but the symptoms were divided into two categories: 
inattentive and hyperactive/impulsive.  Three subtypes of the disorder were also defined: 
‘ADHD – Primarily Inattentive’, ‘ADHD – Primarily Hyperactive/Impulsive’, and ‘ADHD – 
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Combined Type (both inattentive and impulsive)’.  Not surprisingly, this created some confusion.  
Sometimes when the term Attention Deficit Disorder (ADD) is used today it is used in its original 
generic sense – interchangeably with ADHD. On other occasions it is used as a specific descriptor 
of passive ADHD without the H for Hyperactivity.  
ADHD now applies to a broad spectrum of child behaviour.  Children who are considered too 
active (hyperactive) and children who are considered too inactive (hypoactive) are included.  In 
addition to the ADHD hyperactive and inattentive subtypes, DSM-IV-TR186, the version of DSM-
IV updated in 2000 contains yet another category, ‘Attention Deficit/Hyperactivity Disorder – 
Not otherwise specified’, which further broadens the criteria to include ‘individuals whose 
symptom pattern does not meet the full criteria for the disorder’.187 
DSM-IV Chairperson Allen Frances later acknowledged the role of expanded DSM-IV criteria in 
triggering a ‘false epidemic for ADHD’, however he believes this was part of a greater process of 
commercially driven pharmaceuticalization:  
It is no coincidence that rates began skyrocketing immediately after two 
unrelated events that occurred almost simultaneously in the late 1990s.  
First, new drugs for ADD were brought to market that were no better than 
the old drugs, but they were lots more expensive and provided a rich profit 
incentive for aggressive marketing.  Second, FDA deregulation freed drug 
companies to pursue unrestrained direct-to-consumer multimedia 
advertising.  The companies quickly determined that peddling the ADD ill 
was the royal road to expanding the market for their new expensive pills…  
The epidemic started precisely when aggressive drug company marketing 
succeeded in ‘educating’ and sensitizing doctors, parents, and teachers to 
spot ADD in kids previously considered to be on the normal side of the 
spectrum's boundary…  The drug company cause has been furthered by 
heavily subsidized thought leaders (usually psychiatrists), by physicians 
(especially in primary care) who are too free in diagnosis and treatment, and 
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by harried parents and teachers trying to figure out how best to help and 
manage their difficult children.188  
In contrast to the assertions of Dr Frances and other critics, ADHD proponents contend that 
better education of clinicians, improved diagnostic procedures and increased public 
awareness of the condition account for increased prescribing rates internationally.  For 
example the Canadian Attention Deficit Hyperactivity Disorder Resource Alliance, a 
Canadian ADHD patient support group contends: ‘ADHD may seem to be more common 
today than in the past but this is largely due to the increase in research and media scrutiny. 
Research has encouraged awareness within the professional community, leading to better 
diagnoses.  Media coverage, although not always accurate, has heightened public 
awareness of the condition.’189  Other ADHD proponents agree, arguing that greater 
knowledge and awareness of the disorder has ‘empowered physicians and parents’ resulting 
in higher diagnosis and prescribing rates.190 
3.4 Further broadening of ADHD criteria in DSM-5 
The latest edition of the APA’s DSM, DSM-5, was released in May 2013.  Frances regrets 
changes in DSM-IV as helping ‘trigger three false epidemics..for Autistic Disorder…[the] 
childhood diagnosis of Bi-Polar Disorder and the… the wild over-diagnosis of Attention 
Deficit Disorder.’191  Dr Frances warned of similar problems with DSM-5.  After reviewing an 
early draft of DSM-5 he predicted further 'false epidemics' and 'unnecessary, expensive and 
often horrible treatments for conditions that really are made up by the people doing the 
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manual (DSM5)'.192   A draft released for public comment attracted considerable critical 
attention that resulted in significant back-downs by the DSM-5 development committee, 
including abandoning most of the changes proposed for ADHD diagnostic criteria.   
The most obvious of the abandoned proposed changes was the inclusion of four extra ways 
of exhibiting ADHD.  For a diagnosis of the primarily hyperactive subtype, instead of 
children having to display 6 of 9 (67 percent) impulsive/hyperactive diagnostic criteria, it 
was proposed that 6 of 13 (47 percent) would be sufficient. The four additional criteria 
proposed were: 
1. Tends to act without thinking, such as starting tasks without adequate 
preparation or avoiding reading or listening to instructions.  May speak out 
without considering consequences or make important decisions on the spur of 
the moment, such as impulsively buying items, suddenly quitting a job, or 
breaking up with a friend. 
2. Is often impatient, as shown by feeling restless when waiting for others and 
wanting to move faster than others, wanting people to get to the point, speeding 
while driving, and cutting into traffic to go faster than others. 
3. Is uncomfortable doing things slowly and systematically and often rushes 
through activities or tasks. 
4. Finds it difficult to resist temptations or opportunities, even if it means taking 
risks (A child may grab toys off a store shelf or play with dangerous objects; 
adults may commit to a relationship after only a brief acquaintance or take a job 
or enter into a business arrangement without doing due diligence).193 
For anyone aged 17 or older the ADHD diagnostic threshold was proposed to be lowered 
even further.  If the proposed changes were adopted it would be sufficient to meet as little 
as 4 (down from 6) of either the 9 inattentive or 4 of the expanded 13 impulsive/hyperactive 
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criteria.194  These proposed changes would have continued the long term trend of lowering 
the bar for a diagnosis of ADHD.  DSM-III (APA 1980) required six of nine inattentive 
behaviours and six of nine impulsive/hyperactive behaviours.  The bar was lowered 
significantly in DSM-IV (APA1994) when the requirement was reduced to six of nine 
inattentive or six of nine hyperactive/impulsive behaviours195  Effectively any patient was 
required to display at least 12 of 18 (67 percent) behaviours in DSM-III, however for DSM-5 
it was proposed that as few as 4 of 22 (17 percent) would qualify for a diagnosis for anyone 
aged seventeen or older. 
Other more subtle but nonetheless significant proposed changes included: 
1. The relaxation of the DSM-IV expectation that teachers independently provide 
evidence.  DSM-IV states; ‘The clinician should therefore gather information 
from multiple sources (e.g. parents, teachers) and inquire about the individual’s 
behavior in a variety of situations within each setting.196 The wording proposed 
for DSM5 was: ‘In children and young adolescents, the diagnosis should be based 
on information obtained from parents and teachers.  When direct teacher 
reports cannot be obtained, weight should be given to information provided to 
parents by teachers that describe the child’s behavior and performance at 
school’.197    
2. Replacing hyperactive actions in the wording of criteria to feelings or perceptions 
of ‘restlessness’. One of the hyperactive/impulsive diagnostic criteria in DSM-IV 
states; ‘often leaves seat in classroom or in other situations in which remaining 
seated is expected.’198  The wording proposed to replace this in DSM5 was: often 
restless during activities when others are seated (may leave his or her place in 
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the classroom, office or other workplace, or in other situations that require 
remaining seated).199   
3. Pathologising the normal phenomena that ADHD behaviours are ‘typically more 
marked during times when the person is studying or working’ than ‘during 
vacation’.200 
4. The inclusion of adult relevant examples in most of the diagnostic criteria which 
had previously been primarily orientated to children in a school setting.201 
5. The change in the requirement that signs of the behaviour should be displayed 
before age seven to age twelve.202 
All the DSM-5 proposed changes if implemented were likely to increase ADHD patient 
numbers and ADHD pharmaceuticalization. 
In August 2011 Frances criticized the proposed changes: 
We are already in the midst of a false epidemic of ADD…In part this came 
from changes in DSM-IV, but most of the inflation was caused by a 
marketing blitz to practitioners that accompanied new on-patent drugs by 
new regulations that also allowed direct to consumer advertising to parents 
and teachers.  In a sensible world, DSM5 would now offer much tighter 
criteria for ADD and much clearer advice on the steps needed in its 
differential diagnosis.  This would push back, however feebly, against the 
skilled and well financed drug company sell.  DSM5 should work hard to 
improve its text, not play carelessly with the ADD criteria in a way that may 
unleash a whole set of dreadful unintended consequences – unneeded 
medication, stigma, lowered expectations, misallocation of resources, and 
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contribution to the illegal secondary market peddling stimulants for 
recreation or performance enhancement.203 
After widespread criticisms similar to those made by Frances the APA backed down on many 
of its proposed changes for ADHD in DSM5.  It abandoned the proposal to include the 
abovementioned four additional criteria and reduced the number of criteria for people aged 
17 and over to five, not four, as was originally proposed.  However, the existing 18 
diagnostic criteria have been reworded to be applicable to adults as well as children, 
reflecting the ADHD industry’s persistent and successful efforts to expand the adult 
market.204 
Another remaining concern for ADHD critics was the inclusion of an ADHD category titled 
Attention Deficit/Hyperactivity Disorder Not Elsewhere Classified.  This additional category 
reads:  
Attention Deficit/Hyperactivity Disorder (ADHD) Not Elsewhere Classified may be 
coded in cases in which the individuals are below threshold for ADHD or for whom 
there is insufficient opportunity to verify all criteria. However, ADHD-related 
symptoms should be associated with impairment, and they are not better explained 
by any other mental disorder.205   
The inclusion of this additional category effectively enables clinicians to diagnose and 
prescribe without even the protection offered by the already extremely broad DSM-IV 
diagnostic criteria. 
The APA only modified its original proposals after significant past users of the DSM, 
including the British Psychological Association and chapters of the American Psychological 
Association, threatened a boycott of DSM5.206  This supports the contention that the APA’s 
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DSM development process is driven by politics, pressure, and money, rather than science 
and patient welfare. 
3.5 Regulatory Capture and International Drug Research 
The ADHD drug manufacturers are multinational companies that sell the pharmacologically 
identical products around the globe.  The decision whether to licence and subsidise the 
drugs is made by each individual nation’s regulatory authorities.  However, these individual 
decisions are often substantially based on submissions from the drug manufacturers which 
use the same research in different national jurisdictions. 
In 2012 Canadian researcher Professor Marc-André Gagnon concluded that the ‘dominant 
business model’ of the pharmaceutical sector is to promote drugs that often don’t offer any 
significant ‘therapeutic advance’.  He contends research is conducted by the pharmaceutical 
industry ‘like a promotional campaign’. 
Data obtained from clinical research are primarily used to boost and support sales 
rather than to improve prescribing behaviour… Ghostwriters are employed to inflate 
the number of publications showing the drug in a positive light; results that would 
harm sales are not published (publication bias); and negative data are suppressed… 
Pharmaceutical companies consider that private-sector clinical research produces 
private, confidential results that are their own intellectual property… And they are 
not compelled by political and health authorities to make public the data obtained in 
clinical trials.207 
As evidence of these assertions Gagnon highlighted that: 
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 ‘The [world’s] 15 biggest drug companies… spend about twice as much on promotion 
as on research.’208 
 ‘In 2009, Prescrire analysed 109 new [to the French market] drugs or indications 
(excluding generics): 3 were considered a minor therapeutic breakthrough, 76 added 
nothing new to the existing pharmacopoeia, while 19 were deemed to represent a 
possible public health risk.’209  
 In 2004 after causing an estimated 60,000 deaths worldwide primarily from heart 
attacks and strokes Merck pharmaceuticals bestselling arthritis drug Vioxx was 
withdrawn from sale worldwide.  Prior to that ‘Merck mounted a ghostwriting 
campaign [to promote Vioxx]… 96 articles were published, some of which omitted to 
mention the deaths of patients who participated in clinical trials of the 
drug.210…Merck had ‘drawn up a hit list of “rogue” researchers who had criticised 
Vioxx [who] had to be discredited and ‘neutralized’.211 212 
Gagnon concludes ‘as long as pharmaceutical companies hold the purse strings of 
biomedical research, medical knowledge will be selectively constructed for the purpose of 
marketing drugs rather than improving public health.’213  Gagnon’s criticisms of the French 
and Canadian systems are similar to those of critics of the USA drug licencing system 
administered by the Food and Drug Administration (FDA).  In the USA, pharmaceutical 
companies are free to determine who conducts their studies, which studies they publish and 
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Study of Industry Documents from Rofecoxib Litigation’, Journal of American Medical Association, 299: 
15 (2008). 
211  M Rout, “Vioxx maker Merck and Co drew up doctor hit list” The Australian 1 April 2009. 
212  Vioxx was an arthritis and acute pain medication that was launched in the United States in 1999 by Merck & Co 
and was marketed in over eighty countries. Sales in 2003 were worth $2.5 billion. In March 2000 the results of a 
study, the Vioxx Gastrointestinal Outcomes Research (VIGOR), indicated an increased risk of cardiovascular 
events. This trial found that there was an increased relative risk for confirmed cardiovascular events, such as 
heart attack and stroke, 18 months after treatment began. ‘Merck Announces Voluntary Worldwide Withdrawal 
of VIOXX®’, available at http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf (accessed 
7 February 2007).  Merck failed to warn treating doctors or patients about the results of the VIGOR study 
(2000). No information, let alone warnings, about the risks were given, until some two years later.  Even then the 
information that was finally given was unclear.  Consequently, doctors and patients continued prescribing and 
using Vioxx until its withdrawal.  As a result, thousands of people may have suffered serious injury or died as a 
result.  
213
  Gagnon, ‘Corporate influence over clinical research’.    
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which they keep private.  Some pharmaceutical companies use two methods to deny the 
FDA and the American public full information.  The first is to ignore unfavourable studies.  
The second is to spin the results of unfavourable findings for the ‘primary outcome’ – the 
main question the study was designed to answer – and highlight a favourable ‘secondary 
outcome’.214  Pfizer, the manufacturer of antidepressant Zoloft, conducted five studies for 
presentation to the FDA: 
The drug seemed to work better than the placebo in two of them.  In three other 
trials, the placebo did just as well at reducing indications of depression.  Only the 
two favorable trials were published, researchers found, and Pfizer discusses only 
the positive results in Zoloft’s literature for doctors.215  
These tactics are not limited to Pfizer.  In 2008 the Wall Street Journal highlighted that in the 
case of 74 pharmaceutical company sponsored studies into antidepressants, 37 of 38 favourable 
studies were published, but the majority of unfavourable (22 of 36) studies were not.  Of the 
fourteen unfavourable studies that were published, ‘at least 11 of those studies 
mischaracterized the results and presented a negative study as positive… In nine (of 11) of the 
negative studies that were published, the authors simply omitted any mention of the (negative) 
primary outcome.’216  
3.6 Oregon Health and Science University ADHD Drug Effectiveness Review Project 
Both Gagnon’s analysis and the American experience demonstrate the capacity for 
regulatory capture of research and licencing in Western democracies. Research directly 
related to ADHD and drugs marketed in Australia was conducted by the Oregon Health and 
Science University in 2005.  The ADHD Drug Effectiveness Review Project was commissioned 
by fifteen US states in order to determine which drugs were the safest and most cost 
effective.217  The 731-page review analysed 2287 studies, ‘virtually every investigation ever 
                                               
214  David Armstrong and Keith J. Winstein, ‘Antidepressants Under Scrutiny Over Efficacy’, The Wall Street 
Journal, 17 January (2008). 
215  Armstrong and Winstein, ‘Antidepressants Under Scrutiny’. 
216  Armstrong and Winstein, ‘Antidepressants Under Scrutiny’. 
217  Marian S. McDonagh, Kim Petersen, et al (2007), Drug Class Review on Pharmacologic Treatments for 
ADHD: Final Report Update 2, Portland, Oregon Health & Science University.  Available at 
http://www.ohsu.edu/ohsuedu/research/policycenter/customcf/derp/product/ADHD_Final%20Report%20Upda
te%202_Evidence%20Tables.pdf (accessed 13 February 2009). 
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done on ADHD drugs anywhere in the world’.218  Of the studies analysed, ‘The group 
rejected 2,107 investigations as being unreliable, and reviewed the remaining 180 to find 
superior drugs’.219  Instead of being able to make objective comparisons of the safety and 
effectiveness of the different drugs, the review was ‘severely limited’ by a lack of studies 
measuring ‘functional or long-term outcomes’.220 
The review concluded that ‘evidence on the effectiveness of pharmacotherapy for ADHD in 
young children is seriously lacking’221 and that there was ‘no evidence on long-term safety of 
drugs used to treat ADHD in adolescents’.222  The review also found that ‘good quality evidence 
on the use of drugs to affect outcomes relating to global academic performance, consequences 
of risky behaviours, social achievements, etc. is lacking’.223  It was also critical of the lack of 
research into the possibility that some ADHD drugs could stunt growth.224  In addition it found 
that the evidence that ADHD drugs help adults was ‘not compelling’.225  Overall, the report 
ascertained that the quality of evidence was very often ‘poor’.226 
3.7 Imported Regulatory Capture Summary 
In Australia the appearance of new ADHD drugs on the market and government 
subsidisation of the drugs has followed the US experience generally, lagging by a few years 
(refer Chapter 4).  One significant difference is that direct to consumer marketing has 
remained illegal. Therefore US experience is not identical to Australia’s.  
However, the official endorsement by Australian authorities, most notably the professional 
associations and the National Health and Medical Research Council, of the DSM-IV 
diagnostic criteria over which the Australian medical profession has no control, results in 
Australian psychiatric practice being influenced by the same forces that influence American 
                                               
218   Alexander Otto (2005), ‘Are ADHD drugs safe? Report finds little proof’, The News Tribune, 13 September 
2005.  Available at http://www.playattention.com/attention-deficit/articles/are-adhd-drugs-safe-report-finds-
little-proof (accessed 12 May 2007). 
219   Otto, ‘Are ADHD drugs safe?’. 
220   Otto, ‘Are ADHD drugs safe?’.  
221   Oregon Health & Science University, Drug Class Review, p.24.  
222  Oregon Health & Science University, Drug Class Review, p.20.  
223  Oregon Health & Science University, Drug Class Review, p.16.  
224  Oregon Health & Science University, Drug Class Review, p.19. 
225  Oregon Health & Science University, Drug Class Review, p.21. 
226  Oregon Health & Science University, Drug Class Review, pp.77-81. 
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psychiatric practice.  Regulatory capture in the US of the APA has therefore become 
imported regulatory capture in Australia. 
Similarly Australian regulatory authorities have no direct control over much of the research 
that is used to evaluate the safety and efficacy of ADHD medications.  Australia is effectively 
an importer of this evidence with limited capacity to ensure its integrity.  The effect of this 
imported research on Australian policy development and regulatory processes is described 
in greater detail in chapter 5 (particularly 5.3.2, 5.4.1 and 5.4.2).  But first, Chapter 4 
provides statistical information on the prescription of ADHD medications in Australia.   
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Chapter 4.  Statistics on Australian National and Western Australian and New 
South Wales ADHD prescribing rates 
 
This chapter presents and analyses relevant statistical data about national, Western 
Australian (WA) and New South Wales (NSW) child and adult ADHD drug prescribing per 
capita rates from 1992 to 2011.  These data are referred to extensively in subsequent 
chapters.   
4.1 Sources of Data 
Commonwealth Government Sources: There is no single data source that provides accurate 
statistics of Australian national and state ADHD child prescribing rates for the entire study 
period 1992 to 2011.  Between 1992 and 2002 Commonwealth Government state-specific 
prescribing data are limited to total Pharmaceutical Benefits Scheme (PBS) subsidised 
prescription numbers and there is no reliable estimate of patient numbers or their ages.  
Accurate statistical data of ADHD PBS funded state-specific child patient numbers is 
available from the Australia Department of Health and Ageing (DoHA) for the period 2002 to 
2011.  However, it was not until July 2007 that all ADHD medications were subsidised via the 
Pharmaceutical Benefits Scheme.  
For the years 1995 to 2010 DoHA has identified the annual national total of both PBS 
subsidised and unsubsidised ADHD prescriptions.227  However, the DoHA data does not 
identify individual state rates or patient numbers or ages and are therefore only useful for 
identifying national trends in prescribing.  
WA and NSW State Government Sources: Several sources provide data that allows 
estimation of state prescribing rates, particularly for WA and to a lesser extent NSW.  The 
availability of these state-based statistics and significant historical data on policy and 
regulatory processes in these states are the reasons these states were chosen for a detailed 
analysis.   
                                               
227  The Commonwealth Department of Health and Ageing has produced a series of annual reports titled 
‘Australian Statistics on Medicines’ covering the period 1995 to 2010.  These reports are available at 
http://www.pbs.gov.au/info/browse/statistics#ASM (accessed 31 August 2013). 
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Of all Australian states WA has the most comprehensive and detailed historical data about 
both ADHD prescribing rates and regulation and policy development practices.  In addition it 
has historically been an outlier with per capita prescribing rates showing a considerably 
different pattern in WA compared with other Australian jurisdictions. 
Data for NSW is not as comprehensive.  However in recent years, namely between 2007 and 
2012, NSW per capita child prescribing rates have grown significantly and are now the 
highest in Australia.  This followed a significant regulatory and policy process in 2007, the 
Clinical Excellence Commission Prescribing Review, discussed in section 6.10.1. 
4.2 National prescribing rates for ADHD medications 1992-2011  
Information about the pattern of national ADHD prescribing in the study period is presented 
in three figures below. Each covers different time periods and has limitations resulting from 
the data source.  Although chapters 5 and 6 of this thesis later analyse policy processes in 
the 2012 year, significant statistical data were not available at the time of writing for the 
2012 calendar year. 
 
Source: Department of Health and Ageing, Medicare Australia.  Self-generated report available at 











Figure 1. Australian PBS subsidised ADHD prescriptions for all ages 1992-2011 
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In Figure 1 Australian national rates are shown using data sourced from the PBS.  This 
information first became available in 1992 when dexamphetamine was added to the PBS 
hence Figure 1 above commences in 1992. The major limitations of these data are that they 
do not include non-PBS prescriptions and or provide information about the number of 
patients or breakdown by age.  Another limitation is that it does not take account of the 
27.7 percent increase in Australia’s population between 1992 (estimated 17,581,000) and 
2011 (estimated 22,447,000).228  
 
Source: Department of Health and Ageing Australian Statistics on Medicines Available at 
http://www.pbs.gov.au/info/browse/statistics#ASM (accessed 31 August 2013) 
Figure 2 is far more comprehensive than Figure 1 although it covers a shorter timeframe 
(1995 to 2010).  It incorporates both PBS-subsidised and unsubsidised prescriptions, and 
presents the information as the Australian defined daily dose (DDD) per 1000 days between 
1995 (1.031 per 1000) and 2010 (3.888 per 1000 days). The World Health Organisation 
definition of DDD is the ‘assumed average maintenance dose per day for a drug used for its 
                                               
228  ChartsBin statistics collector team (2010), Historical Population of Australia, 1788 to Future, 
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main indication in adults.’229  The most significant limitation for the purpose of this thesis is 
that it does not identify patient numbers or differentiate between prescriptions to adults or 
children.  In addition as the DDD refers to ‘assumed average dose used for adults’ and 
children on typically lower doses are the majority of ADHD medication users, it is likely that 
the measure underestimates the actual Australian average daily dose per 1000 days. 
 
 
Source: Department of Health and Ageing (2012), Letter to Martin Whitely dated 21 April 2012. 
Figure 3 covers the period 2002 to 2012 and provides an accurate breakdown of the age 
demographic of patients receiving PBS subsidised ADHD drugs.  This information was not 
collected by DoHA before 2002.  As in Figure 1 the most significant limitation is that it does 
not include non-PBS prescriptions.  The first ADHD drug subsidised via the PBS was 
dexamphetamine in 1992. Ritalin, although commonly prescribed, was not subsidised until 1 
August 2005.  Ritalin LA, Concerta and Strattera were added in 2007.230  As these 
medications became subsidised the Commonwealth Government data source became more 
comprehensive and useful for this analysis.  For instance in the 1999/2000 financial year 
                                               
229  ‘Definition and general considerations’, World Health Organisation Collaborating Centre for Drug 
Statistics Methodology.  Available at http://www.whocc.no/ddd/definition_and_general_considera/ 
(accessed 31 August 2013). 
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‘around 96 000 prescriptions for Ritalin were dispensed in Australia’.  This was roughly 30 
percent of the total prescribed in 2000.231  Another limitation of Figure 3 is that like Figure 1 
it does not take account of population change.  Between 2002 and 2011 the Australian 
population increased 13.5 percent.232 
Regardless of the distorting factors identified above, the trend in the three figures above is 
so strong that they provide compelling evidence of an explosion in ADHD prescribing for the 
period 1992 to 2011.  Figure 2 provides the most compelling evidence of rapid 
pharmaceuticalization for ADHD during the study period.  Accounting both for population 
changes and unsubsidised prescription it indicates a 277 percent growth in per capita 
prescribing rates between 1995 and 2010. 
Figure 1 shows an even more dramatic increase however this is in part due to the 
substitution of subsidised prescriptions for unsubsidised prescriptions as more medications 
were added to the PBS.  As demonstrated in Figure 2 the proportion of subsidised scripts of 
total prescriptions rose from 49.5 to 74.2 percent between 2005 and 2010.  Nonetheless 
Figure 1 provides evidence that the process of pharmaceuticalization occurred in the 
periods not covered in the data presented in Figure 2. Specifically between 1993 (the first 
full year of PBS subsidisation) and 1995 and between 2010 and 2011 the numbers of ADHD 
PBS subsidised prescriptions increased 220 percent and 3 percent respectively. 
Despite the limitations identified above and the shorter timeframe (2002-2010) Figure 2 is 
very significant.  It demonstrates the rapid pharmaceuticalization of the treatment of ADHD 
in Australia, particularly for children over this period with the total number of children 
receiving PBS subsidised prescriptions growing 98 percent between 2002 and 2010. 
It is notable that there was a small fall in the number of scripts between 2004 and 2005 (see 
Figure 1 and Figure 2), and a small fall in the number of child patients between 2002 and 
2004 (see Figure 3). The reasons for the small timing discrepancy are unclear.  However, 
these small downturns are inconsistent with the long-term trend of rapidly increasing 
                                               
231  Australian Parliament, Medication for Attention Deficit/Hyperactivity Disorder (ADHD): an analysis by 
Federal Electorate (200103), Research Brief No. 2. 200405, 16 November 2004.  Available 
http://www.aph.gov.au/library/pubs/RB/2004-05/05rb02.htm#Exec 
232
  ChartsBin, Historical Population of Australia. 
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pharmaceuticalization.  It is likely that a significant part of the explanation of these small 
falls is the fall in WA prescribing rates since 2003 that is demonstrated in Figure 4. 
4.3 Western Australian inter-temporal statistics on ADHD child prescribing 
The WA Government collects data about the rates of prescribing of ADHD medications.  
Neither WA data nor Australian Commonwealth data are individually sufficient to properly 
evaluate inter-temporal trends in WA prescribing between 1992 and 2011.  In combination, 
however, they do provide sufficient information to identify significant trends in prescribing 
patterns. 
Commonwealth Government data sources on WA prescribing numbers: Commonwealth 
Government data on state-specific prescribing are limited to those collected or derived from 
the PBS.  The most significant limitation is that data regarding prescriptions that are 
privately funded or funded via state public health systems (primarily WA Government 
hospitals, child development clinics and child and adolescent mental health services) are not 
captured by this system.  This limitation was particularly significant before all ADHD 
medications were subsidised via the PBS.   
In addition, as previously identified it was not until 2002 that age-specific patient numbers 
were collected for each state.  Furthermore, these data were not reported until, upon my 
request, DoHA provided me with age-specific, drug-specific, state-based data in April 2012.  
Therefore from 1992 to 2002 Commonwealth Government prescribing data for WA are 
limited to total prescription numbers and there are no reliable estimates of patient 






Source: Department of Health and Ageing, Medicare Australia.  Self-generated report available at 
http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-stats.htm-copy3  (accessed 5 
August 2012) 
WA Government data sources: In August 2003 the WA Health Department began collecting 
detailed data identifying the number of patients by age, gender, health district, prescriber 
and dosage for all ADHD stimulants via the WA Stimulants Regulatory Scheme.  This has 
provided detailed calendar-year data for analysis. However, for the purposes of this thesis, it 
has three significant limitations: 
1. Most significantly, it does not provide detailed demographic data (patient age, 
diagnosis, dose etc.) about the period prior to the introduction of this system which 
occurred simultaneously to the abolition of ‘block authorisation’ (see 6.4.1).  Hence 
it is insufficient, in isolation, to determine the statistical results of the abolition of 
Block Authorisation and tighter prescribing accountability procedures.  In other 
words, it enables the analysis of the ‘after’ period of prescribing accountability 
changes but does not alone provide an accurate ‘before’ baseline estimate of child 
prescribing numbers. 
2. The Stimulants Regulatory Scheme does not provide data about prescriptions of 
atomoxetine hydrochloride (brand name Strattera) which was approved as a second 
















2004, and was subsidised via the PBS from 1 July 2007.  However, Commonwealth 
PBS data on an aged, per state-basis are available for Strattera, which indicates that 
it constitutes a relatively small proportion of the total number of patients who 
receive subsidised ADHD medications. 233  Nonetheless, as for all ADHD medications, 
it cannot be assumed that all Strattera prescriptions are subsidised via the PBS as 
individuals may obtain them free via state health services or pay for scripts without 
subsidisation. 
3. Teething issues with the introduction of the Stimulants Regulatory Scheme, including 
ensuring all prescribers completed all notifications, limits the reliability of prescribing 
numbers reported, particularly for the early years (2003-2006) after the system’s 
introduction in August 2003.  This is likely to result in an underestimation of the 
number of patients prescribed psychostimulants in the WA Department of Health 
estimates in the early years of the introduction of the system. 
Prior to the introduction of the WA Stimulants Regulatory Scheme the WA Health 
Department published estimates of the numbers, including age breakdowns, of Western 
Australian patients using ADHD medications for 2000 and 1994.  There are significant 
limitations as to the accuracy and reliability of these estimates which will be identified when 
they are quoted. 
In order to provide more reliable information, in October 2012 the WA Department of 
Health produced a retrospective analysis of the number of patients dispensed ADHD 
psychostimulants from 1998 to 2011.  However, the analysis states ‘the pre-2003 data 
should be viewed as a crude measure of stimulant use and only data from 2003 onwards 
should be relied upon to give an accurate picture of stimulant prescribing in Western 
Australia’.234  
Nonetheless, when used in combination with Commonwealth Government data, the WA 
data enables the estimation of child and adult ADHD prescribing rates for the 2002 and 2003 
                                               
233  Less than 7% of Western Australian child patients in 2011 took Strattera.  As Strattera is a second line treatment 
to be trialled if psycho-stimulants are ineffective or cause unacceptable side effects it is likely that a significant 
proportion of children who took Strattera had also taken a psychostimulant in the same calendar year. 
Department of Health and Ageing,  Letter to Martin Whitely dated 21 April 2012. 
234
  Department of Health, Western Australia Stimulant Regulatory Scheme 2011 Annual Report, p.15. 
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calendar years, covering the period just prior to the abolition of the block authorisation and 
the introduction of Stimulants Regulatory Scheme in August 2003. 
 
Sources: Department of Health (2012), Western Australia Stimulant Regulatory Scheme 2011 Annual Report. And, 
Department of Health and Ageing (2012), Letter to Martin Whitely dated 21 April 2012. 
Most of the data in Figure 5 are sourced from the WA Health Department Stimulant 
Regulatory Scheme 2011 Annual Report.  The exceptions are the estimate of the population 
for each year which were sourced from the Australian Bureau of Statistics and the 
breakdown between child (4-17) and adult figures for the 2002 and 2003 years.  For these 
years the WA Health Department provided an estimate of the total ADHD cohort number 
but not the breakdown between children and adults.  However DoHA data provides detailed 
information about the numbers of adult and child PBS patient numbers for 2002, 2003 and 
2004.   
Unlike WA Health Department figures these Commonwealth PBS figures for 2002 to 2004 do 
not include non-PBS funded scripts, for Ritalin sold at full price or Ritalin and 
dexamphetamine dispensed for free in state government clinics.  However, they cover the 
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Figure 5 - Percentage of WA population by age prescribed ADHD drugs 
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PBS cohort between 2002 (63.3 percent children) and 2004 (54.9 percent).235  The 2004 WA 
Health Department proportion (58.4 percent)236 was used as the starting point and the 2002 
and 2003 child and adults figures were estimated by interpolating the same pattern of 
relative movement as demonstrated in the commonwealth figures.  As a result it was 
estimated that 66.1 percent were aged 0-17 in 2002, and 62.1 percent were aged 0-17 in 
2003.   
There are many possible reasons for the small (3.5 percent) difference in the proportion of 
children in the Commonwealth and State data for 2004 including:  
 Different age classifications for the state and commonwealth systems. 
 Differences in the date of prescribing (the time of age information capture for the 
state based system) and dispensing of the drugs (the time of age information 
capture for the commonwealth based system).     
 The dispensing of free sample packs as the first dose for newly diagnosed patients. 
 The tendency for a higher proportion of adults to use dexamphetamine, with 
relatively more children using Ritalin.  As only dexamphetamine was PBS subsidised 
from 1992 until 2005, this would lead to the proportion of children in the 
Commonwealth PBS data source being lower than the state based WA figure.  
Irrespective of the reason the difference is modest.  The more complete state based data 
are the data used in Figure 6 for 2004-11 and the basis of the estimate for 2002 and 2003 
years.  
4.3.1 Patient numbers growth from 1992 to 2002   
Because of the absence of reliable data on the relative child to adult patient breakdown 
from either Commonwealth or state data sources it is impossible to reliably estimate the 
number of child and adult ADHD patients for the years prior to 2002.  However, WA Health 
Department estimates of the total number of Western Australians prescribed psycho-
stimulants for all purposes grew by over twenty-one-fold (from 880 to 18,715) from 1989237 
                                               
235  Department of Health and Ageing, Letter to Martin Whitely dated 21 April 2012. 
236  Department of Health, Western Australia Stimulant Regulatory Scheme 2011 Annual Report, .p15. 
237  ‘In 1989 in WA, 880 people were prescribed stimulant medication.’  Government of Western Australia 
(2002), Department of Health, Attentional Problems in Children: Diagnosis and Management of Attention 
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to 2002.  Of the 18,715 estimated to be on stimulants in 2002 an estimated 17,237 (92.1 
percent) were diagnosed with ADHD. 238  Commonwealth Government figures reveal a 
similar trend.  In 2002 WA’s child per capita PBS prescribing rate of dexamphetamine (at the 
time the only PBS-subsidised ADHD drug) was approximately 2.8 times the national average 
(excluding WA). 7,500 of the 31,738 (24 percent) Australian children who received a PBS 
dexamphetamine prescription lived in WA despite WA having about 10 percent of the total 
population.   
Despite the lack of detailed data, there was clearly a massive increase in patient numbers, 
consistent with the increase in PBS prescription numbers between 1993 and 2002 displayed 
in Figure 4.  Between 1993 (the first full year of PBS subsidisation) and 2002 the number of 
PBS subsidised prescriptions of dexamphetamine (the only PBS subsidised psycho-stimulant 
sponsored in this period) grew over fourteen-fold (from 5623 to 81892).239  
4.3.2 Analysis of inter-temporal trends in WA prescribing 
Figure 4 shows that the number of PBS subsidised scripts peaked in 2003 and then declined, 
with the largest fall in 2005.  This significant fall occurred even though Ritalin was added to 
the PBS in 2005 and, all other things being equal, it would be expected that PBS prescribing 
rates would increase as a result.  Although Figure 4 shows that the number of prescriptions 
peaked in 2003, Figure 5 shows the per capita prescribing rate for children peaked in 2002 
(although 2003 numbers are similar).  The small difference in the timing of the peaks may be 
a consequence of the rapid shift in the age profile of the WA ADHD cohort.  In 2002 
Commonwealth PBS data revealed that the proportion of children of the total number of 
patients receiving PBS subsidised dexamphetamine fell from 63.3 percent in 2002 to 54.9 
percent in 2004.240 
Collectively Figure 4 and Figure 5 show there was a massive and consistent increase in ADHD 
child prescribing between 1992 and 2002, and a large (50 percent) decrease in the 
proportion of 4 to 17 year olds prescribed between 2002 and 2010, with the major decline 
                                                                                                                                                  
Deficit Hyperactivity Disorder (ADHD) and Associated Disorders, Office of Mental Health, Department of 
Health, Perth, p.21.  
238  Department of Health, Western Australia Stimulant Regulatory Scheme 2011 Annual Report, p.15. 
239  Australian Government, Medicare Australia.  
240
  Department of Health and Ageing, Letter to Martin Whitely dated 21 April 2012. 
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occurring between 2003 and 2007.  WA adult patient per capita numbers increased 35 
percent (from 0.4 to 0.54 percent) between 2002 and 2011.  Clearly the factors influencing 
WA child and adult prescribing rates are significantly different. 
4.4 A comparison of NSW and WA inter-temporal statistics on ADHD prescribing  
Commonwealth PBS prescribing data allows a comparison of both child and adult 
prescribing rates between 2002 and 2011. 
4.4.1 WA versus NSW Child Prescribing Rates   
Figure 6 below compares NSW, WA and National, ADHD child prescribing per capita rates 
from 2002 to 2011.  The primary source of the data below is statistics provided to me by 
DoHA.  At my request DoHA collated the number of patients by age-group receiving PBS 
subsidised ADHD medication between 2002 and 2011.  
 
Source: Department of Health and Ageing (2012), Letter to Martin Whitely dated 21 April 2012. 
Figure 6 significantly under-estimates prescribing rates until 2007 – particularly before 2005 
when dexamphetamine was the only ADHD drug subsidised via the PBS.  The spike in NSW 
PBS prescribing rates in 2005 and 2007 in Figure 6 was most likely to have been caused by 
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Figure 6 - ADHD per capita prescribing as percentage of the population 






a similar spike in 2007 however in 2005 WA rates fell significantly despite Ritalin being 
added. 
The difference in the statistics and pattern of WA prescribing in Figure 6 (showing a spike in 
2007) and Figure 5 (showing a decline) is also likely to be a result of the addition of Concerta 
and Strattera to the PBS in 2007. Figure 5 is likely a more accurate representation of total 
WA child ADHD per capita prescribing rates as it is based on WA Health Department data 
that includes all prescriptions not just PBS scripts. 
Nonetheless Figure 6 allows a comparison of NSW, WA and National rates as all information 
is collected on the same basis, that is, prescriptions of PBS ADHD drugs by jurisdiction.  
However, NSW has consistently had a higher proportion of its ADHD cohort prescribed 
Ritalin than WA. Therefore caution needs to be exercised in comparisons of the above data, 
particularly prior to 2005.  However, other state based data sources (discussed below) 
confirm the trend of significantly rising NSW rates relative to WA rates over the period 2000 
to 2011.   
Although it does not produce annual figures the NSW Health Department estimated that on 
1 December 2000, 15,927 NSW children were treated with stimulant medication.241  In 2002 
the number of WA children on stimulants is estimated at 11,399 (refer to Appendix 1) and 
between 2000 and 2002 the number of WA PBS subsidised prescriptions of stimulants grew 
19 percent from 68,869 to 81,892 (see Figure 3).  Ignoring the ageing trend of the WA ADHD 
cohort (and therefore probably underestimating) the number of WA children receiving 
stimulants in 2000 is estimated at 9,600.242  Using the estimates of 15,927 for NSW and 
9,600 for WA and the relative populations in 2000 a WA child was approximately twice as 
likely as a NSW child to be treated with stimulants.  
In 2007 NSW and WA per capita child prescribing rates were almost identical (refer to Figure 
6).  Subsequently NSW rates grew substantially (13.5 percent from 2008 the first full year of 
total PBS coverage to 2011) while WA’s fell slightly (5.5 percent).  By 2011 NSW per capita 
                                               
241  P. Salmelainen (2002), Trends in the prescribing of stimulant medication for the treatment of attention 
deficit hyperactivity disorder in children and adolescents in New South Wales, Sydney, NSW Department 
of Health.  Available at http://www0.health.nsw.gov.au/pubs/2002/adhd2002sup.html (accessed 2 May 
2013). 
242
  Year 2000 estimate was calculated by applying a discount of 19% on the 2002 estimate. 
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PBS child prescribing rates were 25 percent above the national rate, while WA rates were 11 
percent below.      
The figures for the period 2007 to 2011 in Figure 6 are relatively reliable as they are 
collected for all states on the same basis and since 2007 all ADHD drugs have been 
subsidised via the PBS. However, the raw PBS data does not include non-PBS prescriptions 
and there may be some variability in the use of non-PBS stimulants between states.  
4.4.2 WA versus NSW Adult Prescribing Rates   
Figure 7 below compares NSW, WA and National, ADHD adult prescribing per capita rates 
from 2002 to 2011.  The source of the data is the same as that for children in Figure 6. 
Therefore the same limitations and concerns about distortion and comparison with Figure 5 
apply. 
Although Figure 7 indicates NSW adult rates are below the Australian average, NSW has had 
the highest per capita rate in 2010 and 2011 of all Australian States excluding WA.  The 
extremely high rates in WA drag up the national average. The only Australian jurisdiction 
that at any time had during the review period in had adult prescribing rates similar to WA 
was the Australian Capital Territory. In 2011 they were 82 percent of WA per capita rate and 
were rising quickly.243 
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Source: Department of Health and Ageing (2012), Letter to Martin Whitely dated 21 April 2012. 
The pattern of comparative prescribing rates for adults in NSW, WA and Australia is very 
different from that for children.  As for children the WA per capita adult rate of prescribing 
in 2002 was much higher than the NSW or national rate.  In 2002 Western Australian adults 
were prescribed PBS subsidised dexamphetamine at 7.1 times the national average 
(excluding WA) and 44 percent of Australian adults who received a PBS dexamphetamine 
prescription lived in WA.244  It is likely the differential in all ADHD drugs prescribed to adults 
is somewhat less dramatic as other states appear likely to have used proportionately more 
methylphenidate.  
Although there has been a modest closing of the gap WA rates were still a multiple of the 
national (3.3 times) and NSW rates in 2011.  It is however worthy of note that despite the 
addition of Ritalin (2005) and Concerta and Strattera (2007) to the PBS there was a sharp fall 
in WA adult prescribing rates between 2005 and 2009 with the major fall occurring in 2006.  
It is also noteworthy that rates have risen in both WA and NSW in 2010 and 2011.    
4.5 Summary of ADHD prescribing statistics 1992-2011 
Australian ADHD prescribing rates grew very rapidly between 1992 and 2011, with WA per 
capita rates growing much faster than the other states.  By 2000, WA child prescribing rates 
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were at least double the national average and adult prescribing rates were over four times 
the national rate.  However, beginning in 2003, WA prescribing rates for children began to 
fall and by 2010 were approximately half of what they were in 2002.  
Child prescribing rates, however, rose in all other states so that by 2011 WA rates were 
(approximately 11 percent) below the national average.  In contrast NSW child prescribing 
rates, which were significantly below WA rates in 2000, have grown rapidly and are now 
significantly higher than WA rates.  Other states have also demonstrated a pattern of 
increasing prescribing rates although South Australian and Victorian child prescribing rates 
both remain lower than WA rates.245 
WA’s adult ADHD prescribing experience has been significantly different from that for WA 
child prescribing.  While there was a modest fall in the mid-2000s the rates have remained 
consistently much higher than all other Australian states.   
This information is used in subsequent chapters to evaluate the impact of policy and 
regulatory processes both nationally (Chapter 5) and in WA and NSW (Chapter 6). 
  
                                               
245
  Department of Health and Ageing, Letter to Martin Whitely dated 21 April 2012. 
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Chapter 5.  National ADHD Policy and Regulation 
 
The previous chapter presented relevant statistical data about national ADHD child 
prescribing rates from 1992 to 2011. This chapter outlines the history of Australian national 
ADHD policy and regulation.  It provides information for the analysis of the relationship 
between regulatory capture and pharmaceuticalization discussed in detail in Chapter 7. 
5.1 Commonwealth Government Responsibilities in Regard to ADHD 
In Australia public sector responsibility for ADHD is split between the Commonwealth and 
State governments.  State governments provide public health services that diagnose and 
treat ADHD.  They are also responsible for regulating the dispensing of prescription drugs, 
like dexamphetamine and methylphenidate, which are potentially divertible for illicit use. 
Chapter 6 discusses the regulation of ADHD by the West Australian and New South Wales 
Governments respectively.  
The Australian Commonwealth Government has primary responsibility for the: 
1. development of standard treatment guidelines through the National Health and 
Medical Research Council (NHMRC); 
2. licencing of and approval for market, and the after-market monitoring  of the safety 
of ADHD medications through the Therapeutic Goods Administration (TGA);  
3. subsidisation of these medications through the Pharmaceutical Benefits Scheme 
(PBS); and 
4. subsidising via Medicare of the diagnosis and ongoing treatment by private sector 
clinicians - primarily paediatricians, psychiatrists and less frequently general 
practitioners.246  
Decisions by the Commonwealth Government therefore have a significant impact on ADHD 
diagnosis and prescribing rates.  These decisions determine which medications are allowed 
to be marketed, give guidance as to the circumstances for their use, determine the price to 
patients, and pay the clinicians who diagnose ADHD. 
                                               
246  In most Australian States only psychiatrists and paediatricians can initially prescribe psycho-stimulants. 
Although in a number of States general practitioners can be co-prescribers and be involved in the ongoing 
management of ADHD and issue repeat prescriptions. In Queensland general practitioners can initiate 
treatment with pychostimulants. 
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The remainder of this chapter identifies and analyses the involvement of the various 
Commonwealth Government agencies involved in the policy formulation and regulation of 
ADHD.  Box 4 below is a timeline of significant events regarding the Commonwealth 
Government’s response to ADHD across all Commonwealth Government agencies.  Events 
that are described in detail in this chapter are italicised below in Box 4.  
Box 4 - Timeline of significant events regarding the Commonwealth Government’s response to 
ADHD 
1992- Dexamphetamine was the first drug to be sponsored via the PBS for the treatment of ADHD. 
1993- Ritalin was licenced by the TGA for the treatment of ADHD. 
1997- The first national guidelines for the treatment of ADHD were developed by a committee 
appointed by the NHMRC.  
1998- The Commonwealth Department of Health and Family Services Health Special Programs 
Branch sponsored research on the prevalence of mental illness amongst young people in Australia 
which estimated 11.2% of Australian children had ADHD. 
2002- Ritalin LA was licenced for use by the TGA. 
2004- Strattera was licenced for the treatment of ADHD. 
2005- Ritalin was subsidised via the PBS. 
2006- The first national guidelines on ADHD were rescinded by the NHMRC and the Royal Australian 
College of Physicians (RACP) was commissioned to develop new national guidelines for the treatment 
of ADHD.  This committee was chaired by Victorian paediatrician Doctor Daryl Efron.  
2007- Concerta, Ritalin LA and Strattera were subsidised via the PBS. 
2007- Doctor Daryl Efron stood down as chairperson of the National ADHD Guidelines Development 
Committee over conflict of interest concerns. 
2009- The NHMRC announced that because of extensive undisclosed conflict of interest concerns with 
research relied upon to develop the draft national guidelines on ADHD the draft guidelines would not 
be adopted.  
2011- A committee was appointed to develop Clinical Practice Points (CPP) to provide national 
guidance on the diagnosis and treatment of ADHD. 
2012- The Clinical Practice Points were released and approved by the NHMRC and Australian Minister 





5.2 Department of Health and Aged Care commissioned research into the prevalence of 
ADHD 
In 1998 the Department of Health and Ageing, Mental Health and Special Programs Branch 
commissioned research into the prevalence of mental illness in Australian children as part of 
a broader National Survey of Mental Health and Wellbeing.247  The results were published 
as, The Mental Health of Young People in Australia.248 
Prevalence rates are estimates of the percentage of a population with a disease or disorder.  
A prevalence rate is different from a diagnosis rate, which is the percentage of the 
population diagnosed with a condition. 249  For diseases with definitive scientific diagnoses, 
if prevalence rates exceed diagnosis rates then real disease is going undiagnosed and 
therefore maybe untreated. 
In spite of the contention of critics that it is impossible to objectively diagnose ADHD, estimates 
of prevalence rates are frequently quoted by proponents to defend against critics’ allegations 
that it is over-diagnosed and over-medicated.  A common claim of ADHD proponents is that 
prevalence rates exceed diagnosis and prescribing rates and that ADHD is in fact under-
diagnosed and under-medicated.  One example is the 1997 guidelines (see 5.3.1) which noted 
that ADHD prescribing rates were below prevalence rates and therefore ADHD is not over-
diagnosed and over-medicated.  The guidelines stated that ‘Current overall prescribing rates are 
0.7 percent for 0 to 19 year olds.  Overall prescribing rates in Australia are less than 1 percent of 
school age children (lower than the 2 to 5 percent incidence of ADHD). The rhetoric of over 
prescribing is not supported.’250 
There have been numerous studies to determine prevalence rates for ADHD.  Estimates of 
ADHD prevalence vary widely.  An American study conducted in 1998 found that prevalence 
                                               
247  The Department of Health and Ageing was called the Department of Health and Community Services until 
October 1998.  For the sake of simplicity it is referred to the Department of Health and Ageing (DoHA) 
throughout the thesis. 
http://web.archive.org/web/20131109190520/http://www.health.gov.au/internet/main/publishing.nsf/Conte
nt/health-history.htm#summary 
248  M. G. Sawyer, F. M. Arney et al (2000), The Mental Health of Young People in Australia, Mental Health and 
Special Programs Branch, Commonwealth Department of Health and Aged Care, Canberra. 
249  ‘Prevalence rates do not equate to diagnostic rates, as they are drawn from surveys and questionnaires 
rather than actual clinical figures.  In this respect, the Committee questions their accuracy.’  Western 
Australia Legislative Assembly, Attention Deficit Hyperactivity Disorder, p.11. 
250  National Health and Medical Research Council (1997), Attention Deficit Hyperactivity Disorder (ADHD), 
Canberra, Australia, p.38. 
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estimates vary between 1.7 per cent and 16 per cent.251  Estimates of prevalence rates also vary 
across cultures, possibly influenced by cultural norms with the highest reported (29 per cent) 
being in India.252 
Published in 2000 and based on data collected in 1998, the research commissioned by the 
Department of Health and Ageing estimated that 11.2 per cent of Australian children age 6 to 17 
had ADHD.253  The lead author of the study, Professor Michael Sawyer, was a member of an 
advisory board for Eli Lilly and received payments from Eli Lilly to attend an international 
conference (see appendix 3). 254 
The study involved the parents of 2737 children completing a checklist on the behaviour of their 
child.255  Parents rated their child on each of eighteen ADHD behavioural symptoms as 
displaying the behaviours rarely, sometimes, often or very often.  Children who recorded 6 of 9 
often or very often in either the inattentive or hyperactive/impulsive behaviours were classified 
as having ADHD.  The survey did not attempt to ensure the child met the full criteria for the 
diagnosis of ADHD.  There was no measure for impairment or attempt to establish that the child 
displayed the behaviours in at least two settings as required by the DSM-IV (refer to box 1 at 
2.1.1).  Neither was the possibility of other explanations for the ADHD type behaviours explored. 
The 11.2 percent estimate was therefore likely to be an overestimate of the percentage of 
Australian children who would qualify for a thorough application of the DSM-IV criteria.  
Nonetheless, this overestimate has been frequently used to support the argument that 
ADHD is under-diagnosed and under-medicated.  A prevalence rate of 11.2 percent equates 
to more than one in nine Australian children having ADHD.  It is widely accepted that ADHD 
                                               
251  Goldman, et al, ‘Diagnosis and treatment of attention-deficit/hyperactivity disorder’. 
252  Department of Health, Government of Western Australia, Inquiry into Attention Deficit Disorder and Attention 
Deficit Hyperactivity Disorder in Western Australia, Legislative Assembly, Transcript of evidence taken on 26 
November 2003 (Professor Stephen Houghton, Psychologist/University Professor, Graduate School of 
Education, University of Western Australia). 
253  Sawyer, et al, The Mental Health of Young People in Australia, p.809. 
254  Royal Australasian College of Physicians (RACP) (2009), Draft Australian Guidelines on Attention Deficit 
Hyperactivity Disorder (ADHD), Melbourne.  Available at  
http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/adhd_draft_appendices.pdf (accessed 2 
December 2012). 
255  ‘The mental disorders were assessed using the parent-version of the Diagnostic Interview Schedule for 
Children Version IV. Parents completed the Child Behaviour Checklist to identify mental health problems 
and standard questionnaires to assess health-related quality of life and service use.  The Youth Risk 
Behaviour Questionnaire completed by adolescents was employed to identify health-risk behaviours.’  M. 
G. Sawyer, R. J. Kosky et al (2000), ‘The National Survey of Mental Health and Wellbeing: the child and 
adolescent component’ in Australian and New Zealand Journal of Psychiatry, 34, p.215. 
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is far more prevalent in boys than in girls, at a ratio of approximately three to one.256  Given 
that ratio, and assuming a prevalence rate of 11.2 percent, approximately one in six boys 
aged 6 to 17, and one in 18 girls aged 6 to 17 would have ADHD.  
The study identified the following rates of prevalence for children for a number of 
psychiatric disorders.257 
Percentage of children and young people with specific disorders: data from the Child and Adolescent 
Component of the National Survey of Mental Health and Wellbeing 
Disorder   All Children          6-12 years    13-17 years 
Males   Females  Males   Females 
Depressive disorder  3.7%   3.7%   2.1%   4.8%   4.9% 
Conduct disorder  3.0%   4.8%   1.9%   3.8%   1.0% 
ADHD    11.2%   19.3%   8.8%   10.0%   3.8% 
 
The gender differential and the finding that nearly one in five boys aged 6 to 12 had ADHD, 
but that nearly half of them would ‘recover’ in their teenage years, supports the assertion 
by ADHD critics that ADHD type behaviours are both masculine and immature behaviours.  
Evidence of the importance of immaturity in the diagnosis of ADHD came from a 2012 
review of the medical records of 937,943 Canadian children.  The review showed that 
children born in December, the last month of their school year intake, were much more 
likely to be diagnosed and medicated (boys 41 percent and girls 77 percent) for ADHD than 
their classmates born in January.258   This study confirmed the late birthday effect 
demonstrated in two earlier smaller US studies.259 
                                               
256  Salynn Boyles (2009), ‘Study confirms ADHD is more common in boys’, WebMD Health News, 15 
September 2004.  Available at http://www.webmd.com/add-adhd/news/20040915/study-confirms-adhd-is-
more-common-in-boys (accessed 4 October 2009). 
257  Sawyer, et al, The Mental Health of Young People in Australia. 
258  The eleven year study of 937,943 children aged six to twelve in the Canadian province of British 
Columbian, titled Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity 
disorder in children, Richard L. Morrow MA. et al (2012), ‘Influence of relative age on diagnosis and 
treatment of attention-deficit/hyperactivity disorder in children’ CMAJ, March 5, 2012.  Available at 
http://www.cmaj.ca/content/early/2012/03/05/cmaj.111619.full.pdf+html  (accessed 10 March 2011).  
259  The Canadian study confirms the ADHD late birthdate effect found in two recent smaller US studies. 
Elder, T.E (2010), ‘The importance of relative standards in ADHD diagnoses: Evidence based on exact 
birth dates’, Michigan State University, June 2010;  WN Evans, MS Morrill, & ST Parente (2010), 
‘Measuring Inappropriate Medical Diagnosis and Treatment in Survey Data: The Case of ADHD among 
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Putting aside these and other concerns about the inadequacies of the DSM-IV diagnostic 
criteria, accurately estimating the prevalence rate of ADHD as defined in DSM-IV requires a 
far more thorough process.  It would involve sampling a significant number of the target 
population (4-17 year olds) and identifying which of those ‘often’ exhibit ADHD behaviours 
(avoiding homework, fidgeting, interrupting, squirming etc.) in the required combinations 
(all subtypes)  
1. in two or more settings, 
2. to the level of significant impairment. 
3. and do not have other conditions that could better explain their behaviour.  
 
Therefore to accurately determine ADHD prevalence rates the following three steps would 
be required: 
Step 1- Every sample’s (child’s) parents in the study would need a complete a 
checklist of the child’s behaviour to identify if they exhibit sufficient behaviours at 
home “often” enough to meet the criteria for an ADHD subtype 
Step 2- The teachers of those children who do exhibit sufficient behaviours at home 
should then complete a similar checklist to identify if they exhibit sufficient ADHD 
behaviours in a school (second) setting. 
Step 3- Those children who exhibit sufficient behaviours at home and at school 
would then need an intensive audit of their behaviour and familial, social and 
environmental circumstances to determine if they are “significantly impaired” and if 
the behaviour was not caused by non-ADHD factors.    
Following the above steps would not diminish ADHD critics’ fundamental concern about the 
subjectivity of the individual behavioural criteria.  Neither would it offer any evidence of 
prevalence of a biochemical brain imbalance, or of the likely effectiveness of psycho-
stimulants.  It would, however, give a more accurate estimate of the proportion of the 
                                                                                                                                                  
School-Age Children’, J Health Econ. 2010 Sep:29(5), pp.657-73.  Epub 2010 August 4.  Available at  
<http://www.ncbi.nlm.nih.gov/pubmed/20739076>(accessed 12 February 2013). 
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target population that exhibit behaviours consistent with a diagnosis of ADHD as defined in 
DSM-IV.   
The Department of Health and Ageing’s sponsored study was methodologically flawed in 
that it missed steps 2 and 3.  That is the 11.2 percent estimate of prevalence ignored the 
requirements that the behaviours occur in at least two settings to a degree that impairs 
effective functioning, and are not due to other factors.  Regardless of the questions on the 
accuracy of the prevalence rate, on numerous occasions commentators have ignored this 
fundamental flaw and used this 11.2 percent prevalence estimate to counter criticism of 
misdiagnosis/over-prescription and argue that, to the contrary, ADHD is under-diagnosed 
and under-medicated. 
One of these claims was a statement in 2001 by Perth paediatrician Dr Ken Whiting who, in 
responding to concerns about Western Australia’s high ADHD prescribing rates, claimed   
‘A recent Federal Government report had put the number of Australian children with 
ADHD at 11 per cent, but the more widely accepted estimate was 5 per cent to 7 per 
cent.  Yet, only about 4 per cent of children were given drugs to treat the condition.  
Even that 4 per cent is a bit suspect and it may actually be less because that number 
would include children who only received one prescription but never continued with 
the medication.’260   
On other occasions Whiting was less cautious.  When interviewed for a television 
programme in 2002, Whiting said ‘if you look at the Federal Government mental health 
study on youth mental health, which was completed in [19]99 under Michael Woolridge 
that showed that 11.2 per cent of children in Australia have ADHD.’261  
Another example of the use of this misleading statistic was by the then State President of 
the Western Australian branch of the Australian Medical Association (AMA), Dr Bernard 
Pearn-Rowe.  He was quoted in an article titled ‘AMA backs drug complaints’ in The 
Australian in 2002 as saying ‘(in Western Australia) local specialists were leading the way in 
diagnosing and treating the condition…a 1999 review by the National Health and Medical 
                                               
260  Kristen Watts (2001), ‘More ill than get treatment’, The West Australian, 8 June 2001. 
261
  Alison Wright (2002), ‘The abuse of ADHD drugs in WA’, 7.30 Report, ABC Television, 1 October 2002. 
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Research Council found 11 per cent of the population aged 4 to 17 years had ADHD, but that 
less than 2 per cent of cases were treated.’262   
Of greater significance is that in November 2009, nearly a decade after the flawed estimate 
was produced, the Federal Health Minister Roxon, the Royal Australian College of Psychiatry 
(RACP) and the National Health and Medical Research Council (NHMRC) used the 11.2 
percent estimate, in a joint press release promoting the 2009 Draft ADHD Guidelines, to 
claim there were 350,000+ Australian children and adolescents with ADHD.263  This was over 
seven times the number (47,127) of children on Pharmaceutical Benefits Scheme sponsored 
ADHD medications in 2007.264  Yet the NHMRC 2009 guidelines chairperson Dr Forbes, in the 
same statement, is quoted as saying, ‘what’s important is that it is likely fewer children will be 
prescribed medication.’265 
In summary the Commonwealth Government relied on and financially supported 
methodologically flawed research that erroneously supported the contention that ADHD 
was massively under-treated. 
5.3 The National Health and Medical Research Council 
The National Health and Medical Research Council (NHMRC) is an independent statutory agency 
funded by the Commonwealth government to develop recommendations for best health policy 
and practice.  It ‘brings together within a single national organisation the functions of research 
funding and development of advice.’  Its objectives include fostering ‘the development of 
consistent health standards between the various States and Territories’ and ‘medical research 
and training and public health research and training throughout Australia.’266   
The NHMRC either produces the guidelines internally or externally by outsourcing the 
development of treatment guidelines to individuals and organisations with the relevant 
                                               
262  Belinda Hickman (2002), ‘AMA backs drug complaints’, The Australian, 20 December 2002, p.4. 
263  The Hon Nicola Roxon MP , Minister for Health and Ageing (2009), National Health and Medical 
Research Council, and Royal Australasian College of Physicians, ‘Draft ADHD Guidelines Released’, 
Joint Media Release, 30 November 2009. 
264  Department of Health and Ageing, Letter to Martin Whitely dated 21 April 2012. 
265  The Hon Nicola Roxon MP, ‘Draft ADHD Guidelines Released’. 
266   National Health and Medical Research Council (NHMRC), ‘How NHMRC develops its guidelines’,  
Australian Government.  Available at http://www.nhmrc.gov.au/guidelines/how-nhmrc-develops-its-
guidelines (accessed 3 July 2013).  
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expertise.  The NHMRC’s practice of commissioning research and guidelines development 
means that its primary responsibility is to ensure the competence and independence of those 
they appoint to conduct this research.  Box 5 below contains an excerpt from the NHMRC 
website that details how it develops guidelines.267 
 
Box 5- Excerpt from the NHMRC Website on Developing Treatment Guidelines 
(available at http://www.nhmrc.gov.au/guidelines/how-nhmrc-develops-its-guidelines )  
‘[The] NHMRC may oversee the entire guideline development process itself (internal development). 
Alternatively, it may partner with another organisation such as a professional college, which then 
carries out much of the development up to and including step 5 below (external development). 
Either way, the process is substantially the same…Guidelines are developed by teams of specialists 
following a rigorous evidence-based approach. The specialists include: 
 Members of working committees that are set up to develop guidelines. Members are high-
level experts nominated by NHMRC's CEO and Council as well as relevant organisations such 
as government agencies, peak professional bodies, advocacy groups and educational 
institutions 
 specialists in evaluating evidence 
 professional technical and scientific writers.’ 
 
They are developed…using a 9-step process, parts of which are specified in the NHMRC Act 
1. A working committee is established consistent with the NHMRC Act. The committee 
provides expert advice to NHMRC during the guideline development process. 
2. Specialists in evaluating medical evidence carry out a systematic literature review. This is 
arguably the most important step in the process because one of the main principles of 
guideline development is that they should be based on the best available evidence. 
3. Professional technical and scientific writers turn the literature review into a set of draft 
guidelines. 
4. The draft guidelines are put out for public consultation, as required by the NHMRC Act. 
5. NHMRC considers all submissions arising from the public consultations and advises if the 
guidelines need to be redrafted due to new evidence or concerns raised by stakeholders. If 
so, the working committee advises the technical and scientific writers about the best way to 
do this. 
6. NHMRC subjects the draft (or redrafted) guidelines to review by an independent reviewer 
who ensures that all the necessary processes have been followed during the guidelines' 
development. 
7. NHMRC may choose to have a peer review of the guidelines. If so, they are sent to a number 
of experts in the subject area for their opinion, primarily on the evidence base used for the 
guidelines. 
8. The guidelines go to NHMRC's Council for its consideration. Council can send the guidelines 
back for further work if, for example, it feels more evidence is required in a particular area. 
When it is satisfied with the final draft, Council makes a recommendation to NHMRC's CEO, 
who makes the decision to issue internally-developed guidelines or approve externally-
developed ones. 
                                               
267
   NHMRC, ‘How NHMRC develops its guidelines’. 
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9. The guidelines are published and disseminated. 
The entire process typically takes around 18 months to two years, although it can take less or more 
time depending on the complexity of the issues being addressed and the number of submissions 
received during consultation. 
 
Since 1997 the NHMRC has commissioned the development of three separate processes to 
provide guidance to clinicians and others on the diagnosis and treatment of ADHD.  Each of 
these processes is described below in order to identify the outcome and degree of 
regulatory capture.  
5.3.1 - The 1997 National Health and Medical Research Council (NHMRC) National ADHD 
Treatment Guidelines 
In 1997 the NHMRC produced guidelines designed to advise clinicians on the diagnosis and 
treatment of ADHD.  These 1997 guidelines were rescinded on the 31st of December 2005 (for 
details of why they were rescinded refer to 5.3.2).   
Although the names of the members of the guidelines development panel were disclosed there 
was no information about potential conflicts of interest.  The panel that developed the 
guidelines consisted of three paediatricians, one child psychiatrist, a general practitioner, a 
psychologist and a consumer representative. 268  The child psychiatrist on the NHMRC panel was 
Dr Florence Levy from New South Wales.269  Later, Dr Levy (in 2002) was one of the signatories 
of the ADHD International Consensus Statement (see 2.2.1.1) and remains a prominent ADHD 
proponent.  One of the three paediatricians was prominent ADHD proponent Dr Paul Hutchins 
(see 6.10.1).  It was later disclosed that Dr Hutchins has served as adviser to manufacturers of 
ADHD drugs although it is not known if this predated 1997.270  There is insufficient information 
on the ADHD related views and associations of the other guidelines panel members. 
                                               
268  The Membership of the NHMRC ADHD study Working Party was: Professor Allan Carmichael (Prof of 
Paediatrics), Dr Paul Hutchins (paediatrician), Professor Frank Oberklaid (paediatrician) and Dr Florence 
Levy (Child Psychiatrist). Also included were Dr Peter Adkins (General Practitioner), Mr Ivan Gall 
(consumer representative) and Mr John McCormack (Educational Psychologist). 
269  Dr Florence Levy was described as Child Psychiatrist, Head, Avoca Clinic, Royal South Sydney Hospital, 
New South Wales. 
270  Clinical Excellence Commission (CEC) (2007), Attention Deficit Hyperactivity Disorder in Children and 
Adolescents in New South Wales – 2007: Final Report of the Special Review, Sydney, p.64.  
109 
 
The process invited public input in two stages.  The first stage invited input on six broad terms of 
reference and received 54 submissions. The second stage invited comments on the draft 
guidelines and received 90 submissions that were described as ‘overall supportive of the draft 
guidelines’.271  The submissions were not made public so it is impossible to determine how 
much influence they had on the final guidelines. 
A key finding of the 1997 guidelines report was that ‘stimulant medication has been shown 
to be effective in the short term in modifying disruptive behaviour and improving 
performance in both children and adolescents with ADHD.’272  The guidelines therefore 
recommended that ‘the use of stimulant medication should be considered for treatment of 
most children with ADHD.’273  The guidelines committee claimed generalised benefits for 
the ‘ADHD population’, regardless of age, stating that ‘stimulants, dexamphetamine or 
methylphenidate, have the same proven benefits for adolescents as for younger children’ 
and ‘stimulant response of adults with childhood ADHD resembles that of children.’274  The 
fact that low dose orally administered stimulants modify behaviour and enhance focus in 
the majority of people, regardless of their ADHD status, was not mentioned. 275   
The 1997 guidelines report emphasised that medicating with ADHD drugs has benefits for 
other family members. ‘Family functioning improves on stimulants with enhanced parental 
warmth and approval, less criticism, less sibling conflict.’276  ADHD type behaviours as 
defined in the DSM diagnostic criteria - fidgeting, interrupting, playing loudly, avoiding 
chores and being disorganised - can all be frustrating and annoying for parents and siblings 
and lead to family disharmony.  However, ethical issues arise from the use of ‘psychotropic 
drugs’ in part at least to enhance family harmony. 
The 1997 guidelines discussed the differences between the American Psychiatric 
Association’s DSM-IV and the World Health Organisation’s ICD-10 diagnostic criteria.  The 
guidelines acknowledged that DSM-IV outlines a broader definition of ADHD and that a child 
                                               
271
  NHMRC,  Attention Deficit Hyperactivity Disorder, pp.99-100. 
272  NHMRC, Attention Deficit Hyperactivity Disorder, p.v. 
273  NHMRC, Attention Deficit Hyperactivity Disorder, p.vii. 
274  NHMRC, Attention Deficit Hyperactivity Disorder, pp.57-59. 
275  Lori Jeanne Peloquin and Rafael Klorman (1986), ‘Effects of Methylphenidate on Normal Children's 
Mood, Event-Related Potentials, and Performance in Memory, Scanning and Vigilance, Journal of 
Abnormal Psychology, Vol. 95, No. 1, pp.88-98.  
276
  NHMRC, Attention Deficit Hyperactivity Disorder, p.26. 
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is more likely to be diagnosed using DSM-IV.  Without directly providing a rationale, the 
guidelines recommended DSM-IV as the ‘minimum criteria necessary for a diagnosis’.277  In 
choosing, without explanation, DSM-IV in preference to ICD-10, the committee opted for 
the criteria associated with higher prescribing rates (see 3.1).  The closest the 1997 
guidelines came to addressing the reasons for its choice was the implied criticism of ICD-10 
in the statement: ‘Insistence on a single diagnosis, simplistic management or on whether 
the problem is primary or secondary can bedevil understanding, compliance and 
professional collaboration.’278  The more rigorous ICD-10 precludes co-morbidity, and insists 
on a single primary diagnosis, that must be treated before the secondary ADHD condition 
(i.e.: symptom) is specifically treated. 
The committee not only opted for the already loose ADHD criteria by choosing DSM-IV, it 
further loosened the requirements by inviting practitioners to diagnose and prescribe 
stimulants when the full criteria of DSM-IV were not met.  A specific example is the 
statement: ‘It is essential that the assessment utilize multiple sources of information, 
preferably from multiple settings.’279  The statement on casual reading sounds thorough. 
However, multiple sources could be as narrow as a teacher’s behavioural checklist along 
with a school report.  The failure to insist on multiple settings violates one of the criteria of 
DSM-IV that the behaviours must be displayed in at least two settings.280 
The 1997 guidelines panel made comprehensive and emphatic pro-medication 
recommendations despite acknowledging the cause/s of ADHD are unknown: 
The aetiology of ADHD is essentially unknown….. It is likely that a variety of 
contributing factors may operate in a vulnerable child to result in the 
behaviours of ADHD.281…Genetic traits, parents' responses and the 
behaviour models observed by the child contribute to uninhibited aggressive 
and anti-social behaviour, causing and compounding economic, social and 
health disadvantage.  These strong adverse intrinsic and environmental 
influences may all contribute to ADHD, as well as compromise its 
                                               
277  NHMRC, Attention Deficit Hyperactivity Disorder, p.xi.  
278  NHMRC, Attention Deficit Hyperactivity Disorder, p.v. 
279  NHMRC, Attention Deficit Hyperactivity Disorder, p.v. 
280  American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn, p.92. 
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  NHMRC, Attention Deficit Hyperactivity Disorder, p.9. 
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management, but medication still may have powerful benefits.282  
So despite a lack of understanding of what was causing a child to be inattentive and/or 
impulsive, the authors recommended medication.  Even if poor parenting and inappropriate 
role models, or even poverty, were significantly contributing to problematic ADHD type 
behaviours, pharmaceutical interventions were still recommended. 
The 1997 guidelines encouraged clinicians to diagnose and medicate very capable children 
even if they did not exhibit the symptoms of ADHD before the age of 7 as required by DSM-
IV: 
Attention deficits and language learning difficulties are often more subtle in 
individuals of high ability whose other strengths may allow them to 
compensate and escape detection by functioning appropriately for their age 
but not their ability.  Able individuals more often exhibit the inattentive 
ADHD type, presenting later in high school or even in adulthood, as their 
abilities and compensatory strategies are overwhelmed by the complexity 
and extent of cognitive and performance demands, and the added anxiety of 
formal examinations, life planning and employment.283  
Problems caused ‘by the complexity and extent of cognitive and performance demands, and 
the added anxiety of formal examinations, life planning and employment’ are related to the 
individual’s environment and the stresses of modern life.  Just as not all individuals are 
gifted with extraordinary intellect, not everybody, even the very bright, are suited to coping 
with high stress situations like examinations.  Nonetheless the guidelines recommended 
medicating an individual to suit their environment, rather than altering an environment to 
suit the individual (or removing them from the environment). 
Another clear message to clinicians in the guidelines was that parents seeking non- drug 
alternatives are motivated by ignorance and irrational prejudices: 
Many parents who seek alternate [non-drug] treatments for their child's 
problems are more ideologically attuned to a ‘natural’ solution, or are 
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seduced by the promise of a rapid improvement. Others are attracted by a 
relatively simple and straightforward explanation for their child's problems, 
while others are uncomfortable about the use of medications in their 
child.284   
In contrast, critics of ADHD prescribing contend the appeal of stimulants over drug free 
alternatives is that stimulants offer the ‘simple and straightforward explanation’, that they 
balance a biochemical imbalance, leading to a ‘rapid improvement’ in behavior.285 
Whilst acknowledging that ‘children with ADHD represent a complex set of problems for 
parents and professionals alike,’ the 1997 guidelines simplified the options for clinicians, to 
‘interventions with demonstrated benefits’, in other words, medication.286  Non-drug 
interventions were not only represented as costly and time wasting, but also as a violation 
of the rights of the child: 
Quite apart from the cost of these programs, which are often considerable, 
there are a number of ways in which they can have adverse effects on the 
child and family. First, such interventions may take up valuable time, both in 
postponing the introduction of an accepted intervention that has been 
shown to be of benefit in children with ADHD, as well as allowing the child 
less time for more fruitful and constructive pursuits. Second, the child with 
ADHD may be made to feel even worse by claims that his/her eyes are not 
working properly or there is something wrong with his/her brain, or in the 
way he/she handles food.287   
The 1997 guidelines statement that pursuing non-drug treatments may make ‘the child with 
ADHD…feel even worse by claims that…there is something wrong with his/her brain’ 
appears contradictory given that the rationale for ADHD prescribing is that children have 
chemically imbalanced brains i.e. have something ‘wrong’ with their brains.  In addition, 
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presenting non-drug treatments as unnecessarily postponing ‘accepted interventions’, 
(meaning stimulants), is further evidence of the pro-medication emphasis of the 1997 
guidelines. 
Additionally, the 1997 guidelines encouraged clinicians to diagnosis outside DSM-IV criteria 
and prescribe ‘off label’, that is, outside approved guidelines for the use of medications.  
They state: ‘Use of medication outside officially listed indications and drug evaluation 
mechanisms is proper if it complies with reasonable theory, expert practice and or 
controlled scientific studies.’288  What constitutes ‘reasonable theory’ is not specified, it was 
left to the clinician to determine.  Any behaviour that could be caused by a biochemical 
imbalance, or even just modified by ‘medication’, clearly in the mind of some clinicians 
constitutes reasonable theory.  The statement, ‘Guidelines encourage caution and evidence 
based practice, though clinical experience may precede research’ further encourages 
clinicians to prescribe ahead of research.289  ‘Off label’ prescribers are offered the 
justification that their clinical experience qualifies them to do so. 
While the 1997 guidelines clearly identified stimulants as being the first-line drug for 
treatment of ADHD, they encouraged the use of other drugs either as complementary or 
second-line treatments.  They even encouraged the use of drugs like Clonidine to manage 
the adverse upper effects of stimulants stating, ‘they may be useful, however, for children 
for whom stimulants are ineffective, have unacceptable side effects, or who have significant 
co-morbid anxiety, depression or tic disorder or may potentially abuse prescribed 
stimulants.’290  There was no cautionary note to highlight the then current concerns with the 
combination of Clonidine with methylphenidate, following the report of three deaths in 
children whose treatment included this combination.291   
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There were at least five references in the 1997 guidelines that were critical of controls by 
state government health authorities on prescribing stimulants including: 
The monitoring process only has jurisdiction over stimulants and is a 
laborious and confusing process for many prescribers. This encourages the 
use of many other psycho-tropics with little scientific evidence for efficacy 
in children, limited clinical experience, potentially serious adverse effects, 
no statutory control and no restriction to specialists.292  
Although the point that these controls may encourage the substitution of other 
psychotropic drugs is valid, the suggestion was to relax controls on stimulants, 
rather than to tighten control on other drugs.  
The report was also critical of restrictions that prevent paediatricians continuing to 
treat ADHD adolescent patients into adulthood.  ‘At present, the recognition and 
understanding of adult ADHD is rudimentary. Initial prescribing in adulthood after 
the age of 18 years, according to statutory Australian guidelines, requires opinion 
from a psychiatrist. More flexibility, allowing paediatricians to continue 
management into early adulthood would be constructive.’293  Clearly, the 
paediatricians on the panel that developed the guidelines opposed restrictions on 
their profession’s ability to diagnose and prescribe for ADHD in young adults.  
The main message from the 1997 guidelines, and therefore from the NHMRC to clinicians, 
was clear: ‘medication can work similarly across the range of cognitive ability and age.’294  If 
a patient was young or old, bright or dull, if they had difficulty organising their life and/or 
are inclined to act on impulse or are inattentive, stimulants were the recommended first 
line response.  The imprimatur of the NHMRC gave this report legitimacy.  It gave official 
sanction to potential prescribers to prescribe off label stimulants and a range of 
psychotropic drugs for ADHD, based on reasonable theory, without placing any practical 
limitations on what constitutes reasonable theory. 
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It is impossible to isolate the impact of these guidelines as many factors contributed to the 
pharmaceuticalized response to ADHD in Australia.  However, it is notable that the number of 
PBS subsidised prescriptions of dexamphetamine the only ADHD drug subsidised through from 
1997 until 2002, grew 66 percent (refer to Figure 1 at 4.2).   
There was a subsequent fall in this rate between 2002 and when the guidelines were officially 
rescinded in 2005. This was probably due to a significant fall in Western Australian prescribing 
rates over this period from 87,103 prescriptions in 2002 to 67,104 in 2005 (refer to Figure 4 at 
4.3 and 6.4).   
5.3.2 The 2009 NHMRC Draft National ADHD Treatment Guidelines 
In line with the NHMRC policy of reviewing its publications after five to ten years, the 
NHMRC 1997 ADHD guidelines were reviewed by the Publications Review Working Party a 
subcommittee (with additional members) of the NHMRC Health Advisory Committee.  The 
Working Party was tasked with reviewing NHMRC publications and guidelines to see if they 
were up to date with recent research.295  It decided that the 1997 guidelines were not 
sufficiently evidence based and had not addressed the issue of co-morbidity.  Consequently 
they were rescinded on 31 December 2005.  The Working Party recommended that the new 
guidelines required a full literature review, an inter-disciplinary approach from Paediatrics 
and Psychiatry, and needed to consider new medications (Strattera, Ritalin LA and 
Concerta).296   
The development of replacement guidelines was outsourced by the NHMRC to the Royal 
Australasian College of Physicians (RACP).297  No specific rationale for the choice of the RACP 
was offered by the NHMRC. However, the RACP is a prominent organisation with 
approximately 9,000 members and is responsible for the training of physicians and 
paediatricians.  It is unclear whether individual members were invited or applied to become 
members of the RACP committee. 
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An obvious alternative organisation to develop the guidelines would have been the Royal 
Australian and New Zealand College of Psychiatry (RANZCP).  There is no public history of 
competition between the RACP and the RANZCP and there is no reason to believe the 
RANZCP opposed the RACP developing the guidelines. However a 2004 Western Australian 
parliamentary inquiry into ADHD found that although both professions use DSM-IV, seeing a 
paediatrician as opposed to a psychiatrist was more likely to result in a child being 
prescribed stimulants for ADHD.298  Whether this is unique to Western Australian is unclear. 
The draft guidelines were dogged by controversy primarily because of allegations of bias 
amongst the guidelines reference group members, and the reliance on research by ADHD 
experts with undisclosed commercial ties to ADHD drug manufacturers.  As a result of the 
controversy the Guidelines were not finally approved by the NHMRC, despite being completed 
by November 2009.  A substitute process began in 2011 when another panel was convened to 
develop the Australian Clinical Practice Points.  These were completed and published in 
September 2012. 
The following section summarises in chronological order the major events in relation to the 
2009 NHMRC Draft National ADHD Treatment Guidelines and Clinical Practice Points. 
5.3.2.1 Timeline of controversy around the 2009 NHMRC Draft National ADHD Treatment 
Guidelines and Clinical Practice Points 
31 December 2005- After the 1997 Guidelines were rescinded on 31 December 2005, the 
development of replacement guidelines was outsourced by the NHMRC, at a cost of 
$135,000, to the Royal Australasian College of Physicians.299  At the time the RACP benefited 
from considerable sponsorship from drug manufacturers.  For example, the RACP 2009 
Annual Physicians Week Conference was sponsored by ADHD drug manufacturer Jansen-
Cilag and included paid exhibitions by Eli Lilly (manufacturer of ADHD Drug Strattera) and 
Novartis (manufacturer of ADHD Drug Ritalin).  On the RACP website, potential sponsors and 
exhibitors were encouraged to fund the RACP Conference with comments like, ‘Sponsorship 
and Exhibition opportunities allow you to align the needs of your company to specific 
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Congress events, whilst exposing your staff directly to your captive target markets [i.e. 
potential prescribers].’300  
April /May2007- The RACP guidelines reference group was initially chaired by Melbourne 
paediatrician and academic Dr Daryl Efron who had been on the advisory boards of ADHD drug 
manufacturer Novartis and Eli Lilly.  Dr Efron resigned as chairperson (but remained a reference 
group member) after his ADHD pharmaceutical company ties were publicised by the Daily 
Telegraph in April 2007.  When asked by the newspaper about these ties, Dr Efron argued his 
pharmaceutical company ties were irrelevant, stating, ‘the important thing is we declare our 
potential conflicts of interest’.301  However, the names of guidelines reference group members 
and their pharmaceutical company ties were not made public until Freedom of Information 
processes revealed them (see 17 November 2008 below).  In the same Daily Telegraph article Dr 
Efron declared he supported the use of Ritalin by children under the age of six despite the 
manufacturer recommending against it.302 
Media exposure of Dr Efron’s pharmaceutical company ties prompted then Howard 
Government Health Minister Tony Abbott’s intervention and Efron’s resignation as chair.  
Abbott said he ‘instinctively questioned’ the long-term use of drugs for non-life-threatening 
conditions.303  This followed comments the previous week by then Prime Minister John Howard 
who said, ‘I am very worried about reports of the over-prescription of Ritalin.’304  Despite the 
Prime Minister expressing these sentiments, Health Minister Tony Abbott stated: ‘I want to see 
new clinical guidelines but I stress it is up to the experts to carefully weigh all the issues.’305  
The then Opposition Health Spokesperson, (later Rudd Government Health Minister) Nicola 
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Roxon, expressed the desire to protect children from unnecessary prescribing.306  Roxon called 
for the names and drug company connections of the guidelines reference group to be made 
public, saying ‘these guidelines are incredibly important and it is important there is public 
confidence in them. Given the controversy surrounding ADHD, releasing the names is the 
sensible option to help restore public confidence in the process.’307  The Australian Medical 
Association’s responded to Roxon’s call by defending prescribing practices, rejecting a ‘full-
blown inquiry’ and insisting the RACP committee complete its work.308  Minister Abbott rejected 
Shadow Minister Roxon’s call for full disclosure.  
November 2007- Rudd Labor won the federal election and Nicola Roxon became Minister of 
Health.  Despite her previous call for full disclosure of reference group members’ names and 
conflicts of interest, she refused to disclose the names of the committee or their drug company 
connections.309  
In addition November 2007 was the deadline for the first of two opportunities for public input 
into the guidelines.  Interested parties were able to make submissions into the scope of the 
guidelines and literature and other evidence that should be considered in the guidelines 
development process.   
July 2008- The second opportunity for public input occurred in July 2008 when interested 
parties were able to comment on the first draft of the guidelines.  In a submission to the RACP 
guidelines committee I highlighted that the most frequently cited author in the first draft, 
Harvard University Professor Dr Joseph Bierderman, was under investigation for undisclosed 
pharmaceutical company payments.  Dr Biederman was cited as the principal author or co-
author 83 times in the Draft Guidelines.  My submission stated: ‘on June 8 2008 the New York 
Times exposed how Dr Biederman was paid US$1.6 million in consulting fees from drug makers 
between 2000 and 2007 but did not disclose this income to his employer Harvard University.310  
Biederman received research funds from fifteen pharmaceutical companies and serves as a paid 
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speaker or adviser to at least seven drug companies.’311 
Dr Biederman was not the only Harvard University researcher, cited in the draft guidelines, 
under investigation for undisclosed drug company payments.  Two other Harvard 
researchers under investigation, Drs Timothy Wilens and Thomas Spencer, were cited thirty-
two and forty-six times respectively.312  At least two other researchers cited in the 
guidelines, Drs Karen Wagner and Augustus John Rush of the University of Texas, were also 
under investigation for similar misconduct.313 
Other researchers cited in the 2009 Draft Guidelines on numerous occasions include: 
 Dr Christopher Gillberg of the Department of Child and Adolescent Psychiatry, 
University of Gothenburg, Sweden.  In 2005 he was convicted of fraud, for failing to 
disclose when required by a court research he claimed proved the existence of an 
invented disorder ‘DAMP’ (Deficits in Attention, Motor control and Perception).314  
Gillberg received a suspended sentence and appealed to the Supreme Court, with his 
last appeal failing in April 2006.  Three of his co-workers also received suspended 
sentences for destroying data from the study and not making it available. 
 Russell Barkley PhD, is a key advisor to the U.S. ADHD support group, Children and 
Adults with Attention Deficit Hyperactivity Disorder (CHADD).  CHADD was exposed 
in 2006 for its conflicts of interest with the pharmaceutical industry.  Specifically 
CHADD did not publish critical information about ADHD drugs, including an FDA 
warning in 2005 that the ADHD drug, Strattera, caused suicidal ideation.  Eli Lilly, the 
maker of Strattera is one of CHADD’s biggest donors. 315  In 2010 Dr. Barkley received 
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funding as a Speaker/Consultant for Eli Lilly, Shire, McNeil, Janssen-Cilag and 
Novartis.316    
 Dr. Laurence Greenhill - co-authored a number of the cited studies.  He is a frequent 
paid speaker for ADHD drug manufacturers.317  Dr. Greenhill has worked as a paid 
consultant to Alza Corp., Bristol-Myers Squibb, Richwood and GlaxoSmithKline, Eli 
Lilly, McNeil Pharmaceutical, Novartis Pharmaceuticals, and Solvay.318  He has been a 
paid speaker for Eli Lilly, Janssen Pharmaceuticals and Novartis Pharmaceuticals.  I 
was in the audience at the International Association for Child and Adolescent 
Psychiatry and Allied Professions conference in Melbourne in September 2006 when 
Dr Greenhill, whilst addressing an international audience of 300 psychiatrists, 
misrepresented the FDA deliberations on the black box warning debate on 
stimulants.  In July 2005, reports of adverse cardiovascular and psychiatric events 
prompted the FDA to convene a Drug Safety Advisory Panel consisting of sixteen of 
America’s top drug safety experts. The experts were provided with details of the 
adverse event reports and given the brief of designing further research to establish 
the safety of ADHD drugs. The Drug Safety Advisory Panel voted to recommend a 
‘black box warning’ for cardiovascular risks on all ADHD stimulant drugs. A black box 
warning is the strongest form of warning issued by the FDA about a drug, the step 
taken just short of removing it from the market.319  Greenhill portrayed the call for a 
black box warning for stimulants as coming from isolated clinicians rather than from 
the specially appointed FDA Drug Safety Advisory Panel.  Doctor Greenhill only 
revealed his extensive drug company connections to attendees at the conference 
when I asked him specifically at the end of his presentation.320 
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19 August 2008- The first draft of the guidelines included the recommendation that ‘Federal, 
State and Territory funding allocations to schools need to be revised to enable schools to access 
funding for students diagnosed with ADHD’.321  Critics contended this would, if implemented, 
have provided an economic incentive to schools to encourage the diagnosis of ADHD in students. 
322  This criticism was based on the experience in the US where there has been an explosion in 
ADHD diagnosis and prescribing rates partly attributed to schools seeking desperately needed 
general purpose funds.323  In 1991 the US Department of Education issued a memorandum 
setting guidelines for schools with children diagnosed ADHD to be made eligible for a special 
subsidy of approximately US$420 per child per year, under the health impaired category.  
Children ‘may get little more than the services of a nurse or clerk handing out a dose of Ritalin 
while the money goes into a general purpose fund’.324   After a letter to the Rudd Government 
from a group of fourteen Australian researchers in education, disabilities and ADHD (led by Dr 
Linda Graham) to the Rudd government gained media coverage, this recommendation was 
dropped.  The letter criticised ‘moves to instruct teachers to look out for ADHD and to allocate 
special funding to schools for students with the disorder’.325 
17 November 2008- Freedom of Information processes revealed the vast majority, at least 
seven, but probably eight of the original ten guidelines reference group members, including 
doctors, have ‘declared receiving grants and air fares, hotels and overseas trips from companies 
making drugs to treat the disorder… [Adelaide Now] has obtained the conflict of interest 
declarations made by nine of the 10 original working group members. The 10th has demanded 
details remain secret.’326  When this de-identified information was reported in the media, it was 
reported that ‘the publicly-funded committee had threatened to quit if their names were 
revealed.’327  Appendix 3 is an extract from the draft guidelines where members declared their 
dualities and potential conflicts of interest.328  This information was not made publicly available 
until November 2009.  
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The General Practitioner representative on the review group was Geraldton GP Dr Kim 
Pedlow.  In 2004 Geraldton was identified, by a spokesperson for the pharmaceutical 
industry sponsored ADHD patient support group the Learning and Attention Disorders 
Society (LADS), Michele Toner, as being an excellent model for regional service delivery.  In 
2004, in response to a question from the then Member for Geraldton, Shane Hill, Toner 
said:  
Geraldton would be the exception [to the poor provision of ADHD diagnosis 
and treatment services in regional WA], because there is an excellent 
sharecare program with a Dr Kim Pedlow who works there.  Geraldton 
would be the exception and services are fairly accessible and doctors travel 
up there fairly regularly, but we get phone calls from isolated areas where 
there are just no services available.329  
In 2004 Geraldton was one of three districts out of a total of 31 to have a prescription rate 
higher than 10 patients per 1000 population of the total population.330  In 2006 Geraldton 
had the second highest child prescription rate compared with the other 31 Health Districts, 
with a rate of 25.7 children per 1000 children aged 2 to 17.331  This pattern has continued 
through to 2011 with Geraldton having both the highest childhood (25.3 children per 1000 2 
to 17 year olds) and the second highest adult prescribing (10.0 children per 1000).332 
27 November 2008- Following up from the media coverage of the conflict of interest issues 
(which did not provide the detail of individual conflicts listed above), independent South 
Australian Senator Nick Xenophon asked for details of potential conflicts of interest in a 
question in the Australian Senate.  The requested details were not provided and the response 
was limited to: ‘Minister [Roxon] has been advised that the conflicts of interest declared by 
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working party members are consistent with the normal range associated with clinician review 
committees of this nature.’333  
June 2009- The draft guidelines document was completed with ‘the majority of the 
identified studies on ADHD medications being sponsored, at least in part, by the 
manufacturers of the medications’.334  In addition, two thirds of the 203 draft 
recommendations were made without any supporting scientific evidence.  They were based 
entirely on reference group consensus and justified as ‘best practice based on clinical 
experience and expert opinion’. 335 
The key recommendations of the draft guidelines encourage the use of stimulants, either 
methylphenidate or dexamphetamine, with the substitution of one for the other in the case 
of adverse side effects or ineffectiveness.  If children do ‘not respond to or are intolerant of 
stimulant medication’, the non-stimulant drug Strattera is recommended.336  If both 
stimulants and Strattera fail to result in a ‘clinical response’ Clonidine can be ‘trialed’.337  
Another example of this pharmaceuticals-first approach is the recommendation that if, as is 
common, ADHD stimulants cause tics or pre-existing tics become worse, the following 
treatment options are recommended: 
 continue the ADHD medication alone; 
 add an anti-tic medication; or 
 trial another ADHD medication.338 
The guidelines also encourage polypharmacy, by recommending concurrent prescribing of a 
range of psychotropic drugs to children with ‘comorbid’ depression and bipolar disorder along 
with ADHD.  This is despite the TGA insisting manufacturers of all selective serotonin reuptake 
inhibitors (SSRI) antidepressants include advice that their use by under-twenty-four-year-olds 
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increases the risk of suicidality.339   
Similar evidence of a pro-pharmaceutical approach is the recommendation that 
methylphenidate be used as a second line treatment in children under six years of age, despite 
the manufacturers’ prescribing information for all stimulants stating they should not be used in 
children under 6 years.  Ritalin prescribing information which is available to clinicians says 
‘Ritalin should not be used in children under 6 years, since safety and efficacy in this age group 
have not been established’. 340  Concerta’s says ‘safety and efficacy has not been established in 
children less than six years old or elderly patients greater than 65 years of age’.341  Dexedrine’s 
(a brand of dexamphetamine) says ‘long-term effects of amphetamines in pediatric patients 
have not been well established. Dexedrine is not recommended for use in pediatric patients 
younger than 6 years of age with Attention Deficit Disorder with Hyperactivity’.342 
The draft guidelines included numerous statements about the possible biological and genetic 
underpinnings of ADHD like: 
‘the dominant current paradigm suggests that disordered fronto-striato-cerebellar brain 
circuitry underpins the executive function deficits at the core of this condition.  Twin 
studies have established a strong genetic component.  This appears to involve 
polymorphisms in a number of genes, including those coding for dopamine 
transporters.’343   
These ‘suggestions’ and ‘appearances’ were apparently sufficient in the view of the RACP 
committee to justify the use of amphetamines as the first line of treatment for ADHD. 
Like the superseded 1998 guidelines the 2009 draft guidelines recommended that stimulants 
can be prescribed ‘off label’ to pre-schoolers if ADHD symptoms are having a severe impact on 
‘family/carers’.344  This raises ethical issues about the use of ‘psychotropic drugs’ in part at least 
to enhance the welfare of family or carers. 
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November 2008. 
340  Ritalin’s prescribing information is available at 
http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf. 
341  Concerta’s prescribing information is available at 
http://www.concerta.net/sites/default/files/pdf/Prescribing_Info-short.pdf#zoom=56. 
342  Dexedrine’s prescribing information is available at http://www.dexedrine.com/docs/dexedrine_PI.pdf. 
343  RACP, Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder, p.8. 
344  RACP, Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder , p.87. 
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Another controversial recommendation in the final draft guidelines was that ‘as ADHD and 
ADHD symptoms are common in individuals entering the justice system, screening for ADHD 
may be indicated in this population’.345  Similarly controversial is the conclusion that ‘the use of 
stimulant medication to treat people with ADHD does not increase the risk of developing 
substance use disorder’.346  As discussed at 2.2 critics contend that providing ADHD stimulants 
facilitates drug abuse and that supplying prisoners with divertible ADHD amphetamines may 
result in amphetamine abuse.  Like the majority of the 203 recommendations, the prisoner 
screening recommendation was based entirely on the consensus of the RACP panel with no 
supporting evidence.  The admission in the guidelines that ‘more research is needed to 
determine whether treatment of ADHD can reduce the risk of crime and recidivism’ further 
fuelled concerns that hypothesis and bias, rather than evidence, is the basis of many of these 
draft guidelines.347 
Another recommendation without any supporting evidence was that ‘given the high rate of 
suicide in Australia’s Indigenous population and the association of impulsivity with suicidal 
ideation among Indigenous youth…there is an urgent need for culturally appropriate 
assessment of ADHD’.348  Similarly the recommendation that ‘in people with intellectual 
disability and ADHD, use of stimulant medication should be considered’ is also controversial.  
Inherent in this recommendation is the assumption that it is possible to distinguish between the 
diagnostic criteria of ADHD and the consequences of intellectual disability.349  
October 2009- The National Health and Medical Research Council (NHMRC) announced that 
because of an investigation involving undisclosed drug company payments to US researcher 
Dr Joseph Biederman, who was cited 82 times in the draft guidelines, the guidelines had not 
been approved and remain in draft format.350 
                                               
345  RACP, Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder, p.xxviii. 
346  RACP, Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder, p.xxiii. 
347  RACP, Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder, p.xxviii.  
348  RACP, Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder, p.54. 
349  RACP, Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder, p.xxi. 
350  NHMRC (2009), ‘Draft Australian Guidelines on ADHD – NHMRC consideration deferred pending 
outcome of USA investigation’, Research Notices , Australian Government, Canberra, ACT.  Available at 
http://www.nhmrc.gov.au/media/notices/2009/draft-australian-guidelines-adhd-%E2%80%94-nhmrc-
consideration-deferred-pending-outcome-u (accessed 30 January 2013). 
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23 November 2009- The NHMRC issued a press release stating that ‘If the US investigation 
remains unresolved by mid-2010, NHMRC will move to redevelop the draft guidelines’.351  
The Sydney Daily Telegraph reported the NHMRC decision to redevelop the guidelines and 
quoted a RACP spokesperson asserting that ‘the College was not aware of the US 
investigation (into Biederman) when drafting the guidelines’.352 
24 November 2009- The Australian reported that contrary to the RACP spokesperson’s 
statement sixteen months earlier ‘(Martin Whitely) wrote to the [RACP] panel in July last 
year, warning that its work had been tainted by Dr Biederman’s research’ and ‘raised similar 
concerns with Ms Roxon’s advisers in August last year’.353 
In addition to relying on compromised researchers and pharmaceutical company controlled 
research, significant evidence that there was little quality long term evidence on the safety 
and effectiveness of ADHD psychostimulants was either ignored or downplayed.  Despite me 
personally handing a copy of the Oregon Health and Science University, Drug Class Review 
on Pharmacologic Treatments for ADHD to committee chairperson Dr David Forbes, and 
including a summary of it in my submission, the valuable detailed analysis of over 2000 
studies into the safety and efficacy of ADHD drugs was ignored.354  The reference group had 
the opportunity to cross reference the detailed analysis in the Oregon Health and Science 
University, Drug Class Review on Pharmacologic Treatments for ADHD to the research they 
relied on, but did not. (For detail of the Oregon Health and Science University, Drug Class 
Review on Pharmacologic Treatments for ADHD refer to 3.5) 
30 November 2009- Throughout 2009, Minister Roxon came under pressure from both sides of 
the ADHD debate.  ADHD critics concerned about the potential of the new guidelines to further 
accelerate the growth in child prescribing rates lobbied Roxon to abandon the draft guidelines 
and seek advice from psychiatrists without ties to the pharmaceutical industry.  ADHD 
proponents, including members of the RACP guidelines reference group, wanted the guidelines 
to be released.  The NHMRC had effectively offered Health Minister Roxon a circuit breaker (see 
23 November 2009); however she rejected the opportunity to put the redevelopment of the 
                                               
351  NHMRC, ‘Draft Australian Guidelines on ADHD – NHMRC’. 
352  Kate Sikora (2009), ‘ADHD guidelines pulled after payment scandal’, The Daily Telegraph, 23 November 
2009. 
353  Nicola Berkovic (2009), ‘Review of “tainted” ADHD guidelines’, The Australian, 24 November 2009. 
354
  McDonagh et al, Drug Class Review on Pharmacologic Treatments for ADHD.  
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guidelines in the hands of clinicians without commercial ties to the pharmaceutical industry.  
Minister Roxon, the NHMRC and the RACP issued a joint press release with Roxon praising the 
draft guidelines stating ‘I am pleased that we can finally provide this more up-to-date 
information on ways to identify and care for those in our community who may be suffering from 
ADHD.’  Despite all the previously highlighted problems, the joint statement also said ‘The RACP 
has conducted a thorough and careful process to develop these draft Guidelines.  They utilised a 
panel of independent experts to review the scientific evidence, and an independent scientific 
writer to prepare the draft document, with the work overseen by an expert working group.’355  
The guidelines replacement chairperson Dr David Forbes mirrored Roxon’s position stating; 
‘There’s been a hiccup that’s emerged but we think that practitioners and children in Australia 
should have the benefit of these while we’re awaiting clarification (from the US).’356  The public 
and the medical profession were left with the mixed message that according to the NHMRC, the 
guidelines were draft and subject to withdrawal, but that Roxon was pleased they finally offered 
‘more up-to-date information’.  
September 2010- The Honourable Mark Butler was appointed Australia’s first Mental Health 
Minister and assumed shared responsibility with the Minister for Health the Hon Nicola 
Roxon for the issue of ADHD. Minister Butler was responsible for mental health related 
issues; however the NHMRC remained the responsibility of the Health Minister. 
July 2011- Mental Health Minister Mark Butler announced that 2009 Draft ADHD Guidelines 
would not be approved and an alternative process the Australian Clinical Practice Points for 
the Diagnosis and Treatment of ADHD in Children would be initiated.  The membership of 
the committee responsible for developing the Clinical Practice Points was made public along 
with their conflict of interest declarations.  
May 2013- Despite the publication of the Clinical Practice Points, and the concerns with the 
2009 draft Guidelines, the latter were still published on the NHMRC website along with the 
explanation in box 6 below.357 
                                               
355  The Hon Nicola Roxon MP, ‘Draft ADHD Guidelines Released’. 
356  Julian Drape (2009), ‘Drugs shouldn’t be first port of call for ADHD kids: report’, Australian Associated 
Press General News, 30 November 2009. 
357  National Health and Medical Research Council (2009), Draft Australian Guidelines on ADHD: Summary 
Information, Canberra, NHMRC.  Available at http://www.nhmrc.gov.au/guidelines/publications/ch54 
(accessed 13 March 2012). 
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Box 6 - NHMRC Statement - Draft Australian Guidelines on ADHD Summary information 
The Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder, 2009 (the Draft 
Guidelines) were developed by the Royal Australasian College of Physicians. The Draft Guidelines 
aim to provide health professionals with a guide to assessment, management and care of 
preschoolers, children, adolescents and adults with ADHD.  
The Draft Guidelines have been available on the NHMRC’s website since late 2009 pending the 
outcomes of conflict of interest investigations against three Harvard Medical School researchers 
whose work is heavily cited throughout the Draft Guidelines. 
In July 2011 Harvard Medical School and Massachusetts General Hospital sanctioned 
Professor Biederman and Drs. Spencer and Wilens for failing to report their industry sponsored 
activities and subsequently violating their organisations’ conflict of interest policies. This 
announcement did not reveal the extent to which the conflicts impacted on the integrity of their 
research. 
Despite repeated inquiries to Harvard Medical School, the Council of NHMRC has not been able to 
determine whether these undisclosed sponsorships affected the findings underpinning the Draft 
Guidelines.  Hence, the Council of NHMRC has not recommended the Draft Guidelines for 
approval. 
NHMRC has released Clinical Practice Points on the Diagnosis, Assessment and Management of 
ADHD in Children and Adolescents (the CPPs). Clinical Practice Points are a resource that outlines 
good clinical practice based on the consensus of an expert working group. These CPPs do not 
replace the draft Guidelines as they have a narrower focus and do not cover the management of 
adults with ADHD.  Instead they aim to provide clarity to clinicians on one of the most 
controversial areas in ADHD - the use of medication, in particular stimulants, in managing children 
and adolescents with ADHD symptoms. The CPPs were developed while the above conflict of 
interest allegation was being investigated by Harvard University. 
The Draft Guidelines will continue to be available on NHMRC website for a limited time only. 
 
In summary despite acknowledging the cause or causes of ADHD are unknown, and despite 
having been made aware of issues in relation to the integrity and rigor of evidence supporting 
the use of pharmaceutical interventions, the guidelines committee made recommendations 
promoting the first line use of medications even outside the manufacturer’s guidelines.  They 
promoted pharmaceutical use on the basis of ‘reasonable theory’ even if there was little or no 
supporting evidence.  However, the use of non-drug treatments was strongly discouraged 
because of a lack of supporting evidence. 
The guidelines development process was ‘internally’ captured.  ADHD proponents developing 
the guidelines in part at least relied on research conducted by other ADHD proponents with 
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significant undisclosed conflict of interests and produced pharmaceuticalized 
recommendations.  However, after the event, as a result of persistent public advocacy by ADHD 
critics and sustained media coverage of the conflict of interest issues, the guidelines were not 
officially endorsed and remained in draft format. The contest between ADHD proponents and 
critics was external to the formal ‘captured’ process.  However, it demonstrates that total 
dominance by ADHD proponents is not inevitable. These issues are discussed in greater detail at 
7.4.2.1. 
5.3.3 The 2012 Australian Clinical Practice Points for the Diagnosis and Treatment of ADHD in 
Children 
Unlike the 2009 guidelines process, from the beginning the names of the Australian Clinical 
Practice Points for the Diagnosis and Treatment of ADHD in Children (Clinical Practice 
Points) development committee were made public as were the details of their conflict of 
interest declarations. 
Also in contrast to the previous ADHD Guidelines development processes the Clinical 
Practice Point development process was balanced in that it included a broad range of views 
and interests.  Although the Clinical Practice Points are described as being ‘based on expert 
consensus’ it may have been more accurate if they were described as being ‘based on 
expert compromise’.358  Neither ADHD proponents nor critics were entirely happy with the 
compromise outcome.  Perhaps this was an inevitable product of a committee which 
contained members with diametrically opposed views like ADHD sceptic, Professor Jon 
Jureidini (a psychiatrist), and ADHD prescribing enthusiast, Professor Michael Kohn (a 
paediatrician).  
Of the ten members invited to participate two members, Professor Kohn359  and notional 
consumer representative, Learning and Attentional Disorders Society (LADS)360 361 member 
                                               
358  National Health and Medical Research Council (2012), Clinical Practice Points on the Diagnosis, 
Assessment and Management of Attention Deficit Hyperactivity Disorder in Children and Adolescents, 
Commonwealth of Australia.  Available at 
http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/mh26_adhd_cpp_2012_120903.pdf 
(accessed 2 august 2013). 
359  Professor Kohn has significant financial connections to ADHD drug manufacturers Eli Lily and Janssen 
Cilag.  He was a member of Strattera Advisory Board for Elli Lilly and is currently undertaking publicly 
funded research on Strattera.  He has received other financial support from both Janssen Cilag and Eli Lilly 
and been paid to prepare and deliver educational materials by Janssen Cilag.  He has also received research 
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Margaret Vikingur had commercial ties to ADHD drug manufacturers.  In addition both 
Professor Kohn and LADS had demonstrated a strong ideological ‘biomedicalized’ ADHD 
proponent bias.  Professor Michael Kohn’s 2009 description of an article in Sydney’s Daily 
Telegraph detailing extreme reactions to ADHD medications reported to the TGA, such as 
psychotic episodes and suicidal ideation as ‘blaspheming the use of Ritalin’ indicates a near 
religious fervour for prescribing amphetamines like drugs to children.362   LADS encouraged 
the illegal use of ADHD amphetamines. Specifically in 1998 LADS was warned twice not to 
recommend the illegal use of a child’s ADHD stimulants by parents if they thought they had 
adult ADHD.363  
The chairperson of the group Professor of Psychiatry Bruce Tonge had previously conducted 
research on ADHD and endorsed the validity of the disorder. However, unlike Kohn or LADS, 
Tonge had not specialised in the disorder or been a frequent proponent.364  Some other 
members of the Clinical Practice Points process including Tonge had commercial ties to 
pharmaceutical companies but none related directly to ADHD.  In contrast to Michael Kohn 
and Margaret Vikingur, psychiatrist Professor Jon Jureidini had been a frequent critic of 
                                                                                                                                                  
support for ADHD studies from Brain Resource Ltd which has received funding from at least 13 different 
pharmaceutical companies.  For details see M. Williams et al (2010), ‘An “integrative neuroscience” 
perspective on ADHD: linking cognition, emotion, brain and genetic measures with implications for 
clinical support’, Expert Review of Neurotherapeutics, 10:10.   
360  LADS is partially funded by drug companies and has a long history of marketing of ADHD as having a 
biological cause best treated with ‘safe, effective medication’.  ‘LADS has accepted limited unrestricted 
grants from pharmaceutical companies’ including Eli Lilly and Novartis.  See 
http://www.ladswa.com.au/page.php?id=6 (accessed 26 June 2009) and  
http://www.nhmrc.gov.au/guidelines/adhd-conflicts-interest (accessed 13 July 2011). 
361  LADS have also publicly endorsed ADHD drugs in press releases prepared by public relations business in 
order to promote ADHD drugs.  Last Say Communications, ADHD – A Day of Calm – Dawn to Dusk: 
Long Lasting Medication to Provide Relief for Kids with ADHD, Media Release, 27 March 2007 
362   ‘Medicating our children’, Reportage Online: Magazine of the Australian Centre for Independent 
Journalism, 22 December 2009.  Available at  http://www.reportageonline.com/2009/12/medicating-our-
children/.  Kohn’s comment was in response to Kate Sikora (2009), ‘We’re turning our children psychotic 
with ADHD medication’, The Daily Telegraph, 13 October, 2009.  Available at 
http://www.dailytelegraph.com.au/lifestyle/body-soul/were-turning-our-children-psychotic/story-e6frf01r-
1225786025127 ↩.  This is not an isolated comment from Professor Kohn. For further information see 
Martin Whitely (June 2011), ‘Where is the evidence to support ‘ADHD expert’ Prof Kohn’s claim that 
amphetamines aid brain development?’, Speed Up & Sit Still.  Available at 
http://speedupsitstill.com/evidence-support-adhd-expert-prof-kohns-claim-amphetamines-aid-brain-
development.  
363  WA Stimulant Committee, Minutes of Meeting held on 4 August, 1998, obtained under Freedom of 
Information Act 1992. 
364  Monash University, Emeritus Prof. Bruce Tonge – Researcher Profile, Melbourne.  Available at 




ADHD diagnosis and prescribing.365  Another member psychiatrist Professor Helen Milroy, 
although not as critical as Jureidini, had also previously expressed concern about 
misdiagnosis and over-prescription.366 
There was significant opportunity for public input with approximately 140 submissions 
spanning the divergent range of views on ADHD and resulting in significant differences 
between draft and final guidelines.367  One of the more notable changes from the draft was 
the removal of the statement that ‘as with any medical intervention, the inability of parents 
to implement strategies may raise child protection concerns’.368  This statement attracted 
widespread media attention and condemnation as it was interpreted as a threat to remove 
children from parents who refused to allow their children to be ‘medicated’ for ADHD.369  
On 23 November 2011 the NHMRC issued a media release denying that a failure to 
medicate may result in the intervention of child protection authorities.370  This statement 
was removed from the final Clinical Practice Points which were released in September 2012.  
The final Clinical Practice Points were significantly different to the 2009 Draft Australian 
Guidelines.  Table 2 below lists both features of the Clinical Practice Points that ADHD critics 
support and statements that they contest.  
 
                                               
365  Penelope Debelle (2011), ‘Festival of Ideas: All in the mind’, Adelaide Advertiser, 1 October 2011.  
Available at  http://www.adelaidenow.com.au/ipad/festival-of-ideas-all-in-the-mind/story-fn3o6wog-
1226151737735 and Sue Dunlevy (2012), Safety fears over ADHD drug, The Sunday Telegraph. 
September 09, 2012.  Available at  http://www.news.com.au/national-news/nsw-act/safety-fears-over-
adhd-drug/story-fndo4bst-1226468000702.  
366  Sarah Ferguson and Nick Rushworth (2006), ‘ADHD – The Quick Fix’, The Sunday Program, Channel 9, 
14 May 2006. Interview previously available at 
http://sunday.ninemsn.com.au/sunday/cover_stories/article_1983.asp?s=1  (accessed 2 April 2008). 
367  For details of the effect of the submissions on the final ADHD Clinical Practice Points see appendix D 
page 16 available at 
http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/mh26_adhd_cpp_appendices_120903_0.
pdf/ 
368  National Health and Medical Research Council (2011), Public Consultation on the Draft Clinical Practice 
Points on the Diagnosis, Assessment and Management of Attention Deficit Hyperactivity Disorder in 
Children and Adolescents, Australian Government, p.15.  Available at 
http://consultations.nhmrc.gov.au/open_public_consultations/a-d-h-d  
369
  Sue Dunlevy (2011), ‘medicate ADHD kids or else, parents told’, The Australian, 21 November 2011.  
Available at http://www.theaustralian.com.au/national-affairs/medicate-adhd-kids-or-else-parents-
told/story-fn59niix-1226200652633 ↩ (accessed 30 November 2011). 
370  See National Health and Medical Research Council, ‘Reassuring parents new draft ADHD clinical practice 
points do not mandate medication’, Media Release, 23 November 2011.  Available at  
http://www.nhmrc.gov.au/media/releases/2011/reassuring-parents-new-draft-adhd-clinical-practice-points-
do-not-mandate-medica  ↩    http://www.nhmrc.gov.au/media/releases/2011/reassuring-parents-new-draft-
adhd-clinical-practice-points-do-not-mandate-medica (accessed 24 November 2011). 
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Table 2 - ADHD Clinical Practice Points statements supported and contested by ADHD 
critics. 
ADHD Clinical Practice Points statements 
supported by ADHD critics. 
 
ADHD Clinical Practice Points statements 
opposed by ADHD critics. 
DIAGNOSIS 
 ‘The clinician should always be mindful 
of seeking a more meaningful 
explanation of the child/adolescent’s 
behaviour than simply labelling it as 
ADHD because it meets diagnostic 
criteria.’ (Page 14) 
 ‘ADHD is a description rather than an 
explanation of a pervasive, persistent, 
disabling pattern of inattentiveness, 
overactivity and/or impulsivity. A 
child/adolescent who meets diagnostic 
criteria for ADHD may not be always best 
served by making that diagnosis. For 
example, their behaviour could be 
understood as a reaction to specific 
cognitive difficulties or 
family/environmental circumstances.’ 
(Page 6) 
 ‘All children and adolescents can display 
active, impulsive and inattentive 
behaviour as part of normal 
development.  This does not mean that 
they have a disorder, and important 
controversies exist about the use of 
ADHD as a diagnosis for children and 
adolescents.’ (Page 10) 
 
DIAGNOSIS 
 ‘The risk of not making a diagnosis is that 
the child/adolescent may not receive 





 ‘Parents/carers must be given 
information on the diagnosis and 
management plan, including any 
potential adverse effects of treatment in 
order to fully inform them and to have 
them make a decision regarding the 
TREATMENT 
 ‘Regardless of whether the cause is 
explicable or not these symptoms impact 
so adversely on the child or adolescent 
and their family that the symptoms 
cannot be left untreated.’ (Page 11) 
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treatment that is offered to their child.’ 
(Page 16) 
 Potential ‘adverse-effects’ of stimulants 
identified in the CPPS include sleep 
disturbance, reduced appetite, 
abdominal pain, headaches, crying 
spells, repetitive movements, slowed 
growth (height and weight), restlessness, 
dizziness, anxiety, irritability 
cardiovascular effects such as 
tachycardia, palpitations and minor 
increases in blood pressure and 
psychosis or mania.  In addition the 
ADHD CPPS say where to report side-
effects in Australia (to the TGA) and 
acknowledge that stimulants are 
Schedule 8 drugs because they can be 
addictive and are abused. (Page 20) 
 ‘Children/adolescents on stimulant 
medication require 3-6 monthly clinical 
assessment and review to ensure the 
management strategies remain 
appropriate and effective.  Monitoring 
should include assessment of side effects 
and particularly psychological symptoms 
and plotting of growth parameters, 
pubertal development, heart rate and 
blood pressure.’ (Page 8) 
 ‘Practical supports for families, such as 
respite care, parenting education and 
guidance and counselling, may be 
helpful or even a sufficient intervention 
perhaps obviating the need for specific 
treatment and psychological 
management of the child.’ (Page 17) 
 
 ‘Use of stimulant medications 
(methylphenidate and dexamphetamine 
sulphate) can reduce core ADHD 
symptoms and improve social skills and 
peer relations in children and 
adolescents diagnosed with ADHD in the 
short term (up to 3 years).’ (Page 8) 
 ‘Both medication and combined 
medication and behavioural treatment 
have been shown to be more effective in 
treating ADHD symptoms than 
psychosocial or behavioural 
interventions alone.’ (p.19) 
 ‘For young children (under 7 years) 
psychological, environmental and family 
interventions should, if possible, be 
trialed and evaluated before initiating 
pharmacological treatment.  If all these 
other interventions have not been 
effective then stimulants might be 
considered for this age group in 
consultation with the parents or 
guardians and including when 
appropriate teachers or other carers.’ (p. 
9) Note: The manufacturers prescribing 
information for all stimulants state 
stimulants should not be used in children 
under 6 years, since safety and efficacy 




                                               
371  Ritalin prescribing information says “Ritalin should not be used in children under 6 years, since safety and 
efficacy in this age group have not been established”.  See Novartis Pharmaceuticals Corporation, Ritalin 
Prescribing Information, December 2010.  Available at 
http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf.  Concerta’s says “safety and 
efficacy has not been established in children less than six years old or elderly patients greater than 65 years 
of age”.  See McNeil Pediatrics (2010), Concerta Highlights of Prescribing Information.  Available at  
http://www.concerta.net/sites/default/files/pdf/Prescribing_Info-short.pdf#zoom=56  Dexedrine’s (a brand 
of dexamphetamine) says “Long-term effects of amphetamines in pediatric patients have not been well 
established. DEXEDRINE is not recommended for use in pediatric patients younger than 6 years of age 
with Attention Deficit Disorder with Hyperactivity”.  See Amedra Pharmaceuticals (2010), Dexedrine 




 ‘There is no one single known cause of 
ADHD….’ (Page 10). 
 ‘….the effect of medication and 
behavioural or educational interventions 
on long-term outcomes such as 
academic and social and emotional 
outcomes, has not been established…..’ 
(Page 11) AND ‘Considering that there is 
insufficient evidence on the long-term 
outcomes and long-term adverse effects 
following use of stimulants, the 
continuing benefit from, and need for 
medication should be regularly 
assessed.’ (Page 21) 
 
OTHER 
 ‘Heredity, genetic, neuro-imaging and 
neuro-psychological studies provide 
evidence for a biological basis for 
inattention and impulsiveness.’ (p. 10) 
 ‘Data from 2000 indicates the 
prevalence rate of ADHD symptoms 
among 6–17 year-olds in Australia is 
around 11%.’ (p. 11) (Refer to 4.4.1) 
 
 
Obviously any impact of the publication and official endorsement of the Clinical Practice 
Points will occur outside the period (1993-2011) for which prescribing data is analysed in 
this thesis.  Nonetheless the Clinical Practice Points process demonstrates that when ADHD 
critics compete with proponents within the formal process, NHMRC ADHD regulatory 
processes are not always ‘captured’. 
5.3.4 Summary of the NHMRC’s involvement in ADHD policy processes 
As outlined in Box 5 the NHMRC processes for the development of treatment guidelines is 
based on selecting ‘experts’ and ‘evaluating medical evidence [by] carry[ing] out a 
systematic literature review’.372  Through the two guidelines’ development processes the 
NHMRC has consistently selected ADHD proponents or outsourced to an organisation that 
has in turn selected ADHD proponents.   
As identified by the NHMRC the ‘systematic literature review’ is ‘arguably the most 
important step in the process’.373  However, the research relied on in the 2009 guidelines 
process (at least) was clouded by extensive undisclosed conflicts of interest issues. 
                                               
372  NHMRC, ‘How NHMRC develops its guidelines’.  
373
  NHMRC, ‘How NHMRC develops its guidelines’.  
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Furthermore, the NHMRC and the Commonwealth Government failed to respond when 
these issues were raised with them privately and only responded slowly when there was 
adverse publicity.   
These observations invite the question as to whether selecting ‘experts’ in a particular 
condition predisposes outcomes that match their particular perspective and agenda.  It also 
raises issues about how it is best to ensure the independence and ‘rigour’ of evidence used 
to generate guidelines. These issues are discussed in greater detail at 7.4.2.1.  
5.4 The Therapeutic Goods Authority 
The Therapeutic Goods Authority (TGA) is a Division of the Australian Department of Health 
and Ageing established under the Therapeutic Goods Act 1989. The TGA has primary 
responsibility for the approval for market and the after-market monitoring of the safety of 
all medications and medical devices.  
The Australian Drug Evaluation Committee (ADEC) was appointed to provide advice to the 
Minister and the Secretary of the Commonwealth Department of Health and Ageing and the 
TGA on the quality, risk-benefit, and effectiveness of any drug referred to it for evaluation.  
In 2010, ADEC was replaced by the Advisory Committee on Prescription Medicines which 
performs a similar function but has more supporting subcommittees to deal with the 
increasing workload.374  The members ‘are appointed by the Minister and must have 
expertise in relevant clinical or scientific fields or appropriate consumer issues’.375   They 
generally work elsewhere and attend regular scheduled committee meetings.  
The TGA acknowledges that ‘from time-to-time committee members will have an interest in 
matters being considered by the advisory committee. This is because of the nature of the 
professional expertise of committee members, and the limited number of people with 
                                               
374  See Department of Health and Ageing (2002), ‘A history of the Australian Drug Evaluation Committee’, 
Australian Government.  Available at http://www.tga.gov.au/archive/committees-adec-history.htm 
375  Department of Health and Ageing (DoHA), (2011), TGA committee members must declare conflict of 
interest, Commonwealth of Australia.  Available at http://www.tga.gov.au/newsroom/btn-committee-
coi.htm (accessed 3 July 2013).  
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expertise and experience in relevant fields in Australia’.376 In response the TGA has rigorous 
conflict of interest declarations that require declarations: 
 prior to appointment on a committee 
 at the time of appointment 
 annually 
 on an ad hoc basis when they arise or become apparent 
 at any meeting at which they might be relevant. 
It is unclear what requirements existed when the events described below occurred. 
5.4.1 Licencing of Ritalin and Ritalin LA via the TGA  
Ritalin, produced by Novartis, is the brand name for the most commonly prescribed form of 
methylphenidate.  Ritalin LA (long acting) is a slow release form of Ritalin developed to allow 
‘once a day’ use to prevent the need for ‘patients’ to take the drug more regularly.  Ritalin LA 
contains a higher dose of the active ingredient methylphenidate hydrochloride which is released 
more slowly through a less permeable membrane. 
In 1993 the TGA approved Ritalin for the treatment of ADHD despite advice from the ADEC that 
was critical of the data in relation to safety and adverse side effects.   ADEC commented:  
The data to support the use of methylphenidate in the treatment of ADHD have 
not been generated as a result of a co-ordinated, structured drug development 
program but rather in a somewhat haphazard manner by the various research 
groups in various locations over a long period of time. As a result the data 
package to support this application is deficient in certain areas when compared 
with that usually required by ADEC and the Department…The data on safety are 
the most deficient. No evaluable data on laboratory testing has been provided. 
Data on the incidence of adverse reactions was provided in only four of the 
short-term placebo-controlled trials. Long-term incidence data is confined only 
to the retrospective analysis of 250 children.377 
                                               
376  DoHA, TGA committee members must declare conflict of interest. 
377  Australian Drug Evaluation Committee, Evaluation of Clinical Data, Part IV, Meeting No. 1993/2, 10 March 
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Nine years later, in 2002, the TGA relied on similarly deficient information when it approved 
the heavier dosage drug Ritalin LA (long-acting).  ADEC’s comments on the submission 
supporting Ritalin LA included the following: 
The clinical evaluator draws attention to the increased risk of overdose 
posed by the Ritalin LA capsule compared with Ritalin immediate release 
tablets due to the increased strength of the LA formulation. There is also no 
safety data on Ritalin LA for longer than 12 weeks.378  
When later questioned in the Australian Parliament the TGA justified their decision to 
licence Ritalin LA by arguing that ‘bioequivalence of the registered Ritalin tablet and the 
proposed Ritalin LA capsule has been satisfactorily demonstrated indicating that significant 
safety difference between 2 products would be unlikely.’ 379  The United States Food and 
Drug Administration has defined bioequivalence as ‘the absence of a significant difference in 
the rate and extent to which the active ingredient or active moiety in pharmaceutical 
equivalents or pharmaceutical alternatives becomes available at the site of drug action 
when administered at the same molar dose under similar conditions in an appropriately 
designed study’.380  In other words the TGA determined that Ritalin and Ritalin LA delivered 
equivalent doses.  This is in direct contradiction to the clinical evaluator’s finding that Ritalin 
LA posed a greater threat of overdose.  Without public disclosure of the deliberative 
material it is impossible to know why the TGA dismissed the concerns raised by ADEC.    
Furthermore, in the absence of data for Ritalin LA the TGA relied on the ‘deficient’ safety 
data from the original 1993 Ritalin application.  The concern raised by the clinical evaluator 
about the ‘increased risk of overdose’ for Ritalin LA over Ritalin and the deficiencies in the 
original Ritalin data might have, but did not, result in the requirement of a rigorous safety 
analysis of Ritalin LA by the TGA. 
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5.4.2 Licencing of Strattera by the Therapeutic Goods Administration 
One of the two studies that supported Eli Lilly’s successful application for approval for 
marketing in Australia in 2004 was chosen at random by me to analyse its independence.  The 
study ‘Atomoxetine in the Treatment of Children and Adolescents with Attention-
Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study’ was 
published in 2001.381  All eighteen authors had pre-existing financial ties to Eli Lilly, with five 
being shareholders and/or employees.  The study was not blind rated.  Many of the raters 
were paid by Eli Lilly and significant potential raters, teachers, in the most relevant setting, 
schools, were excluded from the study. 
The study is attributed to eighteen authors, David Michelson, Douglas Faries, PhD; Joachim 
Wernicke, MD, PhD, Douglas Kelsey, MD, PhD, Katherine Kendrick, BS, F. Randy Sallee, MD, 
PhD, Thomas Spencer, MD and eleven members (mostly MDs) of the Atomoxetine ADHD 
Study Group. Drs Sallee and Spencer (see chapter 4.3.3.1) and all eleven members of the 
study group ‘have acted as paid consultants and/or investigators for studies sponsored by 
Eli Lilly and Company’.382  The other five individually identified authors, Drs Michelson, 
Faries, Wernicke, Kelsey and Ms Kendrick are employees and shareholders of Eli Lilly and 
Company’.383  
The rationale for the study was that ‘several reports have provided evidence that 
atomoxetine is superior to placebo in reducing symptoms of ADHD in children and adults.  
However, the relative efficacy and the relative safety and tolerability of different doses have 
not been assessed.’  Given that Eli Lilly funded the study, and all eighteen authors had 
financial ties to the company, it is hardly surprising that the results supported the use of 
Strattera concluding: 
The data reported here provide additional evidence of the efficacy and 
safety of atomoxetine in older children and adolescents with ADHD and that 
successful treatment with atomoxetine is associated with both symptomatic 
                                               
381  David Michelson, Douglas Faries, et al (2001), ‘Atomoxetine in the Treatment of Children and 
Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-controlled, Dose-
response study’, Pediatrics, Vol. 108, No. 5.  Available at 
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and functional improvement.384  
The study assessed ADHD symptoms, affective symptoms, and social and family functioning 
using parent and investigator rating scales.  It included 297 eight- to eighteen-year-olds 
diagnosed with ADHD and concluded: ‘Social and family functioning also were improved in 
the atomoxetine groups compared with placebo with statistically significant improvements 
in measures of children’s ability to meet psychosocial role expectations and parental 
impact.’385  There was an obvious bias in that one source of ratings, the investigators, 
received payment from Eli Lilly.  Additionally the study was not blinded and parents knew 
whether the child was medicated or un-medicated, therefore parent ratings must be viewed 
with caution.  Even if parents noticed children were more compliant, this benefit is external 
to the child. The children were not asked how the medication affected them.  
Another notable aspect of the study was the decision to exclude teacher ratings and the 
performance of children in an educational setting.  The rationale offered was that: 
This study did not include teacher evaluation…...Although some large studies 
have had success in getting teacher ratings, our experience in multicenter 
trials has been unsatisfactory.  In 2 previous studies, we had extreme 
difficulty getting baseline and endpoint teacher evaluations returned 
consistently.  This probably was because these large multisite studies 
involved several hundred different schools and teachers, as well as a variety 
of attitudes toward participation.  We believed that this problem would 
have been compounded in the study reported here, because it was a year-
round study and included adolescents in junior high and high school with 
multiple teachers seeing students for limited periods.386   
Most of the 18 diagnostic criteria are either classroom specific or most easily applied to a 
classroom setting.  Claims that the study provides ‘additional evidence of the efficacy and 
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385  Michelson et al, ‘Atomoxetine in the Treatment of Children’. 
386
  Michelson et al, ‘Atomoxetine in the Treatment of Children’. 
140 
 
safety of atomoxetine in older children and adolescents with ADHD’,387 when the main 
setting in which ADHD supposedly impacts is ignored, are clearly questionable. 
In summary, Eli Lilly was required by the TGA to provide two studies supporting the use of 
Strattera. Eli Lilly was free to determine who conducted their studies.  For the one study I 
reviewed, they chose paid employees and shareholders to conduct the study.  Eli Lilly were 
also free to choose the design of and controlled the dissemination of results.  
5.4.3 Post licencing monitoring of Strattera by the Therapeutic Goods Administration 
Soon after Strattera came on the market concerns emerged about its safety.  On 17 
December 2004 the US Food and Drug Administration (FDA) issued a statement titled ‘New 
Warning for Strattera’, which stated: 
The drug’s labelling is being updated with a bolded warning about the potential for 
severe liver injury in patients taking Strattera.  The label warns that severe liver 
injury can progress to liver failure in a small percentage of patients.  It cautions 
clinicians to discontinue the drug in patients who develop jaundice or laboratory 
evidence of liver injury.  It also notes that the actual number of cases of severe 
liver injury from the drug is not known because of under-reporting.388  
Soon after the FDA warning, the Australian Therapeutic Goods Administration (TGA) altered the 
Consumer Medicine Information for Strattera, but made no public announcement. 
Less than a year after the information about potentially fatal liver damage came to light, and 
less than two years after Strattera came on to the Australian market, more safety concerns 
emerged.  On 29 September 2005 the FDA issued a public health advisory announcing they had 
put the highest possible black box warning on Strattera for suicidal ideation:  
Strattera increases the risk of suicidal thinking in children and adolescents with 
ADHD.  Patients who are started on therapy should be observed closely for clinical 
worsening, suicidal thinking or behaviours, or unusual changes in behaviour.  
Families and caregivers should be advised to closely observe the patient and to 
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communicate changes or concerning behaviours with the prescriber.389 
This health advisory was well publicised in the US and attracted considerable media attention in 
outlets such as The New York Times and NBC News.390  As well as publicising the warning, the 
FDA insisted that specific information about these dangers be provided to consumers with every 
new prescription of Strattera.391  In contrast, the TGA made little effort to publicise this 
disturbing information.  While six months later (on 19 March 2006) they did put a boxed 
warning for suicidal ideation on the product information made available to prescribers, they did 
not issue a press release to ensure parents were informed.  The decision about whether to 
inform parents and/or patients for suicidality was left with individual prescribers.  The TGA did 
not alert Australian media about the warnings or any subsequent adverse event reports of 
suicidal behaviour.  
It was not until November 2006, when I became aware of the warnings and reports and I raised 
the issue of the TGA’s extremely low-key response in the WA Parliament, that the suicidality 
warning got significant media coverage.392 I stated: 
Although it [the TGA] put a black-box warning of suicide on Strattera on 19 March 
2006, it did almost nothing to inform the public of this.  Even the term ‘black-box 
warning’ is extremely misleading.  Until recently, I mistakenly assumed that it was 
a prominent warning written in black on the outside of drug packaging.  However, I 
was mistaken.  In reality, it is the warning on the product information sheet that is 
available only to doctors, not patients or parents.  Apart from the inadequate, 
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hard-to-find, softly worded information in consumer medicine information, there 
is no mechanism for ensuring that parents and patients are informed.  The TGA 
had no excuse for its half-baked response…The TGA has done almost nothing to 
warn parents that Strattera could cause their children’s liver to fail or cause their 
children to want to kill themselves.393  
When my comments and the information about adverse events were eventually reported, Eli 
Lilly issued a press release:  
Eli Lilly stands by the safety profile of Strattera.  It is an important treatment option 
for people diagnosed with ADHD.  We also stand by the rigorous processes put 
into place by the TGA to ensure patient safety.  As Mr Whitely pointed out, 
following the emergence of new safety-related data, we reported it immediately 
to the TGA and action was undertaken to update public safety information.  Eli Lilly 
worked closely with the TGA to actively inform prescribing specialists, GPs and 
pharmacists of the new precautions in the product information to ensure they are 
able to monitor patients accordingly.  All relevant ADHD patient support groups 
were informed at the time of the Product Information update.  An update was 
posted on the Eli Lilly website.394 
Eli Lilly’s assurance that all relevant ADHD patient support groups were informed was revealing.  
In Western Australia the Learning and Attentional Disorders Society (LADS), who Eli Lilly 
supports and which promotes its products, was informed.  However the group Drug Free 
Attention Difficulties Support (DFADS) incorporated, which I founded, which promotes drug free 
approaches for children with attentional difficulties, was not informed.395  At no point did Eli 
Lilly dispute the facts contained in my parliamentary speech.  Their press release added little 
except to emphasise how ‘Eli Lilly worked closely with the TGA’ and that they praised the 
‘rigorous process put in place by the TGA’.  
                                               
393  Western Australia (2006), Parliamentary Debates, Legislative Assembly, 23 November , p.8772 (Martin 
Whitely). 
394  Cited in WA 36th Parliament, Mr. M. P. Whitely [9.39 am] Thursday, 23 November 2006. 
395  In 2003 I was instrumental in helping to establish Drug Free Attention Difficulties Support (DFADS) designed 
to achieve two objectives.  First to influence public policy as it relates to ADHD and second to provide support 
to parents and patients who wish to try drug-free approaches. 
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A very favourable article on Strattera called ‘Drug to cut schoolyard trade’ had previously 
appeared in the West Australian newspaper on 16 April 2004. It featured both Dr Whiting and 
LADS promoting the drug:  
A new non-stimulant drug to treat attention deficit hyperactivity disorder released in 
Australia this week could help cut the school playground trade in ‘kiddy speed’, a 
Perth paediatrician has claimed. Ken Whiting said atomoxetine hydrochloride, sold as 
Strattera, was a once-daily drug which did not contain the stimulants amphetamine or 
methylphenidate. Excluding stimulants also eliminated the possibility of addiction. 
Substance abuse is known to be higher in people with ADHD, although that risk can be 
reduced by up to 50 per cent with treatment. WA support group The Learning and 
Attentional Disorders Society (LADS) of WA (spokeswoman Michelle Toner) said 
families would welcome new, clinically proved options for better ADHD 
management.396 
Dr Ken Whiting was a key member of LADS and is currently listed as its patron.  
However there was no media coverage when the black box warning for suicidality was issued. 
Several months later when I generated an article in the West Australian highlighting the suicide 
warning Dr Whiting responded: ‘the drug company is trying to make practitioners aware of it so 
that we can watch patients and ensure there’s no problems. It’s important that patients don’t 
stop taking the drug suddenly but see their doctor.’397  
In November 2011 the TGA added a warning about ‘clinically significant increases in heart 
rate and blood pressure’.  The safety advisory warned:  
Atomoxetine [Strattera] is contraindicated in patients with symptomatic 
cardiovascular diseases, moderate to severe hypertension or severe 
cardiovascular disorders, whose condition would be expected to deteriorate 
if they experienced increases in blood pressure or in heart rate that could be 
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clinically important’.  It followed new data obtained from clinical trials 
sponsored by Eli Lilly.398 
From 2004, when Strattera first came on to the market, until March 2012, there were one 
hundred and six voluntary adverse event reports made to the Australian Therapeutic Goods 
Administration, including over fifty of self-harm or suicidal ideation for Strattera.399  It is 
impossible to know the true number of actual events, as the voluntary nature of the reporting 
system means only a fraction of the actual incidents gets reported.  A 2008 study by Curtin 
University pharmacologist Con Berbatis identified that for the prescription of all drugs by 
Australian General Practitioners only two percent of adverse events are reported.400 
A sample from the Adverse Drug Reactions Committee (ADRAC) adverse event reports for 
Atomoxetine Hydrochloride (Strattera) is available in Appendix 4.  The TGA made adverse event 
reports available upon request but did not publish them either through the media or the 
internet.  Without requesting the adverse event reports there was no way of the public 
accessing this information. 
In November 2010, the Gillard Government announced a review of the way the TGA 
communicates ‘to ensure that the Australian public is better informed about the benefits and 
risks of therapeutic goods…and to address community concerns that have been raised about 
the lack of information made available by the TGA.’401 In June 2011 the ‘Review to Improve the 
Transparency of the TGA Final Report’ recommended the ‘TGA make its Adverse Events 
Database available to, and searchable by, the public in a manner that supports the quality use of 
therapeutic goods’.402  However when the change was implemented only summaries of the 
total number of adverse events were made available online, individual de-identified case 
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reports like those summarised at appendix 4 were no longer available on request.  This followed 
significant media and online coverage of the details of these de-identified individual reports.  
The handling of Ritalin, Ritalin LA and Strattera are not the only examples of questionable 
regulatory practices by the TGA.  From January to September 2005 the US FDA issued twenty 
black box warnings (see chapter 3) for prescription drugs sold in both the US and Australia. 
However, the Australian TGA issued warnings for only five of these twenty.403  In response to a 
question on notice in the Senate, the TGA admitted that it did not monitor the FDA’s drug 
warnings stating:  ‘The TGA does not record which drugs sold in the US, with black box warnings 
in the US approved prescribing information document, do not carry black box warnings in the 
Australian prescribing information (P1) document’. 404  
While this example does not relate to ADHD medications the willingness of the TGA to accept 
‘deficient’ foreign safety data as demonstrated in the case of Strattera to approve drugs, yet 
ignore emerging overseas evidence of the dangers of these drugs, as demonstrated by the 
application of boxed warnings, is consistent with the assertion that the TGA has demonstrated a 
neo-liberal corporate bias. 
5.4.4 Off Label Prescribing and the TGA 
Pharmaceutical companies receive approvals from the FDA or TGA for the treatment of 
conditions within specified guidelines.  However, in both the US and Australia, once a drug has 
been approved doctors are free to prescribe it as they see fit, even in contravention to the 
manufacturer’s recommendations (off label).  The individual clinicians are legally liable for any 
harm that may arise from their unapproved speculative prescribing.   
However off label prescribing occurs so regularly that it has, in many cases, become the norm.  
A 2009 study found that 62 percent of U.S. pediatric office visits included off-label prescribing, 
with younger children at higher risk of receiving off-label prescriptions.405  In 2003 an Australian 
nationwide survey of 435 general paediatricians and 187 child and adolescent psychiatrists 40 
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percent reported off-label prescribing of psychotropic medications.406 
Pharmaceutical companies profit but are immune to liability for any damage caused by this ‘off 
label’ use.  Many children are prescribed drugs either at doses above the approved dosage, or in 
combination with contraindicated medications, because of the clinical judgement of prescribers.  
Methylphenidate, for example, is not approved for the treatment of children younger than six.  
In 1995 the ‘off label’ prescribing of Ritalin was so widespread in the US that the Drug 
Enforcement Agency (DEA) expressed concern ‘that children under the age of six are being 
treated with methylphenidate contrary to labelling guidelines in the absence of controlled 
studies suggesting that this is appropriate’.  The DEA entered the debate because they 
considered Ritalin use a possible ‘risk factor for substance abuse’.407  
Whatever protection is provided to Australian consumers by the Therapeutic Goods Authority 
licensing system is weakened by ‘off label’ prescribing.  However, the drug companies benefit 
from increased sales with no liability for the clinical judgement of individual practitioners.  Drug 
companies obviously deserve protection from liability due to individual rogue prescribers, but 
the practice of using psychotropic drugs ‘off label’ is so common that it represents normal 
practice and the drug companies must be aware that this is the case.    
Both the 1998 and 2009 NHMRC guidelines processes recommended ‘off label’ prescribing 
of psychotropic drugs.  For instance the 2009 draft guidelines recommendation that SSRI 
antidepressant medication (fluoxetine/Prozac) 'may be considered for adolescents with 
ADHD and comorbid moderate to severe depression' is in direct contravention of the 
manufacturer's prescribing guidelines which state ’Prozac is not recommended for use in 
children and adolescents under 18 years of age'.408  Similarly as with the draft guidelines the 
recommendation that Methylphenidate be used as a second line treatment in children 
under six years of age directly contravenes the manufacturer’s guidelines that state ‘Ritalin 
should not be used in children under 6 years, since safety and efficacy in this age group have 
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not been established’.409  This government endorsement of off label prescribing gives official 
endorsement to speculative prescribing against the recommendation of commercial 
interests that have the most economically to gain. From a profit maximisation perspective 
this works to enhance the interests of the ADHD drug manufacturers by boosting their sales 
and externalising any legal risks from potential harms from ‘off label’ use to either clinicians 
who prescribes or the government who endorses the practice. 
5.5 The Pharmaceutical Benefits Scheme 
The Commonwealth Government currently subsidises dexamphetamine (since 1992), Ritalin 
(2005), Ritalin LA, Concerta and Strattera (2007).  The subsidisation significantly reduces the cost 
to consumers of the drugs. Before Concerta was added to the PBS, it was $150 a script, but after 
subsidisation it cost $31.30.410  Subsidising drugs through the Pharmaceutical Benefits Scheme 
removes a financial barrier to their use.   
Decisions to subsidise pharmaceuticals via the PBS are ultimately made by the Commonwealth 
Minister for Health or in the case of decisions above $10million per annum the full cabinet.  The 
Minister for Health and the Cabinet almost always follows the recommendations of the 
Pharmaceutical Benefits Advisory Committee (PBAC).  
The PBAC is an ‘independent expert body appointed by the Australian Government.  
Members include doctors, health professionals, health economists and consumer 
representatives [whose] primary role is to recommend new medicines for listing on the 
Pharmaceutical Benefits Scheme.  No new medicine can be listed unless the committee 
makes a positive recommendation.’411  In determining whether to recommend a medicine 
for listing, the PBAC is supposed to consider ‘the medical conditions for which the medicine 
was registered for use in Australia, its clinical effectiveness, safety and cost-
effectiveness…compared with other treatments.’412 The PBAC has two advisory sub-
committees to assist with analysis and advice in these areas, the Drug Utilisation Sub 
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Committee and the Economics Sub Committee. The Drug Utilization Sub Committee 
assesses estimates on projected usage and financial cost and analyses data on actual use.  
The Economics Sub Committee assesses clinical and economic evaluations of medicines 
submitted to the PBAC for listing.413  The current membership includes health economists, 
pharmacologists, epidemiologists, a pharmacist, pharmacologists, general practitioners and 
industry representatives.414 
The following is a detailed analysis of the events relevant to the subsidisation of Strattera 
via the PBS in 2007.  
5.5.1 Case Study: The marketing of Strattera and subsidisation via the Pharmaceutical 
Benefits Scheme 
Strattera is pharmaceutical company Eli Lilly’s brand name for atomoxetine hydrochloride, a 
noradrenaline reuptake inhibitor.  Unlike the most commonly prescribed ADHD drugs 
dexamphetamine and methylphenidate, Strattera is not amphetamine based and has the 
advantage of being non-addictive and unsuitable for illicit use.  It is the only non-stimulant drug 
approved for the treatment of ADHD in Australia.  
Atomoxetine hydrochloride was first trialled in 1982 as an antidepressant branded Tomoxetine 
but was found to be ineffective.415  Eli Lilly refused a request by me to release results of trials of 
Tomoxetine as an antidepressant arguing:  
It is important to note that the population in these trials is different from the 
population in which atomoxetine hydrochloride is approved for use by the TGA in 
Australia. As a result, the relevance of the trials for current clinical practice is 
significantly diminished.416  
Strattera’s now established propensity to cause suicidal ideation may explain why atomoxetine 
hydrochloride was unsuitable as an antidepressant.  Eli Lilly re-branded Tomoxetine as Strattera, 
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a revolutionary non-stimulant ADHD drug.  In 2002 the US FDA approved Strattera for the 
treatment of ADHD.  It was approved in Australia in early 2004. 
Prior to Strattera, Eli Lilly had not marketed an ADHD medication.  When Strattera was first 
marketed in Australia Eli Lilly’s Australian website on Strattera contained a section entitled 
‘What Is ADHD?’  It stated, ‘Attention-Deficit/Hyperactivity Disorder is a neurological condition 
related, in part, to the brain’s chemistry and anatomy’ which ‘manifests itself as a persistent 
pattern of inattention and/or hyperactivity-impulsivity' and that ‘While some children outgrow 
ADHD, about 60 per cent continue to have symptoms into adulthood.’417  It presented the 
hypothesis that the aetiology is ‘neurological’, related to ‘brain chemistry and anatomy’, and 
that in most cases ADHD is a life-long condition, as if it were a certainty.  
This is a clear example of biomedicalism with a profit motive and similar to Eli Lilly’s aggressive 
approach to marketing Strattera in the US.  Eli Lilly marketed Strattera for adult ADHD in a way 
that blurs the lines between the stresses of modern life and disease in advertisement for 
Strattera in the US News & World Report. 
Distracted?  Disorganized?  Frustrated?  Modern Life or Adult ADD?  Many adults 
have been living with Adult attention deficit disorder and don’t recognize it.  Why?  
Because its symptoms are often mistaken for stressful life.418  
Eli Lilly attracted the attention of the US Food and Drug Administration (FDA) for making 
unsubstantiated claims about Strattera.  In June 2005 an American TV advertisement attracted 
the ire of the FDA, which issued a warning letter stating ‘The TV ad is false or misleading 
because it inadequately communicates the indication for Strattera and minimizes the risks 
associated with Strattera.’419  
In Australia Eli Lilly publicised Strattera’s non-addictive properties in an environment of growing 
concern about the safety of stimulants and their illicit use.  In Western Australia Strattera was 
promoted through a very favourable article ‘Drug to cut schoolyard trade’ in the West 
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Advertising, and Communications, Food and Drug Administration, Maryland.  Available at 
http://www.pharmcast.com/WarningLetters/Yr2005/Jun2005/EliLilly0605.htm (accessed 23 September 2008). 
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Australian newspaper on 16 April 2004:  
A new non-stimulant drug to treat attention deficit hyperactivity disorder released 
in Australia this week could help cut the school playground trade in ‘kiddy speed’, 
a Perth paediatrician has claimed.  Ken Whiting said atomoxetine hydrochloride, 
sold as Strattera, was a once-daily drug which did not contain the stimulants 
amphetamine or methylphenidate.  Excluding stimulants also eliminated the 
possibility of addiction.  Substance abuse is known to be higher in people with 
ADHD, although that risk can be reduced by up to 50 per cent with treatment.  WA 
support group The Learning and Attentional Disorders Society (LADS) of WA 
(spokeswoman Michelle Toner) said families would welcome new, clinically proved 
options for better ADHD management.420 
The following day another favourable article entitled ‘Aid for new ADHD drug sought’ appeared 
in the West Australian lobbying for Strattera to be subsidised via the Pharmaceutical Benefits 
Scheme.  The article quoted Western Australian Secondary School Executives’ Association 
president Ray Maher as saying ‘the drug could be a boon to schools and particularly principals 
ultimately responsible for ensuring the security and correct administration of dexamphetamine 
– sometimes referred to as kiddie speed’.421 
At the same time more articles promoting Strattera’s non-addictive advantage appeared in 
other Australian newspapers.  Page 3 of the Brisbane Courier Mail carried an article titled ‘New 
drug combats child addiction fears’.  It quoted Dr Michael McDowell, a developmental 
pediatrician from the Child Development Network at Brisbane’s Mater Hospital, who conducted 
the Australian clinical trials of Strattera, as saying: ‘The fear parents have of amphetamines…is 
the possibility of addiction and abuse, whereas this current medication doesn’t come with that 
risk.’422 Page 3 of the Sydney Morning Herald carried an article titled ‘Milder new drug hailed for 
attention disorder’. It also quoted McDowell:  
There is no risk they will take too much for a psychological high…there’s no risk 
they will sell it on to other children in the playground because it can’t be taken as a 
                                               
420  Liz Tickner (2004), ‘Drug to cut schoolyard trade’, The West Australian, 16 April. 
421  Charlie Wilson-Clark (2004), ‘Aid for new ADHD drug sought’, The West Australian, 17 April. 
422  Kylie Walker (2004), ‘New drug combats child addiction fears’, Courier-Mail, 15 April.  
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recreational drug.  But it does have similar side effects to the other drugs including 
abdominal pain, decreased appetite, increased blood pressure and vomiting. 
There are side effects, but overall they’re milder and I suspect the likelihood that 
parents would stop the medication because of side effects is less than existing 
medications.423  
Comments like McDowell’s, and the fact that Strattera was non-addictive, gave the appearance 
that it was a safer option than stimulants.  The co-operation between the pharmaceutical 
company, the patient support group they sponsor (LADS), researchers they pay, and educators, 
to obtain pharmaceutical benefits scheme subsidisation of Strattera is a clear demonstration of 
biomedicalized access orientated consumerism.  
Subsequent to this lobbying, significant evidence of potential significant harms, particularly 
suicidality and potentially fatal liver damage emerged.  Lobbying efforts by ADHD critics to 
restrict access to Strattera attracted media coverage but were unsuccessful. 424   
In addition I wrote a letter on 22 December 2006 to the then Health Minister, the Hon. Tony 
Abbot expressing my concern that Strattera had been recommended for inclusion in the 
Pharmaceutical Benefits Scheme. 425  The response received from the assistant Minister for 
Health, Christopher Pyne, was dismissive of my concerns concluding; 
All medicines have potential risks. The balance between the benefits offered by the 
medicine and the potential risks associated with its use, need to be considered when 
these products are prescribed. The decision to use a particular medicine should be made 
between the prescribing medical practitioner and the patient, and should entail 
informed consent.426   
On 5 June 2008 following the change of government and the election of the Rudd Labor 
                                               
423  Ben Wyld (2004), ‘Milder new drug hailed for attention disorder’, The Sydney Morning Herald, 15 April.  
424
  For example, see media articles on Strattera:  Amanda Banks (2006), ‘Drug risk warning inadequate: MP’, 
The West Australian, 28 November; Cath Hart (2007), ‘ADHD treatment skips curbs’, The Australian, 16 
April; Stephen Lunn & Julie-Anne Davies (2009), ‘MP wants ADHD drug ban’, The Australian, 12 
January. 
425  Letter from Martin Whitely MLA to the Hon Tony Abbott, Minister for Health and Ageing, 22 December 
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government, I also wrote to the Minister for Health and Ageing, the Hon. Nicola Roxon, outlining 
numerous adverse event reports reported to the TGA, including suicide ideation.427  I asked the 
Health Minister to reverse the decision to subsidise Strattera via the PBS, but this request was 
rejected.  Ultimately the lobbying to prevent the Pharmaceutical Benefits Scheme subsidisation 
was unsuccessful as Strattera was listed on the PBS on 1 July 2007 and remains so.  
Despite its warning for suicidal ideation and potentially fatal liver damage, Strattera was 
placed on the Pharmaceutical Benefits Scheme (PBS) on 1 July 2007 at an anticipated cost to 
taxpayers of $101.2 million over four years.428 
Eli Lilly had applied unsuccessfully on at least three previous occasions to have Strattera 
subsidised via the PBS.  In November 2008 I requested, via Freedom of Information, copies 
of all documents relating to the decision of the Pharmaceutical Benefits Advisory Committee 
(PBAC) to recommend Strattera’s listing on the PBS.  I was particularly interested in what 
consideration had been given by the PBAC to Strattera’s black box warning for suicidal 
ideation and the numerous adverse event reports.  The Department of Health and Ageing 
(DoHA) refused to release all but a tiny percentage of heavily censored and irrelevant 
documents.  
The Administrative Appeals Tribunal heard my appeal against DoHA’s refusal to release the 
documents in April 2010.  The DoHA argued successfully that they had erred in giving me 
any documents because the Health Act 1953 prevented anyone working for the 
Commonwealth revealing information relating to the affairs of a (legal) person (in this case 
Eli Lilly). 
The net effect is that this has created a precedent and the public has no legal right to know 
why the PBAC recommends taxpayers subsidising any drug.  In essence Eli Lilly benefited 
from a price subsidy worth an estimated $101.2 million over four years funded by Australian 
taxpayers but the public is not allowed to know why. 
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428






5.5.2 Other evidence of Pharmaceutical Benefits Scheme Regulatory Capture 
A 2013 review by the Grattan Institute of the cost to the Australian Government of 
subsidising PBS drugs provided evidence of regulatory capture of PBS process and concluded 
both Australian citizens and the Commonwealth Government pay far too much for prescription 
drugs. 429   In contrast to New Zealand, where a total budget figure is set for all subsidised drugs, 
in Australia there is no upper limit on expenditure on PBS drugs.  
‘For Australia’s PBS… decisions on drug pricing are opaque and unconstrained by a 
budget. Key decisions are made by a committee inside the Department of Health and 
Ageing that includes among its six members two representatives of drug companies. 
They have little interest in keeping prices low.’430 
The committee referred to in the quote above is the Pharmaceutical Benefits Pricing 
Authority (PBPA). After a drug has been licenced by the TGA and recommended for PBS 
listing by the PBAC the PBPA recommends the maximum price that can be charged. It also 
recommends the extent of the Government payment to manufacturers through the PBS. 
The PBPA is established at the direction of the Minister for Health. Two of the six members 
on the committee ‘are industry lobbyists from Medicines Australia and the Generic 
Medicines Industry Association’ and its recommendations remain private.431  Having 
significant industry representation in a process that is closed, and has no budgetary 
constraints on its recommendations for the expenditure of taxpayer funds, is consistent 
with the existence of regulatory capture.  
5.6 The effects of other Commonwealth Government policies on the economics of diagnosing 
and treating ADHD 
In addition to the PBS the Australian Government also affects the diagnosis and treatment of 
ADHD through other economic incentives.  Un-timed Medicare co-payments mean that 
                                               
429
  The Grattan Institute is a think tank established to develop Australian public policy.  It was formed in 2008 
and is funded by the Australian and Victorian Governments and the private sector including BHP and 
charitable foundations.  For further information see http://grattan.edu.au/about-us. 
430  Duckett, S.J., P. Breadon et al (2013), Australia’s bad drug deal: high pharmaceutical prices, Grattan 
Institute, Melbourne, p.2.  Available at 
http://grattan.edu.au/static/files/assets/5a6efeca/Australias_Bad_Drug_Deal_FINAL.pdf (accessed 25 June 
2013).  
431  Duckett, Australia’s bad drug deal.  
154 
 
paediatricians receive the same financial reward for a rushed or comprehensive consultation.  
Along with significant patient ’out of pocket costs’ for allied health treatment (for example 
speech and occupational therapy), this may encourage the speedy diagnosis of ADHD rather 
than a full assessment of a child’s medical and social needs.  
In some Australian states extra in-class support is provided to students with a range of 
diagnosed disabilities.  While a diagnosis of ADHD does not qualify for extra in-class support in 
state government schools, parents of a child diagnosed with ADHD may be entitled to a 
fortnightly Commonwealth carer allowance of $87.30 (in 2008).   Australian Government 
welfare agency Centrelink advised ‘An ADHD diagnosis is usually sufficient but does not 
automatically guarantee the allowance. Parents must show the child has a physical, intellectual 
or psychiatric disability (that impacts on the family) and is likely to suffer from the disability 
permanently or for an extended period (that is, for 12 months or more)’.432 
By contrast, in Finland ‘diagnoses’ do not fulfil the gate-keeping function…every student who 
needs it is entitled to additional assistance.  There, results indicating poor academic 
achievement acts as a barometer indicating the need for additional support.433  Finnish schools 
concentrate their resources on students whose failure to thrive is evidenced by poor results 
compared to their peers, rather than via subjective notions of ‘disability’. 
The Australian Government’s approach is to respond to a child’s diagnosis of ADHD rather than 
the individual circumstances of the child.  It is consistent with a case management neo-liberal 
rationalist approach to public sector service delivery which Abraham contends – along with 
regulatory capture – is part of the explanation for the pharmaceuticalization of ADHD (refer to 
2.9). 
5.7 Summary of the Australian Government experience of Pharmaceuticalization and 
Regulatory Capture  
Despite the incomplete nature of records prior to 2008 the magnitude of the increase in 
ADHD prescribing shown in Figures 1,2 and 3 provide strong evidence of the 
pharmaceuticalized response within Australia to ADHD.  The evidence in this chapter 
                                               
432  Source: Email response to Martin Whitely received from Centrelink on 5 February 2008. 
433  Graham, ‘Drugs, labels and (p)ill-fitting boxes’, p.97. 
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indicates that from the period 1993 to 2010 the development of ADHD policy and regulation 
at a Commonwealth level has been captured by ADHD proponents.  The rapid growth in 
National ADHD prescribing rates from 1993 to 2011 coincided with this period of ADHD 
proponent regulatory capture.   
Although the Clinical Practice Point Process began in 2011, the Clinical Practice Points were 
not published until September 2012, so any effect on diagnosing and prescribing practices 
will be outside the period covered in this thesis.  The Clinical Practice Points, however, 
indicate that while regulatory capture by ADHD proponents of Commonwealth Government 
regulatory agency processes may be the ‘norm’, it is not inevitable.   
In addition all of the following events outlined in this chapter are evidence of significant 
regulatory capture by the pharmaceutical industry of the operation of government agencies 
notionally established to protect the public interest: 
 Licencing of Ritalin, Ritalin LA and Strattera via the TGA showed that the licencing 
process for new ADHD drugs was far from rigorous and that the benefit of any doubt is 
given to pharmaceutical companies seeking to licence a product for market. 
 Reluctance of the TGA to publish information about adverse effects risks of ADHD drugs. 
 Failure of the TGA to monitor and act upon the FDA’s imposition of significant safety 
warnings on drugs marketed in Australia with TGA approval.  
 Tacit endorsement of off label prescribing through PBS sponsorship. 
 Department of Health and Ageing actively seeking to prevent public access to 
information (by opposing Freedom of Information access) used to justify significant 
expenditure of public funds via the PBS. 
 Direct involvement of the pharmaceutical industry in determining Pharmaceutical 
Benefits Pricing Authority recommendations on the pricing and level of government 
subsidy of PBS drugs.  
A more comprehensive analysis of the evidence in this chapter in regards to the relationship 




Chapter 6.  Western Australian and New South Wales ADHD policy and 
Regulatory Capture 
 
Chapter 4 presented relevant statistical data about WA and NSW ADHD child prescribing 
rates from 1992 to 2011. This chapter outlines the history of WA and NSW ADHD policy and 
regulation.  It provides information for the analysis of the relationship between regulatory 
capture and pharmaceuticalization discussed in detail in Chapter 7. 
6.1 Western Australian State Government Responsibilities in Regard to ADHD 
The Western Australian (WA) State Government has several responsibilities in regard to 
ADHD including: 
 Educating students diagnosed or at risk of diagnosis of ADHD. 
 Running health and mental health services that potentially diagnose (and treat) 
children with ADHD.   
 Regulating the prescribing and dispensing of pharmaceuticals, including 
dexamphetamine and methylphenidate, with a high potential for diversion for illicit 
use. 
WA State Government schools educate the majority of children in Western Australia.  Given 
that many of the symptoms relate to behaviours demonstrated in a classroom setting, 
schools, or more specifically their teachers, play a central role in providing information that 
forms the basis of the diagnosis.  They also are responsible for the administration of 
medication within school hours.   
The WA State Government also run health services including public hospitals, Child and 
Adolescents Mental Health Services and State Child Development Services which diagnose 
and treat children.  
However, the WA State Government responsibility that has attracted the greatest attention 
is its role in regulating the prescribing of ADHD psycho-stimulants.  The potential for illicit 
diversion, rather than the controversial nature of ADHD and the potential side effects of the 
drugs, is the primary reason most extra accountability controls over the prescription of 
ADHD stimulants were initially established.   
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State Governments have primary responsibility for monitoring Schedule 8 drugs and 
poisons, otherwise known as Controlled Drugs.  However all states have agreed to a 
standardised approach where the classification of drugs is recommended by the National 
Drugs and Poisons Schedule Committee, a committee of the TGA which has representation 
from state health authorities.434   
Schedule 8 drugs are substances and preparations for therapeutic use which have high 
potential for abuse and addiction. They are called Schedule 8 drugs because they are listed 
on Schedule 8 of the Standard for the Uniform Scheduling of Medicines and Poisons, which 
is published under the Commonwealth Therapeutic Goods Act. All drugs on Schedule 8 
require a doctor to have a Schedule 8 permit before prescribing treatment. Individual state 
governments can restrict which clinicians can prescribe schedule 8 drugs and place other 
regulatory controls - for example reporting requirements - on the prescribing and dispensing 
of Schedule 8 drugs.435 436 
Despite Strattera having the highest possible ‘black box’ warning for suicidal ideation and a 
record of serious adverse event reports that, at least superficially, appears worse than 
stimulants, it is not subject to the same level of prescription controls. 437  This is because 
Strattera is a Schedule 4 prescription drugs because it does not have the same risks of 
addiction and abuse.  
Schedule 4 drugs are drugs and poisons (otherwise known as prescription only drugs) which 
can only be prescribed by a doctor, but do not need to be authorised by the WA State 
Health Department.  Neither Schedule 8 nor Schedule 4 drugs can be advertised directly to 
the public and are often subsidised via the Commonwealth Government’s Pharmaceutical 
                                               
434  Department of Health and Ageing (2011), National Drugs and Poisons Schedule Committee (NDPSC), 
Commonwealth of Australia.  Available at  http://www.tga.gov.au/archive/committees-ndpsc.htm 
(accessed 4 July 2013). 
435  Department of Health, (2012), Schedule 8 Medicines Prescribing Code, Pharmaceutical Services Branch, 
Public Health and Clinical Services Division, Department of Health, Perth, Western Australia. Available at 
http://www.public.health.wa.gov.au/cproot/4947/2/S8-medicines-prescribing-code-C20121121AG-2.pdf  
(accessed 19 May 2013). 
436  Pharmacy Guild of Australia.  See http://www.5cpa.com.au/iwov-
resources/documents/The_Guild/PDFs/News%20and%20Events/Publications/Fact%20Sheets/scheduling_
system.pdf (accessed 19 may 2013). 
437  Martin Whitely, ‘Straterra’s sad story – (Warning, it may make you want to kill yourself)’, Speed Up & Sit 
Still, 30 August 2012.  Available at http://speedupsitstill.com/strattera  
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Benefits Scheme, with phone authority needed from the Commonwealth Department of 
Human Services for increased amounts or multiple repeats. 
6.2 Timeline of significant events regarding the Western Australian Government’s 
response to ADHD 
The events detailed in this chapter occurred during the terms of the Court liberal 
Government (1993-2001), the Gallop and Carpenter Labor Governments (2001-2008), and 
the Barnett Liberal Government (2008 to present). 
The majority of this chapter identifies and analyses the history of WA policy formulation and 
regulation in regards to ADHD.  Box 7 below is a timeline of significant events.  
 
Box 7 - Timeline of significant events regarding the Western Australian Government’s response to 
ADHD 
The following is a timeline of significant events regarding the Western Australian State 
Government’s response to ADHD.  I have italicised events that are described in this chapter.  
1989- An estimated 880 Western Australians receive stimulant medication. 
1997- The Report of the Technical Working Party on Attention Deficit Disorder to the Cabinet Sub-
Committee is published. 
1997- The Stimulants Committee was established. 
1998- The International Panel on the Diagnosis and Treatment of ADHD meets and prepares the 
Report of the International Panel on Attention Deficit Hyperactivity Disorder to the Mental Health 
Division of Western Australia (1999). 
2001- Gallop Labor Government elected in February. 
2002- The report Attentional Problems in Children:  Diagnosis and Management of Attention Deficit 
Hyperactivity Disorder (ADHD) and Associated Disorders was published by the Western Australian 
Mental Health Division. 
2003- The Western Australian Government establishes the Stimulants Regulatory Scheme and 
abolishes ‘Block Authorisation’ and the Stimulants Committee is replaced by the Stimulants Panel. 
2004- Western Australian Legislative Assembly Education and Health Standing Committee conducted 
a Parliamentary Inquiry into ADHD. 
2005- Western Australian Minister for Health, Jim McGinty, appointed a Ministerial Implementation 
Committee (MICADHD) to implement the recommendations of the Western Australian Legislative 
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Assembly Education and Health Committee 2004 Parliamentary Inquiry into ADHD.   
2005- The Australian Secondary School Alcohol and Drug Survey (ASSAD) indicated 9,492 (5.5%) of 
12-17 year olds had abused ADHD stimulants in the last year. 
2005- Poisons regulations were enacted to prevent pharmacy shopping for ADHD drugs.  
2007- The Western Australian Government conducts the Amphetamine (Ice) Summit. 
2008- The Carpenter Labor Government narrowly lost office to the Barnett Liberal/National 
Government.  
2009-2010- Two State Government multidisciplinary ADHD clinics were opened.   
2010- The Raine ADHD Study, Long-term outcomes associated with stimulant medication in the 
treatment of ADHD in children was published by the Western Australian Department of Health. 
 
6.3 WA ADHD policy and politics 1994 -2001 
The history of WA ADHD policy and practice will be discussed in two distinct periods.  The 
first is the period 1994 to 2001 when policy development and implementation was 
dominated by the biomedicalized view of ADHD proponents.  The second is the period 2001 
to 2011 when policy development was contested by ADHD proponents and ADHD critics – 
including myself as a State Labor Party MP elected in 2001 - who adhere to the 
‘medicalization thesis’ of ADHD.  
Concerns about WA rates of prescription and the diagnostic practices of some unnamed 
Perth paediatricians first emerged in the mid-1990s.  In 1995 the Court Liberal State 
Government set up the Technical Working Party on Attention Deficit Disorder ‘to report to 
government on the incidence of ADHD in Western Australia and to seek expert opinion on 
the appropriate diagnosis and treatment for the condition’.438  Published in 1997 The Report 
of the Technical Working Party on Attention Deficit Disorder to the Cabinet Sub-Committee 
highlighted that, in 1994, Western Australian child (5-14) prescription rates were between 
two to two and a half times the national average, and that there had been a massive (forty-
                                               
438  The Report of the Technical Working Party on Attention Deficit Disorder to the Cabinet Sub-Committee, 
Parliament House Western Australia, 1996, p.2. 
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three-fold) growth in the prescription of dexamphetamine to five- to fourteen-year-olds 
between 1989 and 1994.439  
The Report of the Technical Working Party identified two ADHD hotspots: one in Perth’s 
affluent western suburbs and the other in Perth’s economically disadvantaged south-east 
corridor.  The report concluded this patchy geographical distribution was probably ‘more 
reflective of the prescribing patterns of paediatricians servicing the various areas than it is of 
social or other factors’.440  The report raised concerns about the rigour of diagnostic 
practices of some clinicians.  ‘The parent is frequently the sole source of information and 
often educational and behavioural information is not sought. When information is sought 
from the school, the questions asked are frequently inappropriate. Behavioural observations 
are rarely obtained.’441  
To address the inconsistency in prescribing rates identified in the Technical Working Party’s 
1997 report, it recommended ‘random audits into the use of Block Authorisations, and that 
paediatricians and psychiatrists found to be failing to abide by the appropriate criteria have 
their Block Authorisation capacity removed’.442   
6.3.1 Block Authorisation  
Block Authorisation exempted frequently prescribing clinicians from the requirement to get 
authorisation for each individual prescription.  With Block Authorisation ‘a practitioner was 
able to apply to the (WA) Department of Health and be granted blanket approval to treat 
any number of patients with stimulant medication, without further notifying of changes to 
individual patient details or dosage,’ provided the dose was within the manufacturers 
prescribing guidelines.443  
When prescribers with Block Authorisation prescribed within dosage limits they were not 
required to request authorisation for each patient.  In contrast, a clinician who prescribed 
infrequently was accountable for every individual script.  The rationale for the policy of 
‘Block Authorisation’ was the assumption that those who prescribed frequently were 
                                               
439  The Report of the Technical Working Party, p.5. 
440  The Report of the Technical Working Party, p.6. 
441  The Report of the Technical Working Party, p.8. 
442  The Report of the Technical Working Party, p.20. 
443
  Western Australia Legislative Assembly, Attention Deficit Hyperactivity Disorder in WA, p.27. 
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considered to be ‘familiar with the guidelines for prescribing stimulants’.444  Effectively the 
heaviest prescribers were the least accountable.  
6.3.2 Western Australian Stimulants Committee 
In response to the Report of the Technical Working Party recommendations the WA Stimulants 
Committee was established by the Western Australian Department of Health in 1997.  The 
Stimulants Committee was supposed to monitor the prescription of psycho-stimulants to ensure 
appropriate prescribing.  The Committee included some of Perth’s most prominent prescribers, 
who themselves had block authorisation, and were therefore exempt from oversight.  The 
recommended audits of Block Authorisations never happened.  
Drs Trevor Parry and Ken Whiting were members of the Stimulants Committee from its 
inception in 1997 until it was abolished in 2003.  Both had Block Authorisation and were 
therefore exempt from prescribing accountability requirements.445  Stimulants Committee 
meeting minutes from 20 February 2002 recorded: 
As there were a number of applications outside the mg/kg range, Dr Oleh Kay, 
enquired if it would be possible to have en-bloc authorisation for doses outside 
the mg/kg446…Dr Whiting said he would be pleased to be exempt in this case 
and he advised that Dr Parry would be also…Dr Harris advised that the 
Department could not be put in a position where members of the Committee 
had en-bloc authorisation to prescribe outside the mg/kg range, as this would 
understandably be seen to be bias.447  
Drs Whiting and Parry were part of the committee tasked with ensuring the safe and 
responsible prescription of amphetamines in Western Australia.  According to Dr Whiting, they 
were happy to extend their personal accountability exemptions to allow them to prescribe 
outside the manufacturers’ prescribing guidelines.  Further, Stimulant Committee meeting 
minutes below show Dr Ken Whiting’s relaxed attitude to prescribing ‘off label’ and monitoring 
                                               
444  The Report of the Technical Working Party, p.20. 
445  WA Stimulant Committee, Minutes of Meeting held on 20 February 2002, obtained under Freedom of 
Information Act 1992  
446  The term mg/kg refers to recommended dose in milligrams of medication per kilogram of body weight. 
447  WA Stimulant Committee, Minutes of Meeting held on 20 February 2002 
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individual clinician’s prescribing patterns. 
20 February 2002- It was raised by Ms Arrigo the issue of co-prescribing 
methylphenidate and dexamphetamine and requested advice from the Committee 
with the aim of incorporating this advice into the Guidelines.448  Dr Whiting advised 
that the Department is being excessively bureaucratic and that it really has nothing 
to do with the Department if a medical practitioner co-prescribes the two drugs 
together.  He advised it comes down to a clinical issue to be determined by the 
patient’s medical practitioner…Ms Arrigo advised that the Department would like 
some guidance in being able to process the applications that come through, and the 
Committee agreed that children being prescribed both drugs together should not 
exceed the milligram per kilo range of each drug.  For adults the dose should not 
exceed 12 tablets of each drug per day.  Anything outside this should be submitted 
to the Committee.449 
21 August 2002- Dr McLaughlin450 raised the issue again of co-prescribing of 
methylphenidate and dexamphetamine and advised that the Department has still 
not found supportive evidence for prescribing both the drugs together…Dr Whiting 
enquired why the Department should be concerned.  He advised that he has quite a 
few patients on both drugs together.  Dr McLaughlin asked if there was any 
documentation to support the prescribing of both drugs together because we would 
be unable to support co-prescribing of both drugs until there was documentation to 
support the practice.  Dr Whiting advised that the Interest Group for ADHD will come 
back with advice to the Department.451 
Other Stimulants Committee minutes obtained through Freedom of Information (FOI) revealed 
that the Committee took a hands-off approach to the most reckless prescribers, even when 
their prescribing resulted in children being hospitalised.  The names of the doctors with the 
questionable prescribing practices were not disclosed in the FOI documents.  The minutes refer 
                                               
448  Ms Rosemary Arrigo, was a public servant from the WA Department of Health who was the Assistant 
Secretary to the Stimulants Committee in January 2001 and from September 2001 to May 2003 
449  WA Stimulant Committee, Minutes of Meeting held on 20 February 2002. 
450  Dr Virginia McLaughlin from the WA Department of  Health was Chairperson of the Stimulants 
Committee the from July 2001 to August 2002 and February 2003 to May 2003. 
451
  WA Stimulant Committee, Minutes of Meeting held on 21 August 2002. 
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to an unnamed doctor (Dr Z) whose child patient was hospitalised because of ‘abnormal limb 
movements, slurred speech and unusual behaviour’ after being prescribed Ritalin at an 
extraordinarily high dose in combination with ‘several’ other drugs.  The 6mg/kg dose was three 
times the recommended maximum dose.  The term mg/kg refers to recommended dose in 
milligrams of medication per kilogram of body weight.  In patients under the age of 18 years, 
doses are not to exceed 1mg/kg/day for dexamphetamine up to a maximum of 60mg per day; 
or not to exceed 2mg/kg/day for methylphenidate up to a maximum of 120mg per day.452  
Although Dr Z had block authorisation, he still needed to apply for special authority to prescribe 
at that level – therefore his actions were illegal.  The Stimulants Committee took no formal action 
except for organising a meeting with Dr Z which was ‘felt to be fruitful’.  Perhaps the most 
revealing comment minuted was ‘that although the stimulant dose was high these were 
inherently safe drugs and yet there was no prescribing restrictions of other far more dangerous 
drugs’.  These minutes demonstrate that the Committee was not prepared to act after an illegally 
prescribed overdose of amphetamine saw a child hospitalised to detox.453 
In 1999 there were concerns about another doctor (Dr H) which prompted an advisory meeting 
between members of the Stimulants Committee and Dr H.  At the meeting Dr H ‘acknowledged 
that some of his patients were on up to 25 tablets daily but they seemed to be doing 
well…[and]…he was aware of the possible problem of patients selling tablets’.  Although the 
Stimulants Committee sent an advisory letter and organised two ‘fruitful’ meetings, it took no 
decisive action.  This did not significantly change Dr H’s prescribing practices.  While they did 
discuss the prospect of curtailing his Block Authorisation capacity and making him accountable 
for every script, change only occurred because Dr H left the state.454 
The Stimulants Committee did not take action against other illegal prescribers.  Dr X was neither 
a paediatrician nor a psychiatrist and was therefore not able to initiate a patient on stimulant 
medication.  Dr X prescribed a patient with dexamphetamine even though it was 
‘contraindicated in this patient’ as he had ‘psychotic symptoms with emerging schizophrenia’.  
The Committee considered two options: recommending to the WA Health Department that 
                                               
452  Information obtained from Government of Western Australia, Department of Health, Stimulant 
Prescribing Code: Explanatory Notes, September 2012, Public Health and Clinical Services, Perth 2012, 
p.4. 
453  WA Stimulant Committee, Minutes of Meeting held on 10 November 1998. 
454  WA Stimulant Committee, Minutes of Meeting held on 2 November 1999. 
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‘action be taken against Dr X as it is illegal what he has allegedly done’, or that the Department 
write to Dr X advising him not to ‘prescribe dexamphetamine or supply it without authorisation 
from the Commissioner of Health’.  The Committee initially decided on the second softer option 
and then failed to follow through.  The draft letter was never sent but ‘retained on file and if 
another allegation comes forward then the Department will have more weight in which to write 
to him’.455 
Further minutes disclose the Committee’s enthusiasm for even fewer restrictions on 
prescribing.  The Committee discussed the option of dropping ‘the age for stimulant prescribing 
from 4 years of age down to 3 years of age’, and ‘members agreed that earlier intervention is 
the best way’.456  The Committee also approved two applications for dexamphetamine to be 
used outside guidelines during pregnancy.  Committee members, notably Dr Trevor Parry, 
argued that for paediatricians, ‘provided they [did] not initiate treatment for [people] over 18 
years of age, there should be the freedom for continuity of care and [this] should not be seen 
as a problem’.457  Other minutes record that the ‘Stimulant Treatment Guidelines have been 
amended to indicate that extended periods between specialist review were allowable at the 
discretion of the specialist, provided that adequate feedback from the GP was ensured.’458 
In August 2002, four months before the announcement that the Stimulants Committee 
would be replaced and prescribing accountability measures would be tightened, Committee 
minutes recorded: ‘Dr Parry advised that the Committee would rarely query an application 
outside the guidelines.  He advised that the Committee’s time would be more usefully spent 
with ongoing monitoring and adaptation of the stimulant guidelines.’459   
These minutes collectively demonstrate that the Stimulants Committee was basically not 
interested in doing the task it was established to do.  That is, it was not interested in 
ensuring responsible practice by individual prescribing clinicians.  Instead, ADHD proponents 
on the committee sought to influence clinical practice by promoting further prescribing.  
                                               
455  WA Stimulant Committee, Minutes of Meeting held on 26 September 2001, and Minutes of Meeting held on 20 
February 2002. 
456  WA Stimulant Committee, Minutes of Meeting held on 20 February 2002. 
457  WA Stimulant Committee, Minutes of Meeting held on 21 August 2002. 
458  WA Stimulant Committee, Minutes of Meeting held on 10 May 2000. 
459
  WA Stimulant Committee, Minutes of Meeting held on 21 August 2002.  
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6.3.3 The 1998 WA Health Department convened International Panel on the Diagnosis and 
Treatment of ADHD  
In May 1998, at my request, the WA (Labor) Opposition Health Spokesperson Jim McGinty 
asked a WA Legislative Assembly parliamentary question on notice.  It referred to ‘the report 
of the Government Working Party on Attention Deficit Disorder’ of the Minister for Health 
and asked, ‘Is Western Australia mis-diagnosing and/or over-prescribing ADHD stimulant 
medication…at a disproportionately higher rate than the other States?’  
The reply from the then Minister for Health the Hon Kevin Prince acknowledged the 
controversy regarding the use of stimulants and announced that an international expert 
panel would review the issue: 
As there was very limited psychiatric input to the Government working party 
on Attention Deficit Disorder I have asked Prof. George Lipton (General 
Manager, Mental Health Division) to arrange for a panel of Nationally and 
Internationally recognised psychiatrists to meet in Perth later this year, to 
consider the reports, and to provide a supplementary report.460 
Later, in response to advocacy by ADHD proponents led by Sandy Moran (see 6.3.4), 
Minister Prince advised a parliamentary committee that: 
The eminent experts would visit Perth in August/September 1998 and 
undertake consultative forums to discuss the local prevalence, diagnosis and 
treatment of ADHD.  They would then spend another 2 days analysing the 
information gained from the forums and the Western Australian and 
Australian literature.  Based on this evidence they would prepare their 
report which would come to the Minister and the Cabinet Sub-Committee 
on ADHD for consideration.  The report would provide advice on sound 
                                               
460  Legislative Assembly - Questions on Notice, Tuesday 19 May 1998, McGinty; Prince, Attention Deficit 
Disorder Page 2768 / 3. 
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modern clinical practice in the diagnosis, treatment and care of people with 
ADHD.461 
McGinty’s question was prompted by my ADHD critic activism within the Labor Party (prior 
to my entering parliament) for action to address what I perceived as the misdiagnosis and 
over-prescription of ADHD psycho-stimulants.  It, along with Sandy Moran’s ADHD 
proponent advocacy, helped build momentum for Minister Prince’s ‘international expert 
panel’ response to ADHD policy development.  
In September 1998 the WA Department of Mental Health convened a three-day symposium 
to address concerns ‘about the number of WA children diagnosed with attention deficit 
disorder and the use of amphetamine-like medication to treat them’.462 The Department 
invited ‘international expert’ Professor Larry Greenhill of New York’s Columbia University. 
Professor Greenhill has received payment from fifteen pharmaceutical companies and is an 
advocate of ADHD prescribing. He has worked as a paid consultant to Alza Corp., Bristol-
Myers Squibb, Richwood and GlaxoSmithKline, Eli Lilly, McNeil Pharmaceutical, Novartis 
Pharmaceuticals and Solvay.463 He has been a paid speaker for ADHD drug manufacturers Eli 
Lilly, Janssen Pharmaceuticals and Novartis Pharmaceuticals.464   
The International Panel also included the following members: 
 Associate Professor Brian Barnett, School of Psychiatry, University of New South 
Wales  
 Dr Brian Greenfield, Associate Professor of Psychiatry, McGill University School of 
Medicine, Montreal Children’s Hospital, Quebec  
 A/Professor Florence Levy, School of Psychiatry, University of New South Wales;  
                                               
461  Western Australian Parliament, n.d, Report of the Standing Committee on Constitutional Affairs in 
Relation to a Petition Regarding Attention Deficit Hyperactivity Disorder, Report 47, Legislative Council, 
p.6.  Available at 
http://www.parliament.wa.gov.au/parliament/commit.nsf/(Report+Lookup+by+Com+ID)/CFD83DAF6BB
3264D48257831003E9414/$file/ca047.pdf. 
462  Wendy Pryer (1999), ‘Dismay at child attention disorder figures’, The West Australian, 1 September. 
463  Greg Birnbaum and Douglas Montaro (1999), ‘Shrinks for Sale. Analyze This: Docs get Drug Co. $$’, 
New York Sunday Post, 28 February. 
464  Associated Press (2006), ‘Study Warns of Ritalin Side Effects in Preschoolers’, 19 October.  Available at 
http://www.foxnews.com/story/0,2933,222559,00.html (accessed 25 July 2008). 
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 Professor Robert McKelvey, Professor and Director, Division of Child and Adolescent 
Psychiatry, Oregon Health Sciences University, Oregon, USA  
 Professor Barry Nurcombe, School of Psychiatry, University of Queensland.465 
Conflict of Interest declarations for participants, if collected, were not made public.  
The panel of ‘international experts’ prepared a report entitled Attention Deficit 
Hyperactivity Disorder (ADHD) in Western Australia - Report of the International Panel on 
the Diagnosis and Treatment of ADHD (‘the International Panel Report’) which was 
presented to the Mental Health Division of the Health Department of Western Australia.466 
The International Panel Report encouraged polypharmacy by recommending concurrent 
prescribing of a range of psychotropic drugs to children with ‘comorbid’ disorders. The 
report acknowledged the debate but did not address the issue of whether ADHD was over 
or under-medicated in WA. Rather it concluded ‘since the effectiveness of stimulants in the 
treatment of ADHD is beyond dispute, the first stage of medication intervention inevitably 
involves their use.’467  
6.3.4 The 1999 Parliamentary Inquiry into a petition concerning ADHD    
In April 1998 the Hon. Ray Halligan, a Liberal Party (Court Government) Member of The 
Legislative Council, tabled a petition concerning ADHD.468  The petition requested the 
Legislative Council to: 
1. In line with the World Health Organisation, National Health and Medical 
Research Councils and Commonwealth Government Policies, acknowledge 
the existence of Attention Deficit Hyperactivity Disorder (including ADD and 
                                               
465  WA Parliament, Report of the Standing Committee on Constitutional Affairs, pp.8-9. 
466  Attention Deficit Hyperactivity Disorder (ADHD) in Western Australia:  Report of the International Panel 
on the Diagnosis and Treatment of ADHD, Mental Health Division, Health Department of Western 
Australia, Perth (n.d.)  
467  Attention Deficit Hyperactivity Disorder (ADHD) in Western Australia:  Report of the International Panel, 
p.20. 
468  Hon. Ray Halligan (1998), Western Australian Legislative Council, Minutes of Proceedings: Tabled Paper 





Associated Learning Disabilities) as affecting an unknown but significant 
number of children, youth and adults in Western Australia. 
2. Ascertain the services and facilities available to those disadvantaged in 
this way within the Ministries of Health, Education, Disabilities, Youth, 
Children and Family Services, Justice and Employment and Training. 
3. Encourage a program of public and professional education and awareness 
to allow the facilitation of early identification and appropriate remediation 
for sufferers of this neurobiological disorder. 
4. Encourage the establishment of a professional advisory board to advise 
Government of the appropriate remediation and protocols within 
Government agencies. 
The petition was re-tabled by Hon Ray Halligan MLC in September 1998 and again in 
September 1999 requesting that the Legislative Council consider the matters in the 
petition.469  The lead petitioner was Sandy Moran, an active member of the Learning and 
Attention Disorders Society (see 6.8).  Moran contended that many of the problems 
experienced by Aboriginal youth were caused by undiagnosed and un-medicated ADHD.470  
As well as being the principal petitioner in May 1998 Sandy Moran wrote a letter stating: 
There are little or no services for ADHD sufferers in any Government 
Services.  Children with ADHD are only treated at Western Australia’s sole 
children’s hospital if they have a co-existing medical problem, which 
requires attention.  A diagnosis of ADHD does not allow services to be made 
available.  Some children are seen at the Child Development Centre (Rheola 
Street) but the majority of children are serviced through the private sector, 
scattered scant regional facilities and the Attention Deficit Society in 
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  Hon. Ray Halligan (1998), Western Australian Legislative Council, Attention Hyperactivity Disorder: 
Petition, 8 September 1998.  Available at 
http://www.parliament.wa.gov.au/48256603002A13E1/0/95B62C65477FFA4A48256691001E2FBC?Ope
n&Highlight=2,sitesearchyes: Hon. Ray Halligan, Western Australian Legislative Council, Attention 




  WA Parliament, Report of the Standing Committee on Constitutional Affairs, pp.2-3. 
169 
 
Mosman Park which is a benevolent society with little or no government 
funding…Parents who have ADHD children and who have the financial 
means will have access to appropriate medical assistance.  There is [sic] 
absolutely no facilities at all for Aboriginal children, many of whom suffer 
from ADD/ADHD…There exists no Government education or direction in the 
wider community to protect these vulnerable children and their families 
from the prejudice generated by a misinformed media…A professional body 
of appropriately credentialed personnel with a substantial degree of clinical 
practice could assist Government policies in being more targeted and as a 
rule more effective in remediating such tragedies in our community.471 
In a subsequent letter to the Committee dated July 23 1998, Sandy Moran wrote that: ‘one 
of the tragedies of our Mental Health System is that ADHD/ADD clients are being diagnosed 
with an exotic array of psychiatric disorders and are subsequently being ‘warehoused’ at 
facilities like Graylands Hospital’.472  In 1999 the persistence of Sandy Moran, and her fellow 
petitioners, was rewarded when a committee of the WA Legislative Council conducted an 
Inquiry titled Report of the Standing Committee on Constitutional Affairs in relation to a 
Petition regarding Attention Deficit Hyperactivity Disorder.  The Legislative Council 
parliamentary committee validated the diagnosis of ADHD but avoided expressing an 
opinion on the safety and efficacy of ADHD medications.  It concluded that ADHD is a 
‘recognisable condition which affects a significant number of children, youth and adults in 
Western Australia’ but acknowledged there is a ‘range of attitudes…about the prevalence… 
and how those suffering from it should be treated.’473 
Despite avoiding the issue of medication use, the committee endorsed the approach 
requested by the petitioners, concluding: 
The Committee agrees with the petitioners that there should be a program 
of public and professional education and awareness to assist in the early 
identification of the condition and to facilitate the remediation of people 
affected by ADHD.  The Committee believes that the professional 
                                               
471  WA Parliament, Report of the Standing Committee on Constitutional Affairs. 
472  WA Parliament, Report of the Standing Committee on Constitutional Affairs. 
473
  WA Parliament, Report of the Standing Committee on Constitutional Affairs. 
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development of those involved in the diagnosis and treatment of people 
with ADHD is integral to ensuring a best practice standard for treating the 
condition…The Committee is aware of anecdotal evidence that suggests that 
many of the problems associated with crime, in all sectors of our 
community, could in some way be attributable to ADHD.  Should further 
research confirm this anecdotal evidence, early intervention could provide 
considerable long term financial savings and benefits to those suffering from 
ADHD, their families, and the community in general.474 
In line with these conclusions the committee recommended establishing a: 
 Professional Advisory Body to develop policies and guidelines ‘to overcome 
apparent existing deficiencies’ in diagnosis and treatment of ADHD. 
 Program of public and professional education and awareness be established 
to assist in the early identification of ADHD and to facilitate the treatment of 
people affected by the condition.475  
When the committee report was debated in the Legislative Council a number of 
members who were not on the committee - the Hon Barbara Scott (Liberal), the 
Hon Greg Smith (Liberal), the Hon Chrissy Sharp (Greens) and the Hon Murray Nixon 
(Liberal)– spoke in support of its findings and recommendations.  They were all 
supportive of the validity of the disorder, with Greg Smith identifying that two of his 
three children took ADHD medications and in his views benefited.  All spoke in 
complimentary terms about the advocacy of Sandy Moran and/or the Learning and 
Attentional Disorders Society (LADS), although Nixon identified that the Education 
Department ‘was aware that there were no reliable tests for ADHD and was 
concerned that some children might be labelled inappropriately’.476   
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476   Hon. Murray Nixon (2000), ‘Standing Committee on Constitutional Affairs – In Relation to a Petition 
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Direct ADHD proponent parliamentary activism during the period of the Court Liberal State 
Government (1993 to 2001) was undertaken by the Member for Dawesville Arthur Marshall. 
In 2003, in a speech in the Western Australian Legislative Assembly, Marshall summarised 
his contribution during this period.  
Sometime in 1994-95 I introduced this problem to the Legislative Assembly. At the 
time it was an estimates debate and I was incensed that the education gurus would 
not recognise that attention deficit hyperactivity disorder actually existed. The 
education system was not allocating money to deal with the problem. After a lot of 
debate, I got funding to the tune of $100 000, which was a needle in a haystack but 
at least it recognised that there was a problem. I subsequently made many speeches 
to improve the public awareness of the problem. I went to meetings in Mandurah. I 
saw family split-ups because of the emotional aspect of this problem with which 
families must deal. My daughter Dixie Marshall, who works for Channel Nine, made a 
documentary that was aired nationally to increase awareness. Finally, everybody is 
starting to recognise that there is a problem that needs to be addressed. …Reports 
have identified that Western Australia has the highest incidence of the use of 
dexamphetamines, and the medical profession has been criticised for this. However, 
I believe that diagnosis of this problem in this State is much better than in other 
States, which should follow suit.477 
During the period 1992 to 2001 the available evidence indicates that a number of WA State 
politicians were sympathetic with the views of ADHD proponents.  This may have helped 
facilitate dominance of ADHD policy and regulation in WA by ADHD proponents. 
6.3.5 Training of Western Australian Paediatricians  
Both ADHD proponents and critics accept that differences in the training of paediatricians 
account for differences in state prescribing rates.  In 2006 Perth paediatrician and University 
of Western Australia Professor of Paediatrics and Child Health, Dr Trevor Parry, 
acknowledged on Channel Nine’s Sunday program, that the prescribing practices of 
paediatricians he trained contributed significantly to WA’s disproportionately high prescribing 
                                               




rates (see Box 8 below). 478   Parry argued rates were historically higher because WA prescribers 
were better at recognising and diagnosing ADHD than those of other states.  Parry’s proud 
acceptance of his leading role in Western Australia’s high child prescribing rates occurred when 
child prescribing rates were in sharp decline. 
Box 8 - Excerpt from transcript of TV program ‘ADHD – the Quick Fix’, Sunday, 14 May 2006 
Reporter: One very influential WA paediatrician Trevor Parry says there’s no problem with the 
state’s prescription rates. 
Dr Trevor Parry: I have always been happy with that, despite what the critics have said about WA 
being the drug capital of Australia. 
Reporter: Parry has had a lot to do with the rates of prescription…since he trained many of those 
practising in the field…You may be practising less but those people you trained are out there 
following your lead. 
Dr Trevor Parry: I can only hope so!  
Reporter: Western Australia also sits apart from the rest of Australia because doctors here 
prescribed the medication for ADHD in higher doses… 
Dr Trevor Parry: People are comfortable that up to ten or twelve tablets a day for a certain weight of 
children…we don’t faint and beat our breasts about that if four a day…for high school children is 
higher than the other states are using then I would hope that for some children other states might 
become a bit more confident. 
 
Four years earlier (in 2002) Parry had referred to Victoria’s prescribing rates, when he said 
‘[Victorian rates] have been the lowest…because they have not strongly believed in the existence 
of ADHD nor have they trained their paediatricians accordingly until quite recently’.479  In 2002 
there were 7,500 Western Australian and only 5,060 Victorian children who received a 
Pharmaceutical Benefits Scheme sponsored prescription of dexamphetamine (see Table 5 at 6.1).  
This is despite the population of Victoria being 4,902,920, approximately two and a half times 
that of Western Australia’s 1,940,485.480   
                                               
478  Sarah Ferguson and Nick Rushworth (2006), ‘Part 1: ADHD – the quick fix’, Sunday, 14 May.  Available at 
http://sgp1.paddington.ninemsn.com.au/sunday/cover_stories/article_1983.asp?s=1 (accessed 10 August 
2009). 
479  Dr Trevor Parry, quoted in George Halasz, et al (2002), ‘Smartening up or dumbing down?: A Look Behind 
the Symptoms, Overprescribing and Reconceptualizing ADHD’, Cries unheard: a new look at attention deficit 
hyperactivity disorder, Altona Vic, Common Ground Publishing , p.80. 
480  Australian Bureau of Statistics (2003), 3239.0.55.001 - Population, Australian States and Territories - 
Electronic delivery, Dec 2002, Commonwealth of Australia, 27 May.. Available at  
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Victorian psychiatrist ADHD critic, Dr George Halasz, agrees with Parry that differences in 
training and medical culture accounted for the difference between WA and Victorian 
prescription rates.  However, Halasz was highly critical of Western Australian practice.  Halasz 
believes the increase in ADHD prescription was a consequence of the ‘dumbing down’ of child 
mental health assessment, diagnosis and treatment, stating ‘the art and science of the 
assessment of child behaviour had become merely the chronicling of a set of symptoms’.481  In 
his opinion this erosion was in part due to the way new doctors were trained.  Halasz believed 
the training provided little opportunity to impart an understanding of the importance of a 
‘development perspective’.   ADHD proponent Victorian Paediatrician Dr Daryl Efron (refer to 
4.4.3.1) also agrees that the attitudes of those training clinicians is a significant determinant of 
prescribing rates.   
Often it comes down to small numbers of high profile, often academic 
individuals at a teaching hospital who maybe believe strongly in the benefits 
of medication, and teaching the trainees for a generation in that particular 
town that stimulants are good and therefore you get lots of children being 
prescribed; whereas, you might have in another town more psychologically 
based clinicians who are less inclined to use medication.482 
A 2004 WA parliamentary inquiry into ADHD heard evidence of Western Australian children 
being diagnosed and prescribed by a private sector paediatrician after a fifteen-minute (and 
sometimes even shorter) consultation.  Dr Halasz who also gave evidence to the Inquiry pointed 
to reduced time for patient care and argued that even fifty to sixty minutes were inadequate to 
assess the development of a child’s symptoms.  
The Inquiry found that the shortage in Perth of appropriately trained child psychiatrists to 
perform time-intensive diagnoses and treatments left a vacuum filled by a relatively small 
number of inadequately trained paediatricians who diagnosed and prescribed quickly. 
‘During their training, paediatricians have not been adequately informed about the extent of 
alternative diagnoses and treatment methods, and are therefore more likely to use drug 
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therapy in the first instance in the management of ADHD.’483  The inquiry was influenced by 
a submission that contended that seeing a paediatrician as opposed to a mental health 
professional (i.e. a psychiatrist) was a ‘risk factor in the use of stimulant medication’.484  The 
submission stated, ‘by virtue of their training and workload it is also possible that 
paediatricians may be more prone to use drug therapy than the other therapies 
recommended for the management of ADHD.’485   
6.4 WA ADHD policy and politics 2002-2012 
The suggestion to audit Block Authorisation prescribing was first made by the Technical 
Working Party in 1996.  Five years later in 2001, when I was elected as the Member for 
Roleystone as part of the new Gallop Labor government, the total number of 
Pharmaceutical Benefits Scheme subsidised dexamphetamine scripts were more than two 
and a half times higher.486  I raised the issue of Block Authorisation in my inaugural speech 
in May 2001 stating, ‘the problem of Block Authorisation continues. I believe making doctors 
accountable on a case-by-case basis for the prescription of stimulant medication is essential 
to dealing with the problem of over prescription’.487  The change of government, my 
election and the appointment of the Honourable Bob Kucera as WA’s Health Minister, 
provided the opportunity for the direction of policy to be reversed.  Minister Kucera, a 
former senior policeman, told me he had seen the problems caused by the diversion of 
amphetamines prescribed for ADHD. 
In 2002 the report Attentional Problems in Children and Young People was published by the 
Western Australian Mental Health Division ultimately overseen by Minister Kucera.  An 
earlier draft was developed by the WA Department of Health with guidance by an ADHD 
Policy Reference Group which consisted of ADHD proponents and some members with a 
more critical perspective. 
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Although the makeup of the committee was arguably balanced, this early draft of the report 
emphasised developing a tiered approach, with teachers and childcare workers referring 
suspected ADHD children for diagnosis by specialist clinicians.  The draft report also stated 
‘ADHD is the most common childhood developmental disorder with the prevalence levels 
estimated to be between 3 to 9 percent’488 and ‘the efficacy of stimulant medication in 
treating many of the symptoms of ADHD is not in question’.489  Soon after I was elected I 
wrote to the Minister for Health that ‘the result of accepting the two statements highlighted 
above is to legitimise, without objective scientific evidence, the prescription of 
amphetamines to children because they are perceived to be behaving in an unacceptable 
manner’.490 
The draft report was, with my input (as an ADHD critic), significantly altered by Minister 
Kucera’s office.  The final draft abandoned the tiered referral approach and recommended 
the abolition of Block Authorisation, as well as the establishment of multidisciplinary clinics 
to diagnose and treat children with behavioural and learning problems.  Minister Kucera 
announced the decision to end Block Authorisation in December 2002 and the practice was 
stopped in August 2003.  The Stimulants Committee was replaced by the Stimulants 
Assessment Panel and although Dr Trevor Parry was initially invited onto the Stimulants 
Assessment Panel,491 it had a significantly different membership.  After Block Authorisation 
was abolished all authorised prescribers were equally accountable for each prescription.492  
The WA Chief Psychiatrist, Dr Rowan Davidson, later told a West Australian Parliamentary 
committee ‘The work of the stimulants panel…is very much directed at trying to provide a 
degree of control and support for issues such as accuracy of diagnosis and monitoring, so 
that we monitor not just the overall patterns but also individual clinician prescribing 
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patterns, and can then ask an individual clinician for appropriate explanations about 
prescribing patterns’.493   
This represented a significant change in the purpose of the stimulants monitoring process.  
The stimulants committee had previously been a rubber stamp which paid limited attention 
to the issue of psychostimulant diversion and very little to the appropriateness of diagnosis 
and prescribing practices.  
The decision to establish the Stimulants Assessments Panel and abolish Block Authorisation was 
announced in December 2002.  Block Authorisation was abolished and the Stimulants Panel 
began to meet and the Stimulant Regulatory Scheme began collecting information in August 
2003.  The first annual report (which covered 17 months of operation from August 2003 to 
December 2004) was published in 2005.   
Minister Kucera’s and my own enthusiasm for the end of Block Authorisation, and for the new 
accountability measures, was not shared by the then president of the Western Australian 
branch of the Australian Medical Association Dr Bernard Pearn-Rowe, who said: 'Families should 
have no doubt that the Health Minister is trying to take away the ability of a doctor to make 
clinical decisions in consultation with parents…I hope the Minister will tell individual parents 
that his policy is responsible for the refusal of treatment, even when recommended as 
appropriate by a qualified medical practitioner.'494  Pearn-Rowe denied that WA clinicians were 
misdiagnosing and overprescribing and claimed that ‘other States and Territories under-
prescribe dexamphetamine because they do not have as many paediatricians who specialise in 
treating ADHD.’495  
6.4.1 Child Prescribing 
Figure 5 in Chapter 4 shows there was a large (50 percent) decrease in the proportion of 4 
to 17 year olds prescribed between 2002 and 2010 with the major decline occurring 
between 2003 and 2007.  It appears very likely the abolition of Block Authorisation, the 
appointment of the Stimulants Panel, and the implementation of the Stimulant Regulatory 
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Scheme were responsible for this fall.  These innovations were supported by a sympathetic 
Minister for Health and driven by me, an ADHD critic who believes ADHD is an inappropriate 
application of the medical model.  Clearly a policy process ‘dominated’ by an ADHD critic 
resulted in a significant and sustained decline in child prescribing rates. 
6.4.2 Why did Western Australian adult prescribing rates continue to grow when child 
prescribing rates fell? 
In contrast to the decline in WA child prescribing rates, the proportion of adults receiving 
ADHD medications has risen from 0.40 percent in 2002 to 0.54 percent in 2011, an increase 
of 35 percent.  Clearly the factors influencing child and adult prescribing rates are 
significantly different.  There is no obvious single reason for the disparity between the post-
2003 decline in child prescribing rates and the increase in adult rates. 
Possible explanations include: 
1. The natural ageing of the ADHD cohort with carryover childhood patients turning 18 
and continuing stimulant medication.  
An obvious explanation is that this may be a result of the ageing in the cohort of ADHD 
children who were first diagnosed in the 1990s and early 2000s who have become adults 
and maintained the diagnosis and remain on prescription ADHD medications.  This may have 
contributed to the 35 percent rise in the per capita rate of adult patients between 2002 and 
2011.  However, the 2011 Stimulants Monitoring System Annual Report showed that 80 
percent of adult patients are first diagnosed and prescribed stimulants as adults.496  
Therefore the ageing of the child ADHD cohort is unlikely to be the dominant reason. 
2. The marketing of ADHD as an under-recognised, under-diagnosed, adult psychiatric 
disorder by Western Australian ADHD support group the Learning and Attentional 
Disorders Society.   
DSM-IV states: ‘Some hyperactive-impulsive or inattentive symptoms that caused 
impairment were present before age 7 years.’497  Despite this and the fact that the 
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diagnostic criteria are defined in terms most applicable to children in a classroom setting, in 
recent years considerable energy has been put into promoting ‘Adult ADHD’.  ADHD 
Proponents contend that ADHD is an under-diagnosed and under-medicated adult 
condition, arguing 60 percent of those with ADHD as children continue to have the disorder 
in to adulthood.498   
As well as promoting the disorders recognition in Western Australian children (see 6.6) the 
Learning and Attentional Disorders Society (LADS) has put considerable effort into ‘raising 
awareness’ of adult ADHD.  In 2003 LADS produced an ADHD facts sheet that attributed a 
variety of adult problems, including car crashes, divorce and even bad manners, to undiagnosed 
Adult ADHD:  
The symptoms of ADHD can cause severe disruptions in the lives of adults: 
Concentration difficulties may result in people becoming procrastinators, and 
earning a reputation for laziness and a lack of motivation.  They may be 
embarrassed in social situations as their concentration drifts during conversations.  
They may have a tendency to interrupt others or to make tactless comments.  
Physically, they may engage in high-risk activities.  People with ADHD receive more 
traffic infringements and licence suspensions, particularly for speeding.  They are 
involved in more motor vehicle accidents.  Intimate relationships may be more 
difficult to sustain, with higher rates of separation and divorce occurring in this 
group.  Educational and professional under-achievement is common, and causes 
great frustration.  Adults with ADHD often find it difficult to manage their ADHD 
children…Dexamphetamine and Methylphenidate improve symptoms in up to 78 
per cent of adults with ADHD.499 
In 2004, in verbal evidence given on behalf of LADS to the 2004 WA parliamentary inquiry into 
ADHD, Michelle Toner even attributed criminality and drug abuse to undiagnosed, and 
therefore un-medicated, ADHD. 
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The research shows that people with ADHD are six times more likely to develop a 
substance abuse problem.  However, if they are treated with stimulant 
medication, the risk is reduced to the same as someone without ADHD…Some 
excellent work has been done by Dr Tony Mastrioni on the New South Wales 
prison system.  He estimates that 30 per cent of the prison population in NSW has 
ADHD, either diagnosed or undiagnosed.500  
Critics contend that criminal and drug-taking behaviour are in themselves dysfunctional and 
most often impulsive acts.  They counter the argument that ADHD, when left un-medicated, 
causes criminal behaviour or drug abuse as a confusion of cause and effect.  They argue that 
attributing undiagnosed ADHD as the cause of dysfunction in a population that is already 
identified as a dysfunctional population is the ‘equivalent of being able to bet on a horse after 
the race has finished.’501 
Regardless of the merits of the two perspectives, it is likely that the marketing (or awareness 
raising) of Adult ADHD as an underdiagnosed psychiatric disorder by LADS in WA contributed to 
the growth in WA adult prescribing rates. 
3. A culture of ‘doctor shopping’ for dexamphetamine by young Western Australian 
Adults 
Critics including Curtin University Professor of Public Health Bruce Maycock contend there is 
a group of young adult WA ‘dexie’ abusers, who ‘doctor shop’ for dexamphetamine in 
preference to methylphenidate and have learned how to tick the right ADHD boxes and say 
the right things to a small number of high prescribing Perth psychiatrists.502  While there is 
no quantitative research on the extent of doctor shopping for ADHD dexamphetamine by 
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WA adults, U.S. research published in 2011 revealed nearly a quarter of all adults seeking 
treatment for ADHD feigned symptoms to get a cheap supply of amphetamines.503   
Doctor shopping occurs when in order to secure a supply of federal government subsidised 
amphetamines drug abusers go to a sympathetic doctor and fake the symptoms of ADHD 
and receive prescriptions for dexamphetamine.  They then go to a pharmacist and get the 
original prescription filled and take the repeat prescriptions to another pharmacist shortly 
after, despite the fact that they have just been dispensed with a month’s supply.  They will 
then get the repeat prescriptions filled in an extraordinarily short period by simply going 
from one pharmacist to another.  The pharmacists are unaware that the ‘patient’ is a drug 
abuser, and, in some cases, minor drug trafficker and is filling the prescriptions very quickly 
so that the drugs can be either abused shared or sold. 
A 2005 survey of WA 12 to 17 year olds revealed that the vast majority of high school 
students (84 percent) who have abused amphetamines had abused prescription ADHD 
amphetamines504 (for more detail see 6.5).  The age range of these drug abusers would in 
2011 have been 18 to 23.  It is possible that for some their habit of abusing 
dexamphetamine has transformed into doctor shopping.  Faking the symptoms of ADHD to 
obtain a supply of dexamphetamine seems far more likely amongst adult ‘patients’ than 
children (or their parents).  For adults, the diagnosis relies heavily on self-reports of 
behaviour, but for children third party reports of teachers and parents are the central 
evidence.  The Stimulants Regulatory System may therefore have been more effective as a 
drug abuse prevention strategy for children than adults. 
A number of statistics are consistent with the contention that young adult Western 
Australians abuse prescription dexamphetamine: 
                                               
503  Meredith Melnick (2011), ‘Faking It: Why nearly 1 in 4 adults who seek treatment don’t have ADHD’, 
Time Healthland, 28 April.  Available at http://healthland.time.com/2011/04/28/faking-it-why-nearly-1-in-
4-adults-who-seek-treatment-dont-have-adhd/ (accessed 24 May 2011).  
504  A 2005 survey of Western Australian secondary school students (the Australian School Students Alcohol 
and Drug Survey or ASSAD) found that 84 per cent of those who had abused amphetamines in the last year 
had abused prescription amphetamines. Drug and Alcohol Office WA (2007), ASSAD Drug Report 2005, 
Mt Lawley, pp.30-32. 
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 During 2011, 137 patients had their authority to receive psychostimulants withdrawn 
because they had abused prescription drugs.505   
 Despite the fact that methylphenidate (Ritalin, Concerta) is the most commonly 
prescribed ADHD stimulant in Australia, (73 percent of all scripts in 2010)506 in 2011 
the vast majority (81.3 percent) of WA adults who received stimulants were 
prescribed dexamphetamine.  In contrast only 22.3 percent of WA children who 
received stimulants for ADHD were prescribed dexamphetamine.507   
 The majority (53 percent) of those diagnosed as adults are first diagnosed between 
ages 18 and 29.508  
 In 2011 one WA clinician (a psychiatrist) alone was responsible for prescribing to 
1473 patients (1346 adults and 127 children).509    
These facts are consistent with the contention that these confirmed 137 prescription drug 
abusers may be the tip of the iceberg and that a significant proportion of these young 
Western Australians are targeting doctors with a reputation for being easy targets in order 
to get a taxpayer subsidized supply of dexamphetamine. 
In summary, there is insufficient empirical evidence to determine the relative importance of 
the above three factors and other factors.  However, it seems likely that the ageing of the 
ADHD cohort, the marketing of Adult ADHD and doctor shopping for ‘dexies’ have all 
contributed to rising adult prescribing rates.  Clearly different factors drove the decrease in 
child prescribing rates.  This indicates that different policy responses are required for adults 
and children if the intention is to decrease prescription rates.  This may be particularly true if 




                                               
505  Department of Health, Western Australian Stimulant Regulatory Scheme 2011 Annual Report, p.19.  
506  Statistics relate to 2010 calendar year and were obtained from the Medicare Australia website, Available at 
https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml  
507  Department of Health, Western Australian Stimulant Regulatory Scheme 2011 Annual Report, pp.28 & 43.   
508  Department of Health, Western Australian Stimulant Regulatory Scheme 2011 Annual Report, p.41. 
509
  Department of Health, Western Australian Stimulant Regulatory Scheme 2011 Annual Report, pp.21 & 37.  
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6.4.3 Limitations on Stimulant Dispensing 
The abolition of Block Authorisation and the establishment of the Stimulants Panel were not 
the only measures designed to curtail ADHD amphetamine use.  In the Government Gazette 
of Tuesday, 15 November 2005, the Poisons Amendment Regulations 2005 were published.  
The regulations came into effect on 1 January 2006.510  The new regulations were designed 
to limit the incentives to engage in doctor shopping.   
The changes to stimulant dispensing regulations required repeat scripts to be held by the 
pharmacist who issued the first script.  The changes were made in response to a 
recommendation of the WA Legislative Assembly Education and Health Standing Committee 
2004 Inquiry into ADHD. Recommendation 9 of the Inquiry stated: ‘The Committee 
recommends that Western Australian legislation be amended in line with New South Wales, 
to restrict the frequency with which repeat Schedule 8 medication prescriptions may be 
dispensed.’511 
The Committee was influenced by evidence of amphetamine abusers going from pharmacy 
to pharmacy and getting months’ worth of repeat scripts filled in days.  The parliamentary 
inquiry was told of a teenager receiving 175 days’ worth of repeat scripts in 13 days and an 
adult patient receiving 125 days’ worth of repeat scripts in 40 days.  All repeat scripts for a 
‘patients’ psycho-stimulants are now held by one pharmacist and can only be filled as 
required for prescribed dose usage.  Implementation of this initiative post-dated the fall in 
teenage amphetamine in W.A. teenage abuse rates between 2002 and 2005.  Therefore, 
unlike the end to Block Authorisation, it cannot be viewed as a likely cause of this initial 
decline.  
6.4.4 The 2004 WA Legislative Assembly Education and Health Standing Committee into 
ADHD 
In 2004 a second WA Parliamentary Inquiry was held into ADHD. This was conducted by the 
Education and Health Standing Committee of the Legislative Assembly.  The committee included 
six parliamentarians, three from the Labor Party (including me as a co-opted, non-voting 
                                               
510  Western Australian Government Gazette of Tuesday, 15 November 2005, the Poisons Amendment 
Regulations 2005.    
511  WA Legislative Assembly, Attention Deficit Hyperactivity Disorder in Western Australia, p.70. 
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member), one from the Liberal Party and one from the National Party, none of whom had any 
commercial interest in ADHD.   
Opposition Health Spokesperson Mike Board suggested the Inquiry to Health Minister Bob 
Kucera.  On Minister Kucera’s suggestion Board and I negotiated the terms of reference for 
the Inquiry. The Inquiry was conducted in a co-operative bi-partisan manner and reached 
unanimous conclusions.  The terms of reference of the Inquiry were to inquire into: 
 the extent of the incidence, diagnosis and use of stimulant medication for the 
treatment of attention deficit disorder (ADD) and attention deficit hyperactivity 
disorder (ADHD) in WA, taking into account all previous reports and inquiries; 
 an analysis of those figures compared to other States of Australia and other 
countries; 
 the analysis of emerging medical opinion and varying medical and behavioural 
approaches for the treatment of ADD and ADHD; 
 the divergence of public opinion and the need for a more defined state policy; 
 the relationship, if any, between those diagnosed with and/or medicated for, ADD or 
ADHD and drug addiction; and 
 the relationship, if any, between ADD or ADHD and the educational, economic and 
social wellbeing of individuals, and that the committee report to the Assembly by 30 
June 2004.512 
Of the committee members I had a predetermined ADHD critic position and one other 
member Paul Andrews MLA, like me a former high school teacher, had expressed concern 
about ADHD prescribing.  None of the other four members had publicly expressed concern 
about ADHD prescribing.  However, in introducing the motion to establish the Inquiry Board 
said:  
‘The incidence of attention deficit disorder and attention deficit hyperactivity 
disorder in Western Australia is significant; it is something like 400 per cent higher 
                                               
512  MF Board (2003), Hansard, Parliament of Western Australia, Wednesday 16 Apri, pp.6844b-6848a.  
Available at 
http://www.parliament.wa.gov.au/Hansard/hansard.nsf/0/0955f38e4cc755dec8257570007f6abc/$FILE/A3
6%20S2%2020030416%20p6844b-6848a.pdf  (accessed 12 June 2013).  
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than the national average. It is a massive and major issue…People are confused 
about the issue; they do not know whether the prescription of drugs to settle down 
children is in the interests of those children…The jury is out to some degree about 
the extent of long-term addiction or non-addiction and whether the prescription of 
drugs to deal with ADD and ADHD may have long-term effects on young people.’ 513 
Board was prominent through the process, chairing many of the hearings.  When the 
committee reported its findings to the Western Australian Parliament all members who 
spoke expressed similar views including:   
Hon Michael Board MLA- The committee found that in most instances the medical 
profession errs on the side of caution, saying that as something has not been proved 
it will take a slow, cautious approach. However, the opposite seems to occur with 
ADHD.  
MR Paul Andrews MLA- The first rule of medicine is to do no harm. There is a huge 
debate about whether the use of medication for the treatment of ADHD is effective. 
There is a huge debate about the very biological existence of ADHD. There is so 
much doubt about it that we must question whether the first rule of medicine has 
been understood by the medical profession and the wider community.  
MR Ross Ainsworth MLA- There is a problem but it is very loosely defined because 
there is no clear evidence of a physical condition around which a boundary can be 
put to indicate that it is ADHD and that everything outside it is something else. The 
edges are very blurred; there is a range of behaviours that would fit some of the 
criteria for assessment as ADHD, but in many cases the behaviours are brought 
about by a range of other conditions that have nothing to do with what is described 
as ADHD.514 
                                               
513  Board, Hansard, 16 April 2003, pp.6844b-6848a.   
514  Ross Ainsworth MLA (2004), Hansard, Parliament of Western Australia, Thursday11 November , 
pp.8024c-8030a.  Available at 
http://www.parliament.wa.gov.au/Hansard/hansard.nsf/0/4d630a272cef0e46c82575700016f766/$FILE/A3
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Box 9 below includes the most significant findings and recommendations in relation to the 
core controversies of ADHD.515 
Box 9 - Excerpt from the Findings of the 2004 WA Legislative Assembly Education and Health 
Standing Committee into ADHD 
Finding 3- The consumption of dexamphetamine in Western Australia is disproportionately high in 
comparison with other Australian and international jurisdictions. Prescriptions for dexamphetamine 
were almost four times the national average in the period 1999 to 2003. 
Finding 4- During their training, paediatricians have not been adequately informed about the extent 
of alternative diagnoses and treatment methods, and are therefore more likely to use drug therapy 
in the first instance in the management of ADHD. 
Finding 10- The behavioural symptoms underlying the diagnosis of ADHD are a key factor in the 
controversy surrounding the condition as many are within the range of ‘normal’ childhood 
behaviour. 
Finding 11- The clinical diagnosis of ADHD is most often based on reported behavioural observations 
made by parents and/or teachers. There are no tests that identify the existence of ADHD in a 
biological sense. This is one of the reasons for the divergent views on the existence of ADHD as a 
clinical entity. 
Finding 12- Comorbidities or coexisting conditions may be misdiagnosed as ADHD due to the 
similarity in behavioural symptoms. 
Finding 13- There is a paucity of evidence on the long-term effects of psychostimulant medication on 
children. 
Finding 14- Individuals who are prescribed psychostimulant medication may also be prescribed other 
medications to alleviate side effects. 
Finding 15- There have been cases in Western Australia of prescribed stimulant medication levels 
exceeding the recommended dosage, which have resulted in some children requiring hospital 
admission for detoxification and reported episodes of psychotic behaviour. 
Finding 21- The greater use of dexamphetamine in Western Australia for the treatment of ADHD is 
inconsistent with practice in all other Australian States and Territories. 
Finding 23- There are divergent opinions in relation to a connection between ADHD, stimulant 
medication and later substance misuse. The Committee found that there have been no conclusive 
results from the studies undertaken on the connection between ADHD, stimulant medication and 
later substance abuse. Further, no science-based evidence was provided to the Committee of a 
causal link between undiagnosed ADHD and illicit substance misuse. 
Finding 24- There is a growing body of evidence to suggest that stimulant medication is sometimes 
diverted for illicit use. 
Finding 26- There is evidence that repeat prescriptions for stimulant medication are on occasions 
dispensed too frequently in Western Australia, creating the opportunity for abuse.  Currently there 
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  WA Legislative Assembly, Attention Deficit Hyperactivity Disorder in Western Australia. 
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are no restrictions on dispensing repeat prescriptions of Schedule 8 medication in Western Australia. 
Finding 28- The practices and attitudes of individual teachers and schools may influence the rate at 
which students are diagnosed and possibly medicated for ADHD. 
Finding 35- Some parents and/or carers of children suspected to have ADHD experience pressure to 
have their child formally diagnosed and medicated before that child is included in academic and 
social activities. 
Finding 37- Whilst there is evidence of a correlation between the diagnosis of ADHD and family 
social and economic dysfunction, whether ADHD is the cause of the dysfunction or ADHD behaviours 
are the result of the dysfunction is not clear. 
 
The committee had received 83 written submissions and met with 37 witnesses with the full 
range of views on ADHD. Arguably my, along with Paul Andrews, membership of the 
committee resulted in it making findings and recommendations in the main consistent with 
the mild ADHD critic view; that is, ADHD is frequently misdiagnosed and the medications are 
over-prescribed.  The report and individual hearings attracted media coverage that may 
have contributed to public awareness of concerns about over-prescription that may have 
contributed to the fall in WA child prescribing rates demonstrated in Figure 5. 
The Parliamentary Inquiry and advocacy of individual politicians after the February 2001 State 
Election clearly favoured an ADHD critic perspective in comparison to the period before 2001.  
While this coincided with a change of government from Liberal/National to Labor this was never 
a partisan issue. Rather than party affiliations, attitudes of individual politicians influenced their 
advocacy and policy outcomes. 
6.5 Amphetamine Abuse and ADHD Prescribing In Western Australia  
Throughout the 1990s and early 2000s there had been considerable media reporting of the 
diversion of ADHD amphetamines amongst teenagers and young adults.516 When data on 
teenage abuse rates first became available through the 2005 Australian Secondary Students’ 
Alcohol and Drug Survey (ASSAD) it confirmed there was considerable diversion of 
dexamphetamine for illicit use.  Even though prescription rates had begun to drop by 2005 
the ASSAD survey estimated that 9,492 (being 5.5 percent) of WA secondary school students 
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who had abused prescription amphetamines.517  This represented 84 percent of the total 
number of students who had self-reported abusing amphetamines in the previous 12 
months. Some may have abused both diverted ADHD amphetamines and illegally produced 
Methamphetamine but clearly diverted dexamphetamine and Ritalin represented a very 
significant portion of the problem.  
The same survey found that 27 percent of twelve to seventeen year-olds who had been 
prescribed stimulant medication either gave it away or sold it.518 Of these, 67 percent had 
done so in the last year and 30 percent in the last week.519  The ASSAD survey also showed 
that 45 percent of WA high school students who had ever taken dexamphetamine or 
methylphenidate were not prescribed the drugs by a doctor.520  
Students were also asked how many dexamphetamine tablets or Ritalin they usually have at 
one time and where or from whom they usually get dexamphetamine or Ritalin.  Most 
students (53 percent) had only one or two dexamphetamine or Ritalin at one time, 26 
percent reported taking three to four and 21 percent reported having 5 or more at one 
time.  Students who were not prescribed dexamphetamine or Ritalin by their doctor 
reported they were given them by someone who is prescribed them (24 percent) or given 
them by someone who doesn’t have a prescription for them (17.2 percent).  Fourteen 
percent bought dexamphetamine either from someone who was prescribed them (9 
percent) or someone who did not have a prescription for them (5 percent).  Four percent 
reported trading or swapping something for dexamphetamine or Ritalin and two percent 
got them from other means or sources.521 
Specific data about the abuse of prescription ADHD drugs was not collected until the 2005 
ASSAD survey.  However, from the 2002 ASSAD Survey to the 2005 ASSAD Survey there was 
a reduction in ‘last 12 month amphetamine abuse’ by Western Australian 12-17 year olds 
from 10.3 percent to 6.5 percent.522  Subsequent ASSAD surveys showed that between 2005 
and 2008 as prescribing rates continued to fall so did teenage amphetamine abuse rates. In 
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519  Drug and Alcohol Office WA, ASSAD Drug Report 2005, p.33. 
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521  Drug and Alcohol Office WA, ASSAD Drug Report 2005, p.33. 
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188 
 
total between 2002 and 2008 there was a massive 51 percent decline in teenage (last 12 
months) amphetamine abuse rates.523  Over the same time period, 2002 to 2008, the 
proportion of WA children prescribed ADHD medications fell from 2.6 percent to 1.39 
percent - a drop of 47 percent. Rates continued to fall until 2010 bottoming out at 1.3 
percent before rising marginally to 1.34 percent in 2011 (see Figure 5 at 4.3). 
Interstate comparisons of dexamphetamine prescription rates and amphetamine abuse 
rates confirm that high prescribing rates are associated with high amphetamine abuse rates.  
In the 2003 Commonwealth Department of Health and Aged Care Survey the national 
average of dexamphetamine prescriptions was 11.3 per 1000 population, Victoria reported 
the lowest rate of 6.7, while WA was clearly the highest with a rate of 43.2.524  In 2004 WA 
had the highest level of amphetamine abuse of all states, with a rate of 4.5 percent of the 
population aged 14 years and over having abused amphetamines in the past year.  This was 
well above the national average of 3.2 percent. Victoria had one of the lowest rates of just 
2.8 percent.525  The proportion of people presenting for treatment with amphetamine abuse 
as the principal drug of concern in 2005/6 also confirmed this trend. The Australian average 
was 11 percent of all treatment episodes with amphetamines identified as the principal drug 
of concern, while WA reported the highest rate of 24.6 percent and Victoria the lowest with 
a rate of 6.3 percent.526 
Far from supporting the commonly made assertion that medicating for ADHD prevents illicit 
drug abuse by self-medicating untreated ADHD sufferers, all the above evidence supports 
the assertion that prescribing amphetamines facilitates their abuse.  It also supports the 
contention that the abolition of Block Authorisation and change in personnel between the 
Stimulants Committee (1997-2003) and the stimulants panel (2003 onwards) not only 
reduced child prescribing rates but also reduced teenage amphetamine abuse rates.  Given 
that the rationale for state government controls on stimulant prescribing is to prevent 
diversion these reforms achieved their intended purpose at least in regard to those under 
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18 years of age.  
6.6 Learning and Attentional Disorders Society: a Western Australian ADHD Patient 
Support Group 
A 2004 survey revealed that, ‘two-thirds of global health charities and patient groups now 
accept support from drug or device manufacturers.’ 527  Australian investigative health 
journalist Ray Moynihan contends these groups are not simply puppets of the drug 
companies. Rather he asserts they are motivated by a desire to help, arguing 
pharmaceutical manufacturers sponsor these groups as a means of ‘helping to paint a 
picture of an under-diagnosed medical disorder best treated with drugs’.528   
Moynihan considers that prominent US ADHD support group Children and Adults with 
Attention Deficit Hyperactivity Disorder (CHADD) is no mere ‘advocacy group’ but more like 
a ‘highly energised political or religious organisation’.529  In 2003 CHADD Chief Executive 
Officer E. Clark Ross admitted that the ‘science’ to support the validity of ADHD ‘really is a 
matter of belief’.530 
CHADD honours high-profile ADHD proponents in the ‘ADHD Hall of Fame’. Inductees include 
Distinguished Professor of Psychiatry at the University of Utah School of Medicine, Paul 
Wender.531  In 1995 Wender claimed to have found a reliable biological marker, foot tapping. 
Fidgeting and foot movements (known in our research setting as ‘Wender’s sign’) are 
very common signs of hyperactivity in adult ADHD patients – so much so that such 
patients can usually be diagnosed in the waiting room by a knowledgeable 
receptionist…I seriously entertain the possibility that this foot movement may be a 
biological marker for ADHD532…The reduction of the foot sign in ADHD patients may also 
                                               
527  Quoted in Ray Moynihan and Alan Cassels (2005), Selling Sickness: How the World’s Biggest Pharmaceutical 
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531  Breggin, Talking back to Ritalin, p.236. 
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York, p.20.  
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be an indicator of stimulant [drug] response.533  
CHADD has been influential in the US where drug companies can advertise directly to 
consumers. However, in Australia this is not the case, which potentially makes pharmaceutical 
companies potentially more reliant on ADHD support groups to help them maximise patient 
numbers and profits.  Like CHADD, Western Australian ADHD support group the Learning and 
Attentional Disorders Society (LADS) is partially funded by ADHD drug manufacturers and has a 
long history of promoting the biomedicalized thesis that ADHD has a biological cause that is best 
treated with ‘safe’, ‘effective’ medication.534  In a 2004 paid community newspaper 
advertisement for LADS, executive officer Michelle Toner was quoted as saying: 
[ADHD was] caused by an imbalance of the chemical dopamine in the brain…it was as 
inheritable as height and could create problems with inattention, impulsiveness, 
memory, organisation, time management and hyperactivity…not all people diagnosed 
with ADHD were hyperactive and the extreme behaviours often associated with it 
were uncharacteristic…ADHD medication had been used since 1937 and the ‘hysteria’ 
sometimes associated with it was often unfounded and uninformed.535  
In a similar vein LADS has reassured parents that they are not a cause of their child’s behaviour.  
A LADS ADHD fact sheet produced by Perth Clinical Psychologist Derek Cohen begins: 
If I had to select one fundamental issue to comment on in the therapy of ADHD 
children it would be the erroneous conclusion drawn by many parents and 
professionals alike that ADHD children have behaviour problems that simply require 
more discipline. While ADHD children present with problem behaviours, these are due 
to underlying neuropsychological factors.536  
On occasions LADS have presented completely inaccurate information.  In 2003, on a Perth 
community television program Face the Facts, speaking on behalf of LADS, Michelle Toner and 
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psychiatrist Dr Roger Patterson made some noteworthy statements. Dr Patterson said:  
Dexamphetamine has the amphetamine name in it and this is what people are starting 
to worry about because they are giving them to children – or they are taking them 
themselves…let me dispel that, they are taking a medicinal form of amphetamine…this 
is not addictive stuff. In fact, I wish it was a little more addictive so that my younger 
patients would remember to take it rather than having to be reminded by their long-
suffering parents.537  
Toner’s statements on the same TV program were even more notable. ‘In order to get a high 
equivalent to what people are taking [as] street speed, you would have to take close to 200 
tablets. Children take 1 or 6 tablets a day and it is not addictive at all.’538 Two hundred of the 
standard 5 milligram dexamphetamine tablets would deliver a dose of 1 gram which would kill 
most people.539  
Also obviously ignorant of the effects of 1 gram of dexamphetamine, the interviewer went on to 
ask Toner: ‘Right, but if you do have ADHD and you take the medication, is it successful?’ Toner 
replied, ‘Oh yes…a lot of people discovered they had ADHD by accident.  For example, truckies 
who needed uppers to keep them awake while they were driving across the Nullarbor suddenly 
found that they were driving a whole lot better…when they were taking dexies.’540  As for 
Michelle Toner’s claim about truckies driving ‘a whole lot better’, she was presumably unaware 
that driving with non-prescription dexamphetamine is illegal and carries penalties including 
disqualification from driving, fines and/or imprisonment.  Research has found that rather than 
‘driving a whole lot better’ people who use dexamphetamine illicitly or for ADHD make more 
mistakes while driving, probably because the drug causes tunnel vision which stops them seeing 
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peripheral information like red lights.541 
In the 1990s LADS was warned twice not to recommend the illegal use of a child’s stimulant by 
parents. Minutes from meetings of the WA Stimulants Committee (formed to monitor the 
prescription of psychostimulants, see chapter 5) revealed that in August 1998 the Committee 
wrote to LADS asking it to stop advising parents to take their child’s medication if they thought 
they had adult ADHD.542  
An example of direct scripted cooperation between LADS and an ADHD drug manufacturer is 
the press release in box 10 below, prepared by public relations business Last Say 
Communications on behalf of the manufacturer of Concerta, Janssen Pharmaceuticals.543  LADS 
provided the human face for the Concerta story helping to create an emotionally charged sense 
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Box 10 – ADHD: A Day of Calm – Dawn to Dusk Long Lasting Medication to Provide Relief for Kids with 
ADHD 
 
From April 1st 2007, an effective way of delivering medication over a 12-hour period will be available on 
the PBS and help children with ADHD normalise their lives.  This long acting form of methylphenidate 
(Concerta) will overcome the stigma of taking their daily medication during school hours, an issue faced by 
many children with ADHD. 
 
‘School can be hell for kids with ADHD,’ says Michelle Toner of the Learning and Attentional Disorders 
Society (LADS), an organisation supporting children with Attention Deficit Hyperactivity Disorder (ADHD) 
and their parents.  ‘We always have a box of tissues handy at the LADS office for mums who drop their 
kids off at school and then come in for a cry. 
 
‘Often, the worst problem faced by these kids is the attitude of other children, and the stigma of carrying 
the ADHD label. Parents work long and hard with teachers to put strategies in place which help their 
children cope with the demands of the classroom and playground.’ 
 
‘ Medication is often a valuable part of their treatment plan, but the vast majority can only afford short-
acting versions, which require a lunchtime dose to be taken at school.’ 
 
‘Young people hate being singled out like that and many schools don’t like the responsibility of medicating 
children. As a result lots of kids refuse to take their lunchtime dose. For them schoolwork becomes 
harder, the playground becomes a minefield, and bullying often occurs.’ 
 
‘The inclusion of a sustained release methylphenidate on the PBS will be welcomed by these families. Not 
only will it assist with the school day, but tackling homework should beco e a lot easier as well’. 
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As with LADS ‘access orientated’ advocacy in regards to the listing of Strattera on the PBS (refer 
to 5.5.1) LADS willingly allied itself with ADHD drug manufacturers in promoting Concerta. 
6.7 The Raine Study: a unique Western Australian long-term data review of the safety and 
efficacy of ADHD psychostimulant use by children  
In January 2005 the Western Australian Minister for Health Jim McGinty, appointed a 
Ministerial Implementation Committee (MICADHD) to implement the recommendations of 
the WA Legislative Assembly Education and Health Committee 2004 Parliamentary Inquiry 
into ADHD.  The committee included both members who were ADHD proponents and critics.  
A number of ADHD proponents on the committee suggested a review of the Raine Study 
data to see if it provided useful data on the long-term safety and effectiveness of ADHD 
stimulants. 
The Raine Study started in 1989, when 2900 pregnant women were recruited into this 
comprehensive health and wellbeing research study at King Edward Memorial Hospital in Perth.  
The mothers were assessed during pregnancy. The children were assessed at birth, and at one 
year, then two, three, five, eight, ten, fourteen, seventeen and twenty years of age.  At each 
follow up information was collected from the parents and the child.  Information on the child’s 
height, weight, eating, walking, talking, eating, behaviour, educational performance any medical 
conditions or illness etc. was collected.544   
By age fourteen ‘of the 1785 adolescents (remaining) in the sample, 131 (7.3 per cent) had 
received a diagnosis of ADHD’. At age five none of the 131 had taken ADHD stimulants. By age 
fourteen, twenty-nine had never taken stimulants, forty-one had been on prescription 
stimulants in the past but were not taking them, and sixty-one were on ADHD stimulants. This 
gave three groups for comparison, the ‘never medicated’, ‘previously medicated’ and the 
‘currently medicated’ groups. In addition analysis of the effect of the duration of stimulant 
treatment was undertaken.545 
Published in February 2010, the data showed significant evidence of long-term harm from the 
                                               
544  Information on the Raine Study is available at http://www.rainestudy.org.au/about/what (accessed 7 May 
2010).   
545  Government of Western Australia (2010), Raine ADHD Study: Long-term outcomes associated with 
stimulant medication in the treatment of ADHD in children, Department of Health, Perth.  Available at 
http://www.health.wa.gov.au/publications/subject_index/a/adhd.cfm (accessed 20 May 2013)  
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sustained use of stimulants by children to treat ADHD. The review provided the world’s first 
independent data on the long-term effects (eight years) of psycho-stimulant medication.546  
The statistically significant differences that existed at age fourteen occurred between age five 
and fourteen, after some of the children were medicated. To the extent that (non-statistically 
significant differences) existed at age five these were ‘controlled for by using the “propensity for 
medication” score, the symptom severity before commencement of medication treatment, and 
a number of sociodemographic measures’. 
The two most significant findings of the MICADHD Raine Study Review were: 
1. Long-term cardiovascular changes: ‘The most noteworthy finding in the study was the 
association between stimulant medication and diastolic blood pressure. Compared to 
not receiving medication, the consistent use of stimulant medication was associated 
with a significantly higher diastolic blood pressure (of over 10mmHg). This effect did not 
appear to be solely attributable to any short-term effects of stimulant medication, as 
when comparing groups who were currently receiving medication, it was found that 
those who had consistently received medication at all time points had a significantly 
higher mean diastolic blood pressure than those who had not consistently received 
medication in the past (difference of 7mmHg). These findings indicate there may be a 
lasting longer term effect of stimulant medication on diastolic blood pressure above and 
beyond the immediate short-term side effects.’ 547 
2. School performance: ‘In children with ADHD, ever receiving stimulant medication was 
found to increase the odds of being identified as performing below age-level by a 
classroom teacher by a factor of 10.5 times.’548 
In addition the report indicated that there was a marginally negative outcome for both ADHD 
symptoms (inattention and hyperactivity) and depression with the long-term use of stimulant 
medication.549 
The finding that amphetamine use may permanently raise diastolic blood pressure was of great 
                                               
546  Government of Western Australia, Raine ADHD Study. 
547  Government of Western Australia, Raine ADHD Study, p.52. 
548  Government of Western Australia, Raine ADHD Study, p.6. 
549  Government of Western Australia, Raine ADHD Study, p.5. 
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significance. It had been previously recognised that while stimulants were in the patient’s 
system, heart rate and blood pressure were elevated, leading to the associated risks of heart 
attacks and strokes. But it was assumed that when the short-term stimulant effects wore off the 
cardiovascular system returned to normal. 
The finding that past stimulant use increased the probability of an ADHD diagnosed child ‘being 
identified as performing below age-level by a classroom teacher by a factor of 10.5 times’ 
undermines the hypothetical basis of medicating for ADHD. As stated in the MICADHD report 
the basis for the belief that amphetamines have long-term educational benefits are short-term 
studies which ‘indicate that immediate management of ADHD symptoms allows children to 
function more effectively within a classroom. It is hypothesised that this makes children more 
available for learning and allows children to learn skills and concepts which are necessary to 
function well within a classroom in the future.’550 The analysis of the Raine Study data was the 
first time this hypothesis had been tested. 
The suggestion that the Raine Study would be a possible source of long-term data on stimulant 
medication was first made by MICADHD members who were ADHD proponents with a long 
history of prescribing and advocating the use of stimulants. They were obviously expecting very 
different results. I expected the results to show no long-term educational benefits or some 
adverse educational outcome from stimulants, but even I was surprised by the strength of the 
negative outcomes.  
Initially, the ADHD proponents on MICADHD tried to claim that the outcomes for the medicated 
children were most probably worse than those for un-medicated children, because the 
medicated children had more severe ADHD. As a member of the committee, however, I insisted 
on a comparison of the groups at age five, which was prior to any of the children having been 
medicated. This analysis established that there were no statistically significant differences in 
developmental, behavioural and health measures before the children were medicated. 
                                               
550  Government of Western Australia, Raine ADHD Study, p.30.  The short term studies referred to in the Raine 
Study are Howard B. Abikoff, et al (2007), ‘Methylphenidate effects on Functional Outcomes in the 
Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)’, Journal of Child and 
Adolescent Psychopharmacology, 17(5), pp. 581–92; C. L. Carlson & M. R. Bunner (1993), ‘Effects of 
Methylphenidate on the Academic Performance of Children with Attention-Deficit Hyperactivity Disorder and 
Learning Disabilities’, School Psychology Review, 22(2), pp. 184–98; Irene M. Loe & Heidi M. Feldman 
(2007), ‘Academic and educational outcomes of children with ADHD’, Journal of Pediatric Psychology, 
32(6), pp. 643–54. 
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Subsequently ADHD proponent members of MICADHD sought to prevent the publication of the 
data in relation to the long-term safety and efficacy of psycho-stimulants claiming 
methodological weaknesses despite having approving the design of the study before the results 
were known. Instead they sought to design and publish the results of a second study which 
found that social and educational outcomes of children diagnosed with ADHD were worse than 
those in the general population.551  This is similar to the behaviour outlined in the Wall Street 
Journal in relation to research controlled by pharmaceutical companies on mental health drugs 
that 'spin the results of negative findings for the primary outcome – the main question the study 
was designed to answer – and highlight a positive secondary outcome’.552 
The chairperson of MICADHD paediatrician Prof Lou Landau resisted the efforts to supress the 
long-term medication research and the results were published and received considerable 
publicity in Australia in February 2010. When published, Professor Ian Hickie from the Brain and 
Mind Research Institute, dismissed the poor educational outcomes saying, ‘typically those kids 
who go on the medication are considerably worse to start with’.553  Professor Hickie had not 
been involved in the research and was presumably unaware of the comparison of the never 
medicated and medicated groups at age five.  Professor Hickie is a very prominent psychiatrist 
and media commentator on a range of mental health issues who was later embroiled in 
controversy because of allegations by the editor of The Lancet that he exaggerated the benefits 
and understated the risks of an antidepressant (Agolomatine) he was paid to promote by its 
manufacturer Servier.554  Professor Hickie’s online 2009 CV acknowledged receipt of $411,000 
from four different pharmaceutical companies, mostly for research on psychotropic medications 
for depression, psychosis and bipolar disorder.555  
As with all studies there are limitations with the MICADHD study. While the sample size (131) 
                                               
551
  Martin Whitely (2010), Speed Up & Sit Still: The Controversies of ADHD Diagnosis and Treatment, Perth, 
UWA Publishing, p.56. 
552  Armstrong and Winstein, ‘Antidepressants Under Scrutiny’  
553  Interview with Professor Ian Hickie on ABC PM program with Mark Colvin, ‘New Research Reignites Debate 
over ADHD’, 17 February 2002.  Available at http://www.abc.net.au/pm/content/2010/s2822748.htm 
(accessed 15 March 2010). 
554  Sue Dunlevy (2012), ‘Campaign targets depression guru Ian Hickie’, The Australian, 13 February.  
Available at .http://www.theaustralian.com.au/news/health-science/campaign-targets-depression-
guru/story-e6frg8y6-1226269135293 (accessed 7 May 2013). 
555  Professor Ian Hickie received the following grants totalling $411,000 from pharmaceutical companies: $10,000 
from Roche Pharmaceuticals (1992); $30,000 from Bristol-Myers Squibb (1997); $40,000 from Bristol-Myers 
Squibb (1998–1999); $250,000 from Pfizer Australia (2009); $81,000 from Pfizer Australia (n.d.). Cited in Ian 
Hickie, Curriculum Vitae, last updated 23 August 2009.  
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was small, ‘it was larger than those in many short-term studies that supported the use of 
stimulants as a safe and effective treatment for children with ADHD’.556  The evidence from 
the Review does not prove that psycho-stimulants cause failure at school and permanent 
cardiovascular deterioration but it raises serious concerns.  It is notable that despite the fact 
that the follow up data at age 17 and 20 has been available since 2010, promised follow up 
research is yet to be undertaken. 
6.8 Summary of Western Australia’s ADHD history 
WA’s history is one of rapid growth in ADHD prescribing until 2003, followed by a significant 
contraction in child prescribing rates with a simultaneous increase in adult prescribing rates. 
This is a more complex pattern than the general national pattern of consistently increasing 
rates. It is also notable that WA rates grew much faster than national rates and by 2002 
were 2.4 times the national rate for children (see Figure 6 at 4.4.1) and 5 times the national 
rate for adults (see Figure 7 at 4.4.2). 
The downward turning point for child prescribing rates followed closely after an ADHD critic-
dominated policy development process that resulted in the introduction of tighter 
prescribing accountability measures and more detailed prescribing reporting in late 2003. By 
2011 WA child per capita prescribing rates were 11 percent below the national average.  
Adult rates initially fell slightly and then rose consistently and in 2011 were 3.3 times the per 
capita national average. 
Throughout the period of rapidly increasing child and adult prescribing rates (1993 to 2002) 
policy development and regulatory processes were almost exclusively dominated by ADHD 
proponents with a ‘biomedicalized’ perspective.  Most notably the Stimulants Committee 
tasked with ensuring clinicians prescribed responsibly showed little interest in their 
appointed task. They sought to remove already loose controls and advocated for further 
personal exemptions from accountability measures for themselves. 
The Stimulants Committee was established in response to concerns about misdiagnosis and 
over-prescription however, it became dominated by ADHD proponents. The WA Health 
                                               
556  Government of Western Australia (2010), Department of Health, ‘Study raises questions about long-term effect 
of ADHD medication’, Media Release, 17 February. 
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Department 2002 report Attentional Problems in Children and Young People contained a 
number of ADHD proponent friendly recommendations however these were ignored and 
reversed by ADHD critic political intervention.  
This suggests change is not ‘linear’ or ‘neutral’ in that a contest between competing 
interests and ideologies in both policy formation and implementation has resulted in a 
series of ‘wins’ and ‘losses’ for ADHD proponents and critics in WA. In summary ADHD 
proponents captured processes and ‘won’ with rapidly increasing child prescribing rates 
until 2002/2003, however subsequently ADHD critics have had considerable success in 
reducing child (but not adult) prescribing rates.  These issues are discussed in greater detail 
in Chapter 7. 
6.9 New South Wales ADHD policy and regulatory history 
As outlined at 4.4.1 New South Wales (NSW) child prescribing per capita rates are now 
significantly above the national rate and have risen rapidly since 2007. Prior to 2007 WA had 
had much higher rates but NSW rates are now significantly higher (see Figure 6). The 
following section analyses policy and regulation in NSW of ADHD prescribing that occurred 
since 2007. 
6.9.1 ADHD in Children and Adolescents in New South Wales – 2007 Clinical Excellence 
Commission Prescribing Review 
In April 2007 NSW District Court Judge Paul Conlon, when sentencing a twenty-year-old man 
for aggravated sexual assault, said that in his experience ADHD medications were causing 
significant criminality and drug abuse. ‘I have huge concerns. The tide of cases is amazing…I 
am starting to lose count of [the number of] offenders coming before the courts who were 
diagnosed at a very young age with ADHD for which they were “medicated”.’557 Judge 
Conlon also said he had seen signs that children prescribed psychostimulant drugs like 
Ritalin went on to develop addiction to drugs like methamphetamine. He also expressed 
frustration at the failure of the medical profession to effectively self-regulate:  
                                               
557  Janet Fife-Yeomans (2007), ‘The Ritalin Generation – Top judge condemns the ADHD explosion’, The Daily 
Telegraph, 26 April. 
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My own research indicates that ADHD is perhaps the most over-diagnosed condition 
in today’s society…I think it’s an absolute disgrace and those doctors and 
psychiatrists really need to look much more closely at the child and consider other 
methods of treatment other than putting them on these drugs and chemicals…In 
other words, they need to apply greater professional rigour.558  
Then NSW Health Minister Reba Meagher responded to Judge Paul Conlon’s comments by 
setting up a committee to review NSW ADHD diagnosing and prescribing. The purpose of 
the ‘review was to: 
1- Advise on the current development of clinical guidelines in Australia for the 
treatment of ADHD and on treatment via the prescription of the stimulant 
medications dexamphetamine and methylphenidate. 
2- Assess current practice in the assessment and treatment of ADHD. 
3- Undertake a clinical audit of a cross-section of medical practitioners approved under 
Section 29 of the Poisons and Therapeutic Goods Act 1966 to prescribe stimulant 
medication for ADHD, to assess whether current practice complies with the 
requirements of the Act and its regulations, which are referenced in the NSW Health 
Criteria for the Diagnosis and Management of Attention Deficit Hyperactivity 
Disorder in Children and Adolescents, Version 6, June 2004. 
The focus of the review [was] on children and adolescents less than 18 years of age, but may 
also consider the ‘impact of treatment and prescribing practice in adults.’559 
The review was conducted without public input into either its membership or process, and was 
restricted to a literature review, a survey of prescribers outlining their prescribing practices and 
a review of the data from the NSW Stimulants Committee. The review chairperson Professor 
Philip Mitchell and two other committee members, Drs Patrick Concannon and Paul Hutchins, 
have served as advisers to manufacturers of ADHD drugs.560  In addition, many of the members 
of the review committee were prescribers who were in effect reviewing their and their 
colleagues’ practice. Professor Philip Mitchell and Doctors Patrick Concannon and Paul Hutchins 
                                               
558  Fife-Yeomans, ‘The Ritalin Generation’. 
559  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p9.  
560  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.64. 
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declared their connections to drug manufacturers, but claimed there were no conflicts of 
interest.561  Dr Concannon later was also a member of the NHMRC 2009 ADHD Guidelines 
Reference Group and Chairperson of the NSW Stimulants Committee (see 5.3.2).  Dr Hutchins 
was a member of the NHMRC Committee that developed the 1997 National ADHD Guidelines 
(see 5.3.1). 
The review report states as established fact the hypothetical proposition that ADHD is a brain 
dysfunction, specifically a ‘neurodevelopmental condition’.562  It also stated ‘since their origin in 
1989, the New South Wales guidelines have been regularly updated to reflect the current 
international consensus.’563  It quoted the International Consensus statement on ADHD 
published in January 2002.  One of the review panel members Doctor Florence Levy was one of 
87 signatories of the International Consensus Statement. Along with Dr Hutchins she was a 
member of the NHMRC 1997 National ADHD Guidelines Committee.  
The review concluded that, ‘the overall impression was of conscientious doctors giving plenty of 
time trying to offer the best total management in these very complex situations’.564 The review, 
however, was restricted to an audit of 137 of the 19,382 patients (0.7 per cent) and was a file 
review only.  In other words only the clinician’s file notes were reviewed. There was no fresh 
diagnosis of the children by interviewing parents and teachers. Participation in the audit and the 
practice survey by prescribers was voluntary, with only 207 of 367 prescribers co-operating.565  
The review described the 56 per cent response rate of prescribers as ‘excellent’, despite the 
potential bias that those who were confident in the rigour of their practices were more likely to 
participate and the tendency to overestimate one’s own professional competence.566 
Another notable aspect of the review was the willingness of clinicians to prescribe a range 
of psychotropic drugs in conjunction with stimulants.  The proportion of other drugs 
prescribed by surveyed clinicians with stimulants was: Clonidine (75 per cent), atypical 
antipsychotics (71 per cent), SSRI antidepressants (66 per cent), anti-epileptic medications 
                                               
561  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, pp.64–
65.  
562  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.14. 
563  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.10. 
564  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.32.  
565  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p. 20.  
566  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.25.  
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(55 per cent), tricyclic antidepressants (27 per cent), other antidepressants (14 per cent) and 
conventional antipsychotics (12 per cent).567 Some of these drugs are contraindicated for 
use with stimulants and/or are not recommended for use in children. For example no SSRI 
or any antidepressant is ‘currently approved in Australia for the treatment of MDD [major 
depressive disorder] in children and adolescents (persons aged less than 18 years).’568   
The prescribing patterns of clinicians were similar to those in Western Australia, with a 
minority of prescribers specialising in ADHD.  ‘For 7% of practices, patients with this 
condition (ADHD) comprised 51-90% of their patients and for one practice (0.5% of the 
sample) having patients with this condition accounted for more than 90% of their patients.’ 
569  The review also confirmed that NSW paediatricians, like their WA colleagues, were far 
more likely to be frequent prescribers than a child psychiatrist with ’34 percent of 
paediatricians, and only 5 percent of child psychiatrists, prescribing to 100 or more 
patients.’570   
The review report also contained the common ADHD proponent claim that prescribing rates 
are less than prevalence rates. It quoted the flawed Commonwealth Government 
commissioned research that estimated an 11.2 percent prevalence estimate (refer to 4.4.1) 
without identifying the complete absence of measurement for dysfunction in that estimate 
and concluded that ‘as the prevalence of ADHD in Australia is up to 11 percent of children 
and adolescents, we would consider that the rate of prescribing of stimulants for ADHD in 
NSW (0.5 percent to 1.5 percent) is conservative.’571  
The review report also quoted the fourteen-month results of the Multimodal Treatment of 
Attention Deficit Hyperactivity Disorder (MTA) study which were supportive of the use of 
stimulants to treat ADHD.572  However, the review did not reference the three-year follow-up 
results of the MTA. The three-year data indicated no long-term benefits and significant risks of 
                                               
567  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.24. 
568  Therapeutic Goods Administration (2004), Use of SSRI Antidepressants in Children and Adolescents, 
Department of Health and Ageing, Canberra, 15 October (updated May 2011).  Available at 
http://www.tga.gov.au/safety/committees-adrac-ssri-041015.htm  (accessed 13 February 2013). 
569  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.20. 
570  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.27.  
571  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.12.  
572  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.15;  Allegra 
Stratton (2007), ‘Questions raised about drugs as treatment for ADHD sufferers’ The Guardian, 12 November. 
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stunted growth.573  
The review report stated that; 
‘many of the children and families were battling with very complex situations…many 
children had significant learning difficulties, social problems, and other developmental 
conditions and were living in dysfunctional and sometimes chaotic families, including 
changes in carers. Several children were being reared by grandparents and a number 
were in foster homes or experiencing multiple placements. Domestic violence and 
parental substance abuse were not uncommon.’574 
Some of the other more notable features of the review were: 
 ‘When conducting a routine review of a patient on stimulants 67% of prescribers 
normally assessed blood pressure.’575  Given that the risks of cardiovascular adverse 
events, particularly strokes and heart attacks, are increased significantly by using 
stimulants, it is arguable all prescribing clinicians should routinely assess blood 
pressure.  
 ‘The following details were recorded at review sessions, Weight (79%), Height 
(68%).’576  Given that growth retardation is an established side effect of stimulants, it 
is arguable all prescribing clinicians should routinely measure weight and height.  
 ‘When making the diagnosis of ADHD 76% of clinicians assess vision and 
hearing.’577  This means that almost a quarter of clinicians don't check if a child's lack 
of attention may be caused by an inability to see or hear properly.  
 When prescribing stimulants, only 70 percent of clinicians provide current Consumer 
Medicine Information.578  Providing Consumer Medicine Information to parents and 
patients requires minimal effort and the failure to do so by 3 in 10 surveyed 
clinicians reflects a disregard for the principle of informed consent.  
                                               
573  Whitely, Speed Up & Sit Still, p.175. 
574  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p 32.  
575  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.23. 
576  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.31. 
577  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.21. 
578
  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales, p.23. 
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It is noteworthy that the above figures were based on clinicians’ self-reporting their practice 
habits and are therefore are likely to overstate practice competence.  
The catalyst for the review was Judge Conlon’s comments. After the review was completed the 
Daily Telegraph reported (25 February 2008), that as a result of a complaint by an undisclosed 
ADHD support group, Judge Conlon was ‘gagged’ from making further comments on his 
experience of ADHD medications leading to drug abuse and criminality.579  Judge Conlon had 
called on the medical profession to apply greater ‘professional vigour’.  The outcome was a 
review conducted by a group with extensive conflicts of interest who - on the basis of self-
reporting by prescribing clinicians - concluded there was no problem while the catalyst for the 
study, Judge Conlon, was prevented from further comment.  
The controls on clinicians prescribing ADHD stimulants in NSW are similar to those that existed 
in WA prior to the abolition of ‘Block Authorisation’ in August 2003.  Provided that they 
prescribe within ‘routine prescribing criteria' in relation to patient dosages and age restrictions 
‘Paediatricians and Child Psychiatrists who wish to prescribe stimulants may apply to the 
[Health] Department…for a general authority number (CNS Number) which allows the 
prescription of stimulants for patients under their care, without further application, provided 
that… 
• All prescriptions issued using the CNS number are notified (using the Notification form) 
to the Department each month. [and]  
• The prescriber participates in clinical audits concerning the prescription of stimulant 
medications as requested by the Department of Health.’580  
In other words, like those WA authorised prescribers who prior to August 2003 had block 
authorisation, NSW paediatricians and child psychiatrists with a  general authority number (CNS 
Number) can prescribe for unlimited individual patients without requiring individual approvals.  
Again similar to the provision that existed in WA prior to August 2003 special case by case 
approval must be sought for dosages above the prescribing criteria or for very young patients. 
 
                                               
579  Janet Fife-Yeomans (2008), ‘Go sit in the corner – Judge who spoke out against Ritalin kids gagged’, The 
Daily Telegraph, 25 February. 
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  CEC, Attention Deficit Hyperactivity Disorder in Children and Adolescents in New South Wales. 
204 
 
In NSW ‘Other Designated Prescribers’ doctors who are not psychiatrists and paediatricians, 
can prescribe to individual patients. However they ‘must obtain an authority for each 
individual patient. Applications which fall outside the routine prescribing criteria will not be 
approved.’581  
The pattern of total regulatory capture by ADHD proponents and rapidly rising prescribing 
rates for the period 2007 to 2011 is consistent with the national pattern for the period 1993 
to 2011 outlined in Chapter 5.  The relationship between regulatory capture and 
pharmaceuticalization in NSW is discussed in greater detail in Chapter 7. 
6.10 WA and NSW comparative history of regulation and prescribing rates 
As highlighted at 4.4 WA and NSW inter-temporal prescribing rates have exhibited 
considerably different patterns most notably: 
 From 1992 to 2002 WA and NSW per capita prescribing rates grew rapidly although 
WA rates were much higher throughout the whole period being at least twice as high 
for children and four times higher for adults. 
 From 2003 WA child prescribing rates fell approximately 50 percent and NSW rose 
rapidly. By 2011 NSW per capita PBS child prescribing rates were 25 percent above 
the national rate, while WA rates were 11 percent below. 
 WA adult rates in 2011 were similar to those in 2002. NSW rates have grown 
substantially (approximately 50 percent) from 2008 to 2011 however they were still 
less than a third of WA rates.  
WA rates for children fell significantly after regulatory changes resulting from a critic 
dominated process.  In contrast NSW child prescribing rates grew rapidly after a proponent 
‘captured’ process.  This is consistent with the contention that regulatory capture influences 
prescribing rates and is part of the explanation of ADHD pharmaceuticalization.  These 
issues are discussed in greater detail in Chapter 7.  
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Chapter 7.  Discussion, Conclusions and Recommendations 
 
This chapter finishes the thesis by synthesising the contents of previous chapters and testing 
the working hypothesis and discussing the theoretical and policy implications for Australia 
and similar jurisdictions. 
7.1 The Hypothesis 
The central hypothesis of this research is that regulatory capture of the development and 
implementation of ADHD policy has contributed to variations in Australian geographical and 
inter-temporal ADHD medication child prescribing rates. 
7.2 Pharmaceuticalization for childhood ADHD in Australia  
As identified at various points in this thesis there are limitations in the Commonwealth 
Government data sources in regard to ADHD prescribing rates. However, irrespective of 
these limitations the trend in the available data is so strong that it provides ample evidence 
of an explosion in Australian ADHD child prescribing rates for the period 1993 to 2011.  The 
clearest evidence of this pharmaceuticalization is presented in Figure 2. Specifically from 
1995 to 2010 there was a 277 percent per capita increase in prescription rates.  In addition 
Figure 3 demonstrates that between 2002 and 2011 the number of children receiving PBS 
subsidised ADHD medication grew 98 percent while Australia’s population only grew 13.5 
percent (see 4.2).  
WA is an exception to this trend.  From 2003 there has been a significant and sustained fall 
in child ADHD prescribing rates indicating a less pharmaceuticalized response to childhood 
ADHD in WA for that period.  However, during the period 1993 to 2003 WA was an outlier 
with child ADHD per capita prescribing rates being multiples of the national average (see 
4.4). Over the period 2003 to 2008 WA child prescribing rates fell sharply while in other 
states they rose and have continued to rise.  Since 2008 there has been a further small fall 
so that in 2011 WA’s per capita child prescribing rate was 11 percent below the national 
average (see 4.4.1).  
The latest available state based data for 2011 and historical data indicates there is 
considerable variation between state per capita child prescribing rates indicating variations 
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in the degree of pharmaceuticalization across jurisdictions.582  Furthermore the divergence 
in the pathway of child and adult prescribing rates in WA, with WA adult per capita 
prescribing rates remaining way above the national average, indicates that different factors 
influence different demographics within the same geographical jurisdiction.  The review of 
NSW and WA policy development and regulatory processes indicates that the degree of 
capture correlates with prescribing rates.  ADHD proponent domination of processes is 
associated with high and increasing prescribing rates whereas the one example of a critic 
dominated process has been associated with falling rate for children.  However, the 
divergence in the pathway of child and adult prescribing rates in WA, with WA adult per 
capita prescribing rates remaining way above the national average, indicates that different 
factors can influence different demographics within the same geographical jurisdiction.   
7.3 The contest to influence ADHD policy and regulation in Australia 
Although some ADHD proponents have sought to portray the validity of the diagnosis and 
appropriateness of the pharmaceutical treatments as incontrovertible (see 2.4) there is 
ample evidence presented throughout this thesis that ADHD diagnosis and treatment and 
related policy and regulation is very controversial.  The controversy attracts considerable 
and sustained attention both within medical-psychiatric circles and the media and general 
public.  However, the extent to which policy development and regulatory processes are 
contested between ADHD proponents and ADHD critics is highly variable.   
American based processes, particularly the American Psychiatric Association’s development 
of the Diagnostic and Statistical Manual of Mental Disorder, have been dominant in 
determining whether ADHD is recognised and how it is diagnosed and treated in Australia.  
These processes have not been influenced by Australian regulators or professional bodies.  
These processes have therefore have been ‘uncontested’ within Australia in their 
development, although there has been some media and professional criticism of their 
adoption in Australia (see Chapter 3).    
The development of proposed and abandoned changes for ADHD diagnostic criteria in 
DSM5 published in 2013 demonstrates that the development of ADHD criteria is essentially 
                                               
582
  Department of Health and Ageing, Letter to Martin Whitely dated 21 April 2012. 
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a political rather than a scientific process.  The proposed addition of four additional 
potential ways of displaying ADHD was abandoned in the face of criticism.  This is evidence 
that the DSM outcomes are negotiated, rather than scientifically self-evident.  Despite this 
the DSM outcomes have been exported to Australia with very little scrutiny within Australia 
(see 3.6).  
Throughout this thesis there are several examples of processes within Australia in which 
ADHD proponents have set policy or applied regulations in an ‘uncontested internal 
process’. The meaning of ‘uncontested internal process’ in this context is where there are 
no ADHD critics, only ADHD proponents, involved in the formal policy development or 
regulatory process.  These processes have also typically been closed with no or little 
opportunity for public input.  Examples include the: 
 NHMRC Australian ADHD Guidelines processes (1997 and 2009) 
 WA Stimulants Committee (1997-2003) 
 WA International Panel on ADHD (1999) 
 NSW ADHD in Children and Adolescents Special Review (2007)  
Some of these proponent dominated closed processes have attracted limited criticism and 
scrutiny after the event.  However, only one process identified in this thesis, the 2009 draft 
ADHD guidelines, was subject to sustained external media scrutiny prompted by ADHD 
critics. 
There are also a few examples of ‘balanced’ processes in which ADHD proponents and critics 
have contested the outcomes within the formal policy development process.  These 
examples include the Australian ADHD Clinical Practice Points process, the WA Ministerial 
Implementation Committee on ADHD (MICADHD) process and the WA Technical Working 
Party on ADHD.  However, while it is premature to assess the impact of the ADHD Clinical 
Practice Points process there is evidence that for the other two contested processes some 
of the implementation of recommendations from those processes have been ‘captured’ by 
ADHD proponents.  This was particularly the case with the Technical Working Party on ADHD 
process in which the resulting Stimulants Committee was totally dominated by ADHD 
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proponents who sought to loosen controls on prescribing and promoted a heavily 
pharmaceuticalized approach to ADHD (see 6.3.2).    
Throughout the period of this thesis and within the three jurisdictions analysed (Australian 
National, WA and NSW) there is only one example of an uncontested internal ADHD critic 
dominated process.  That example is the redraft of the WA Mental Health Division 
Attentional Problems in Children and Young People report which resulted in the abolition of 
Block Authorisation and the establishment of the Stimulants Regulatory Regime in WA in 
2003. 
In summary most important local and imported policy development and regulatory 
processes, have been dominated by ADHD proponents.  Some local processes have been 
contested by proponents and critics and only one dominated by ADHD critics.   
7.4 Regulatory Capture 
Regulatory capture occurs if a government or non-government agency created to act in the 
public interest instead advances commercial or industry interests at the expense of the 
public interest. Theorists propose that regulatory capture is a result of a mismatch of 
resources and effort where commercial entities with a significant interest in a policy or 
regulatory process focus on influencing the outcome.  The public, who are less immediately 
and foreseeably affected by the outcome and lack the resources of commercial entities, are 
far less likely to seek to influence the outcome (see 2.8). 
7.4.1 Imported Regulatory Capture 
Despite a complete lack of Australian input and widespread concerns about improper 
pharmaceutical company influence upon the American Psychiatric Association, (see 3.2) 
Australian agencies, both Commonwealth and State Government and Non- Government, 
have endorsed and promoted the use of the ADHD DSM-IV diagnostic criteria.  There have 
been some isolated calls to end the dominance of the DSM model on Australian psychiatric 
practice.  However, they have been ineffective.  The dominance by the American Psychiatric 




Alternative diagnostic criteria, the International Clarification of Diseases 10 (ICD-10) 
produced by the World Health Organisation (WHO), has been consistently ignored by 
Australian regulatory agencies despite Australia being a member of the WHO.  DSM-IV 
criteria have been associated with increased prescribing rates as compared to jurisdictions 
relying on ICD-10.  It is therefore likely that regulatory capture of the American Psychiatric 
Association has contributed significantly to Australia’s increasingly pharmaceuticalized 
response to ADHD.   
The decision to use DSM-IV, rather than ICD-10, has been made in several important 
Commonwealth Government ADHD policy processes, without providing a rationale (see 
5.3).  In addition in no process has there been any attempt to compare the educational, 
social and health outcomes of countries using ICD-10 criteria with those using DSM-IV.  A 
cursory examination of the wellbeing of children using DSM-IV indicates both higher ADHD 
prescribing rates and reduced wellbeing (see 3.1).  From a public interest perspective this 
observation at least invites proper examination of this issue before endorsing either the 
DSM-IV or the ICD-I0 approach.  Each of the processes that have recommended DSM-IV, 
rather than ICD-10, has been a captured process. It is therefore not surprising, that the 
criteria associated with higher prescribing rates, were preferred.  However, it is noteworthy 
that there has been a convergence of the contents of the DSM and ICD over time. 
Over time there has also been a progressive broadening of the DSM-IV diagnostic criteria for 
ADHD and the conditions that predated ADHD and increasing international prescription 
rates.  This expansion of both the diagnostic criteria and pharmaceutical markets has happened 
without significant accompanying breakthroughs in the science of the diagnosis or treatments.  
It is notable that several unsubstantiated claims of scientific breakthroughs in the diagnosis and 
treatment of ADHD have received considerable media coverage (see 2.3.1.2).   
Other examples of significant imported regulatory capture include the reliance on International 
‘experts’ with significant and in some cases hidden commercial ties to ADHD drug 
manufacturers.  Notable examples include the:  
 Influence on the 2009 National Draft Guidelines by Harvard Professors Biederman, 
Spencer and Wilens (see 5.3.2.1).  
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 Western Australian International Panel on ADHD (see 6.3.3). 
 International Consensus Statement that has been quoted in a number of Australian 
policy processes (see 2.4). 
There has also been a pattern of selective attention to international research where 
research favourable to the perspective of ADHD proponents is promoted but research 
unfavourable to their perspective is ignored.  Examples of significant unfavourable research 
which have had virtually no effect on Australian public policy include the:  
 Oregon Health and Science University ADHD Drug Effectiveness Review Project – that 
critiqued unfavourably ‘virtually every investigation ever done on ADHD drugs 
anywhere in the world’ determining there is a dearth of research on the long term 
effects of medications (see 3.5). 
 British Columbian Birthday Study titled Influence of relative age on diagnosis and 
treatment of ADHD in children – that revealed amongst the over 938,000 studied, 
children born in the last month of their school year were much more likely to be 
diagnosed and medicated for ADHD than their older classmates (see 5.3). 
An example of the same phenomena is the MICADHD Raine Study ADHD Review.  It 
provided unique and significant evidence in regards to the long term safety and efficacy of 
ADHD stimulants that attracted some media attention in Australia but has had little practical 
effect in Australia and has been virtually ignored internationally (see 6.7). 
7.4.2 Regulatory Capture of Australian Commonwealth Government Processes  
Decisions by the Commonwealth Government determine which medications are licenced for 
sale and which are subsidised via the Pharmaceutical Benefits Scheme.  It also gives 
guidance as to the circumstances for their use and determines the price patients pay for the 
medications.  The Commonwealth Government also subsidise the payments to clinicians 
who diagnose the ‘disorder’. 
An early example of questionable but influential research sponsored by the Commonwealth 
Government was the 1998 prevalence estimate discussed at 4.4.1. The research was 
significantly methodologically flawed, resulting in a significant overestimate of the true 
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proportion of children who would qualify for a DSM-IV diagnosis.  Despite this the 11.2 
percent estimated prevalence rate remains frequently quoted by both ADHD proponents 
and even an Australian Government Health Minister to demonstrate the significance of the 
issue and the extent of under-diagnosis and under-treatment.   
Analysing the relative influence of ADHD proponents with a ‘biomedicalized’ and ADHD 
critics with a ‘medicalization’ perspective on Commonwealth Government policy and 
regulatory processes is most logically done both on an inter-temporal and agency by agency 
basis.  Chronological analysis enables the identification of cross agency inter-temporal 
trends.  Agency analysis enables the identification of patterns of behaviour in regards to 
specific functions. 
The following Table (Table 4) is a summary of the history of Commonwealth Government 




Outcomes of Process Nature of process, 
captured, contested, 






of Ritalin LA 
in 2002 
The Therapeutic Goods Authority (TGA) licenced Ritalin for 
use in Australia despite being warned by the Australian 
Drug Evaluation Committee the safety and efficacy data to 
support the submission was ‘deficient in certain areas 
when compared to that usually required by the Australian 
Drug Evaluation Committee and the Commonwealth 
Department of Health’. (see 4.5.1) 
……………………………………………… 
Without any specific data for Ritalin LA the TGA used the 
‘deficient’ safety data from the original 1993 Ritalin 
application to approve Ritalin LA for use to treat ADHD 
despite the fact that it contained a higher dose of 
methylphenidate with an increased risk of overdose. (see 
There is insufficient 
information to 
determine if any conflicts 
of interest existed in 
either process however, 
the licencing processes 
were not rigorous and 
the outcome clearly 
favoured ADHD 








The NHMRC established a working party to produce 
guidelines designed to advise clinicians on the diagnosis 
and treatment of ADHD.  The guidelines working party 
made comprehensive and emphatic pro-medication 
recommendations despite acknowledging the cause/s of 
ADHD are unknown.  Non-drug interventions were 
dismissed as costly and time wasting and a violation of the 
rights of the child to effective treatment.  The guidelines 
encouraged clinicians to diagnose outside the already 
broad DSM-IV criteria and prescribe outside approved 
guidelines for the use of medications.  The guidelines 
identified stimulants as being the first-line of treatment 
and encouraged the use of other drugs either as 
complementary or second-line treatments based on 
reasonable theory and clinical experience without placing 
any practical limitations on what constitutes reasonable 
theory. (see 4.4.2) 
There was no conflict of 
interest information 
collected at the time the 
guidelines were 
developed. However, 




commercial ties to the 
pharmaceutical industry 
or have been strong 
















The Department of Health and Ageing commissioned 
research published in 2000 but based on data collected in 
1998 that estimated that 11.2 percent of Australian 
children age 6 to 17 had ADHD.  The research was 
methodologically flawed in that it ignored the 
requirements that ADHD behaviours occur in at least two 
settings to a degree that impairs effective functioning and 
are not due to other factors. As a result the research 
significantly overestimated the proportion of children that 
would qualify for a diagnosis using the full DSM-IV 
diagnostic criteria.  This fundamental flaw has been 
ignored on numerous occasions - including by the Federal 
Health Minister - and used to counter criticism of 
misdiagnosis/over-prescription and argue that to the 
contrary ADHD is under-diagnosed and under-medicated.   
There is no publicly 
available information 
about potential conflicts 
of interest for the 











The TGA licenced Strattera (atomoxetine) for use in 
Australia.  The TGA relied on research funded by 
manufacturer Eli Lilly and run and designed by 
researchers chosen by Eli Lilly. The TGA does not 
consider previous research conducted by Eli Lilly that 
demonstrated Strattera is unsuitable as an 
antidepressant.  For the one of the two studies used to 
support its licencing application for Strattera by Eli Lilly that 
I reviewed to analyse its independence Eli Lilly chose 
employees and shareholders to conduct the study and 
controlled the dissemination of results. (see 4.6.2) 
……………………………………………… 
The TGA placed the highest possible boxed warning on 
Strattera for suicidal ideation. As is standard practice in 
Australia this boxed warning is placed on the product 
information made available to prescribers but not on 
Consumer Medicine Information sheets that are provided 
to patients, or parents of child patients, on request.  The 
TGA did this six months after the US FDA took similar 
action however, the TGA did not issue a press release or 
seek any publicity to ensure patients or parents were 
informed.  The TGA left the decision about whether to 
inform parents and/or patients for suicidality with 
individual prescribers.  The TGA also issued similarly low 
key warnings for Strattera for potentially fatal liver damage 
(2005) and an increased risk of adverse cardiovascular 
events (2011).  In addition the TGA did not publicise or 
alert Australian media about any of subsequent 113 
voluntary adverse event reports – including more than fifty 
of suicidal/homicidal ideation - up until November 2010.  
All through this period the TGA made adverse event 
There is insufficient 
information to 
determine if any conflicts 
of interest existed in 
either process.  However, 
the licencing processes 
and post market 
regulation were not 
rigorous and the 
outcome clearly 
favoured ADHD 
proponents.   
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reports available upon request but did not publish them 





Despite the then current warnings for suicidal ideation and 
potentially fatal liver damage for Strattera the 
Pharmaceutical Benefits Scheme Advisory Committee 
(PBAC) recommended Strattera’s inclusion on the PBS in 
November 2006.  Because of the high estimated cost (an 
anticipated cost to taxpayers of $101.2 million over four 
years) Howard Government cabinet approval was needed. 
This was obtained and Strattera was subsidised via the PBS 
beginning 1 July 2007.  In 2010 the Department of Health 
and Ageing successfully defended my appeal against denial 
of access via Freedom of Information processes to the 
documents used by the PBAC to recommend the PBS 
listing of Strattera. The Department argued successfully 
that the Health Act 1953 afforded the same privacy rights 
to Eli Lilly as are afforded to the Commonwealth health 
records of individuals.  This Administrative Affairs Tribunal 
determination created a precedent denying public access 
even via Freedom of Information processes to the records 
of dealings between Commonwealth Government 
agencies and pharmaceutical companies.   
There is insufficient 
information to 
determine if any conflicts 
of interest existed in 
either process.  However, 
the licencing processes 
were not rigorous and 
the outcome clearly 
favoured ADHD 
proponents including the 
manufacturer of 








The NHMRC outsourced the development of 
replacement (for the 1997) guidelines to the Royal 
Australasian College of Physicians (RACP) who receive 
significant sponsorship from ADHD pharmaceutical 
manufacturers.  The guidelines development process 
was dogged by a series of controversies primarily 
because of allegations of conflicts of interest and bias 
amongst the guidelines committee members and the 
reliance on research by ADHD ‘experts’ with undisclosed 
commercial ties to ADHD drug manufacturers.  As a 
result of the controversies the Guidelines were not 
There were significant 
conflict of interests both 
with the guidelines 
development committee 
and the research they 
relied upon. This was a 
‘captured’ process that 
produced outcomes that 
clearly favoured the 
perspective of ADHD 
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finally approved by the NHMRC despite being 
completed by November 2009.  The recommendations 
contained within the draft guidelines strongly 
encouraged the use of stimulants as the first line 
treatment even outside manufacturer’s prescribing 
guidelines.  If drugs had severe adverse side effects or 
were ineffective substitute or complementary drugs 
were recommended.  The basis of two thirds of the 203 
recommendations was committee consensus and the 
majority of studies cited in the guidelines were 
’sponsored, at least in part, by the manufacturers of the 
medications’.583  The guidelines also recommended 
prison screening for adult ADHD and special emphasis 
on identifying ADHD in indigenous populations without 
identifying any supporting evidence other than 
identifying high rates of dysfunctionality.   
Unfavourable media coverage of numerous conflict of 
interest issues culminating in scrutiny around the issues 
of undisclosed drug company payments to Harvard 
Professors Biederman, Wilens and Spencer prompted by 
ADHD critic scrutiny eventually resulted in the 











In response to the conflict of interest issues with the Draft 
ADHD Guidelines - particularly those in relation to research 
by Professors Biederman, Spencer and Wilens - in July 
2011 Mental Health Minister Mark Butler announced that 
a committee would develop National ADHD Clinical 
Practice Points.  The Clinical Practice Points were intended 
to provide guidance on the diagnosis and treatment of 
ADHD in children.  Unlike the Draft Guidelines process:  
 the names of the development committee were 
The process was a 
contested process with 
representation from 
critics, neutrals and 
proponents. 
                                               
583
  RACP, Draft Australian Guidelines, p.82. 
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made public as were their ‘conflict of interest’ 
declarations. 
 ADHD proponents and critics were included on the 
development committee. 
 included significant opportunity for public input 
with approximately 140 submissions spanning the 
divergent range of views on ADHD. 
 
Any effect of the Clinical Practice Points on child prescribing rates will occur outside the 
period (1993-2011) for which data is analysed in this thesis.  The Clinical Practice Points 
process however demonstrates that when contested by ADHD critics Commonwealth ADHD 
regulatory processes are not always ‘captured’ by ADHD proponents.  However, despite the 
balanced nature of the Clinical Practice Point process, for all other significant processes 
there has been a consistent pattern of regulatory capture and outcomes that favoured the 
perspective of ADHD proponents. 
7.4.2.1 Regulatory Capture and the National Health and Medical Research Council 
The NHMRC’s practice of outsourcing research and guidelines development processes mean 
that in these cases its primary responsibility is to ensure the competence and independence 
of those they appoint to conduct these tasks.  In relation to the two guidelines development 
processed (the 1997 guidelines and the draft 2009 guidelines) the NHMRC delegated the 
task to ‘expert’ clinicians and to a lesser extent non-expert consumer representatives with 
significant commercial ties to ADHD drug manufacturers and/or an ideological pro-ADHD 
medication bias.  These processes were ‘proponent captured’ and promoted the use of 
pharmaceutical treatments based on ‘expert consensus’ (2009 draft guidelines), ‘reasonable 
theory’ (1997 guidelines) and ‘clinical experience’ (1997 guidelines), often without even 
poor quality supporting evidence and against manufacturers’ guidelines (1997 guidelines & 
2009 draft guidelines). 
As well as having been ADHD proponent captured, these processes were also ‘closed’ 
processes, meaning that the public were not entitled to know either the identity of those 
developing the guidelines or details of any conflicts of interest.  In the case of the draft 
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guidelines the NHMRC effectively delegated the process to the Royal Australian College of 
Physicians that had significant commercial ties to the pharmaceutical industry.  The Royal 
Australian College of Physicians in turn delegated the task to ‘ADHD experts’ with similar 
ties. 
In the case of the 1997 guidelines the closed proponent captured process escaped scrutiny, 
even retrospective scrutiny.  However, in the case of the 2009 draft guidelines a series of 
media disclosures facilitated by ADHD critics exposed the depth and breadth of the 
‘capture’. The information about the conflicts of interest were obtained through Freedom of 
Information (FOI) processes and other publicly available sources as earlier (non-FOI) 
requests for disclosure were refused.   
The response of the NHMRC was to ignore the revelations or defend the 2009 draft 
guidelines as rigorous and independent.  The initial media disclosure in 2007 that the 
majority of the guidelines development process had undisclosed commercial ties to ADHD 
drug manufacturers resulted in the original chairperson Doctor Daryl Efron stepping down 
but remaining on the committee.   
An ‘independent chairperson’ without ADHD related commercial ties, Doctor David Forbes, 
was appointed as a replacement. The parliamentary response on behalf of the Minister for 
Health that she had been ‘advised that the conflicts of interest declared by working party 
members are consistent with the normal range associated with clinician review committees 
of this nature’584 supports the contention that regulatory capture of similar processes are 
the norm (see 4.4.3).   
Subsequent private written disclosures of the ‘corruption of research’ issues surrounding 
Professors Biederman, Spencer and Wilens by ADHD critics to both the NHMRC and relevant 
Federal Minister were either inadvertently overlooked or deliberately ignored.  It was 
national media disclosure in 2009 of the Biederman issue that was the trigger for the 
NHMRC’s decision not to endorse the guidelines; however the ‘draft guidelines’ remain 
available to clinicians and the public and ADHD proponents frequently quote them to 
‘validate’ their perspective. 
                                               
584
  Commonwealth of Australia, Parliamentary Debates, (Senator Joe Ludwig) 
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The NHMRC process for developing of guidelines is based on selecting ‘experts’ and 
‘evaluating medical evidence’ via a ‘literature review’.  This thesis demonstrates that at least 
in regard to ADHD, selecting those identified as ‘experts’ on a controversial issue facilitates 
regulatory capture.  It also demonstrates that NHMRC evidence selection processes were 
inadequate.  In summary, during the period 1997 to 2009, ADHD proponent 
‘biomedicalization theorist’ capture of the NHMRC has been ‘closed and total.  Notably 
throughout this period the total number of PBS subsidised ADHD drugs tripled (see 4.3). 
7.4.2.2 Regulatory Capture and the Therapeutic Goods Authority (TGA) 
Dexamphetamine was licensed for use in Australia prior to the timeframe of this thesis.  
Although used much earlier in the US, methylphenidate was licensed as a number of 
products (Ritalin 1993, Ritalin LA 2002) throughout the study period.  Atomoxetine 
(Strattera) was licenced in 2004.  As discussed at 4.6.1 the TGA licensed Ritalin and Ritalin LA 
in the absence of long-term data and using short term data that was ‘deficient in certain 
areas when compared to that usually required by the Australian Drug Evaluation Committee 
and the Commonwealth Department of Health’.  This experience of the TGA’s licencing of 
Ritalin LA in 1993 closely parallels the experience in the USA of the Food and Drug 
Administration’s licencing of Ritalin SR in 1978 (see 3.5).  Both processes - as Abraham 
identified are typical of regulatory capture - gave the ‘manufacturer the benefit of scientific 
doubt about the safety and efficacy of their product’ (see 2.9). 
For the purpose of this thesis the analysis of the TGA approval of Strattera (atomoxetine) is 
limited to the examination of one (chosen at random) of the two studies chosen by Eli Lilly to 
support the application to licence Strattera for use in Australia.  Eli Lilly funded the research, set 
the parameters, controlled the dissemination of the results and handpicked and paid the 
researchers.  The total direct control by Eli Lilly, the manufacturer of Strattera, of this significant 
piece of evidence used by the TGA to determine if the product is licensed is consistent with the 
practices identified by Professor Marc-André Gagnon (see 3.5).  It is compelling evidence of the 
regulatory capture in Australia by profit driven ‘ADHD proponents’.  In addition the safety data 
held by Eli Lilly collected to examine the suitability of atomoxetine as an antidepressant, when 
branded Tomoxetine, was not considered by the TGA  (see 4.6.1).   
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The TGA’s responsibility as a government body extends to monitoring the after-market 
(after licensing) safety of therapeutic drugs.  The TGA’s 2006 admission that it does not 
monitor FDA black box warnings and its almost non-existent effort to publicise the black box 
warning for suicidality for Strattera demonstrate regulatory capture.  Similarly the low key 
nature of warnings that are placed on product information sheets that are available to 
patients on request from pharmacists indicates that the TGA does not make informing 
patients a focus of their work.  In addition, adverse event reports were only available upon 
request and were not publicly reported by the TGA until 2012.  However, when summaries 
of the adverse event were made available online the TGA stopped making individual de-
identified reports available on request.  Irrespective the voluntary nature of the reports and 
the low proportion of events reported also meant there is no comprehensive database from 
which to assess the real world incidence of adverse reports.  Neither the TGA or any other 
government or non-government agencies make any effort to monitor the safety and efficacy 
of ‘off label’ use of medications even though such use is common for many psychotropic 
drugs including Ritalin to children aged 5 and younger (see 4.7).  These are all examples of 
the TGA, commonly through omission, acting in the interests of the pharmaceutical industry 
rather than consumers and the public interest. 
7.4.2.3 Regulatory capture and the Australian Drug Evaluation Committee (ADEC) and the 
Pharmaceutical Benefits Scheme Advisory Committee 
For the purpose of this thesis there is insufficient information in relation to the operation of 
the Australian Drug Evaluation Committee (now replaced by the Advisory Committee on 
Prescription Medicines)  to assess the degree or nature of regulatory capture (if any).  
However, the licencing of Ritalin and Ritalin LA indicate that historically other 
Commonwealth Government agencies, in particular the TGA, have ignored or downplayed 
ADEC’s negative advice and licenced ADHD drugs.  
The decision made by the PBSAC to recommend Strattera for subsidy despite the after-
market issuing of a black box suicidality warning, along with a liver damage warning and 
significant adverse event reports, is notable.  The process of deciding to subsidise Strattera 
via the Pharmaceutical Benefits Scheme was a contested process between access orientated 
ADHD proponents and injury orientated ADHD critics.  ADHD proponents clearly got the 
220 
 
outcome they desired.  Furthermore, the denial to the public of access to any 
documentation referring to an application by a pharmaceutical manufacturer even via 
Freedom of Information processes is additional evidence of the primacy of commercial 
interest over the public interest. 
Although not related specifically to ADHD drugs, the Grattan Institute review of the cost to 
the Australian Government of subsidising PBS drugs provides further evidence of regulatory 
capture of PBS processes by corporate interests (see 4.5.1). 
7.4.2.4 The Role of Commonwealth Parliamentarians 
Unlike in Western Australia, where there has been two parliamentary inquiries and activism by 
both ADHD proponent and ADHD critic politicians, (see chapter 6) there has been relatively little 
proactive interest in ADHD by Commonwealth politicians.  
In 2007 the then Prime Minister John Howard expressed concern about ‘reports of the over-
prescription of Ritalin’ but left the policy response to Health Minister Tony Abbott.  Minister 
Abbott expressed similar concerns but dealt with conflict of interest issues amongst ADHD 
experts in the 2009 guidelines process by leaving it to the same ‘experts to carefully weigh all 
the issues’.  Opposition spokesperson Nicola Roxon echoed ADHD critic concerns about the 
ADHD proponent captured 2009 guidelines process, calling for full public disclosure of the 
names and commercial ties of the guidelines committee.  However she refused to release these 
details when she became the Health Minister.  After she was replaced as Health Minister by 
Mark Butler, ADHD critic media pressure continued.  Minister Butler responded by initiating the 
‘balanced’ Clinical Practice Point process.  Minister Butler however left the 2009 draft guidelines 
available for public access pleasing ADHD proponents who continue to refer to them for expert 
guidance (see 5.3.3). 
The above indicates that the attitudes of Commonwealth politicians have not been influential in 
terms of ADHD policy development; rather they have responded to media coverage and 
lobbying from both ADHD proponents and critics.  Whether this is a result of a lack of interest or 
a belief that the process of ADHD regulation should be depoliticised is unclear.  At different 
times responsible Ministers Tony Abbott and Nicola Roxon have expressed the view that ADHD 
related policy outcomes should be determined by ‘experts’.  The failure to ensure the 
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independence of the ‘experts’ has allowed these processes to be repeatedly captured. 
In developed nations like Australia regulatory decisions about which products are approved 
for market are usually made after some form of risk assessment.  Risk assessment inevitably 
involves decisions about what ‘evidence to include…how to interpret the available evidence 
[and]…respond to uncertainties, and how much of different kinds of evidence would be 
necessary or sufficient to sustain different types of judgements’.585  These decisions are 
‘routinely and inevitably influenced by the socio-economic and cultural contexts in which 
they are developed’.586  However, as demonstrated by both Ministers Abbott and Roxon the 
influence of these factors is often understated. Outcomes of ‘expert’ processes are regarded 
as if they are the product of pure science.   
 
At least in the case of ADHD a more interventionist approach, where Commonwealth 
politicians ensure, rather than assume, the independence from industry influence of ‘expert 
processes’ may have helped prevent their capture.  This would go against the long term 
trend of Australian Governments, with both Labor and Conservative since the late 1980s, 
facilitating greater pharmaceutical industry involvement in decisions relating to the licencing 
and pricing of pharmaceuticals.  This has been attributed to ‘the then Labor [Hawke] 
Government’s concern for the future of Australian high-technology manufacturing’, a 
concern shared by subsequent governments.587  Perhaps rising ADHD prescribing rates have 
in part been a result of the pharmaceutical company friendly regulatory culture encouraged 
by successive Australian Governments.        
 
 7.4.2.5 Summary of regulatory capture in regard to Commonwealth Government 
processes in relation to ADHD 
The evidence in Chapter 4 indicates that from the period 1993 to 2010 the development of 
ADHD policy and regulation at a Commonwealth level has been captured by ADHD 
proponents.  The rapid growth in National ADHD prescribing rates from 1993 to 2011 
coincided with this period of ADHD proponent regulatory capture.  Although the Clinical 
                                               
585
  Millstone E. and Van Zwanenberg. P. et al (2004), Science in Trade Disputes Related to Potential Risks 
586  Millstone E. and Van Zwanenberg. P. et al (2004), Science in Trade Disputes Related to Potential Risks 
587  Lofgren H and de Boer R (2004) Pharmaceuticals in Australia: developments in regulationand governance. 
Social Science & medicine 58 pp. 2397-2407 
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Practice Point Process began in 2011 they were not published until September 2012.  So any 
effect on diagnosing and prescribing practices is outside the period covered in this thesis.  
However the Clinical Practice Points indicate that although regulatory capture by ADHD 
proponents of Commonwealth Government regulatory agency processes may be the ‘norm’, 
it is not inevitable.   
7.5 Western Australia the Outlier 
Table 5 below briefly outlines in chronological order Western Australia’s history of regulation 
and policy development in relation to ADHD. 
Table 5 – Summary of Western Australia’s history of regulation and policy development in 
relation to ADHD 
Agency, process 
and date 
Outcomes of Process Nature of process, 
captured, contested, 
neutral or critic 
dominated 





Working Party on 
Attention Deficit 
Disorder 
The Technical Working Party on Attention Deficit 
Disorder task was ‘to report to government on the 
incidence of ADHD in WA and to seek expert 
opinion on the appropriate diagnosis and 
treatment for the condition’.588  Published in 1997 
The Report of the Technical Working Party 
highlighted that, in 1994, Western Australian ADHD 
prescribing rates had grown very rapidly 
between1989 and 1994 and were much higher 
(approximately two and a half times) than the 
Australian national average.  It also identified large 
differences in suburban prescribing rates within the 
Perth metropolitan area and recommended 
random audits of the prescribing practices of 
clinicians with ‘block authorisation’, to ensure 
The committee was 
balanced, including both 
ADHD proponents and 
members who later 
expressed public 
concerns about ADHD 
over-prescription.   
                                               
588
 The Report of the Technical Working Party, p.2. 
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responsible prescribing. (see 6.2)  
1997 - 2002     





In response to the Technical Working Party on 
Attention Deficit Disorder recommendations the 
WA Department of Health established the 
Stimulants Committee.  The Committee included 
some of Perth’s heaviest prescribers, who had 
block authorisation.  It was tasked with monitoring 
the prescription of psycho-stimulants to ensure 
appropriate prescribing.  The recommended audits 
of Block Authorisations never happened.  
Stimulants Committees minutes demonstrate that 
the committee made only token efforts to ensure 
responsible practice by individual prescribing 
clinicians and even effectively turned a blind eye to 
illegal prescribing. Instead the committee sought to 
influence clinical practice by promoting further 
prescribing.  (see 6.2.2) 
This was an example of 
complete regulatory 
capture by ADHD 
proponents of a process 
specifically intended to 
address concerns about 
inappropriate 
prescription by ADHD 
proponents. 
1998                  
The WA Minister 





Panel on ADHD 
for a symposium. 
The symposium was established to address 
concerns ‘about the number of WA children 
diagnosed with attention deficit disorder and the 
use of amphetamine-like medication to treat 
them’.589 The Department invited ‘international 
expert’ Professor Larry Greenhill of New York’s 
Columbia University. Professor Greenhill has 
received payment from fifteen pharmaceutical 
companies and is a prominent advocate of ADHD 
prescribing. The other members of the 
International Panel were prominent ADHD 
proponents.  The International Panel Report 
validated the ‘effectiveness of stimulants’ as 
‘beyond dispute’ and encouraged polypharmacy. 
The symposium was 
captured by ADHD 
proponents. 
                                               








panel to prepare 




Young People  
The draft of the report Attentional Problems in 
Children and Young People recommended 
developing a tiered approach, with teachers and 
childcare workers referring children suspected of 
having ADHD for diagnosis by specialist clinicians 
and validated the diagnosis of ADHD for ‘3 to 9 
percent’ of children.  It also promoted the use of 
stimulant medication to treat ADHD.  
………………………………………  
Before it was published by the WA Mental Health 
Division it was substantially rewritten (key 
recommendation were altered) by me with the co-
operation of the Health Minister Bob Kucera. The 
final report abandoned the tiered referral approach 
and recommended the abolition of Block 
Authorisation. (see 6.3) 
The initial development 
of the draft report was 
undertaken by a 
‘balanced’ committee 
that included both ADHD 
proponents and 
members who later 
expressed public 
concerns about ADHD 
over-prescription.   
…………………… 
The final rewrite of key 
recommendations in this 
report became 
dominated by ADHD 
critics.  






(EHSC) into ADHD 
The committee made findings and 
recommendations broadly consistent with the view 
that ADHD is frequently misdiagnosed and the 
medications are over-prescribed.  (see 6.5) 
  
The committee contained 
two (of six) 
parliamentarians who 
were ADHD critics. 









One of the recommendations of the EHSC 
Parliamentary Inquiry was to facilitate research into 
the long-term safety and efficacy of ADHD 
medications. The idea to review Raine Study data 
to evaluate the long term safety and efficacy of 
ADHD stimulants was first suggested by ADHD 
proponents on the MICADHD committee.  They had 
significant input to the design of the study.  
However, when the results showed that amongst 
The Committee was a 
balanced process with 
both ADHD proponents 






of the EHSC WA 
Parliamentary 
Inquiry into ADHD 
2005-2010 
ADHD diagnosed children taking stimulants long 
term was associated with significantly worse 
educational outcomes and raised diastolic blood 
pressure, they criticised the methodology and 
sought to retrospectively alter the methodology 
and prevent publication of the results. 
However, the MICADHD committee was balanced, 
with both ADHD proponents and critics, and the 
committee was informed as the research progressed 
ADHD proponents were unsuccessful in preventing 
the publication or the data. (see 6.7)  
 
WA’s ADHD history is one of rapid growth in prescribing until 2003, followed by a significant 
contraction in child prescribing rates and teenage amphetamine abuse rates, concurrent 
with a simultaneous increase in adult prescribing rates.  This is a more complex pattern than 
the general national pattern of consistently increasing rates.  It is also notable that WA rates 
grew much faster than national rates.  By 2002, despite WA having less than 10 percent of 
the Australian population,590 24 percent of children and 44 percent of adults receiving 
Pharmaceutical Benefits Scheme sponsored ADHD drugs lived in Western Australia. (See 
Figure 5 at 4.3)   
WA’s ADHD history in the period of the rapid growth in child prescribing rates (1993-2002) 
followed a pattern of regulatory capture and pharmaceuticalization.  The clearest example is 
the Stimulants Committee that was established in response to concerns about misdiagnosis 
and overprescribing raised in the 1997 Technical Working Party Report.  The Stimulants 
Committee was dominated by ADHD proponents who were frequent prescribers. (Refer 
5.4.2)  Similarly the 1998 International Panel on ADHD was dominated by proponents with a 
biomedicalized viewpoint. 
                                               
590  Australian Bureau of Statistics (2003), ‘Proportion in Working Ages Set to Decline’, Media Release, 2 
September.  Available at 
http://www.abs.gov.au/ausstats/abs@.nsf/mediareleasesbytitle/F4A2F9DD7183EE99CA256D9500046E75
?OpenDocument (accessed 8 September 2011).  
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However, the earlier 1997 Technical Working Party Report was a more balanced process 
with a greater diversity of views.  Although it validated the diagnosis and drug treatment of 
ADHD it raised concerns about inappropriate prescribing and recommended audits of heavy 
prescribers with block authorisation. These recommendations were either not implemented 
or, as was the case with the Stimulants Committee, adjusted to a significantly more ADHD 
proponent friendly approach. 
The downward turning point for child prescribing rates followed closely after the 
introduction of tighter prescribing accountability measures and more detailed prescribing 
reporting in late 2003.  These policy changes occurred because of the direct intervention by 
myself - an activist ADHD critic politician - and a sympathetic Minister, both of whom were 
criticised by proponents who were ‘shut out’ of the process.  This ADHD critic dominance of 
a policy process is unique in Australia for the period of this study and is the likely 
explanation for the significant downturn in WA’s child prescribing rates.  Subsequent WA 
ADHD policy processes were balanced with significant input from both ADHD critics and 
proponents. 
The downturn in child prescribing rates occurred simultaneously with a similar decline in 
teenage amphetamine abuse rates.  In contrast, adult per capita prescribing rates have 
continued to increase since the introduction of the prescribing accountability measures.  
Clearly different factors drove adult and child prescribing rates.  Possible explanations for the 
increasing proportion of adults include the ageing of the ADHD cohort, the marketing of ‘Adult 
ADHD’ and doctor shopping for dexamphetamine by adult West Australians.  
In summary the evidence of regulatory capture of WA Government processes up until 2001 
is considerable.  However, in 2002 ADHD critic dominance of a policy development process 
resulted in the tightening of prescribing controls including the abolition of Block 
Authorisation.  The changes were not implemented until late 2003.  During the period of 
regulatory capture child prescribing rates grew at a rapid rate.  However, soon after the 





7.6 New South Wales 
In NSW in 2007 media coverage of comments by a judge expressing concerns in relation to 
potential harms resulting from the prescription of amphetamines for ADHD resulted in the 
State Government commissioning a review of diagnosing and prescribing practices.  The 
NSW State Government invited ‘ADHD experts’, many of whom had commercial ties to the 
pharmaceutical industry and/or clinicians who were frequent prescribers, to review the 
prescribing practices of themselves and their peers. 
This review found that there was no basis for concerns about possible harms and that rather 
than being over-diagnosed and over-prescribed, ADHD was under-diagnosed and the drugs 
used to treat it were consequently under-prescribed. Recommendations from this review 
encouraged the further diagnosis of, and prescription for, ADHD.  The recommendations of 
the review were made based on the consensus of the ‘experts’ on the review committee 
and the self-reporting of prescribing practices by clinicians.  The review was followed by a 
significant increase in ADHD child prescribing rates from 2007 to 2011.  The catalyst for the 
review was comments by a judge based on his courtroom experience.  However, he was 
‘gagged’ from making further comments on his experience of ADHD medications leading to 
drug abuse and criminality (see 6.9.1). 
The similarities between the ADHD history of NSW from 2007 until 2011 and Western Australia 
from 1993 to 2002 are considerable. NSW grants a General Authority Number - the equivalent 
of WA’s now abolished ‘Block Authorisation’ - where frequent prescribers are exempt from the 
case-by-case monitoring requirements imposed on those who prescribe infrequently. In both 
periods respective State child prescribing rates rose rapidly.   Like WA from 1993 to 2002, 
‘regulatory capture’ by ADHD proponents in NSW appears almost absolute and this has been 
associated with a rapidly increasing pharmaceuticalized response.  The notable difference is that 
in 2007 the voice of a prominent NSW ADHD critic was silenced. In contrast in WA in 2002 policy 






7.7 Non Government Processes 
There are numerous not-for-profit and for-profit non-government agencies involved in the 
regulation or provision of services related to ADHD.  The limited evidence that is available is 
consistent with the assertion that ADHD proponents dominate these agencies, a 
phenomenon that Hanson and Yosifon describe as deep capture (see 2.5).  Possible 
explanations include economic incentives and ideological self-selection, where individuals 
with values and beliefs in line with a biomedicalized ADHD perspective chose to involve 
themselves in ADHD related policy processes and work in a co-operative manner with drug 
manufacturers.  
The WA ADHD support group, the Learning and Attentional Disorders Society (LADS), have 
accepted funding from ADHD drug manufacturers and has openly co-operated with them to 
market their products.  LADS has consistently promoted the biomedicalized thesis that 
ADHD has a biological cause that is best treated with ‘safe’, ‘effective’ medication.  LADS 
have presented completely inaccurate information, particularly in relation to the addictive 
properties of stimulants to be diverted for illicit use.  On two occasions in the late 1990s 
LADS was counselled about promoting the illegal non-prescription use of a child’s stimulants 
by their parents.  LADS have engaged in ‘access orientated’ advocacy in regards to the listing 
of ADHD drugs on the PBS (see 6.6).   
Ideally researchers engage in unbiased scientific inquiry. It is questionable whether this is a 
realistic expectation when researchers are chosen and paid for by ADHD pharmaceutical 
manufacturers.  The scandal involving high profile ADHD advocates, Harvard University’s 
Biederman, Spencer and Wilens is a clear example of commercial conflicts of interest 
resulting in either the corruption of or the suspicion of the corruption of supposedly 
independent research.  Despite disclosure of the issues around Biederman, Spencer and 
Wilens, to the Royal Australian College of Physicians draft guidelines development group 
during the public input process, it was only critical media coverage of the issue that 




Many other researchers engaged in ADHD drug trials have pre-declared positions supporting 
the validity of the diagnosis and the safety and efficacy of ADHD drugs. They may be 
predisposed to finding results consistent with their beliefs and ignore or minimise the 
significance of those that are inconsistent.  For example many of the International 
Consensus Statement signatories are researchers who in signing the consensus statement 
declare the validity of the disorder is beyond dispute.  These include Australian ADHD 
experts such as Dr Florence Levy who have been involved in Australian consensus processes 
that have determined the ‘official’ Commonwealth and State Government responses to 
ADHD (refer to 5.3.1 and 6.9.1).  
The dismissive response to the unexpected results produced in the Raine Study ADHD 
Medication Review by the ADHD proponents on MICADHD who first suggested the study 
and designed and conducted the research is significant.  It was consistent with the 
contention that the effort that goes into validating and promoting research is frequently 
influenced by personal bias.  However, as the MICADHD process was a contested process 
the attempt by ADHD proponents to ignore the research was unsuccessful.  This supports 
the contention that open contested policy development, research and regulatory processes 
help to enhance the rigour of these processes. 
Professional associations like the RACP in Australia and the APA in America presumably 
include professionals with a broad spectrum of views about ADHD amongst their 
membership.  In April 2006 the WA magazine Medical.WA Forum conducted a poll of 245 
Western Australian general practitioners.  Fifty-six per cent of the GPs polled thought that 
ADHD drugs were over-prescribed to children in Western Australia and 16 per cent thought 
they were not. The other 28 per cent of GPs basically did not express an opinion.591  
However, the members of the RACP ADHD Guidelines Committee were almost exclusively ADHD 
proponents.   
This mismatch between the range of professional views on ADHD and the narrow ADHD 
proponent dominance of the RACP process supports the contention that ADHD proponents seek 
to influence processes that they specialise in treating and hold strong views about and/or earn 
                                               
591  Rob McEvoy (2006), ‘Poll Results – General Practitioners May 2006’, Medical.WA Forum, 2 May.  Available 
at http://www.medicalhub.com.au/view-editions (accessed 17 June 2007). 
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income from treating.  In contrast, it is difficult to make an income from specialising in ‘not’ 
diagnosing a condition and it is therefore very difficult to develop specialist expertise in ADHD 
for those who do not believe it is a valid psychiatric disorder.  On the other hand, there are 
substantial incentives, both commercial and professional, for ‘believers’ in ADHD to become 
experts.  This is consistent with Stigler’s theory that ‘regulatory capture’ is a logical consequence 
of regulatory and policy processes being dominated by the most motivated and best resourced 
(see 2.5).     
7.8 How does Australia’s ADHD experience of Regulatory Capture relate to Abraham’s 
theories? 
Abraham contends the medicalization thesis is the best explanation for the international 
pharmaceuticalization of ADHD.  Abraham bases his theory on British and U.S. experience.  This 
thesis addressed the question of whether Abraham’s ‘medicalization thesis’ explanation of 
pharmaceuticalization is applicable to childhood ADHD in Australia. 
For the massive growth in national child prescribing rates to be consistent with the alternate 
‘biomedicalization’ thesis there would need to have been significant scientific 
breakthroughs validating the diagnosis and/or safety and efficacy of the drugs used to treat 
it.  Despite many ‘false dawns’ where ADHD proponents have claimed to be on the verge of 
discovering the cause or causes of ADHD, the aetiology of the ‘disorder’ remains confused 
and uncertain.  Although they attracted considerable international media attention, claims 
of finding the genetic basis of ADHD were shown on close examination to be 
unsubstantiated (see 2.6).  In summary there have been no scientific breakthroughs in 
either the understanding of the aetiology, diagnosis or treatment of ADHD that support a 
biomedicalized explanation of the massive and continuing growth in ADHD prescribing rates 
from 1993 until 2012. 
Although there have been no advances in the science of diagnosing ADHD there has been a 
pattern of the American Psychiatric Association (APA) broadening the behavioural 
diagnostic criteria for ADHD.  This was a result of consensus during committee processes of 
the APA.  The principal author of the DSM-IV, Professor Allen Frances, has criticised the 
subsequent explosion in international ADHD prescribing rates, offering an explanation 
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consistent with the medicalization thesis (see 3.3).  Consensus amongst ADHD medication 
advocates has also driven significant Australian ADHD policy processes.  The Australian 1997 
guidelines and the 2009 draft guidelines were both the result of consensus amongst a 
committee, the majority of whom had commercial connections to ADHD drug 
manufacturers (see 5.3). 
It is likely that there are many factors affecting ADHD child prescribing rates.  Abraham 
contends there are multiple factors that contribute to medicalization and 
pharmaceuticalization but the most important factor is regulatory capture.  It is impossible 
to quantify the relative effects of factors.  Nonetheless, the Australian experience of 
regulatory capture being the norm and being associated with rapidly growing prescribing 
rates is consistent with Abraham’s contention. 
WA’s history post 2003 is an outlier from this general pattern of regulatory capture.  Abraham 
acknowledges that his theory of regulatory capture and pharmaceuticalization is not absolute 
and that in exceptional cases other outcomes may occur. The direct intervention of an activist 
ADHD critic parliamentarian and a sympathetic responsible minister are unusual circumstances 
that explain WA’s deviation from the norm of regulatory capture and increasing 
pharmaceuticalization. 
Abraham bases his theories on 150 years of United Kingdom’s pharmaceutical regulation 
history supplemented by an analysis of U.S trends.592  Abraham contends a primary driver of 
the cycle of regulatory capture and pharmaceuticalization is ‘neo-liberal corporate bias’.593  
By ‘neo-liberal’ Abraham means the ideology that the ‘state should be minimal and subject 
to the tests of the market’.594  He contends this laissez-faire, self-regulatory philosophy 
combined with a pro commercial interest bias heavily favours the interests of the 
pharmaceutical industry often at the expense of consumer interests. 
Abraham draws predominantly on British experience.  The United Kingdom’s regulatory 
environment is similar to Australia’s in that government is central to the provision of health 
services and direct to consumer advertising of prescription medications is outlawed.  
                                               
592  Abraham, ‘From Evidence to Theory’, p.173. 
593  Abraham, ‘From Evidence to Theory’, p.173. 
594
  Abraham, ‘From Evidence to Theory’, p.168. 
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Abraham is particularly critical of the regulatory capture of drug regulators in the United 
Kingdom, concluding: 
The present drug regulatory systems are insufficiently rigorous in their political 
relations with the pharmaceutical industry, because they prevent proper public 
accountability, are highly vulnerable to industrial capture, and permit the industry’s 
scientific experts to have extensive conflicts of interest while providing their expert 
advice. A regulatory system capable of delivery of publicly defensible assessments, 
which are uncompromisingly in the interests of public health, is needed.595 
Clearly the prevention of public disclosure via Freedom of Information processes of the 
documents relating to the approval of ‘medications’ for Pharmaceutical Benefits Scheme 
subsidisation in Australia is contrary to Abraham’s recommendation that a ‘regulatory 
system capable of delivery of publicly defensible assessments…is needed’ (see 4.6.4).  
As outlined at 7.4.2.2, other Australian examples of ‘insufficiently rigorous’ drug regulation 
processes include: 
 The TGA licencing of Ritalin and Ritalin LA (see 5.4.1). 
 The TGA licencing of new drugs relying on only two studies chosen by the applying drug 
manufacturer (see 5.4.2).   
 The NHMRC recommending the ‘off label’ prescribing of Ritalin and other drugs 
in treatment guidelines (see 5.3.1 and 5.3.2). 
 The TGA not publicising information about product warnings and adverse events 
(see 5.4.3).  
Abraham considers that pharmaceuticalization is in part a result of a consistent pattern of 
‘failures of injury-oriented adversarial consumerism and the successes of access-oriented 
collaborative consumerism’.596 Furthermore he contends the pharmaceutical industry:  
encourages consumerism when it is about patients’ access to medications but 
vigorously contests the relevance and expertise of consumerism when it condemns 
                                               
595  Cited in Richard C. Horton (2003), Second Opinion: Doctors, Diseases and Decisions in Modern 
Medicine, Granta Publications, London, p.xv. 
596
  Abraham, ‘The Sociological Concomitants’, p.297. 
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the safety problems of some pharmaceutical products…One may conclude that 
pharmaceuticalization has expanded largely because the drug industry has used its 
power to have a central influence on all the key sociological factors driving the 
phenomenon. Consequently, pharmaceuticalization has increased mainly in 
accordance with the commercial interests of the pharmaceutical industry.597   
One clear Australian example of the dominance of access over injury-orientated 
consumerism relates to the decision to subsidise Strattera (atomoxetine) via the 
Pharmaceutical Benefits Scheme on 1 July 2007.  Eli Lilly facilitated access orientated 
consumer pressure via an ADHD patient support group, LADS, which successfully 
counteracted injury orientated consumerism, resulting in taxpayer subsidized access to 
Strattera. 
The post market regulation of Strattera by the Therapeutic Goods Administration and the 
processes of subsidisation via the Pharmaceutical Benefits Scheme by the relevant 
government agencies are consistent with Abraham’s assertion that regulatory capture 
results in pharmaceuticalization, counter to the public interest, through the exaggeration of 
benefits and minimisation of risks in public benefit assessment processes (see 2.9).  They are 
also consistent with the findings of the UK House of Commons Committee Inquiry into 
Pharmaceutical Company Influence, which detailed concerns that the ‘regulatory system, 
the medical profession and Government have all failed to ensure that industry’s activities 
are more clearly allied to the interests of patients and the National Health Service’ (see 
2.10).  
7.9 The applicability of other regulatory capture theorists to Australia’s experience 
An early theorist of the concept of regulatory capture, George J Stigler, contended regulatory 
capture is a logical outcome of economic incentives.  Commercial enterprises - pharmaceutical 
companies and their allies in the case of ADHD - focus attention and resources on protecting 
their economic and professional interests.  In contrast, those who are less immediately and 
foreseeably affected by the outcome don’t try to influence the relevant policy and regulation.  
According to Stigler this regularly leads to policy and regulatory outcomes that favour the 
                                               
597
  Abraham, ‘The Sociological Concomitants’, p.305. 
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interests of those whose activities are at face value being regulated (see 2.5). 
There are numerous examples in this thesis of policy committee processes being 
dominated by ADHD proponents who specialise in diagnosing and treating the condition 
and nominate for inclusion onto these committees. Examples include the: 
 1997 NHMRC Guidelines Development Committee (see 4.4.2) 
 2009 NHMRC RACP Guidelines Development Committee (see 4.4.3) 
 1997-2003 WA Stimulants Committee (see 5.4.2) 
 2007 NSW Child ADHD Review Committee (see 6.9) 
With a few notable exceptions the competition between ADHD proponents and ADHD critics to 
influence policy and regulatory outcomes has been dominated by ADHD proponents.  They have 
been better resourced, better organised and more strategic in their approach.  ADHD 
proponents have had commercial, professional and ideological motivations for promoting the 
disorder and the drugs that treat it.  In contrast ADHD sceptics do not have the same 
commercial or professional incentives (or resources) and are typically ideologically motivated. 
There are numerous examples where the regulation of ADHD prescribing has become 
what Briody and Prenzler would describe as ‘systemically captured’ and McMahon would 
identify as the third and ‘deepest’ level of regulatory capture. In these cases the ADHD 
industry has effectively self-regulated, with only the superficial appearance of external 
independent oversight.  
These examples include the operation of the: 
 WA Stimulants Committee (1997-2003) where very heavy prescribers of ADHD 
medication oversighted their own prescribing and/or exempted themselves from 
accountability requirements. (refer to 6.3.2) 
 The NHMRC ADHD guidelines development process, in which a group of ADHD 
industry insiders relied on consensus and commercially compromised research to 
develop guidelines that promoted ‘medication’ based responses. (refer to 5.3) 
 The NSW Government commissioned ADHD prescribing review established in 
response to judicial concerns about ADHD prescribing related crime. The review 
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was conducted by a committee of prescribing clinicians with extensive ties to the 
pharmaceutical industry who found there was no evidence of over-prescribing and 
that in contrast ADHD was underdiagnosed and under-treated. (see 6.9) 
None of the examples cited above involved direct, illegal corruption. Although the issues 
involving non-disclosure of millions of dollars in pharmaceutical company payments to 
prominent ADHD medication advocates Harvard University’s Biederman, Spencer and 
Wilens were the catalyst for abandoning the draft ADHD guidelines (see 5.3.2) there are 
no known Australian examples of direct criminal corruption in regards to the regulation of 
ADHD. Obviously where total ADHD proponent dominance is effectively achieved there is 
little need for less direct forms of influence.  
As noted at 2.8, Grabosky and Braithwaite argue regulatory capture is more likely where 
the following preconditions exist: 
1- only one industry is being regulated 
2- the regulator is part of a larger organisation  
3- there is conflict between the regulator and the regulated, 
4- regular contact occurs between the regulator and the regulated, and/or where 
significant personnel interchange occurs between the regulator and the regulated. 
Although it is often argued it is comorbid with other psychiatric disorders ADHD is 
conceptualised as a discrete disorder.  The regulatory responses and ‘expert’ committees 
and review panels processes set up to develop diagnosis and treatment guidelines by state 
and commonwealth government agencies are all specific to ADHD. This meets Grabosky and 
Braithwaite’s first precondition and may contribute to the potential for regulatory capture 
by isolating expertise and interest in an issue to a relatively small number of motivated 
enthusiasts.  
In relation to the second precondition, developing and implementing ADHD related policy is 
only a tiny fraction of the work of government regulatory agencies like the NHMRC and 
state and federal health departments and ministers.  Even for non-government agencies like 
the RACP, ADHD represents a tiny fraction of their areas of interest. 
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In regards to the third precondition, there are few instances of direct conflict between the 
regulator and the regulated. Rather, it has been common for government departments and 
ministers to respond to public concern about ADHD prescribing by delegating the detail of 
their response to committees and review groups composed of ADHD industry insiders, 
typically using the rationale that they are experts.   
With regards to the fourth precondition, regulators, especially the TGA, have come to rely 
on the regulated, the pharmaceutical industry, for the evidence used to determine whether 
the products should be licenced for market.  In addition, state governments concerned 
about reports of indiscriminate prescribing have sought the advice of ADHD specialist 
clinicians, themselves frequent prescribers, for advice on the appropriateness of prescribing 
practices. 
In summary, in Australia ADHD has effectively become a medical speciality with the majority 
of prescribing done by a tiny minority of prescribers.  These ‘experts’ and their allies have 
typically dominated not only clinical practice and regulatory processes, but also the public 
debate, research and the development of diagnosis and treatment guidelines.  On rare 
occasions ADHD critics have successfully competed to influence research and policy and 
regulatory outcomes.  However, these incidents have been the exception rather than the 
rule.  These outcomes are consistent with the theory of regulatory capture and its 
application to psychiatric practice in general and ADHD in particular as espoused by John 
Abraham.   
7.10 Policy Recommendations 
The primary finding of this thesis is that regulatory capture of ADHD policy and regulatory 
processes is normal but not universal and that this is a consequence of unequal resourcing and 
motivation of proponents and critics.  Consequently the most significant policy implication for 
the regulation of ADHD and similar conditions is that governments should facilitate robust 
contested policy and regulatory processes.     
Specifically the following policy innovations could be taken by governments to ensure robust 
competition and prevent ‘capture’ of health and mental health processes by the pharmaceutical 
industry and allied interests: 
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1. Ensuring diverse views are robustly represented in health and mental health policy 
and regulatory process.   
Rather than enabling a process of self-selection by like-minded ‘experts’ with the aim of 
achieving a consensus outcome, these processes should be open and contested, with a range of 
views competing to influence outcomes. 
2. Addressing the inequity of resourcing of competing perspectives on controversial 
mental health and health policy issues by direct government funding of independent 
non-government pharmaceutical and medical/psychiatric watchdogs.   
The pharmaceutical industry has demonstrated that it has sufficient resources to effectively 
organise, lobby and market to enhance its own economic interests. However, there is no 
significant counterbalancing economic interest that supports those concerned about the 
inappropriate and unsafe use of pharmacological interventions.  Industry domination of 
notional consumer support groups further exacerbates this problem of regulatory capture by 
creating the false impression of independent consumer driven advocacy.  Governments could 
address this imbalance by funding independent non-government watchdogs specifically tasked 
with critiquing research and clinical practice in the medical/psychiatric and pharmaceutical 
fields. 
3. Require full public disclosure of all relevant safety and efficacy data, and pre-
registration of research, used to support the TGA licencing and PBS subsidisation of 
pharmaceutical products in Australia. 
Two methods employed by pharmaceutical companies for denying both regulators and the 
public adequate access to relevant research are:  
 ignoring and not publishing results of negative studies 
 spinning the results of negative findings for the ‘primary outcome’ – the main question 
the study was designed to answer – and highlighting a positive ‘secondary outcome’.598  
Gagnon (refer 3.5) concludes ‘as long as pharmaceutical companies hold the purse strings of 
                                               
598  Armstrong and Winstein, ‘Antidepressants Under Scrutiny’. 
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biomedical research, medical knowledge will be selectively constructed for the purpose of 
marketing drugs rather than improving public health.’599  However, it is unreasonable to expect 
pharmaceutical companies to expend significant resources developing new products and then 
relinquish control over the conduct of their research.  The situation is further complicated by the 
globalised nature of pharmaceutical research as it would be impractical and wasteful to require 
national licencing and subsidisation of pharmaceutical products purely on intra-national 
research.   
Therefore there must be a mechanism for ensuring the rigour and integrity of all research 
including foreign research relied on to support the licencing and subsidisation of products in 
Australia.   A system that rewards pharmaceutical companies for innovation and invention by 
protecting legitimate ‘commercial in confidence information’ – such as chemical formulations 
and financial information - but prevents the selective disclosure of safety and efficacy data is 
required.  Public registration of research (regardless of where it is conducted) that may be relied 
upon later by pharmaceutical companies applying for TGA licencing or PBS subsidisation could 
help achieve this. The purpose of the research and proposed methodology could be recorded in 
advance.  Then the results of the research in terms of safety and efficacy could be recorded 
after the research is completed.  This system would help prevent pharmaceutical companies 
hiding negative results or adjusting the purpose or methodology of research ‘post hoc’.   
Obviously this system would only work prospectively and not enable access to studies 
already concluded.  To address this shortfall details of all research conducted on a particular 
drug should be provided to the relevant regulator for consideration and made available for 
public scrutiny.  This would help to address the problem of a narrow base of selective 
research used to licence and subsidise drugs. Regulators would have access to all related 
research.   This would prevent a repeat of the situation which happened with Strattera, 
where research conducted by the drug manufacturer Eli Lilly was not made publicly 
available or provided to the relevant regulator because without external scrutiny the 
manufacturer determined it was not relevant (refer to 4.5.1).   
4. Avoid direct capture of Australian psychiatric practice by the American Psychiatric 
Association over which Australian governments and the Australian medical/mental 
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health professions have no control by making the International Classification of 
Diseases (ICD) the only diagnostic criteria utilised in Australia. 
By only providing financial support (including Medicare co-payments and PBS drug 
subsidisation) for the treatment of mental health disorders diagnosed using the World Health 
Organisation’s (WHO) ICD criteria, the dominance of the American Psychiatric Association’s DSM 
could be ended.  Australia is a member of the WHO but has no capacity to influence the APA.  
Alternatively, given that there are also concerns about capture of WHO processes Australia 
could develop its own diagnostic framework. 
5. Facilitate informed consent by Australian pharmaceutical consumers by improving 
public disclosure of adverse event risks. 
This could be achieved by:  
 Strengthening Consumer Medicine Information (CMI) requirements so that every 
warning currently included in information to prescribers is also on the CMI. Prescribing 
doctors should also be obliged by law to hand patients or parents a CMI, and it should 
be compulsory to insert CMI sheets in medication packaging. 
 Putting black box warnings on the outside packaging of drugs as with cigarette 
packaging so consumers are aware of very significant risks. Currently black box warnings 
are often only highlighted on information made available to prescribers and are not 
seen by consumers. 
 Make adverse drug event reporting for a specified range of serious reactions (suicidal 
ideation, strokes, psychosis etc.) mandatory and regularly publish full details on the 
internet. Voluntary reporting means that only a tiny fraction of adverse events ever get 
reported.  Arguably reckless prescribers may be less likely to report serious adverse 
events than cautious prescribers, because they may be concerned about acknowledging 
the consequences of their prescribing practices. The public has a right to know and 
policy makers need to know about the frequency of adverse events so they can make 
informed decisions about the risk benefit profile of medications. 
 Reforming Commonwealth Freedom of Information legislation to end the entitlement 
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of corporations to rely on privacy provisions originally intended to protect the health 
records of individuals (refer to 4.6.4).   
6. Require full public disclosure of pharmaceutical industry funding sources for clinicians, 
researchers, patient groups, advisory board members and members of committees 
involved in regulatory and policy development processes.   
Parents and patients are entitled to know what factors other than patient welfare might be 
motivating the doctors and patient support groups that are advising them. Likewise, 
government and the public are entitled to know about the commercial ties of researchers 
and advisers.  
7. Prohibit pharmaceutical company donations to political parties and candidates and 
compensate if necessary through increased public funding of political parties.   
Governments are responsible for multi-million-dollar decisions about which drugs get approved 
and subsidised and must make these decisions without fear or favour.  There is currently 
retrospective disclosure of political donations and there is no evidence of direct corruption.  
However, there has been very little scrutiny of pharmaceutical company operation by 
parliamentarians.  Although a similar case could be made for a range of industries, the 
pharmaceutical industry is unique in that it produces mind and body altering chemicals that are 
ingested by children a particularly vulnerable consumer group. Many of these chemical 
interventions are lifesaving; most are warranted but as with ADHD some are highly 
questionable. Government must be free from improper influence of the pharmaceutical 
industry. 
8. Research the extent and health impacts of ‘off label’ prescribing and if necessary 
enforce restrictions that limit PBS subsidisation to drugs that are prescribed ‘on label’. 
Off label prescribing does not necessarily result in adverse outcomes.  However it is unregulated 
and outside safety and efficacy parameters established through evidence based licencing 
processes.   Although medications that are prescribed outside approved guidelines are not 
supposed to receive PBS subsidisation the extent to which medications prescribed ‘off label’ are 
subsidised is unknown.  The net health benefit (or loss) of off label prescribing is also unknown 
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and warrants investigation.  
Therefore the Commonwealth Government should commission or conduct research into the 
incidence and impact of ‘off label’ prescribing.  The research should concentrate on the health 
impacts of off label prescribing and the extent of PBS subsidisation of the off label use of 
medications.  Based on the outcome of this research the Commonwealth Government may 
consider if over time it is worth encouraging ‘off label’ prescribing to become ‘on label’.  This 
may be achieved in part by gradually enforcing restrictions that limit PBS subsidisation of 
medications to those prescribed within the approved guidelines.  This may encourage 
pharmaceutical companies to apply to the TGA to expand the range of authorised uses of their 
products and would help ensure that prescribing practices are supported by robust evidence.  
The abovementioned recommendations are primarily designed to ensure, open, contested 
regulatory and policy processes and clinical practice reliant on scientifically robust independent 
evidence.  Many of the abovementioned recommendations are similar to those made by the UK 
House of Commons Committee, outlined at 2.7. 
7.11 Conclusion   
The purpose of this thesis was to examine the relationship between regulatory capture of 
ADHD policy and regulatory processes and child ADHD prescribing rates in Australia 
nationally and within state jurisdictions.  The history of ADHD policy and regulation 
nationally from 1992 to 2012, in Western Australia from 1993 to 2011 and in New South 
Wales from 2007 to 2011 indicates regulatory capture and corresponding 
pharmaceuticalization is highly probable, but not inevitable.  With the exception of Western 
Australia post 2001 and the balanced national ADHD Clinical Practice Point process in 2011-
2012, all the other State and Commonwealth Government processes examined have been 
captured by ADHD proponents in the policy development and/or implementation phase.  
Even WA’s balanced 1997 Technical Working Party process was captured in the 
implementation phase when the Stimulants Committee set up as a result of the Working 
Party recommendations was captured by ADHD proponents.   
All of these captured processes have been associated with subsequent ADHD child 
pharmaceuticalization, i.e. rapidly increasing per capita child prescribing rates. Conversely 
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the only ADHD critic dominated process was associated with subsequent ADHD child de-
pharmaceuticalization, i.e. rapidly falling per capita child prescribing rates.  In summary the 
evidence in relation to Government policy and regulation indicates that in relation to ADHD 
in Australia for the period 1993 to 2011, regulatory capture leading to 
pharmaceuticalization was normal but not inevitable.   
Australian regulatory capture has been reinforced by ‘imported regulatory capture’.  
Specifically there has been a pattern of selective attention to international research and 
practices favourable to the perspective of ADHD proponents.  Most notably despite 
significant and substantiated concerns about improper pharmaceutical company influence 
upon the American Psychiatric Association (APA), Australian agencies, both government and 
non- government, have endorsed and promoted the use of the ADHD DSM-IV diagnostic 
criteria.  Alternative diagnostic criteria in the International Clarification of Diseases 10 (ICD-
10) produced by the World Health Organisation (WHO), has been consistently ignored by 
Australian regulatory agencies and stakeholders, despite Australia being a member of the 
WHO.  The use of DSM-IV criteria are associated with increased prescribing rates as 
compared to jurisdictions relying on ICD-10.  It is therefore likely that regulatory capture of 
the American Psychiatric Association has contributed significantly to Australia’s increasingly 
pharmaceuticalized response to ADHD.   
Caution needs to be displayed in generalising the findings of this thesis.  It relates 
specifically to ADHD in Australia and it is impossible to quantify the relative importance of 
the many factors that may influence prescribing rates.  However, the positive relationship 
between regulatory capture and pharmaceuticalization demonstrated in this thesis is 
consistent with Abraham’s contention that ‘regulatory capture’ is the most significant driver 
of pharmaceuticalization in general and ADHD pharmaceuticalization in particular.  Further 
research is warranted on the relationship between ‘regulatory capture’ and 
pharmaceuticalization for ADHD and other controversial medical/psychiatric conditions in 
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Appendix 1- Extract from U.S. Prescribing Information for Dexedrine produced by Glaxo Smith 
Kline 
 
Full document available at 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017078s040lbl.pdf  




AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES 
FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. 
PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING 
AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS 
SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY. MISUSE OF AMPHETAMINES MAY CAUSE 
SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS… 
 
WARNINGS 
Serious Cardiovascular Events 
Sudden Death in Patients with Pre-existing Structural Cardiac Abnormalities or 
Other Serious Heart Problems: Children and Adolescents: Sudden death has been reported in 
association with CNS stimulant treatment at usual doses in children and adolescents with structural 
cardiac abnormalities or other serious heart problems. Although some serious heart problems alone 
carry an increased risk of sudden death, stimulant products generally should not be used in children 
or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart 
rhythm abnormalities, or other serious cardiac problems that may place them at increased 
vulnerability to the sympathomimetic effects of a stimulant drug. 
 
Adults: Sudden deaths, stroke, and myocardial infarction have been reported in adults taking 
stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also 
unknown, adults have a greater likelihood than children of having serious structural cardiac 
abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or 
other serious cardiac problems. Adults with such abnormalities should also generally not be treated 
with stimulant drugs (see CONTRAINDICATIONS). 
 
Hypertension and Other Cardiovascular Conditions: Stimulant medications cause a modest increase 
in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and 
individuals may have larger increases. While the mean changes alone would not be expected to have 
short-term consequences, all patients should be monitored for larger changes in heart rate and 
blood pressure. Caution is indicated in treating patients whose underlying medical conditions might 
be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing 
hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia (see 
CONTRAINDICATIONS)… 
 
Psychiatric Adverse Events 
 
Pre-Existing Psychosis: Administration of stimulants may exacerbate symptoms of behaviour 
disturbance and thought disorder in patients with a pre-existing psychotic disorder… 
 
Long-Term Suppression of Growth: Careful follow-up of weight and height in children ages 7 to 10 
years who were randomized to either methylphenidate or non-medication treatment groups over 14 
263 
 
months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication 
treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated 
children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in 
growth rate (on average, a total of about 2 cm less growth in height and 2.7kg less growth in weight 
over 3 years), without evidence of growth rebound during this period of development. Published 
data are inadequate to determine whether chronic use of amphetamines may cause a similar 
suppression of growth, however, it is anticipated that they likely have this effect as well. Therefore, 
growth should be monitored during treatment with stimulants, and patients who are not growing or 
gaining height or weight as expected may need to have their treatment interrupted 
 
Seizures: There is some clinical evidence that stimulants may lower the convulsive threshold in 
patients with prior history of seizures, in patients with prior EEG abnormalities in absence of 
seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of 
seizures. In the presence of seizures, the drug should be discontinued. 
 
Visual Disturbance: Difficulties with accommodation and blurring of vision have been reported with 
stimulant treatment… 
 
Pediatric Use: Long-term effects of amphetamines in pediatric patients have not been well 
established. Amphetamines are not recommended for use in pediatric patients under 3 years of age 
with Attention Deficit Disorder with Hyperactivity described under INDICATIONS AND USAGE. 
 
Clinical experience suggests that in psychotic children, administration of amphetamines may 
exacerbate symptoms of behavior disturbance and thought disorder. Amphetamines have been 
reported to exacerbate motor and phonic tics and Tourette’s syndrome. Therefore, clinical 





Cardiovascular: Palpitations, tachycardia, elevation of blood pressure. There have been isolated 
reports of cardiomyopathy associated with chronic amphetamine use. 
 
Central Nervous System: Psychotic episodes at recommended doses (rare), overstimulation, 
restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of 
motor and phonic tics, and Tourette’s syndrome. 
 
Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other 








Individual patient response to amphetamines varies widely. While toxic symptoms occasionally 
occur as an idiosyncrasy at doses as low as 2 mg, they are rare with doses of less than 15 mg; 30 mg 









(accessed 11 November 2011) 
 
…WARNING: SUICIDAL IDEATION IN CHILDREN AND ADOLESCENTS STRATTERA (atomoxetine) increased 
the risk of suicidal ideation in short–term studies in children or adolescents with Attention–
Deficit/Hyperactivity Disorder (ADHD). Anyone considering the use of STRATTERA in a child or adolescent 
must balance this risk with the clinical need. Co-morbidities occurring with ADHD may be associated with 
an increase in the risk of suicidal ideation and/or behavior. Patients who are started on therapy should be 
monitored closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in 
behavior. Families and caregivers should be advised of the need for close observation and communication 
with the prescriber…  
 
All reactions occurred in children 12 years of age or younger. All reactions occurred during the first month 
of treatment. It is unknown whether the risk of suicidal ideation in pediatric patients extends to longer–
term use. A similar analysis in adult patients treated with STRATTERA for either ADHD or major depressive 
disorder (MDD) did not reveal an increased risk of suicidal ideation or behavior in association with the use 
of STRATTERA…  
 
The following symptoms have been reported with STRATTERA: anxiety, agitation, panic attacks, insomnia, 
irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania and 
mania…  
 
5.2 Severe Liver Injury  
 
Postmarketing reports indicate that STRATTERA can cause severe liver injury. Although no evidence of liver 
injury was detected in clinical trials of about 6000 patients, there have been rare cases of clinically 
significant liver injury that were considered probably or possibly related to STRATTERA use in postmarketing 
experience. Because of probable underreporting, it is impossible to provide an accurate estimate of the true 
incidence of these reactions…  
 
Serious Cardiovascular Events Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other 
Serious Heart Problems  
Children and Adolescents — Sudden death has been reported in association with atomoxetine treatment at 
usual doses in children and adolescents with structural cardiac abnormalities or other serious heart 
problems…  
 
Effects on Blood Pressure and Heart Rate  
STRATTERA should be used with caution in patients with hypertension, tachycardia, or cardiovascular or 
cerebrovascular disease because it can increase blood pressure and heart rate. Peripheral vascular effects 
— There have been spontaneous postmarketing reports of Raynaud’s phenomenon (new onset and 
exacerbation of preexisting condition). 
 
Emergence of New Psychotic or Manic Symptoms  
Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in 
children and adolescents without a prior history of psychotic illness or mania can be caused by 
atomoxetine at usual doses.  
Aggressive Behavior or Hostility  
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Patients beginning treatment for ADHD should be monitored for the appearance or worsening of aggressive 
behavior or hostility. Aggressive behavior or hostility is often observed in children and adolescents with 
ADHD. In short–term controlled clinical trials, 21/1308 (1.6%) of atomoxetine patients versus 9/806 (1.1%) 
of placebo–treated patients spontaneously reported treatment emergent hostility-related adverse events. 
Although this is not conclusive evidence that STRATTERA causes aggressive behavior or hostility, these 
behaviors were more frequently observed in clinical trials among children and adolescents treated with 
STRATTERA compared to placebo (overall risk ratio of 1.33 [95% C.I. 0.67–2.64– not statistically significant]).  
 
Allergic Events  
Although uncommon, allergic reactions, including angioneurotic edema, urticaria, and rash, have been 
reported in patients taking STRATTERA…  
Commonly observed adverse reactions in acute child and adolescent, placebo–controlled trials — 
Commonly observed adverse reactions associated with the use of STRATTERA (incidence of 2% or greater) 
and not observed at an equivalent incidence among placebo–treated patients (STRATTERA incidence 
greater than placebo) are listed in Table 1…  
 
Table 1: Common Treatment–Emergent 
Adverse Reactions Associated with the Use of 
STRATTERA in Acute (up to 18 weeks) Child 
and Adolescent Trials Adverse Reaction*  
Percentage of Patients Reporting Reaction  
  STRATTERA  Placebo  
  (N=1597)  (N=934)  
Gastrointestinal Disorders  
Abdominal pain†  18  10  
Vomiting  11  6  





General Disorders and Administration Site  
Conditions  
Fatigue  8  3  
Irritability  6  3  
Therapeutic response unexpected  2  1  
Investigations  
Weight decreased  3  0  
 
 
Metabolism and Nutritional Disorders  
Decreased appetite  16  4  
Anorexia  3  1  
Nervous System Disorders  
Headache  19  15  
Somnolence‡  11  4  
Dizziness  5  2  
Skin and Subcutaneous Tissue Disorders  




What are possible side effects of STRATTERA? See “What is the most important information I should 
know about STRATTERA?” for information on reported suicidal thoughts and actions, other mental 
problems, severe liver damage, and heart problems. 
  
Other serious side effects include:  
 serious allergic reactions (call your doctor if you see swelling, hives, or experience other allergic 
reactions)  
 slowing of growth (height and weight) in children  
 problems passing urine including  
 trouble starting or keeping a urine stream  
 cannot fully empty the bladder  
 
Common side effects in children and teenagers include:  
 upset stomach  
 decreased appetite  
 nausea or vomiting  
 dizziness  
 tiredness  
 mood swings  
 
Common side effects in adults include:  
 constipation  
 dry mouth  
 nausea  
 decreased appetite  
 dizziness  
 trouble sleeping  
 sexual side effects  
 menstrual cramps  
 problems passing urine 
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Professor David Forbes, WA 
 
In relation to ADHD I have a clinical and administrative role in the Child & Adolescent Health Service, 
Department of Health, WA Government. My role is not involved in service delivery to children with 
ADHD. I have no previous or current professional or personal pecuniary interest in any companies or 
other organisations involved in the development, manufacture or marketing and distribution and 
education of drugs and medicinal preparations. 
 
Members of the Reference Group 
 
Dr Patrick Concannon, NSW 
 
As a health professional in this clinical area, I: 
 am employed as Senior Staff Specialist at Royal North Shore Hospital; 
 work part-time in private developmental paediatrics; 
 have attended two Advisory Board meetings (Novartis Pharmaceuticals (2006) and Janssen-
Cilag (2007)). The sitting fee was directed to a local charity; 
 have lectured at a Janssen-Cilag sponsored clinical meeting. The fee was directed to a local 
charity; 
 have been sponsored (Eli Lilly) to attend the 1999 annual conference of the American 
Academy of Child & Adolescent Psychiatry; 
 participated as a principal investigator in international Metadate CD (Celltech) Study. The 
funds received were paid into a Royal North Shore Hospital Child & Family research fund and 
my involvement was approved by the RNSH ethics committee; 
 have acted as a Medical Consultant to the NSW Board of Studies (1988 to present); 
 am currently Chair of the NSW Health Department’s Stimulant Committee; and 
 was a member of the NSW ADHD Review (2007). 
 
Dr Daryl Efron, Vic 
 
As a health professional in this clinical area, I: 
 am a senior Paediatrician at the Royal Children’s Hospital (Vic) Centre for Community Child 
Health; The Centre for Community Child Health applied for and received educational grants 
for ADHD research from Novartis, Eli Lilly and Janssen-Cilag in 2004-2006. These funds have 
been used in accordance with the Hospital’s ethical guidelines, to support research into 
various aspects of ADHD; 
 have been an honorary (unpaid) member of ADHD advisory boards for Novartis and Eli Lilly 
in 2003-2004; 
 am one of four Chief Investigators in a NHMRC-funded, multi-centre research study into the 
cognitive and behavioural effects of a medication (atomoxetine) for ADHD; and 
 am a member of the ADHD Coalition of Victoria – a voluntary, multidisciplinary advocacy 
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group for ADHD in Victoria. 
 
Dr Brad Jongeling, WA 
 
As a health professional in this clinical area, I: 
 am employed by the Western Australian Child and Adolescent Community Health Service as 
a senior paediatrician providing assessment to children with developmental disability, 
including ADHD; 
 work in private paediatric practice assessing children with general and developmental 
paediatric issues including assessment of ADHD; 
 have participated as a site (Joondalup CDC/State CDC) principal investigator in the 
international Metadate CD (Celltech) Study – concluded in 2005. This medication is not 
prescribed in Australia. Funds received from this study were paid into a Princess Margaret 
Hospital (PMH) research account and were used according to PMH ethical guidelines – 
principally for the employment of a research nurse. My involvement was approved by PMH 
ethics committee; 
 am a member of the WA Health Department Implementation Committee (clinical guidelines 
subcommittees) on ADHD following a WA Parliamentary Inquiry into ADHD; and 
 have until recently been the Chair RACP, Paediatric & Child Health Division – WA and have 
arranged local conferences which some pharmaceutical companies have sponsored. 
 
Dr John Wray, WA 
 
As a health professional in this clinical area, I: 
 am employed by the Western Australian Child and Adolescent Community Health Service as 
a senior paediatrician providing assessment to children with developmental disability, 
including ADHD; 
 am a member of the WA Health Department Implementation Committee and the Clinical 
Subcommittee of the WA Parliamentary Inquiry into ADHD; 
 am the Western Australian representative of the Child Development and Behaviour Special 
Interest Group, of the Paediatrics & Child Health Division of the RACP; 
 have received several competitive grants – no pharmaceutical research grants – to 
undertake research in the area of autism. One research project collaborates with an 
independent company that produces digestive enzymes for children with autism; 
 have been a paid member of a global research team in a pharmaceutical company (Eli-Lilly) 
sponsored research program examining the long-term efficacy of atomoxetine in children 
with ADHD (2001 to 2008, now completed); 
 have appeared before the Australian Pharmaceutical Benefits Advisory Committee in 
support of inclusion of risperidone on PBS for children with autism; 
 attended two international conferences (American Academy of Child and Adolescent 
Psychiatry) sponsored by Eli-Lilly in 2001 and 2002 (airfare, accommodation and travel paid 
directly by pharmaceutical company, with approval from employer); and 
 infrequently, deliver professional development lectures at meetings that have been partially 
or fully sponsored by pharmaceutical companies. I have never received payment for these 
lectures. 
 
Dr Mark Kneebone, NSW 
 
As a health professional in this clinical area, I: 
 am a general psychiatrist in full-time private practice in NSW; 
 have an interest in complementary treatment approaches with an evidence base; 
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 attended medical psychiatric meetings in November 2007 and March 2008 that were 
sponsored by Wyeth; 
 attended three ADHD case presentation dinner meetings in 2007, sponsored by Eli-Lilly; and 
 enrolled to participate in an Eli-Lilly sponsored clinical trial of Strattera in adults with ADHD. 
No financial reimbursement or inducement was offered or provided to participate. 
 
Dr Julian Trollor, NSW 
 
As a health professional in this clinical area, I: 
 am a paid employee of the South Eastern Sydney Illawarra Area Health Service as a Senior 
Staff Specialist Neuropsychiatrist and the University of New South Wales as a Senior 
Research Fellow; 
 have sought, on behalf of various conference organising committees, sponsorship from 
numerous drug companies; 
 have received personal payments for consultancy and review work for Novartis, Eli-Lilly and 
Pfizer; 
 have reviewed material and provided advice to Janssen-Cilag for which no remuneration was 
received; and 
 have attended many pharmaceutical sponsored education sessions. 
 
Dr Peter Jenkins, Vic 
 
As a health professional in this clinical area, I: 
 am a Consultant Child and Adolescent Psychiatrist and Clinical Director of Eastern Health 
Child & Adolescent Mental Health; and 
 am a Fellow of the Royal Australasian and New Zealand College of Psychiatrists, 
 am a member of the Faculty of Child and Adolescent Psychiatry of this College and a 
member of the Executive group of this Faculty. 
 
Associate Professor John Brennan, NSW 
 
As a health professional in this clinical area, I am employed as Director of the Child and Adolescent 
Mental Health Service at Sydney Children’s Hospital (SCH). 
 
Professor Michael Sawyer, SA 
 
As a health professional in this clinical area, I: 
 am employed by the Children, Youth and Women’s Service of South Australia and the 
University of Adelaide. I also conduct a range of research activities for the South Australian 
Departments of Education and Children’s Services; 
 declined to participate as lead investigator in a 2002–2008 study investigating the relative 
impact of buprenorphine versus methodone maintenance therapy during pregnancy on 
children’s outcomes. I remain on the study as a co-investigator providing methodological 
support for a colleague at Flinders University who subsequently undertook this study, and as 
a co-supervisor of a PhD student working on the study; 
 was a member of the ADHD advisory board for Eli Lilly to advise on the introduction of 
atomoxetine into Australia; resigned from committee after attending initial meetings 
because of the desire to avoid conflicts of interest; 
 was sponsored (Eli Lilly) to attend the 2002 annual conference of the American Academy of 
Child & Adolescent Psychiatry; 
 am an author of the textbook Medications for School-age Children (Brown RT and Sawyer 
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MG. Guilford Press: New York. 1998); and 
 am an author of the “Child and adolescent” chapter for Therapeutic Guidelines.Psychotropic. 
Version 6. 2008. Therapeutic Guidelines Limited: Melbourne. 
 
Associate Professor Geoff Mitchell, Qld 
 
As a health professional in this clinical area, I: 
 am an Associate Professor of General Practice employed by the University of Queensland; 
 currently hold an NHMRC grant to investigate the effects of methylphenidate (MPH) as a 
treatment for fatigue in palliative care; 
 currently hold an NHMRC grant to investigate the effects of methylphenidate (MPH) as a 
treatment for inattention and higher brain function in children with traumatic brain injury; 
 have previously held (1999–2006) funding from AHMAC, RACGP, PHCRED and Queensland 
Medical Laboratories investigating single patient trials of MPH and dexamphetamine (DEX). 
 
Dr Kim Pedlow, WA (see below) 
 
As a health professional in this clinical area, I: 
 am a rural generalist medical practitioner with special interest in obstetrics, paediatrics and 
minor surgery; 
 am a member of LADDS in Western Australia; 
 was Medical Advisor to the Geraldton Network ADHD Project (1996); 
 have published in the Australian Family Physician journal on the Geraldton network. 
 
Professor Vicki Anderson, Vic 
 
As a health professional in this clinical area, I: 
 am Director of the Psychology Department at Royal Children’s Hospital (Vic); 
 am Theme Director of Critical Care & Neurosciences at the Murdoch Children’s Research 
Institute; 
 lead a research team, the Australian Centre for Child Neuropsychology Studies, which is 
currently involved in a clinical trial to test the effects of Omega-3 on attentional behaviours. 
The research project  has been funded by Naturel, a Norwegian company. The trial has been 
approved by appropriate bodies in Australia, and our ethics approval gives us the right to 
publish data regardless of whether the trial is positive for the drug or not. I receive no direct, 
personal benefit from the company. [Trial subsequently cancelled] 
 
Professor David Hay, WA 
 
As an academic and research professional in this clinical area, I: 
 am employed as a Professor of Psychology by Curtin University; 
 undertake research work on ADHD that is, or has been funded by the US National Institute 
of Mental Health (NIMH), NHMRC and ARC (International Linkage); 
 am a Member of the European Network for Hyperkinetic Disorders; 
 am a Member of the NIMH, ADHD Molecular Genetics Network; 
 am involved in both the Project Grants Scheme and the Training Awards Committee of the 
NHMRC; 
 receive royalties from the sale of a 2001 book Attention, Genes and ADHD (Levy and Hay); 
 attended a meeting of the International Collaboration on ADHD and Substance Abuse 
(ICASA) in Barcelona in September 2008. Curtin University paid for my airfare. My expenses 
in Barcelona were paid by grants to the Trimbos Institute, which administers ICASA, from 
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Janssen-Cilag, Eli Lilly, UCB Pharma and Shire. This sponsorship was provided under 
unrestricted conditions. The sponsors had no influence on who participated in ICASA, the 
topics discussed or any resultant activities, including research; 
 was a main speaker at the Janssen-Cilag Sydney meeting “Continuities and Discontinuities of 
Youth Mental Health” in November 2007. I undertook this with the approval of my 
employer. The company organised my flight and hotel directly and I received no 
reimbursement. At the instruction of my University, I refused the honorarium; 
 was funded by Shire Pharmaceuticals (who at the time and presently do not operate in 
Australia) to attend their International Planning Meeting in Amsterdam in 2005; and 
 work as a consultant with organisations that may pertain to ADHD including the WA 
Departments of Health, Education and Training and Community Development. Also the 
Royal Australian and New Zealand College of Psychiatry (WA Branch). I receive no financial 
benefit from any of these. 
 
Professor Loretta Giorcelli, NSW 
 
As an academic and consultancy professional in this clinical area, I: 
 undertake national and international consultancy work involving consultation to school 
systems, schools, universities and courts on matters related to thee ducation and inclusion 
of learners with additional needs. Some of this work involves the examination of empirical 
evidence regarding best practice for the integration or inclusion of learners with ADHD and 
comorbid/overlapping conditions; 
 have authored a chapter and assisted in the organisation of conferences and seminars about 
students with ADHD and overlapping conditions. I have also given numerous presentations 
on the educational implications of students with ADHD since 1996; and 
 attended one meeting of Janssen-Cilag in 2005 as an educational adviser. Accommodation 
expenses for one night were paid. There was no honorarium. 
 
Dr Michelle Pearce, WA 
 
As an educationalist, I: 
 have been employed by the NSW Department of Education as a school principal; the 
Association of Independent Schools in Western Australia as an educational consultant; and 
the University of Notre Dame and Curtin University as a sessional lecturer; 
 offer advice, lectures, articles and professional development that focus on strategies 
teachers can use to support children with attentional, behavioural and learning difficulties, 
regardless of whether they have a diagnosis of ADHD or not; and 
 have contributed strategies that have been successful with teenagers with ADHD to improve 
their concentration and organisation, to Novartis Pharmaceuticals Australia. Several of these 
strategies were published by Novartis in point form in a 2005 pamphlet. 
 
Ms Geraldine Moore, Vic 
 
I am a consumer advocate in this clinical area. I: 
 provide my time voluntarily to The ADHD Coalition of Victoria; 
 have published a book titled ADHD Potatoes: A Journey from Darkness into Light. This book 
was published by Hybrid Publishers of Melbourne. It told the story of my own family dealing 
with the challenge of ADHD in the 1990s, and the emergence of the support movement for 
ADHD in Victoria with which I was associated, throughout that period; and 
 launched my book in Melbourne in November 2005. There was a subsidiary launch in Sydney 
in 2006 attended by about 15 people. The venue was donated by the Children’s Hospital and 
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the main speaker donated her services. Travel, accommodation, publicity and 
communication expenses were paid by myself. The cost of finger food and drinks for the 
attendees at the Sydney launch (around $100) was paid by Eli Lilly. 
 
Ms Joy Toll OAM, NSW 
 
I am a consumer advocate in this clinical area and for the past 25 years have 
provided my time voluntarily to the Learning Difficulties (LD) Coalition of NSW Inc. I: 
 am founder (1995) and currently Secretary of ADDults with ADHD (NSW) Inc. and previously 
founder (1988) and President for 10 years of the Learning Difficulties (LD) Coalition of NSW 
Inc.; 
 was invited as President of the LD Coalition of NSW Inc to attend a 2003 international 
meeting of ADHD support organisations in Rome, representing parents of children with 
ADHD. Eli Lilly was a sponsor of this international meeting. Travel and accommodation for 
the two nights was provided by the conference organisers. I received no financial benefit 
from attending this meeting – in fact my employer required me to take time off without pay; 
 as Secretary of ADDults with ADHD (NSW) Inc., in the absence of other sponsors, 
approached Eli Lilly to sponsor the cost of printing the organisation’s information pamphlet; 
 as Secretary of ADDults with ADHD (NSW) Inc., attended two consultation meetings with 
Janssen-Cilag during the development of a new Australian website: 
http://www.livingwithadhd.com.au. I received no financial reimbursement. The company 
provided taxi vouchers to cover my travel expenses; and 
 as Secretary of ADDults with ADHD (NSW) Inc., since 2003 have attended annual 
consultation meetings with Eli Lilly who provide taxi vouchers to cover my travel expenses 








Appendix  4 -  A Sample from the Adverse Drug Reactions Committee (ADRAC) adverse event reports 
for Atomoxetine Hydrochloride (Strattera) 
 
Source: Adverse events information related to Strattera obtained from the Therapeutic Goods 
Administration’s Public Case Detail reports. 
 11 year old boy who ‘threw a cricket stump javelin style at a school teacher’ and ‘threatened 
to kill himself’ 
 8 year old boy who ‘hit his head against a wall’ and had ‘thoughts of suicide – stating that he 
wants to kill himself’ 
 18 year old male who suffered ‘swollen, painful and tender testicles’ 
 25 year old woman who wanted to kill herself 
 12 year old girl who experienced; ‘anorexia, weight loss, fidgeting and compulsive behaviour 
that included ripping out fingernails and toenails, picking and cutting clothing, and anger 
outbursts’ 
 7 year old girl who ‘became very agitated while travelling in the family car and had explosive 
mood swings. She said that she intended to open the door and get out of the car, and she 
tried to open the car door’ 
 9 year old boy who ‘developed abnormal behaviour, including strange facial expressions with 
bilateral eyelid ptosis and became very emotionally withdrawn’ 
 9 year old boy who displayed ‘aggression, was totally irrational for three days and became 
violent, all of which was totally out of character’ 
 11 year old boy who ‘became agitated, emotionally labile and experienced thoughts of self-
harm’ 
 13 year old boy who ‘experienced chest pains and hostile and aggressive behaviour, but the 
problems immediately disappeared with the cessation of Strattera’ 
 9 year old boy who slammed ‘his head against walls, had extreme mood swings, violent 
outbursts’ and was ‘always angry, depressed or sad and said he wanted to kill himself’ 
 10 year old boy who ‘experienced nausea, then became acutely depressed, aggressive and 
had suicidal thoughts’ 
 22 year old man who experienced suicidal and homicidal ideation 
 7 year old girl who experienced ‘abdominal pain , nausea, severe right sided headache, 
shooting pains, white spots in visual fields, academic regression and faecal and urinary 
incontinence’ 
 7 year old boy who experienced ‘suicidal ideation and mood changes’ and suffered from 
‘increased aggression’ and ‘threats to self with knife, picking his skin, poking self with knife’ 
 12 year old boy experienced ‘very strong suicidal ideation…talking about dead bodies and 
about hanging himself’ 
 11 year old boy who ‘attempted suicide’ and who experienced ‘headache(s), stomach 
cramps, muscle rigidity and poor concentration’ 
 7 year old boy who experienced ‘suicidal ideation’ 
 10 year old boy who developed ‘psychotic symptoms’ and began ‘talking about suicide’ 
 11 year old boy who experienced ‘a psychotic episode and took an overdose of his mother’s 
thyroxine’ 
 9 year old boy who ‘experienced suicidal thoughts’ 
 11 year old boy who became ‘extremely agitated’ and ‘talked about wanting to die’ 
 13 year old boy who experienced ‘suicidal ideation, physical and verbal aggression to family’ 
and became ‘angry, withdrawn, socially isolatory, impulsive, moody’ 
 15 year old boy who was ‘expressing suicidal thoughts’ 
 11 year old boy who ‘took Strattera for the treatment of ADHD to complement Ritalin, under 
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the influence of which he became suicidal and depressed’ 
 12 year old girl who ‘ripped out her fingernails and toenails’ 
 9 year old girl who ‘experienced self-harming’ 
 9 year old boy who expressed ‘suicidal ideation’, ‘aggression’ and ‘self harm’ and made 
‘drawings of him hanging upside down from a tree, in (the) ocean’ 
 10 year old boy who was psychotic and experienced auditory hallucinations including 
‘hearing voices in his head to kill his sister’ 
 8 year old boy who lost his appetite and experienced homicidal ideation, lost weight and was 
angry and confused 
 15 year old girl who experienced suicidal ideation and started cutting herself to the extent 
that was ‘life threatening’ 
 another 15 year old girl who experienced suicidal ideation and started cutting herself with 
razors, scissors and knives 
 10 year old boy who experienced suicidal ideation 
 another 10 year old boy who had abnormal thoughts about ‘others jumping off buildings’ 
 8 year old boy who talked about killing himself ‘in a boastful manner’ 
 17 year old male who ‘was verbally and physically aggressive.  These behaviours have never 
been seen in this man previously’’ 
 8 year old boy who ‘had lost appetite, was homicidal, losing weight, and lashing out/angry, 
patient had bruising’                                                          
 22 year old male who engaged in ‘psychotic behaviour’ 
 Two reports of a 14 year old girl who ‘started cutting herself.  It was reported that she felt 
compelled to start cutting herself and cut her arms with razors, scissors, knives.  The patient 
had suicidal ideation while causing self-harm’        
 10 year old boy who ‘experienced suicidal thoughts’                           
 10 year old boy who ‘had thoughts about others jumping off buildings’           
 8 year old boy who was ‘talking about killing himself/suicide.  Patient was not depressed and 
discussed suicide in a boastful manner.  Treating paediatrician continued atomoxetine and 
considered adding Risperidone.  Past history included sexual 
abuse’                                                                             
 7 year old girl had ‘severe abdominal pain’ which ‘caused or prolonged inpatient 
hospitalisation’  
 10 year old boy who had ‘suicidal thoughts and threats, despair/depression… and violent 
outbursts’                                             
 8 year old boy had ‘suicidal tendencies’                                 
 6 year old boy who had ‘seizures’ 
 12 year old girl who was ‘ripping their fingernails and toenails out.’  
 17 year old male who had ‘suicidal thoughts; paranoia’ 
 13 year old boy who experienced ‘suicidal ideation’                                        
 17 year old male who experienced ‘suicidal ideation’ 
 13 year old boy who ‘commenced on Strattera … and was more agitated than usual and 
extremely strong suicidal ideation and urges – he climbed on a roof to jump off.  Also had 
extremely strong ideation to seriously hurt and put in intensive care some of the other 
schoolchildren.’ 
 
 
  
